Date,Article_title,Stock_symbol,Url,Publisher,Author,Article,Lsa_summary,Luhn_summary,Textrank_summary,Lexrank_summary
2009-08-31T08:00:00.000+08:00,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink",LLY,https://www.benzinga.com/benzingastaff1/2009/8/31/negative-implications-eli-lillys-lly-efficient-says-leerink,BenzingaStaff1,,,,,,
2009-09-09T08:00:00.000+08:00,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors,LLY,https://www.benzinga.com/134753/zignals-stock-charts-7-divided-elites-from-thestockadvisors,Zignals,,,,,,
2009-09-24T08:00:00.000+08:00,Eli Lilly and Company (LLY) Wins Evista Patent Till 2014,LLY,https://www.benzinga.com/16597/health-care/eli-lilly-and-company-lly-wins-evista-patent-till-2014,BenzingaStaff1,,,,,,
2009-09-29T08:00:00.000+08:00,Eli Lilly (LLY) trading in a congestion zone,LLY,https://www.benzinga.com/18416/health-care/eli-lilly-lly-trading-in-a-congestion-zone,Craig Jones,,,,,,
2009-10-19T08:00:00.000+08:00,The Week’s Must-Haves and Have-nots According to Jim Cramer,LLY,https://www.benzinga.com/markets/analyst-research/26058/the-week%E2%80%99s-must-haves-and-have-nots,Benzinga Staff 5,,,,,,
2009-10-21T08:00:00.000+08:00,Eli Lilly Posts Higher Returns than Expected Behind Increased Sales Volumes (NYSE: LLY),LLY,https://www.benzinga.com/general/27608/eli-lilly-posts-higher-returns-than-expected-behind-increased-sales-volumes-nyse-lly,Benzinga Staff15,,,,,,
2009-10-21T08:00:00.000+08:00,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)",LLY,https://www.benzinga.com/markets/company-news/earnings/27322/today%E2%80%99s-earnings-preview-ba-ms-wfc-ebay-lly-mo,Benzinga Staff15,,,,,,
2009-11-02T08:00:00.000+08:00,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)",LLY,https://www.benzinga.com/pre-market-outlook/33826/stocks-running-early-hgsi-vrtx-dndn-jwn,Benzinga Staff,,,,,,
2009-11-13T08:00:00.000+08:00,Eli Lilly Calls Active (NYSE: LLY),LLY,https://www.benzinga.com/markets/options/41138/eli-lilly-calls-active-nyse-lly,Michael J. Zerinskas,,,,,,
2009-12-01T08:00:00.000+08:00,"Company News for December 01, 2009 - Corporate Summary",LLY,https://www.benzinga.com/48404/company-news-for-december-01-2009-corporate-summary,Zacks,,,,,,
2009-12-08T08:00:00.000+08:00,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)",LLY,https://www.benzinga.com/analyst-research/upgrades/55664/10-stocks-to-shine-in-2010-c-nyt-lvlt-kbh-lly-bsx-moh-dow,Benzinga Staff 5,,,,,,
2009-12-10T08:00:00.000+08:00,Eli Lilly (LLY) Is Facing Big Challenges,LLY,https://www.benzinga.com/media/cnbc/59647/eli-lilly-lly-is-facing-big-challenges,Craig Jones,,,,,,
2009-12-10T08:00:00.000+08:00,LLY Issues Disappointing Long-term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/59241/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,,,
2009-12-10T08:00:00.000+08:00,SEC On Trail Of Insider Trading Transactions,LLY,https://www.benzinga.com/markets/company-news/58782/sec-on-trail-of-insider-trading-transactions,Benzinga Staff 5,,,,,,
2009-12-10T08:00:00.000+08:00,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)",LLY,https://www.benzinga.com/pre-market-outlook/58628/benzinga%E2%80%99s-top-pre-market-losers-cien-lly-osip-prov-cytk-aol-siga,BenzingaStaff3,,,,,,
2009-12-10T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)",LLY,https://www.benzinga.com/markets/company-news/earnings/58494/benzinga%E2%80%99s-earnings-roundup-gil-lly-cost-unfi-rok,BenzingaStaff3,,,,,,
2009-12-10T08:00:00.000+08:00,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines",LLY,https://www.benzinga.com/markets/company-news/58489/lilly-lly-outlines-innovation-strategy-reviews-promising-pipeline-of-pote,BenzingaStaff1,,,,,,
2009-12-11T08:00:00.000+08:00,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY),LLY,https://www.benzinga.com/markets/company-news/60269/eli-lilly%E2%80%99s-eps-guidance-exceeds-estimates-lly,Benzinga Staff 5,,,,,,
2009-12-11T08:00:00.000+08:00,LLY Has Strong Product Pipeline,LLY,https://www.benzinga.com/analyst-research/analyst-color/60223/lly-has-strong-product-pipeline,Monica Gerson,,,,,,
2009-12-11T08:00:00.000+08:00,LLY Issues Disappointing Long Term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/60133/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,,,
2009-12-21T08:00:00.000+08:00,Play Biotech M&A With This ETF (XBI),LLY,https://www.benzinga.com/trading-ideas/long-ideas/69621/play-biotech-m-a-with-this-etf-xbi,ETF Professor,,,,,,
2009-12-21T08:00:00.000+08:00,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)",LLY,https://www.benzinga.com/markets/company-news/69068/top-gainers-in-nasdaq-chtt-bucy-incy-sblk-mail,Monica Gerson,,,,,,
2009-12-22T08:00:00.000+08:00,Eli Lilly (LLY) Lacks Near Term Upside Drivers,LLY,https://www.benzinga.com/analyst-ratings/price-target/70305/eli-lilly-lly-lacks-near-term-upside-drivers,Benzinga Staff 5,,,,,,
2010-01-05T08:00:00.000+08:00,Eli Lilly (LLY) To Outsource Drug Testing,LLY,https://www.benzinga.com/markets/company-news/76431/eli-lilly-lly-to-outsource-drug-testing,Benzinga Staff 5,,,,,,
2010-01-26T08:00:00.000+08:00,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)",LLY,https://www.benzinga.com/markets/company-news/99276/fda-approval-for-diabetes-drug-lifts-novo-shares-nvo-amln-lly,Benzinga Staff 5,,,,,,
2010-01-28T08:00:00.000+08:00,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain",LLY,https://www.benzinga.com/markets/company-news/103414/eli-lilly-co-lly-profits-are-up-but-concerns-remain,Daniel Hayden IV,,,,,,
2010-01-28T08:00:00.000+08:00,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute",LLY,https://www.benzinga.com/markets/company-news/103233/bristol-bmy-lilly-lly-up-sales-and-settle-dispute,Benzinga Staff 5,,,,,,
2010-01-28T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)",LLY,https://www.benzinga.com/markets/company-news/102602/benzinga%E2%80%99s-earnings-roundup-tyc-bdx-twc-bll-lly,BenzingaStaff3,,,,,,
2010-01-29T08:00:00.000+08:00,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC,LLY,https://www.benzinga.com/media/cnbc/104192/eli-lilly-lly-has-a-healthy-pipeline-ceo-tells-cnbc,Benzinga Staff 5,,,,,,
2010-02-01T08:00:00.000+08:00,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)",LLY,https://www.benzinga.com/trading-ideas/10/02/106399/five-stocks-to-buy-since-analysts-hate-them-lly-can-eep-lxk-pcx,Benzinga Staff 5,,,,,,
2010-02-03T08:00:00.000+08:00,Pharma Stocks Dive On Missed Expectations,LLY,https://www.benzinga.com/market-update/109642/pharma-stocks-dive-on-missed-expectations,Monica Gerson,,,,,,
2010-02-05T08:00:00.000+08:00,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)",LLY,https://www.benzinga.com/markets/company-news/115676/market-round-up-ubs-goog%C2%B8-aapl-mot%C2%B8-pg-pfe-mrk-lly-cvs-wag,Monica Gerson,,,,,,
2010-02-18T08:00:00.000+08:00,"Carl Icahn On CNBC (AMLN, GELG, LGM)",LLY,https://www.benzinga.com/media/cnbc/132752/carl-icahn-on-cnbc-amln-gelg-lgm,Bud Fox,,,,,,
2010-02-23T08:00:00.000+08:00,"Market Roundup (BAC, JPM, DELL, WAG, LLY)",LLY,https://www.benzinga.com/markets/company-news/138439/market-roundup-bac-jpm-dell-wag-lly,Monica Gerson,,,,,,
2010-02-25T08:00:00.000+08:00,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY),LLY,https://www.benzinga.com/markets/company-news/144430/eli-lilly-banks-on-its-restructured-development-process-to-offset-sales-,Benzinga Staff 5,,,,,,
2010-03-03T08:00:00.000+08:00,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY),LLY,https://www.benzinga.com/markets/company-news/154809/transition-tthi-secures-licensing-deal-with-eli-lilly-lly,Benzinga Staff 5,,,,,,
2010-03-08T08:00:00.000+08:00,AMLN Is Waiting For A Decision On Byetta,LLY,https://www.benzinga.com/media/cnbc/163501/amln-is-waiting-for-a-decision-on-byetta,Craig Jones,,,,,,
2010-03-15T08:00:00.000+08:00,"Benzinga’s News Roundup (PEP, ALKS, MRK)",LLY,https://www.benzinga.com/markets/company-news/173095/benzinga%E2%80%99s-news-roundup-pep-alks-mrk,BenzingaStaff3,,,,,,
2010-03-15T08:00:00.000+08:00,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)",LLY,https://www.benzinga.com/pre-market-outlook/173049/benzinga%E2%80%99s-top-pre-market-gainers-pvh-amln-chrd-isis-nvax,BenzingaStaff3,,,,,,
2010-03-17T08:00:00.000+08:00,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,LLY,https://www.benzinga.com/178858/this-healthcare-etf-xlv-is-seeing-above-average-call-buying,David Bettencourt,,,,,,
2010-03-21T08:00:00.000+08:00,How Will Obama-Care Play Into The Markets And ETFs?,LLY,https://www.benzinga.com/183562/how-will-obama-care-play-into-the-markets-and-etfs,David Bettencourt,,,,,,
2010-03-22T08:00:00.000+08:00,Investors Flock To Healthcare ETFs On Historic Reform,LLY,https://www.benzinga.com/185428/investors-flock-to-healthcare-etfs-on-historic-reform,David Bettencourt,,,,,,
2010-03-23T08:00:00.000+08:00,Before Jumping Into A Single Health Care Stock Consider This ETF,LLY,https://www.benzinga.com/188732/before-jumping-into-a-single-health-care-stock-consider-this-etf,David Bettencourt,,,,,,
2010-03-24T08:00:00.000+08:00,Investors Need To Pay More Attention To Dividend ETFs In 2010,LLY,https://www.benzinga.com/190222/investors-need-to-pay-more-attention-to-dividend-etfs-in-2010,David Bettencourt,,,,,,
2010-03-29T08:00:00.000+08:00,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/197656/there-are-still-some-bargains-in-the-market-barron%E2%80%99s-lly-pfe-gs-ms-c,Benzinga Staff 5,,,,,,
2010-04-01T08:00:00.000+08:00,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/204686/citigroup-rates-teva-pharmaceutical-industries-teva-a-buy-after,Daniel Hayden IV,,,,,,
2010-04-19T08:00:00.000+08:00,"Company News for April 19, 2010 - Corporate Summary",LLY,https://www.benzinga.com/230041/company-news-for-april-19-2010-corporate-summary,Zacks,,,,,,
2010-04-19T08:00:00.000+08:00,Eli Lilly Slashes Earnings Guidance (LLY),LLY,https://www.benzinga.com/markets/company-news/229891/eli-lilly-slashes-earnings-guidance-lly,Bud Fox,,,,,,
2010-04-19T08:00:00.000+08:00,Bulls Bet on Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/long-ideas/229651/bulls-bet-on-eli-lilly,Michael J. Zerinskas,,,,,,
2010-04-19T08:00:00.000+08:00,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results,LLY,https://www.benzinga.com/markets/company-news/229516/us-stock-futures-point-to-a-weak-opening-investors-eyeing-citigroup-resu,Monica Gerson,,,,,,
2010-04-19T08:00:00.000+08:00,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit,LLY,https://www.benzinga.com/markets/company-news/229455/eli-lilly-co-lly-reports-a-5-drop-in-first-quarter-profit,Benzinga Staff 5,,,,,,
2010-04-19T08:00:00.000+08:00,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/229454/stocks-to-watch-on-april-19-c-hal-lly-ibm-zion,Monica Gerson,,,,,,
2010-04-19T08:00:00.000+08:00,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb",LLY,https://www.benzinga.com/markets/company-news/229447/eli-lilly-and-co-lly-profit-falls-5-as-revenues-climb,Daniel Hayden IV,,,,,,
2010-04-21T08:00:00.000+08:00,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)",LLY,https://www.benzinga.com/markets/company-news/237003/afternoon-market-update-abbott-labs-nyse-abt-boeing-nyse-ba-tempur-pedic,Monica Gerson,,,,,,
2010-04-28T08:00:00.000+08:00,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)",LLY,https://www.benzinga.com/markets/company-news/249094/whistleblower-gets-rewarded-in-astrazeneca-case-azn-lly,Benzinga Staff 5,,,,,,
2010-05-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/257335/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,,,
2010-05-13T08:00:00.000+08:00,Companies Dodge $60 Billion in Taxes,LLY,https://www.benzinga.com/markets/company-news/10/05/280860/companies-dodge-60-billion-in-taxes,Michael J. Zerinskas,,,,,,
2010-05-27T08:00:00.000+08:00,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?",LLY,https://www.benzinga.com/10/05/304265/with-interest-rates-this-low-should-investors-look-to-equity-dividend-yields,Options House,,,,,,
2010-06-07T08:00:00.000+08:00,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",LLY,https://www.benzinga.com/markets/company-news/10/06/317702/top-5-large-cap-nyse-stocks-in-the-healthcare-sector-with-the-high,Monica Gerson,,,,,,
2010-06-10T08:00:00.000+08:00,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/326447/mannkind-corp-glosses-over-fda-meeting-hapoalim-balks-mnk,Benzinga Staff,,,,,,
2010-06-10T08:00:00.000+08:00,News Summary,LLY,https://www.benzinga.com/markets/company-news/10/06/326430/news-summary,Monica Gerson,,,,,,
2010-06-28T08:00:00.000+08:00,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/351319/hapoalim-securities-expects-eli-lilly-to-acquire-amylin-p,Monica Gerson,,,,,,
2010-06-30T08:00:00.000+08:00,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/06/355821/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,,,
2010-07-02T08:00:00.000+08:00,Calls Purchased on Eli Lilly & Co. (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/07/360666/calls-purchased-on-eli-lilly-co-lly,Michael J. Zerinskas,,,,,,
2010-07-06T08:00:00.000+08:00,Lechleiter Says LLY Has The Most Exciting Pipeline,LLY,https://www.benzinga.com/markets/company-news/10/07/363530/lechleiter-says-lly-has-the-most-exciting-pipeline,Monica Gerson,,,,,,
2010-07-06T08:00:00.000+08:00,"News Summary (LLY, TM)",LLY,https://www.benzinga.com/markets/company-news/10/07/362862/news-summary-lly-tm,Monica Gerson,,,,,,
2010-07-22T08:00:00.000+08:00,Markets Surge on Strong Corporate Earnings (SPY),LLY,https://www.benzinga.com/global/10/07/390044/markets-surge-on-strong-corporate-earnings-spy,Ronald Weisenstein,,,,,,
2010-07-22T08:00:00.000+08:00,"Eli Lilly Beats Estimates, Raises Forecast (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389573/eli-lilly-beats-estimates-raises-forecast-lly,Daniel Hayden IV,,,,,,
2010-07-22T08:00:00.000+08:00,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389534/eli-lilly-reports-strong-sales-beats-on-profit-lly,Ronald Weisenstein,,,,,,
2010-07-22T08:00:00.000+08:00,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance",LLY,https://www.benzinga.com/markets/company-news/10/07/389479/eli-lilly-posts-better-than-expected-q2-results-raises-2010-eps-gu,Monica Gerson,,,,,,
2010-07-26T08:00:00.000+08:00,Corporate Catalysts For The Week Starting July 26,LLY,https://www.benzinga.com/markets/company-news/10/07/393588/corporate-catalysts-for-the-week-starting-july-26,Monica Gerson,,,,,,
2010-07-30T08:00:00.000+08:00,July Impressive -- S&Ps Up 6.9% 07-30-2010,LLY,https://www.benzinga.com/10/07/404892/july-impressive-s-ps-up-6-9-07-30-2010,optionsXpress,,,,,,
2010-08-02T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/405780/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-fr,Monica Gerson,,,,,,
2010-08-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August 2010,LLY,https://www.benzinga.com/10/08/407524/stocks-going-ex-dividend-the-second-week-of-august-2010,Fred Fuld,,,,,,
2010-08-09T08:00:00.000+08:00,Revenues Dip at Alkermes - Analyst Blog,LLY,https://www.benzinga.com/10/08/419705/revenues-dip-at-alkermes-analyst-blog,Zacks,,,,,,
2010-08-09T08:00:00.000+08:00,Finally There Is A Cure For Tobacco Addiction (CIGX),LLY,https://www.benzinga.com/markets/company-news/10/08/418540/finally-there-is-a-cure-for-tobacco-addiction-cigx,Monica Gerson,,,,,,
2010-08-11T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/422556/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Lisa Levin,,,,,,
2010-08-12T08:00:00.000+08:00,Amgen's Vectibix Disappoints - Analyst Blog,LLY,https://www.benzinga.com/10/08/426077/amgens-vectibix-disappoints-analyst-blog,Zacks,,,,,,
2010-08-13T08:00:00.000+08:00,All Is Not Well In The Pharmaceutical Industry,LLY,https://www.benzinga.com/markets/company-news/10/08/427658/all-is-not-well-in-the-pharmaceutical-industry,Monica Gerson,,,,,,
2010-08-13T08:00:00.000+08:00,Eli Lilly Cuts Revenue Guidance - Analyst Blog,LLY,https://www.benzinga.com/10/08/427545/eli-lilly-cuts-revenue-guidance-analyst-blog,Zacks,,,,,,
2010-08-13T08:00:00.000+08:00,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/427398/eli-lilly-loses-strattera-patent-case-hapoalim-securities,Scott Rubin,,,,,,
2010-08-13T08:00:00.000+08:00,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",LLY,https://www.benzinga.com/markets/company-news/10/08/427275/u-s-probing-pharmaceutical-corruption-gsk-pfe-bmy-lly,Ronald Weisenstein,,,,,,
2010-08-17T08:00:00.000+08:00,Eli Lilly Halts Development Of Alzheimer Drug (LLY),LLY,https://www.benzinga.com/markets/company-news/10/08/431859/eli-lilly-halts-development-of-alzheimer-drug-lly,Scott Rubin,,,,,,
2010-08-17T08:00:00.000+08:00,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/430766/top-4-large-cap-stocks-in-the-healthcare-sector-with-the-highe,Lisa Levin,,,,,,
2010-08-18T08:00:00.000+08:00,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog,LLY,https://www.benzinga.com/10/08/434309/fda-panel-to-review-eli-lillys-cymbalta-analyst-blog,Zacks,,,,,,
2010-08-20T08:00:00.000+08:00,Jefferies Reiterates Hold Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/437629/jefferies-reiterates-hold-rating-on-eli-lilly-lly,Michael J. Zerinskas,,,,,,
2010-08-26T08:00:00.000+08:00,Repros Schedules Meeting with FDA - Analyst Blog,LLY,https://www.benzinga.com/10/08/445043/repros-schedules-meeting-with-fda-analyst-blog,Zacks,,,,,,
2010-08-26T08:00:00.000+08:00,VVUS) Unconfirmed rumor that (LLY) will buy the company for $9.00 Cash,LLY,https://www.benzinga.com/markets/company-news/10/08/444239/vvus-unconfirmed-rumor-that-lly-will-buy-the-company-for-9-00-cash,Franklin Price,,,,,,
2010-08-30T08:00:00.000+08:00,Incyte Evenly Poised - Analyst Blog,LLY,https://www.benzinga.com/10/08/448427/incyte-evenly-poised-analyst-blog,Zacks,,,,,,
2010-08-30T08:00:00.000+08:00,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/448162/goldman-sachs-introduces-and-adjusts-estimates-for-major-,Monica Gerson,,,,,,
2010-09-01T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY),LLY,https://www.benzinga.com/company-news/10/09/453140/u-s-court-of-appeals-upholds-validity-of-lillys-evista-patents-lly,Benzinga Staff,,,,,,
2010-09-03T08:00:00.000+08:00,PDLI Gives Third-Quarter Outlook - Analyst Blog,LLY,https://www.benzinga.com/10/09/456734/pdli-gives-third-quarter-outlook-analyst-blog,Zacks,,,,,,
2010-09-10T08:00:00.000+08:00,More Unconfirmed Chatter On Vivus Takeover (VVUS),LLY,https://www.benzinga.com/news/m-a/10/09/467374/more-unconfirmed-chatter-on-vivus-takeover-vvus,Roger Nachman,,,,,,
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476393/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,,,
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476391/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,,,
2010-09-17T08:00:00.000+08:00,Thumbs Up for ALKS Drug - Analyst Blog,LLY,https://www.benzinga.com/10/09/480240/thumbs-up-for-alks-drug-analyst-blog,Zacks,,,,,,
2010-09-20T08:00:00.000+08:00,Pipeline Setback for TTHI - Analyst Blog,LLY,https://www.benzinga.com/10/09/483429/pipeline-setback-for-tthi-analyst-blog,Zacks,,,,,,
2010-09-21T08:00:00.000+08:00,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY),LLY,https://www.benzinga.com/news/10/09/484545/jeffrey-a-winton-named-vp-at-eli-lilly-and-company-lly,Benzinga Staff,,,,,,
2010-09-21T08:00:00.000+08:00,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/09/484253/j-p-morgan-has-underweight-rating-on-eli-lilly-lly,Roger Nachman,,,,,,
2010-09-22T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00",LLY,https://www.benzinga.com/news/10/09/487087/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-will-be-taken-out-by-eli-li,Franklin Price,,,,,,
2010-09-23T08:00:00.000+08:00,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY),LLY,https://www.benzinga.com/life/politics/10/09/488801/lilly-ceo-says-regional-innovation-important-to-the-nations-economy-lly,Benzinga Staff,,,,,,
2010-09-23T08:00:00.000+08:00,Yield Versus Yield,LLY,https://www.benzinga.com/10/09/488911/yield-versus-yield,Roger Nusbaum,,,,,,
2010-09-28T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)",LLY,https://www.benzinga.com/media/cnbc/10/09/495771/mad-money-lightning-round-cramer-considers-apple-as-one-of-the-best-stocks-e,Monica Gerson,,,,,,
2010-09-29T08:00:00.000+08:00,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share,LLY,https://www.benzinga.com/news/10/09/498994/unconfirmed-rumor-that-eli-lilly-co-lly-is-readying-bid-for-mannkind-corp-mnkd-at-,Franklin Price,,,,,,
2010-09-30T08:00:00.000+08:00,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)",LLY,https://www.benzinga.com/market-update/10/09/500887/benzingas-top-pre-market-nasdaq-gainers-snts-llnw-apwr-mnkd,Lisa Levin,,,,,,
2010-10-04T08:00:00.000+08:00,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog,LLY,https://www.benzinga.com/10/10/507625/j-j-galapagos-in-anti-cancer-deal-analyst-blog,Zacks,,,,,,
2010-10-04T08:00:00.000+08:00,Bristol Myers at Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/10/507623/bristol-myers-at-neutral-analyst-blog,Zacks,,,,,,
2010-10-04T08:00:00.000+08:00,Male Menopause: Another Treatment for Pharmaceutical Companies,LLY,https://www.benzinga.com/10/10/507557/male-menopause-another-treatment-for-pharmaceutical-companies,Fred Fuld,,,,,,
2010-10-06T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s",LLY,https://www.benzinga.com/news/10/10/511391/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-is-in-talks-with-eli-lilly-,Franklin Price,,,,,,
2010-10-06T08:00:00.000+08:00,Eli Lilly's Core Product Trends For The Week Ending 9/24,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/510677/eli-lillys-core-product-trends-for-the-week-ending-924,Joe Young,,,,,,
2010-10-07T08:00:00.000+08:00,5 Most Undervalued Stocks in the S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/514189/5-most-undervalued-stocks-in-the-s-p-500,Benzinga Staff,,,,,,
2010-10-11T08:00:00.000+08:00,Eli Lilly Drug Fails Phase 3 Trial (LLY),LLY,https://www.benzinga.com/news/10/10/517595/eli-lilly-drug-fails-phase-3-trial-lly,Roger Nachman,,,,,,
2010-10-12T08:00:00.000+08:00,Eli Lilly Product Trends: Increases Across The Board,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/519146/eli-lilly-product-trends-increases-across-the-board,Joe Young,,,,,,
2010-10-12T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/518907/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-di,Lisa Levin,,,,,,
2010-10-18T08:00:00.000+08:00,Lilly Declares Fourth-Quarter 2010 Dividend of $.49,LLY,https://www.benzinga.com/news/dividends/10/10/530313/lilly-declares-fourth-quarter-2010-dividend-of-49,Benzinga Staff,,,,,,
2010-10-19T08:00:00.000+08:00,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk",LLY,https://www.benzinga.com/analyst-ratings/10/10/531902/in-core-product-trends-report-citigroup-rates-eli-lilly-high-risk,BenzingaStaffL,,,,,,
2010-10-20T08:00:00.000+08:00,Viagra Treatment for Muscular Dystrophy,LLY,https://www.benzinga.com/10/10/535843/viagra-treatment-for-muscular-dystrophy,Fred Fuld,,,,,,
2010-10-20T08:00:00.000+08:00,"\"\"\"Change Of Heart\"\" By FDA For LLY\"",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/534669/change-of-heart-by-fda-for-lly,Joe Young,,,,,,
2010-10-20T08:00:00.000+08:00,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)",LLY,https://www.benzinga.com/market-update/10/10/534484/benzingas-top-downgrades-kof-lly-itw-amln,Lisa Levin,,,,,,
2010-10-20T08:00:00.000+08:00,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN),LLY,https://www.benzinga.com/pre-market-outlook/10/10/534462/amylin-pharmaceuticals-crushed-in-pre-market-amln,Roger Nachman,,,,,,
2010-10-20T08:00:00.000+08:00,Citigroup Downgrades LLY To Hold,LLY,https://www.benzinga.com/market-update/10/10/534441/citigroup-downgrades-lly-to-hold,Lisa Levin,,,,,,
2010-10-21T08:00:00.000+08:00,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/541397/hapoalim-securities-reiterates-sell-rating-on-eli-lilly-l,Michael J. Zerinskas,,,,,,
2010-10-21T08:00:00.000+08:00,Lilly Beats by a Penny; Ups View - Analyst Blog,LLY,https://www.benzinga.com/10/10/540787/lilly-beats-by-a-penny-ups-view-analyst-blog,Zacks,,,,,,
2010-10-21T08:00:00.000+08:00,"Stock Market News for October 21, 2010 - Market News",LLY,https://www.benzinga.com/10/10/540018/stock-market-news-for-october-21-2010-market-news,Zacks,,,,,,
2010-10-21T08:00:00.000+08:00,"Company News for October 21, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/10/540015/company-news-for-october-21-2010-corporate-summary,Zacks,,,,,,
2010-10-21T08:00:00.000+08:00,"Trading Plan for October 21, 2010",LLY,https://www.benzinga.com/10/10/539085/trading-plan-for-october-21-2010,Ryan Mallory,,,,,,
2010-10-21T08:00:00.000+08:00,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)",LLY,https://www.benzinga.com/market-update/10/10/538421/earnings-scheduled-for-october-21-mcd-cat-t-lly-cs-ual-bax-nvs-unp-ups-bb,Monica Gerson,,,,,,
2010-11-08T08:00:00.000+08:00,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/11/588610/eli-lilly-buying-alzheimers-drug-maker-is-it-a-buy-lly,Roger Nachman,,,,,,
2010-11-08T08:00:00.000+08:00,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M,LLY,https://www.benzinga.com/news/10/11/588344/lilly-to-acquire-avid-radiopharmaceuticals-for-up-to-550m,Benzinga Staff,,,,,,
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,LLY,https://www.benzinga.com/10/11/596175/pharma-biotech-industry-outlook-nov-2010-zacks-analyst-interviews,Zacks,,,,,,
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596174/pharma-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,,,
2010-11-09T08:00:00.000+08:00,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596170/pharma-and-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,,,
2010-11-09T08:00:00.000+08:00,LLY's Avid Interest in Alzheimer's - Analyst Blog,LLY,https://www.benzinga.com/10/11/594924/llys-avid-interest-in-alzheimers-analyst-blog,Zacks,,,,,,
2010-11-11T08:00:00.000+08:00,J.P. Morgan Reiterates Incyte Corporation Rating,LLY,https://www.benzinga.com/analyst-ratings/10/11/601270/j-p-morgan-reiterates-incyte-corporation-rating,BenzingaStaffL,,,,,,
2010-11-12T08:00:00.000+08:00,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases",LLY,https://www.benzinga.com/10/11/605894/zacks-analyst-blog-highlights-lions-gate-entertainment-amylin-pharmaceuticals-amylin-ph,Zacks,,,,,,
2010-11-12T08:00:00.000+08:00,Eli Lilly's Dividend Security Threatened,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/605424/eli-lillys-dividend-security-threatened,Joe Young,,,,,,
2010-11-15T08:00:00.000+08:00,Hospira Launches Gemcitabine HCL,LLY,https://www.benzinga.com/news/10/11/611457/hospira-launches-gemcitabine-hcl,Benzinga Staff,,,,,,
2010-11-16T08:00:00.000+08:00,Citi Gives Valuation Update On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/614548/citi-gives-valuation-update-on-eli-lilly,Benzinga Staff,,,,,,
2010-11-19T08:00:00.000+08:00,"Zings Of The Day (GOOG, LLY)",LLY,https://www.benzinga.com/news/10/11/628877/zings-of-the-day-goog-lly,Roger Nachman,,,,,,
2010-11-22T08:00:00.000+08:00,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta,LLY,https://www.benzinga.com/news/10/11/631930/impax-laboratories-receives-tentative-fda-approval-for-generic-cymbalta,Benzinga Staff,,,,,,
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641454/amylin-stays-neutral-analyst-blog,Zacks,,,,,,
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640698/company-news-for-november-24-2010-corporate-summary,Zacks,,,,,,
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640550/fda-approves-axiron-analyst-blog,Zacks,,,,,,
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641590/amylin-stays-neutral-analyst-blog,webmaster,,,,,,
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640738/company-news-for-november-24-2010-corporate-summary,webmaster,,,,,,
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640610/fda-approves-axiron-analyst-blog,webmaster,,,,,,
2010-11-29T08:00:00.000+08:00,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug,LLY,https://www.benzinga.com/news/10/11/649175/acrux-and-eli-lilly-receive-fda-approval-for-testosterone-drug,Benzinga Staff,,,,,,
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667562/neutral-on-incyte-analyst-blog,Zacks,,,,,,
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667598/neutral-on-incyte-analyst-blog,webmaster,,,,,,
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667408/cbsts-fast-injection-cubicin-okd-analyst-blog,Zacks,,,,,,
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667491/cbsts-fast-injection-cubicin-okd-analyst-blog,webmaster,,,,,,
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666201/merck-strikes-deal-with-smartcells-analyst-blog,Zacks,,,,,,
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666755/merck-strikes-deal-with-smartcells-analyst-blog,webmaster,,,,,,
2010-12-09T08:00:00.000+08:00,'Mad Money Lightning Round': Go for BlackRock,LLY,https://www.benzinga.com/10/12/686549/mad-money-lightning-round-go-for-blackrock,webmaster,,,,,,
2010-12-09T08:00:00.000+08:00,Best Stocks For Creating A Passive Income Stream,LLY,https://www.benzinga.com/10/12/686102/best-stocks-for-creating-a-passive-income-stream,Mark Riddix,,,,,,
2010-12-10T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)",LLY,https://www.benzinga.com/media/cnbc/10/12/686930/mad-money-lightning-round-cramer-advises-investors-to-buy-blackrock-lly-deck,Lisa Levin,,,,,,
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694384/loss-at-biod-narrower-than-expected-analyst-blog,Zacks,,,,,,
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694430/loss-at-biod-narrower-than-expected-analyst-blog,webmaster,,,,,,
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700168/lilly-study-stopped-on-safety-concerns-analyst-blog,Zacks,,,,,,
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700205/lilly-study-stopped-on-safety-concerns-analyst-blog,webmaster,,,,,,
2010-12-17T08:00:00.000+08:00,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)",LLY,https://www.benzinga.com/movers/10/12/712175/fridays-putcall-ratio-leaders-psun-lo-coco-lly-mchp,Michael J. Zerinskas,,,,,,
2010-12-20T08:00:00.000+08:00,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/10/12/718287/safeguard-scientifics-to-realize-at-least-36m-in-initial-sale-proceeds-from-eli-li,Benzinga Staff,,,,,,
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720827/rolling-bla-for-amlns-metreleptin-analyst-blog,Zacks,,,,,,
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720800/rolling-bla-for-amlns-metreleptin-analyst-blog,webmaster,,,,,,
2010-12-22T08:00:00.000+08:00,Amylin and Lilly Seek Expanded Use of BYETTA,LLY,https://www.benzinga.com/news/10/12/727156/amylin-and-lilly-seek-expanded-use-of-byetta,Benzinga Staff,,,,,,
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725713/incys-inc424-meets-goal-analyst-blog,Zacks,,,,,,
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725777/incys-inc424-meets-goal-analyst-blog,webmaster,,,,,,
2010-12-22T08:00:00.000+08:00,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share,LLY,https://www.benzinga.com/news/m-a/10/12/725156/unconfirmed-rumors-circulate-that-neurocrine-biosciences-inc-nbix-will-be-take,Franklin Price,,,,,,
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/724943/eli-lilly-acquires-avid-analyst-blog,Zacks,,,,,,
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/725063/eli-lilly-acquires-avid-analyst-blog,webmaster,,,,,,
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728913/label-expansion-sought-for-byetta-analyst-blog,Zacks,,,,,,
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728947/label-expansion-sought-for-byetta-analyst-blog,webmaster,,,,,,
2011-01-03T08:00:00.000+08:00,'Mad Money Lightning Round': Baidu's Terrific,LLY,https://www.benzinga.com/11/01/748400/mad-money-lightning-round-baidus-terrific,webmaster,,,,,,
2011-01-03T08:00:00.000+08:00,Xoma: Key Diabetes Drug Study Preview,LLY,https://www.benzinga.com/11/01/748401/xoma-key-diabetes-drug-study-preview,webmaster,,,,,,
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751433/bristol-myers-outlook-mixed-analyst-blog,Zacks,,,,,,
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751451/bristol-myers-outlook-mixed-analyst-blog,webmaster,,,,,,
2011-01-04T08:00:00.000+08:00,Citi Comments On Eli Lilly Product Trends,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/749739/citi-comments-on-eli-lilly-product-trends,Benzinga Staff,,,,,,
2011-01-04T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)",LLY,https://www.benzinga.com/media/cnbc/11/01/748853/mad-money-lightning-round-cramer-advises-investors-to-buy-baidu-axl-f-gm-lly,Lisa Levin,,,,,,
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759651/label-expansion-for-roches-actemra-analyst-blog,Zacks,,,,,,
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759680/label-expansion-for-roches-actemra-analyst-blog,webmaster,,,,,,
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/761923/data-on-sanofi-cancer-candidate-analyst-blog,Zacks,,,,,,
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/762034/data-on-sanofi-cancer-candidate-analyst-blog,webmaster,,,,,,
2011-01-12T08:00:00.000+08:00,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application,LLY,https://www.benzinga.com/news/11/01/774888/statement-from-lilly-on-fda-advisory-committee-recommendation-regarding-liprotamas,Benzinga Staff,,,,,,
2011-01-12T08:00:00.000+08:00,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/01/773340/benzingas-top-upgrades-lly-cpno-vz-sle,Lisa Levin,,,,,,
2011-01-12T08:00:00.000+08:00,Hapoalim Upgrades Eli Lilly To Hold (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/773123/hapoalim-upgrades-eli-lilly-to-hold-lly,Jonathan Chen,,,,,,
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777587/fda-panel-rejects-llys-candidate-analyst-blog,Zacks,,,,,,
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777678/fda-panel-rejects-llys-candidate-analyst-blog,webmaster,,,,,,
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781769/mercks-blood-thinner-in-trouble-analyst-blog,Zacks,,,,,,
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781796/mercks-blood-thinner-in-trouble-analyst-blog,webmaster,,,,,,
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784435/community-to-put-directors-in-tenet-analyst-blog,Zacks,,,,,,
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784451/community-to-put-directors-in-tenet-analyst-blog,webmaster,,,,,,
2011-01-19T08:00:00.000+08:00,FDA To Review Alzheimer's Brain Scan (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/01/789789/fda-to-review-alzheimers-brain-scan-lly,Gary Cassady,,,,,,
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794495/bleeding-risk-with-mrks-candidate-analyst-blog,Zacks,,,,,,
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794579/bleeding-risk-with-mrks-candidate-analyst-blog,webmaster,,,,,,
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794199/mannkind-in-jeopardy-analyst-blog,Zacks,,,,,,
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794337/mannkind-in-jeopardy-analyst-blog,webmaster,,,,,,
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799127/fda-panel-reviews-lilly-drug-analyst-blog,Zacks,,,,,,
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799214/fda-panel-reviews-lilly-drug-analyst-blog,webmaster,,,,,,
2011-01-24T08:00:00.000+08:00,Citi Increases EPS Estimate on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/Analyst%20Color/11/01/801170/citi-increases-eps-estimate-on-eli-lilly-lly,BenzingaStaffJ,,,,,,
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805010/earnings-preview-eli-lilly-analyst-blog,Zacks,,,,,,
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805014/earnings-preview-eli-lilly-analyst-blog,webmaster,,,,,,
2011-01-26T08:00:00.000+08:00,Teva and APP Announce Launch of Generic Gemzar,LLY,https://www.benzinga.com/news/11/01/807844/teva-and-app-announce-launch-of-generic-gemzar,Benzinga Staff,,,,,,
2011-01-27T08:00:00.000+08:00,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/812715/jefferies-comments-on-eli-lillys-fy-2010-earnings-lly,BenzingaStaffJ,,,,,,
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812304/eli-lilly-tops-ests-guides-in-line-analyst-blog,Zacks,,,,,,
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812300/cost-control-helps-amylin-cut-loss-analyst-blog,Zacks,,,,,,
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812311/cost-control-helps-amylin-cut-loss-analyst-blog,webmaster,,,,,,
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812315/eli-lilly-tops-ests-guides-in-line-analyst-blog,webmaster,,,,,,
2011-01-27T08:00:00.000+08:00,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance",LLY,https://www.benzinga.com/news/11/01/811635/lilly-reports-fourth-quarter-and-full-year-2010-results-provides-2011-financial-gu,Benzinga Staff,,,,,,
2011-01-27T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/811630/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2011-01-27T08:00:00.000+08:00,Eli Lilly Beats EPS Estimates By 1 Cent (LLY),LLY,https://www.benzinga.com/news/11/01/811344/eli-lilly-beats-eps-estimates-by-1-cent-lly,Daniel Hayden IV,,,,,,
2011-01-27T08:00:00.000+08:00,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",LLY,https://www.benzinga.com/news/earnings/11/01/810773/earnings-scheduled-for-january-27-cat-msft-pg-t-bmy-lly-amzn-azn-twc-sndk,Lisa Levin,,,,,,
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815895/company-news-for-january-28-2011-corporate-summary,Zacks,,,,,,
2011-01-28T08:00:00.000+08:00,Hapoalim Reiterates Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/815843/hapoalim-reiterates-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,,,
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815978/company-news-for-january-28-2011-corporate-summary,webmaster,,,,,,
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820694/earnings-preview-alkermes-analyst-blog,Zacks,,,,,,
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820709/earnings-preview-alkermes-analyst-blog,webmaster,,,,,,
2011-02-02T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of February,LLY,https://www.benzinga.com/11/02/829884/stocks-going-ex-dividend-the-second-week-of-february,Fred Fuld,,,,,,
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828839/hospira-misses-2011-view-weak-analyst-blog,Zacks,,,,,,
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828927/hospira-misses-2011-view-weak-analyst-blog,webmaster,,,,,,
2011-02-02T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab",LLY,https://www.benzinga.com/news/11/02/828042/lilly-bristol-myers-squibb-stop-enrollment-in-one-of-two-phase-iii-lung-cancer-tri,Benzinga Staff,,,,,,
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831315/roche-misses-on-tamiflu-decline-analyst-blog,Zacks,,,,,,
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831448/roche-misses-on-tamiflu-decline-analyst-blog,webmaster,,,,,,
2011-02-04T08:00:00.000+08:00,Jefferies Updates Estimates on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/835131/jefferies-updates-estimates-on-eli-lilly-lly,BenzingaStaffJ,,,,,,
2011-02-11T08:00:00.000+08:00,Two ETFs for the Recovery in Big Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/02/855024/two-etfs-for-the-recovery-in-big-pharma,Charles Lewis Sizemore CFA,,,,,,
2011-02-11T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/853373/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2011-02-11T08:00:00.000+08:00,Eli Lilly Announces Senior Leadership Changes,LLY,https://www.benzinga.com/news/11/02/853269/eli-lilly-announces-senior-leadership-changes,Benzinga Staff,,,,,,
2011-03-03T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study",LLY,https://www.benzinga.com/news/11/03/900231/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-top-line-results-from-durat,Benzinga Staff,,,,,,
2011-03-08T08:00:00.000+08:00,Citi Comments On LLY 10-K,LLY,https://www.benzinga.com/analyst-ratings/11/03/910658/citi-comments-on-lly-10-k,BenzingaStaffL,,,,,,
2011-03-09T08:00:00.000+08:00,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/915528/stocks-to-watch-when-human-genome-sciences-reopens-after-benly,Jonathan Chen,,,,,,
2011-03-10T08:00:00.000+08:00,Health Insurers Triple S&P 500 Returns,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/917642/health-insurers-triple-s-p-500-returns,Minyanville,,,,,,
2011-03-14T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/03/922785/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2011-03-14T08:00:00.000+08:00,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health,LLY,https://www.benzinga.com/news/11/03/922669/lilly-makes-an-irrevocable-offer-to-acquire-janssen-animal-health,Benzinga Staff,,,,,,
2011-03-15T08:00:00.000+08:00,Citi Maintains Hold Rating On LLY,LLY,https://www.benzinga.com/analyst-ratings/11/03/926646/citi-maintains-hold-rating-on-lly,BenzingaStaffL,,,,,,
2011-03-17T08:00:00.000+08:00,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group,LLY,https://www.benzinga.com/news/11/03/934210/lilly-announces-important-action-regarding-recall-of-alcohol-prep-pads-made-by-tri,Benzinga Staff,,,,,,
2011-03-18T08:00:00.000+08:00,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid,LLY,https://www.benzinga.com/news/11/03/935436/lilly-and-avid-receive-complete-response-letter-from-fda-for-amyvid,Benzinga Staff,,,,,,
2011-03-18T08:00:00.000+08:00,Jefferies Comments On Eli Lilly Strattera Appeal,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/03/935425/jefferies-comments-on-eli-lilly-strattera-appeal,Benzinga Staff,,,,,,
2011-03-29T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)",LLY,https://www.benzinga.com/media/cnbc/11/03/958281/mad-money-lightning-round-cramer-likes-gentex-micron-technology-aes-chs-asna,Lisa Levin,,,,,,
2011-04-01T08:00:00.000+08:00,Axiron Topical Solution CIII Now Available in Pharmacies,LLY,https://www.benzinga.com/news/11/04/972011/axiron-topical-solution-ciii-now-available-in-pharmacies,Benzinga Staff,,,,,,
2011-04-04T08:00:00.000+08:00,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer,LLY,https://www.benzinga.com/news/11/04/976203/two-novel-lilly-molecules-target-genetic-mutations-that-can-lead-to-cancer,Benzinga Staff,,,,,,
2011-04-07T08:00:00.000+08:00,Market Holds Its Ground 04-07-2011,LLY,https://www.benzinga.com/11/04/988099/market-holds-its-ground-04-07-2011,optionsXpress,,,,,,
2011-04-14T08:00:00.000+08:00,Jefferies: LLY Q1 Earnings Could Be Under Pressure,LLY,https://www.benzinga.com/analyst-ratings/11/04/1003652/jefferies-lly-q1-earnings-could-be-under-pressure,BenzingaStaffL,,,,,,
2011-04-15T08:00:00.000+08:00,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/04/1007106/top-percentage-gainers-and-losers-as-of-10am-41511-ago-opxa-m,Benjamin Lee,,,,,,
2011-04-15T08:00:00.000+08:00,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)",LLY,https://www.benzinga.com/news/11/04/1006905/bydureon-recommended-for-approval-in-europe-lly-alks,Franklin Price,,,,,,
2011-04-15T08:00:00.000+08:00,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe",LLY,https://www.benzinga.com/news/11/04/1006514/eli-lilly-amylin-pharmaceuticals-and-alkermes-announce-bydureon-recommended-for-a,Benzinga Staff,,,,,,
2011-04-16T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…",LLY,https://www.benzinga.com/11/04/1019162/ceoworld-daily-business-roundup-jnj-chk-amd-t-axp-aapl-intc-jpm-goog-lly-csco%E2%80%A6,CEO World,,,,,,
2011-04-17T08:00:00.000+08:00,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)",LLY,https://www.benzinga.com/news/earnings/11/04/1009581/earnings-scheduled-for-april-18-amtd-txn-key-c-lly-gci-hal-mtb-bro-amln-,Lisa Levin,,,,,,
2011-04-17T08:00:00.000+08:00,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)",LLY,https://www.benzinga.com/news/11/04/1009576/stocks-to-watch-for-april-18-c-txn-jnj-hal-lly,Lisa Levin,,,,,,
2011-04-17T08:00:00.000+08:00,Monday's Economic and Earnings Schedule,LLY,https://www.benzinga.com/news/11/04/1009538/mondays-economic-and-earnings-schedule,Nick Smith,,,,,,
2011-04-18T08:00:00.000+08:00,Jefferies Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1010875/jefferies-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,,,
2011-04-18T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/markets/futures/11/04/1010216/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2011-04-18T08:00:00.000+08:00,Eli Lilly Reports Upbeat Q1 Earnings,LLY,https://www.benzinga.com/news/11/04/1010013/eli-lilly-reports-upbeat-q1-earnings,Lisa Levin,,,,,,
2011-04-18T08:00:00.000+08:00,US Stock Futures Down As Investors Await Citigroup Earnings,LLY,https://www.benzinga.com/markets/futures/11/04/1009937/us-stock-futures-down-as-investors-await-citigroup-earnings,Lisa Levin,,,,,,
2011-04-19T08:00:00.000+08:00,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/04/1015547/hapoalim-upgrades-lly-from-hold-to-buy-raises-pt-to-39,BenzingaStaffL,,,,,,
2011-04-19T08:00:00.000+08:00,Deutsche Bank Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1014883/deutsche-bank-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,,,
2011-04-19T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…",LLY,https://www.benzinga.com/11/04/1019160/ceoworld-daily-business-roundup-bp-gs-gm-rimm-yhoo-txn-ibm-yhoo-c-intc-wmt-aapl%E2%80%A6,CEO World,,,,,,
2011-04-20T08:00:00.000+08:00,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized",LLY,https://www.benzinga.com/life/politics/11/04/1019527/five-stocks-that-may-end-up-umm-higher-if-marijuana-is-legalized,Gary Cassady,,,,,,
2011-04-26T08:00:00.000+08:00,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease,LLY,https://www.benzinga.com/news/11/04/1031961/lilly-and-medtronic-announce-drug-device-collaboration-for-parkinsons-disease,Benzinga Staff,,,,,,
2011-04-27T08:00:00.000+08:00,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1038056/u-s-district-court-order-maintains-patent-exclusivity-for-lillys-cymbalta-l,Benzinga Staff,,,,,,
2011-04-27T08:00:00.000+08:00,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)",LLY,https://www.benzinga.com/markets/11/04/1037789/biotech-pharma-stocks-snapshot-technology-and-medical-devices-on-the-rise-with,Investor Ideas,,,,,,
2011-04-29T08:00:00.000+08:00,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1044930/lilly-in-advanced-talks-to-resolve-sec-foreign-bribery-probe-dj-lly,Benzinga Staff,,,,,,
2011-04-29T08:00:00.000+08:00,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY),LLY,https://www.benzinga.com/news/fda/11/04/1044686/new-treatment-for-chronic-low-back-pain-approved-by-health-canada-lly,Theo Kratz,,,,,,
2011-04-30T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/11/04/1046145/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,,,
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY),LLY,https://www.benzinga.com/news/fda/11/05/1049748/update-fda-approves-tradjenta%E2%84%A2-tablets-for-the-treatment-of-type-2-diabetes-l,Theo Kratz,,,,,,
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly,LLY,https://www.benzinga.com/news/fda/11/05/1049361/update-fda-approves-new-treatment-for-type-2-diabetes-marketed-by-eli-lilly,Benzinga Staff,,,,,,
2011-05-02T08:00:00.000+08:00,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)",LLY,https://www.benzinga.com/news/fda/11/05/1049275/lilly-boehringer-win-fda-approval-for-diabetes-drug-bloomberg-lly,Benzinga Staff,,,,,,
2011-05-03T08:00:00.000+08:00,"Defense, Defense 05-03-2011",LLY,https://www.benzinga.com/11/05/1053661/defense-defense-05-03-2011,optionsXpress,,,,,,
2011-05-10T08:00:00.000+08:00,Using the Euro as a Barometer 05-10-2011,LLY,https://www.benzinga.com/11/05/1072884/using-the-euro-as-a-barometer-05-10-2011,optionsXpress,,,,,,
2011-05-12T08:00:00.000+08:00,Going Large: First Trust Introduces Mega-Cap ETF,LLY,https://www.benzinga.com/etfs/broad-u-s-equity-etfs/11/05/1080403/going-large-first-trust-introduces-mega-cap-etf,ETF Professor,,,,,,
2011-05-16T08:00:00.000+08:00,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1087453/eli-lilly-provides-its-perspective-in-response-to-amylin-lawsuit,Benzinga Staff,,,,,,
2011-05-16T08:00:00.000+08:00,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position",LLY,https://www.benzinga.com/news/legal/11/05/1086529/lilly-says-suit-is-without-merit-will-vigorously-defend-position,Theo Kratz,,,,,,
2011-05-16T08:00:00.000+08:00,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg,LLY,https://www.benzinga.com/news/legal/11/05/1086386/lilly-rejected-by-u-s-supreme-court-on-gemzar-patent-bloomberg,Theo Kratz,,,,,,
2011-05-16T08:00:00.000+08:00,Lilly Provides Statement in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1086356/lilly-provides-statement-in-response-to-amylin-lawsuit,Benzinga Staff,,,,,,
2011-05-16T08:00:00.000+08:00,Bank Of America Raising PT On LLY To $43,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085632/bank-of-america-raising-pt-on-lly-to-43,BenzingaStaffT,,,,,,
2011-05-16T08:00:00.000+08:00,Amylin Pharmaceuticals Files Suit Against Eli Lilly,LLY,https://www.benzinga.com/news/legal/11/05/1085504/amylin-pharmaceuticals-files-suit-against-eli-lilly,Benzinga Staff,,,,,,
2011-05-18T08:00:00.000+08:00,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,LLY,https://www.benzinga.com/11/05/1092918/glaxosmithkline-and-isis-pharmaceuticals-partnership-shouldnt-be-overlooked-as-a-long-,CEO World,,,,,,
2011-05-19T08:00:00.000+08:00,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup,LLY,https://www.benzinga.com/11/05/1098726/a-mega-cap-etf-joins-the-first-trust-alphadex-lineup,Invest With An Edge,,,,,,
2011-05-19T08:00:00.000+08:00,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients,LLY,https://www.benzinga.com/news/fda/11/05/1096707/eli-lilly-announces-study-determined-best-dose-and-showed-55-response-rate-wi,Benzinga Staff,,,,,,
2011-05-19T08:00:00.000+08:00,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma,LLY,https://www.benzinga.com/news/fda/11/05/1096701/eli-lilly-presents-data-on-cixutumumab-in-five-subtypes-of-sarcoma,Benzinga Staff,,,,,,
2011-05-22T08:00:00.000+08:00,Top Healthcare and Major Drugs stocks to watch- Sector Performance,LLY,https://www.benzinga.com/11/05/1103086/top-healthcare-and-major-drugs-stocks-to-watch-sector-performance,CEO World,,,,,,
2011-05-23T08:00:00.000+08:00,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1106075/eli-lilly-and-investor-group-form-new-critical-care-company-biocritica-,Benzinga Staff,,,,,,
2011-05-23T08:00:00.000+08:00,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1104830/lilly-and-investor-group-form-new-critical-care-company-biocritica-sign,Allie Wickman,,,,,,
2011-05-24T08:00:00.000+08:00,Diabetes Device Market to Reach $24 Billion by 2017,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/05/1107925/diabetes-device-market-to-reach-24-billion-by-2017,Allie Wickman,,,,,,
2011-06-01T08:00:00.000+08:00,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",LLY,https://www.benzinga.com/analyst-ratings/11/06/1128490/hapoalim-securities-terminates-healthcare-coverage-including-bristol-m,BenzingaStaffL,,,,,,
2011-06-01T08:00:00.000+08:00,Hapoalim Cutting Ocverage On Multitude Of Names,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1128380/hapoalim-cutting-ocverage-on-multitude-of-names,Jonathan Chen,,,,,,
2011-06-01T08:00:00.000+08:00,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,LLY,https://www.benzinga.com/markets/11/06/1125693/top-4-large-cap-stocks-in-the-drug-manufacturers-major-industry-with-the-highe,Monica Gerson,,,,,,
2011-06-02T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1132491/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,,,
2011-06-06T08:00:00.000+08:00,Will Prozac Murder Trial Doom Eli Lilly Stock?,LLY,https://www.benzinga.com/news/global/11/06/1142243/will-prozac-murder-trial-doom-eli-lilly-stock,Luci Morland,,,,,,
2011-06-08T08:00:00.000+08:00,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order,LLY,https://www.benzinga.com/news/legal/11/06/1151354/update-amylin-pharmaceuticals-issues-statement-regarding-u-s-district-court,Benzinga Staff,,,,,,
2011-06-08T08:00:00.000+08:00,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation,LLY,https://www.benzinga.com/news/legal/11/06/1151229/u-s-district-court-rules-in-favor-of-eli-lilly-in-amylin-litigation,Benzinga Staff,,,,,,
2011-06-08T08:00:00.000+08:00,FDA Approves Updates to Lilly's HumalogLabel,LLY,https://www.benzinga.com/news/fda/11/06/1148694/fda-approves-updates-to-lillys-humaloglabel,Benzinga Staff,,,,,,
2011-06-09T08:00:00.000+08:00,Synthes and Eli Lilly Sign Development and Collaboration Agreement,LLY,https://www.benzinga.com/news/contracts/11/06/1154159/synthes-and-eli-lilly-sign-development-and-collaboration-agreement,Benzinga Staff,,,,,,
2011-06-10T08:00:00.000+08:00,CIGNA and Forest Laboratories Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1157166/cigna-and-forest-laboratories-open-near-52-week-highs,Nelson Hem,,,,,,
2011-06-15T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1172064/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,,,
2011-06-15T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/fda/11/06/1170407/boehringer-ingelheim-and-eli-lillys-new-type-2-diabetes-treatment-tradjenta-t,Benzinga Staff,,,,,,
2011-06-20T08:00:00.000+08:00,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share,LLY,https://www.benzinga.com/news/11/06/1184774/lilly-declares-third-quarter-2011-dividend-of-0-49share,Allie Wickman,,,,,,
2011-06-21T08:00:00.000+08:00,Colgate and Forest Labs to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1186875/colgate-and-forest-labs-to-open-near-52-week-highs,Nelson Hem,,,,,,
2011-06-21T08:00:00.000+08:00,"News Summary for June 21, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/06/1186746/news-summary-for-june-21-2011,Allie Wickman,,,,,,
2011-06-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/06/1186469/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,,,
2011-06-21T08:00:00.000+08:00,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe,LLY,https://www.benzinga.com/news/11/06/1186219/eli-lilly-and-amylin-pharmaceuticals-announces-bydureon-receives-marketing-author,Benzinga Staff,,,,,,
2011-06-22T08:00:00.000+08:00,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1191905/goldman-sachs-suggests-buying-put-spreads-on-eli-lilly-and-company,Michael J. Zerinskas,,,,,,
2011-06-23T08:00:00.000+08:00,Forest Labs and Watson Pharma to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1195494/forest-labs-and-watson-pharma-to-open-near-52-week-highs,Nelson Hem,,,,,,
2011-06-23T08:00:00.000+08:00,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1195168/deutsche-bank-sees-no-catalyst-at-eli-lilly-investor-mee,Jonathan Chen,,,,,,
2011-06-24T08:00:00.000+08:00,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe,LLY,https://www.benzinga.com/news/11/06/1197748/eli-lilly-linagliptin-recommended-for-approval-in-the-treatment-of-type-2-diabete,Allie Wickman,,,,,,
2011-06-27T08:00:00.000+08:00,Citi Maintains Hold Rating on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/06/1202059/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffL,,,,,,
2011-06-27T08:00:00.000+08:00,Jefferies Maintains Buy on Amylin Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1202018/jefferies-maintains-buy-on-amylin-pharmaceuticals,BenzingaStaffJ,,,,,,
2011-06-28T08:00:00.000+08:00,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)",LLY,https://www.benzinga.com/media/cnbc/11/06/1209847/fast-money-picks-for-june-29th-lulu-xhb-bac-lly,Craig Jones,,,,,,
2011-06-28T08:00:00.000+08:00,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men,LLY,https://www.benzinga.com/news/11/06/1207695/eli-lilly-newly-published-study-showed-axiron-topical-solution-restored-testoster,Allie Wickman,,,,,,
2011-06-28T08:00:00.000+08:00,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities,LLY,https://www.benzinga.com/news/11/06/1206345/eli-lilly-announces-new-investment-to-boost-its-biotechnology-capabilities,Eddie Staley,,,,,,
2011-06-29T08:00:00.000+08:00,Citi Maintains Hold Rating On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1211165/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffB,,,,,,
2011-07-01T08:00:00.000+08:00,Sideline Money Flows In 07-01-2011,LLY,https://www.benzinga.com/11/07/1221874/sideline-money-flows-in-07-01-2011,optionsXpress,,,,,,
2011-07-01T08:00:00.000+08:00,Wells Fargo Maintains Market Perform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1220335/wells-fargo-maintains-market-perform-on-eli-lilly,BenzingaStaffJ,,,,,,
2011-07-01T08:00:00.000+08:00,J.P. Morgan Comments On Eli Lilly Investor Day,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219784/j-p-morgan-comments-on-eli-lilly-investor-day,BenzingaStaffB,,,,,,
2011-07-01T08:00:00.000+08:00,Deutsche Bank Discusses Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219781/deutsche-bank-discusses-eli-lilly-investor-meeting,Jonathan Chen,,,,,,
2011-07-08T08:00:00.000+08:00,Citi Reiterates Hold and PT of $38 on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/07/1748861/citi-reiterates-hold-and-pt-of-38-on-eli-lilly,Emily Austin,,,,,,
2011-07-13T08:00:00.000+08:00,Twelve Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1761358/twelve-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,,,
2011-07-17T08:00:00.000+08:00,Earnings Expectations for the Week of July 18,LLY,https://www.benzinga.com/news/earnings/11/07/1771585/earnings-expectations-for-the-week-of-july-18,Nelson Hem,,,,,,
2011-07-18T08:00:00.000+08:00,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter,LLY,https://www.benzinga.com/11/07/1775111/eli-lilly-earnings-preview-analysts-predict-higher-earnings-over-prior-quarter,Benzinga Staff Writer,,,,,,
2011-07-18T08:00:00.000+08:00,Citi Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1773155/citi-comments-on-eli-lilly,BenzingaStaffT,,,,,,
2011-07-18T08:00:00.000+08:00,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy,LLY,https://www.benzinga.com/news/11/07/1772753/eli-lilly-announces-new-data-showed-minimal-potential-for-drug-interaction-betwee,Eddie Staley,,,,,,
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772738/jefferies-raises-pt-on-eli-lilly-to-34,Joe Young,,,,,,
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772736/jefferies-raises-pt-on-eli-lilluy,Joe Young,,,,,,
2011-07-21T08:00:00.000+08:00,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1791044/deutsche-bank-maintains-eli-lilly-hold-38-50-pt,Hilary Farrell,,,,,,
2011-07-21T08:00:00.000+08:00,Fifteen Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1790212/fifteen-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,,,
2011-07-21T08:00:00.000+08:00,Earnings Roundup For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1788800/earnings-roundup-for-july-21,Monica Gerson,,,,,,
2011-07-21T08:00:00.000+08:00,"News Summary for July 20, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/07/1787811/news-summary-for-july-20-2011,Allie Wickman,,,,,,
2011-07-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/07/1787761/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,,,
2011-07-21T08:00:00.000+08:00,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30",LLY,https://www.benzinga.com/news/11/07/1787730/lilly-sees-year-eps-4-25-4-35-had-seen-4-15-4-30,Paul Quintaro,,,,,,
2011-07-21T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings,LLY,https://www.benzinga.com/news/earnings/11/07/1787367/update-eli-lilly-reports-11-drop-in-q2-earnings,Monica Gerson,,,,,,
2011-07-21T08:00:00.000+08:00,US Stock Futures Down As Investors Await Earnings Reports,LLY,https://www.benzinga.com/news/11/07/1787175/us-stock-futures-down-as-investors-await-earnings-reports,Monica Gerson,,,,,,
2011-07-21T08:00:00.000+08:00,Earnings Scheduled For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1786911/earnings-scheduled-for-july-21,Monica Gerson,,,,,,
2011-07-22T08:00:00.000+08:00,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions",LLY,https://www.benzinga.com/news/11/07/1792845/ema-gives-negative-opinion-on-ariclaim-cymbalta-xeristar-extensions,Paul Quintaro,,,,,,
2011-07-27T08:00:00.000+08:00,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform,LLY,https://www.benzinga.com/news/11/07/1809176/hearing-supreme-court-asked-to-overturn-obamas-health-care-reform,Paul Quintaro,,,,,,
2011-07-28T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August,LLY,https://www.benzinga.com/11/07/1814889/stocks-going-ex-dividend-the-second-week-of-august,Fred Fuld,,,,,,
2011-07-28T08:00:00.000+08:00,BYDUREON™ Reply Submitted to FDA,LLY,https://www.benzinga.com/news/11/07/1811607/bydureon-reply-submitted-to-fda,Allie Wickman,,,,,,
2011-07-29T08:00:00.000+08:00,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent,LLY,https://www.benzinga.com/news/11/07/1817664/u-s-court-of-appeals-affirms-validity-of-lillys-strattera-patent,Eddie Staley,,,,,,
2011-07-29T08:00:00.000+08:00,Bank of America Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1816199/bank-of-america-comments-on-eli-lilly,Lydia Davidson,,,,,,
2011-08-01T08:00:00.000+08:00,Leerink Swann Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/11/08/1820940/leerink-swann-upgrades-eli-lilly-to-market-perform,BenzingaStaffT,,,,,,
2011-08-09T08:00:00.000+08:00,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion,LLY,https://www.benzinga.com/news/11/08/1844270/eli-lilly-announces-review-of-data-on-long-term-raloxifene-treatment-for-postmeno,Eddie Staley,,,,,,
2011-08-10T08:00:00.000+08:00,"Bydureon FDA Action Date Set For January 28, 2012",LLY,https://www.benzinga.com/news/11/08/1849139/bydureon-fda-action-date-set-for-january-28-2012,Allie Wickman,,,,,,
2011-08-15T08:00:00.000+08:00,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study,LLY,https://www.benzinga.com/news/11/08/1857293/effient-showed-significant-26-reduction-in-cardiovascular-events-over-clopidogrel,Eddie Staley,,,,,,
2011-08-25T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes,LLY,https://www.benzinga.com/news/11/08/1884300/eli-lilly-announces-linagliptin-receives-approval-in-europe-for-the-treatment-of-,Eddie Staley,,,,,,
2011-09-01T08:00:00.000+08:00,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ",LLY,https://www.benzinga.com/news/11/09/1897134/mustafa-nevzat-could-attract-other-suitors-ultimately-be-sold-for-about-1b-wsj,Allie Wickman,,,,,,
2011-09-07T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations,LLY,https://www.benzinga.com/news/11/09/1904416/boehringer-ingelheim-and-lilly-to-feature-type-2-diabetes-research-in-presentatio,Abe Raymond,,,,,,
2011-09-12T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/09/1911749/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2011-09-12T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors",LLY,https://www.benzinga.com/news/11/09/1911646/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-analyses-find-type-2-diabe,Eddie Staley,,,,,,
2011-09-13T08:00:00.000+08:00,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases,LLY,https://www.benzinga.com/news/11/09/1914100/lilly-invests-30-million-in-partnership-to-address-non-communicable-diseases,Matthew Kennedy,,,,,,
2011-09-26T08:00:00.000+08:00,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients,LLY,https://www.benzinga.com/news/11/09/1944389/eli-lilly-announces-alimta-helped-keep-most-common-form-of-lung-cancer-at-bay-in-,Eddie Staley,,,,,,
2011-09-26T08:00:00.000+08:00,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/09/1943232/alimta-receives-positive-opinion-from-chmp-as-continuation-maintenance-therapy-fo,Matthew Kennedy,,,,,,
2011-10-05T08:00:00.000+08:00,Lilly CEO Says Not Interested in Pfizer Nutrition Business,LLY,https://www.benzinga.com/news/11/10/1967659/lilly-ceo-says-not-interested-in-pfizer-nutrition-business,Matthew Kennedy,,,,,,
2011-10-05T08:00:00.000+08:00,Lilly CEO Wants Better Chance to Win Worker Green Cards,LLY,https://www.benzinga.com/news/11/10/1966932/lilly-ceo-wants-better-chance-to-win-worker-green-cards,Matthew Kennedy,,,,,,
2011-10-06T08:00:00.000+08:00,Lilly's Cialis is Approved for Treatment of Enlarged Prostates,LLY,https://www.benzinga.com/news/11/10/1971009/lillys-cialis-is-approved-for-treatment-of-enlarged-prostates,Matthew Kennedy,,,,,,
2011-10-07T08:00:00.000+08:00,Will Earnings Be a Catalyst?,LLY,https://www.benzinga.com/11/10/1973558/will-earnings-be-a-catalyst,optionsXpress,,,,,,
2011-10-07T08:00:00.000+08:00,Notable Call Options Activity in Eli Lilly,LLY,https://www.benzinga.com/markets/options/11/10/1973347/notable-call-options-activity-in-eli-lilly,Michael J. Zerinskas,,,,,,
2011-10-07T08:00:00.000+08:00,Resistance 10-07-2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/10/1973244/resistance-10-07-2011,optionsXpress,,,,,,
2011-10-07T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 7, 2011",LLY,https://www.benzinga.com/news/11/10/1972040/financial-breakfast-morning-news-summary-for-october-7-2011,Allie Wickman,,,,,,
2011-10-07T08:00:00.000+08:00,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH,LLY,https://www.benzinga.com/news/11/10/1971917/cialis-for-once-daily-use-now-fda-approved-to-treat-men-with-signs-and-symptoms-o,Eddie Staley,,,,,,
2011-10-12T08:00:00.000+08:00,New Study Shows Cialis Significantly Improved Study Endpoints in Men,LLY,https://www.benzinga.com/news/11/10/1981047/new-study-shows-cialis-significantly-improved-study-endpoints-in-men,Matthew Kennedy,,,,,,
2011-10-14T08:00:00.000+08:00,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/11/10/1985660/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,,,
2011-10-17T08:00:00.000+08:00,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",LLY,https://www.benzinga.com/news/earnings/11/10/1990058/eli-lilly-earnings-preview-analysts-expect-rising-revenue-falling-eps,Benzinga Staff Writer,,,,,,
2011-10-20T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/11/10/2000402/earnings-roundup,Lisa Levin,,,,,,
2011-10-20T08:00:00.000+08:00,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales,LLY,https://www.benzinga.com/news/earnings/11/10/2000232/eli-lilly-sees-zyprexa-expiration-to-significantly-hurt-sales,Matthew Kennedy,,,,,,
2011-10-20T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit,LLY,https://www.benzinga.com/news/earnings/11/10/2000063/update-eli-lilly-reports-decline-in-q3-net-profit,Lisa Levin,,,,,,
2011-10-20T08:00:00.000+08:00,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est,LLY,https://www.benzinga.com/news/earnings/11/10/2000061/eli-lilly-reports-q3-eps-1-13-vs-1-13-est-revenues-6-15b-vs-6-06b-est,Matthew Kennedy,,,,,,
2011-10-20T08:00:00.000+08:00,Eli Lilly and Company's Profit Falls,LLY,https://www.benzinga.com/news/earnings/11/10/1999660/eli-lilly-and-companys-profit-falls,Benzinga Staff Writer,,,,,,
2011-10-20T08:00:00.000+08:00,Earnings Scheduled For October 20,LLY,https://www.benzinga.com/news/earnings/11/10/1999160/earnings-scheduled-for-october-20,Monica Gerson,,,,,,
2011-10-24T08:00:00.000+08:00,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder",LLY,https://www.benzinga.com/news/11/10/2008385/eli-lilly-fda-approves-first-generic-olanzapine-to-treat-schizophrenia-bipolar-di,Allie Wickman,,,,,,
2011-10-24T08:00:00.000+08:00,UPDATE: Jefferies Lowers PT on Eli LIlly to $33,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2006785/update-jefferies-lowers-pt-on-eli-lilly-to-33,Phil Marsh,,,,,,
2011-10-24T08:00:00.000+08:00,Jefferies Lowers PT on Eli Lilly to $33,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/10/2006338/jefferies-lowers-pt-on-eli-lilly-to-33,Joe Young,,,,,,
2011-10-25T08:00:00.000+08:00,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior,LLY,https://www.benzinga.com/news/11/10/2010278/lilly-cuts-2011-financial-guidance-due-to-xigris-withdrawal-expects-3-84-3-89-vs-,Allie Wickman,,,,,,
2011-10-25T08:00:00.000+08:00,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011,LLY,https://www.benzinga.com/news/11/10/2010277/update-lilly-sees-charge-0-75-0-95-pretax-reaffirms-forecast-adj-eps-2011,Matthew Kennedy,,,,,,
2011-10-25T08:00:00.000+08:00,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results,LLY,https://www.benzinga.com/news/11/10/2010184/lilly-announces-withdrawal-of-xigris-following-recent-clinical-trial-results,Allie Wickman,,,,,,
2011-10-28T08:00:00.000+08:00,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2022356/update-first-global-upgrades-eli-lilly-to-moderate-outpe,Phil Marsh,,,,,,
2011-10-28T08:00:00.000+08:00,Lilly's ALIMTA Receives EC Approval,LLY,https://www.benzinga.com/news/11/10/2022155/lillys-alimta-receives-ec-approval,Matthew Kennedy,,,,,,
2011-10-28T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 28, 2011",LLY,https://www.benzinga.com/news/earnings/11/10/2021852/financial-breakfast-morning-news-summary-for-october-28-2011,Allie Wickman,,,,,,
2011-10-28T08:00:00.000+08:00,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/10/2021722/eli-lilly-announces-alimta-first-chemotherapy-approved-in-europe-as-continuation-,Eddie Staley,,,,,,
2011-10-28T08:00:00.000+08:00,First Global Upgrades Eli Lilly from Market Perform to Market Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/10/2021589/first-global-upgrades-eli-lilly-from-market-perform-to-market,Joe Young,,,,,,
2011-10-31T08:00:00.000+08:00,Watch for YM BioSciences' Upcoming Clinical Data Catalyst,LLY,https://www.benzinga.com/general/topics/11/10/2079938/watch-for-ym-biosciences-upcoming-clinical-data-catalyst,M.E. Garza,,,,,,
2011-11-03T08:00:00.000+08:00,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+',LLY,https://www.benzinga.com/news/11/11/2092411/fitch-downgrades-eli-lillys-bank-loan-rating-to-a-from-a,Allie Wickman,,,,,,
2011-11-07T08:00:00.000+08:00,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent,LLY,https://www.benzinga.com/news/11/11/2101884/siemens-petnet-solutions-signs-nationwide-commercial-agreement-to-manufacture-and,Eddie Staley,,,,,,
2011-11-08T08:00:00.000+08:00,From Earlier: Amylin to End Diabetes Drug Deal with Lilly,LLY,https://www.benzinga.com/news/11/11/2107467/from-earlier-amylin-to-end-diabetes-drug-deal-with-lilly,Matthew Kennedy,,,,,,
2011-11-08T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/11/2105587/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,,,
2011-11-08T08:00:00.000+08:00,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin,LLY,https://www.benzinga.com/news/11/11/2105283/lilly-and-amylin-mutually-agree-to-end-diabetes-alliance-and-transition-exenatide,Eddie Staley,,,,,,
2011-11-10T08:00:00.000+08:00,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region,LLY,https://www.benzinga.com/news/11/11/2116583/lilly-ceo-lechleiter-outlines-opportunities-for-improved-health-and-economic-grow,Allie Wickman,,,,,,
2011-11-16T08:00:00.000+08:00,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI,LLY,https://www.benzinga.com/news/11/11/2135187/new-analysis-of-data-presented-at-aha-regarding-effect-of-effient-on-cardiovascul,Eddie Staley,,,,,,
2011-11-16T08:00:00.000+08:00,Kenexa Announces Partnership With Eli Lilly and Company,LLY,https://www.benzinga.com/news/11/11/2132807/kenexa-announces-partnership-with-eli-lilly-and-company,Eddie Staley,,,,,,
2011-11-22T08:00:00.000+08:00,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories,LLY,https://www.benzinga.com/news/11/11/2145579/eli-lilly-spokesperson-says-the-company-does-not-comment-on-rumors-response-to-ch,Charles Gross,,,,,,
2011-11-22T08:00:00.000+08:00,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter,LLY,https://www.benzinga.com/news/11/11/2145546/forest-laboratories-moving-higher-may-be-attributed-to-takeover-chatter,Charles Gross,,,,,,
2011-12-01T08:00:00.000+08:00,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment",LLY,https://www.benzinga.com/news/11/12/2166511/lilly-announces-first-and-only-international-prospective-observational-study-desi,Eddie Staley,,,,,,
2011-12-06T08:00:00.000+08:00,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC",LLY,https://www.benzinga.com/media/cnbc/11/12/2181787/3m-eli-lily-general-electric-receive-positive-mad-moneyjim-cramer-mention-c,Charles Gross,,,,,,
2011-12-07T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $39.79,LLY,https://www.benzinga.com/intraday-update/11/12/2183781/eli-lilly-hits-52-week-high-of-39-79,Benzinga Staff,,,,,,
2011-12-12T08:00:00.000+08:00,Katherine Baicker Elected to Lilly Board of Directors,LLY,https://www.benzinga.com/news/11/12/2197077/katherine-baicker-elected-to-lilly-board-of-directors,Eddie Staley,,,,,,
2011-12-12T08:00:00.000+08:00,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting",LLY,https://www.benzinga.com/news/11/12/2197071/from-earlier-lilly-oncology-reveals-findings-from-study-of-jak2-inhibitor-for-blo,Allie Wickman,,,,,,
2011-12-13T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.13,LLY,https://www.benzinga.com/intraday-update/11/12/2200750/eli-lilly-hits-52-week-high-of-40-13,Benzinga Staff,,,,,,
2011-12-14T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.25,LLY,https://www.benzinga.com/intraday-update/11/12/2204887/eli-lilly-hits-52-week-high-of-40-25,Benzinga Staff,,,,,,
2011-12-15T08:00:00.000+08:00,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)",LLY,https://www.benzinga.com/media/cnbc/11/12/2211590/fast-money-picks-for-december-16th-aet-m-mant-etr-cov-lly-adbe,Craig Jones,,,,,,
2011-12-15T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.49,LLY,https://www.benzinga.com/intraday-update/11/12/2209095/eli-lilly-hits-52-week-high-of-40-49,Benzinga Staff,,,,,,
2011-12-20T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for December 20, 2011",LLY,https://www.benzinga.com/news/earnings/11/12/2218382/financial-breakfast-morning-news-summary-for-december-20-2011,Allie Wickman,,,,,,
2011-12-20T08:00:00.000+08:00,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly",LLY,https://www.benzinga.com/news/11/12/2218340/immunogen-inc-announces-antibody-drug-conjugate-collaboration-with-lilly,Allie Wickman,,,,,,
2011-12-21T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.44,LLY,https://www.benzinga.com/intraday-update/11/12/2222032/eli-lilly-hits-52-week-high-of-41-44,Benzinga Staff,,,,,,
2011-12-21T08:00:00.000+08:00,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed,LLY,https://www.benzinga.com/news/11/12/2221601/ligand-enters-into-platform-captisol-license-and-supply-agreements-with-lilly-ter,Allie Wickman,,,,,,
2011-12-22T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.85,LLY,https://www.benzinga.com/intraday-update/11/12/2224883/eli-lilly-hits-52-week-high-of-41-85,Benzinga Staff,,,,,,
2011-12-27T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.87,LLY,https://www.benzinga.com/intraday-update/11/12/2229518/eli-lilly-hits-52-week-high-of-41-87,Benzinga Staff,,,,,,
2011-12-27T08:00:00.000+08:00,Best Biotech Stocks of 2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2229504/best-biotech-stocks-of-2011,Nelson Hem,,,,,,
2011-12-30T08:00:00.000+08:00,ETF Showdown: Fun With Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2233813/etf-showdown-fun-with-pharma,ETF Professor,,,,,,
2012-01-03T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.97,LLY,https://www.benzinga.com/intraday-update/12/01/2236264/eli-lilly-hits-52-week-high-of-41-97,Benzinga Staff,,,,,,
2012-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration,LLY,https://www.benzinga.com/news/12/01/2241544/update-eli-lilly-says-decline-in-2012-guidance-reflects-zyprexa-patent-expiration,Matthew Kennedy,,,,,,
2012-01-05T08:00:00.000+08:00,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est,LLY,https://www.benzinga.com/news/12/01/2241532/eli-lilly-guides-2012-eps-3-10-3-20-vs-3-67-est,Matthew Kennedy,,,,,,
2012-01-10T08:00:00.000+08:00,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline,LLY,https://www.benzinga.com/news/12/01/2252048/shangpharma-announces-opening-of-new-facility-to-support-lillys-pipeline,Eddie Staley,,,,,,
2012-01-17T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday January 17, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2269076/benzingas-m-a-chatter-for-tuesday-january-17-2012,Charles Gross,,,,,,
2012-01-17T08:00:00.000+08:00,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/01/2266699/update-deutsche-bank-raises-pt-to-40-maintains-hold-on-el,David Johnson,,,,,,
2012-01-24T08:00:00.000+08:00,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed,LLY,https://www.benzinga.com/news/12/01/2285216/elanco-animal-health-announces-lillys-agreement-to-acquire-chemgen-corp-terms-not,Eddie Staley,,,,,,
2012-01-29T08:00:00.000+08:00,Earnings Expectations for the Week of January 30,LLY,https://www.benzinga.com/news/earnings/12/01/2297577/earnings-expectations-for-the-week-of-january-30,Nelson Hem,,,,,,
2012-01-31T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/12/01/2302855/earnings-roundup,Lisa Levin,,,,,,
2012-01-31T08:00:00.000+08:00,FDA Approves Lilly & Co's Jentadueto Tablets,LLY,https://www.benzinga.com/news/12/01/2302679/fda-approves-lilly-cos-jentadueto-tablets,Matthew Kennedy,,,,,,
2012-01-31T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for January 31, 2012",LLY,https://www.benzinga.com/news/earnings/12/01/2302337/financial-breakfast-morning-news-summary-for-january-31-2012,Allie Wickman,,,,,,
2012-01-31T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/12/01/2302160/update-eli-lilly-reports-27-decline-in-q4-profit,Monica Gerson,,,,,,
2012-01-31T08:00:00.000+08:00,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/01/2302063/from-earlier-fda-approves-lillys-jentadueto-tablets-for-the-treatment-of-adult-pa,Eddie Staley,,,,,,
2012-01-31T08:00:00.000+08:00,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est,LLY,https://www.benzinga.com/news/earnings/12/01/2302017/eli-lilly-reports-q4-eps-0-87-vs-0-81-est-revenues-6-05b-vs-5-90b-est,Allie Wickman,,,,,,
2012-01-31T08:00:00.000+08:00,US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/12/01/2301996/us-stock-futures-signal-higher-start-on-wall-street,Monica Gerson,,,,,,
2012-01-31T08:00:00.000+08:00,Earnings Scheduled For January 31,LLY,https://www.benzinga.com/news/earnings/12/01/2301396/earnings-scheduled-for-january-31,Monica Gerson,,,,,,
2012-02-02T08:00:00.000+08:00,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2313085/amylin-pharmaceuticals-continues-to-soar-in-wake-of-bydureon-,Scott Rubin,,,,,,
2012-02-07T08:00:00.000+08:00,Stocks Going Ex-Dividend the Third Week of February 2012,LLY,https://www.benzinga.com/markets/12/02/2325637/stocks-going-ex-dividend-the-third-week-of-february-2012,Fred Fuld,,,,,,
2012-02-07T08:00:00.000+08:00,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/02/2322652/new-study-evaluates-cialis-in-parallel-with-tamsulosin-in-men-with-signs-and-symp,Eddie Staley,,,,,,
2012-02-07T08:00:00.000+08:00,Eli Lilly Says Cialis Data Met Primary Endpoint,LLY,https://www.benzinga.com/news/12/02/2322593/eli-lilly-says-cialis-data-met-primary-endpoint,Matthew Kennedy,,,,,,
2012-02-17T08:00:00.000+08:00,CHMP Recommends Approval of BYETTA for Use With Basal Insulin,LLY,https://www.benzinga.com/news/12/02/2353416/chmp-recommends-approval-of-byetta-for-use-with-basal-insulin,Matthew Kennedy,,,,,,
2012-03-02T08:00:00.000+08:00,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/03/2392473/update-jp-morgan-upgrades-eli-lilly-to-neutral,David Johnson,,,,,,
2012-03-02T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for March 2, 2012",LLY,https://www.benzinga.com/markets/bonds/12/03/2391807/financial-breakfast-morning-news-summary-for-march-2-2012,Allie Wickman,,,,,,
2012-03-02T08:00:00.000+08:00,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/03/2391645/jp-morgan-upgrades-eli-lilly-from-underweight-to-neutral-main,webmaster,,,,,,
2012-03-07T08:00:00.000+08:00,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies",LLY,https://www.benzinga.com/news/12/03/2403574/boehringer-ingelheim-and-lillys-new-oral-type-2-diabetes-treatment-for-adults-jen,Eddie Staley,,,,,,
2012-03-08T08:00:00.000+08:00,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2407015/fresh-del-monte-blackrock-and-other-stocks-insiders-are-buyin,Nelson Hem,,,,,,
2012-03-09T08:00:00.000+08:00,S&P Indices Announces Changes to U.S. Index,LLY,https://www.benzinga.com/news/12/03/2412847/s-p-indices-announces-changes-to-u-s-index,Charles Gross,,,,,,
2012-03-15T08:00:00.000+08:00,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2427762/a-look-at-the-new-russell-high-yield-etf-hdiv-abt-kft,ETF Professor,,,,,,
2012-03-21T08:00:00.000+08:00,"Benzinga's M&A Chatter for Wednesday March 21, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2442482/benzingas-m-a-chatter-for-wednesday-march-21-2012,Charles Gross,,,,,,
2012-03-21T08:00:00.000+08:00,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer",LLY,https://www.benzinga.com/news/12/03/2441463/forest-labs-spiking-higher-on-takeover-chatter-lilly-rumored-buyer,Charles Gross,,,,,,
2012-03-21T08:00:00.000+08:00,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2440492/st-jude-novo-nordisk-and-other-health-care-stocks-worth-a-loo,Nelson Hem,,,,,,
2012-03-23T08:00:00.000+08:00,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe,LLY,https://www.benzinga.com/news/12/03/2444804/amylin-pharmaceuticals-announces-byetta-approved-for-use-with-basal-insulin-in-eu,Eddie Staley,,,,,,
2012-03-28T08:00:00.000+08:00,ImmunoCellular's Intellectual Property Steadily Increases,LLY,https://www.benzinga.com/news/fda/12/03/2452222/immunocellulars-intellectual-property-steadily-increases,Chemistfrog,,,,,,
2012-03-28T08:00:00.000+08:00,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis",LLY,https://www.benzinga.com/news/12/03/2452099/lillys-anti-il-17-monoclonal-antibody-ixekizumab-met-primary-endpoint-in-phase-ii,Charles Gross,,,,,,
2012-03-28T08:00:00.000+08:00,Amylin Rejected $3.5 Billion Offer; Stock Soars,LLY,https://www.benzinga.com/news/12/03/2451652/amylin-rejected-3-5-billion-offer-stock-soars,Scott Rubin,,,,,,
2012-04-03T08:00:00.000+08:00,Where the Rubber Meets the Road for Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/04/2469605/where-the-rubber-meets-the-road-for-obamacare,Marco Rabinowitz,,,,,,
2012-04-03T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2468272/benzingas-top-pre-market-gainers,Lisa Levin,,,,,,
2012-04-09T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2480326/benzingas-top-pre-market-gainers,Lisa Levin,,,,,,
2012-04-09T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline,LLY,https://www.benzinga.com/news/12/04/2480069/eli-lilly-announces-fda-approves-amyvid-for-use-in-patients-being-evaluated-for-a,Eddie Staley,,,,,,
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma,LLY,https://www.benzinga.com/news/12/04/2484028/safeguard-scientifics-will-realize-additional-proceeds-from-eli-lillys-acquisitio,Paul Quintaro,,,,,,
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/12/04/2484026/safeguard-scientifics-to-realize-additional-proceeds-from-eli-lillys-acquisition-,Allie Wickman,,,,,,
2012-04-12T08:00:00.000+08:00,Why we added biotech stock Sequenom to the lineup,LLY,https://www.benzinga.com/markets/12/04/2493883/why-we-added-biotech-stock-sequenom-to-the-lineup,Covestor,,,,,,
2012-04-12T08:00:00.000+08:00,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration,LLY,https://www.benzinga.com/media/cnbc/12/04/2492316/lillys-ceo-on-cnbc-says-hopes-to-offset-decline-due-to-patent-expiration,Paul Quintaro,,,,,,
2012-04-16T08:00:00.000+08:00,How I approach biotech investing,LLY,https://www.benzinga.com/markets/12/04/2501106/how-i-approach-biotech-investing,Covestor,,,,,,
2012-04-18T08:00:00.000+08:00,Why our portfolio is John Deere green,LLY,https://www.benzinga.com/markets/12/04/2506146/why-our-portfolio-is-john-deere-green,Covestor,,,,,,
2012-04-22T08:00:00.000+08:00,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)",LLY,https://www.benzinga.com/news/earnings/12/04/2517141/earnings-expectations-for-the-week-of-april-23-aapl-xom-ups,Nelson Hem,,,,,,
2012-04-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for April 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/04/2526765/financial-breakfast-morning-news-summary-for-april-25-2012,Allie Wickman,,,,,,
2012-04-25T08:00:00.000+08:00,Eli Lilly &amp; Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est,LLY,https://www.benzinga.com/news/earnings/12/04/2526430/eli-lilly-amp-reports-q1-eps-0-92-vs-0-79-est-revenues-5-6b-vs-5-35b-est,webmaster,,,,,,
2012-04-25T08:00:00.000+08:00,Earnings Scheduled For April 25,LLY,https://www.benzinga.com/news/earnings/12/04/2525743/earnings-scheduled-for-april-25,Monica Gerson,,,,,,
2012-04-30T08:00:00.000+08:00,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,LLY,https://www.benzinga.com/news/12/04/2541492/fda-considering-letting-patients-purchase-drugs-without-prescriptions,Marco Rabinowitz,,,,,,
2012-05-04T08:00:00.000+08:00,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20",LLY,https://www.benzinga.com/markets/options/12/05/2560452/option-alert-eli-lilly-july-42-call-block-trade-6-000-contracts-curren,Charles Gross,,,,,,
2012-05-07T08:00:00.000+08:00,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2563156/update-bank-of-america-increases-po-on-eli-lilly-co-to-4,Dwight Einhorn,,,,,,
2012-05-07T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2562943/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,webmaster,,,,,,
2012-05-10T08:00:00.000+08:00,Option Alert: Heavy Volume in Lilly Calls,LLY,https://www.benzinga.com/markets/options/12/05/2578275/option-alert-heavy-volume-in-lilly-calls,Charles Gross,,,,,,
2012-05-17T08:00:00.000+08:00,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC,LLY,https://www.benzinga.com/media/cnbc/12/05/2599685/eli-lilly-receives-positive-mad-moneyjim-cramer-mention-cnbc,Charles Gross,,,,,,
2012-05-18T08:00:00.000+08:00,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2600591/bmo-capital-markets-initiates-coverage-on-eli-lilly-at-ma,webmaster,,,,,,
2012-05-24T08:00:00.000+08:00,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg,LLY,https://www.benzinga.com/news/12/05/2617193/fda-fee-bill-gets-enough-support-for-passage-as-vote-continues-bloomberg,Paul Quintaro,,,,,,
2012-05-24T08:00:00.000+08:00,New Phase 3 data for Tradjenta,LLY,https://www.benzinga.com/news/12/05/2615591/new-phase-3-data-for-tradjenta,Paul Quintaro,,,,,,
2012-05-29T08:00:00.000+08:00,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/05/2625014/eli-lilly-announces-jentadueto-tablets-recommended-for-approval-in-treatment-of-a,Eddie Staley,,,,,,
2012-05-31T08:00:00.000+08:00,15 Great Stocks with Great Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/05/2633305/15-great-stocks-with-great-yield,Matthew Kanterman,,,,,,
2012-05-31T08:00:00.000+08:00,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?,LLY,https://www.benzinga.com/personal-finance/financial-advisors/12/05/2632730/vivus-qnexa-is-not-guaranteed-approval-remember-pr,Ross Drew,,,,,,
2012-05-31T08:00:00.000+08:00,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin,LLY,https://www.benzinga.com/news/12/05/2630739/lily-new-data-showed-livalo-met-primary-endpoint-of-ldl-c-reduction-when-compared,Allie Wickman,,,,,,
2012-06-01T08:00:00.000+08:00,Eli Lilly Says Amyvid Now Available in Select US Markets,LLY,https://www.benzinga.com/news/12/06/2635635/eli-lilly-says-amyvid-now-available-in-select-us-markets,Paul Quintaro,,,,,,
2012-06-01T08:00:00.000+08:00,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid",LLY,https://www.benzinga.com/news/12/06/2635310/cardinal-health-to-manufacture-distribute-eli-lilly-and-companys-brain-imaging-ag,Eddie Staley,,,,,,
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation,LLY,https://www.benzinga.com/news/12/06/2639368/eli-lilly-announces-lung-cancer-study-showed-encouraging-results-for-alimta-based,Eddie Staley,,,,,,
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy,LLY,https://www.benzinga.com/news/12/06/2639303/eli-lilly-announces-patients-with-most-common-type-of-lung-cancer-lived-longer-wi,Eddie Staley,,,,,,
2012-06-06T08:00:00.000+08:00,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ,LLY,https://www.benzinga.com/news/12/06/2648591/eli-lillys-ceo-says-no-large-pharma-deals-coming-wsj,Paul Quintaro,,,,,,
2012-06-08T08:00:00.000+08:00,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group",LLY,https://www.benzinga.com/news/12/06/2654225/update-lilly-says-1-serious-adverse-event-in-8-mg-group-4-serious-adverse-events-,Paul Quintaro,,,,,,
2012-06-08T08:00:00.000+08:00,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/12/06/2654224/lilly-and-incytes-oral-jak1-and-jak2-inhibitor-baricitinib-showed-positive-result,Allie Wickman,,,,,,
2012-06-11T08:00:00.000+08:00,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's",LLY,https://www.benzinga.com/news/12/06/2659370/lilly-releases-data-on-diabetes-drug-patients-lost-weight-on-lillys-drug-gained-o,Paul Quintaro,,,,,,
2012-06-19T08:00:00.000+08:00,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program",LLY,https://www.benzinga.com/news/12/06/2678818/lilly-declares-third-quarter-2012-dividend-resumes-share-repurchase-program,Allie Wickman,,,,,,
2012-06-26T08:00:00.000+08:00,Lilly Puts Statement Out on Pdufa Vote,LLY,https://www.benzinga.com/news/12/06/2699330/lilly-puts-statement-out-on-pdufa-vote,Paul Quintaro,,,,,,
2012-06-27T08:00:00.000+08:00,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/06/2701418/update-goldman-sachs-raises-pt-on-eli-lily-company-to-38,Joe Young,,,,,,
2012-06-27T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/06/2700552/goldman-sachs-maintains-eli-lilly-company-at-sell-raises-,Juan Lopez,,,,,,
2012-06-28T08:00:00.000+08:00,Lilly Statement on Affordable Care Act Ruling by Supreme Court,LLY,https://www.benzinga.com/news/12/06/2705869/lilly-statement-on-affordable-care-act-ruling-by-supreme-court,Paul Quintaro,,,,,,
2012-07-02T08:00:00.000+08:00,Bristol-Myers to Acquire Amylin,LLY,https://www.benzinga.com/news/12/07/2714085/bristol-myers-to-acquire-amylin,Brett Callwood,,,,,,
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722715/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,,,
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722706/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,,,
2012-07-10T08:00:00.000+08:00,"Immigrants: Restless Dreamers, Economic Pillars",LLY,https://www.benzinga.com/general/entrepreneurship/12/07/2731818/immigrants-restless-dreamers-economic-pillars,Marcus Goncalves,,,,,,
2012-07-11T08:00:00.000+08:00,Lilly's Schizophrenia Drug as Effective as Placebo -IBD,LLY,https://www.benzinga.com/news/12/07/2735535/lillys-schizophrenia-drug-as-effective-as-placebo-ibd,Charles Gross,,,,,,
2012-07-11T08:00:00.000+08:00,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study,LLY,https://www.benzinga.com/news/12/07/2734749/eli-lilly-announces-negative-clinical-trial-results-from-schizophrenia-study,Allie Wickman,,,,,,
2012-07-11T08:00:00.000+08:00,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study,LLY,https://www.benzinga.com/news/12/07/2734421/lilly-announces-pomaglumetad-methionil-did-not-meet-primary-endpoint-of-clinical-,Allie Wickman,,,,,,
2012-07-13T08:00:00.000+08:00,3 New Bets by a Biotech Hedge Fund,LLY,https://www.benzinga.com/news/12/07/2743392/3-new-bets-by-a-biotech-hedge-fund,Insider Monkey,,,,,,
2012-07-13T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2741560/jefferies-company-maintains-eli-lilly-at-hold-raises-pt-f,Juan Lopez,,,,,,
2012-07-18T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2752833/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,,,
2012-07-22T08:00:00.000+08:00,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2763844/pharmacokinetic-study-results-released-evaluating-interactions-between-livalo-and,Charles Gross,,,,,,
2012-07-23T08:00:00.000+08:00,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2764558/from-earlier-pharmacokinetic-study-results-released-evaluating-interactions-betwe,Eddie Staley,,,,,,
2012-07-23T08:00:00.000+08:00,Earnings Expectations for the Week of July 23,LLY,https://www.benzinga.com/news/earnings/12/07/2763770/earnings-expectations-for-the-week-of-july-23,Nelson Hem,,,,,,
2012-07-24T08:00:00.000+08:00,What You Need in Order to Retire Before Age 60,LLY,https://www.benzinga.com/general/topics/12/07/2766077/what-you-need-in-order-to-retire-before-age-60,Minyanville,,,,,,
2012-07-25T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/07/2773875/boehringer-ingelheim-and-eli-lilly-and-company-announced-jentadueto-tablets-recei,Eddie Staley,,,,,,
2012-07-25T08:00:00.000+08:00,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales,LLY,https://www.benzinga.com/news/12/07/2773705/update-eli-lilly-sees-250m-generics-effect-on-emerging-market-sales,Paul Quintaro,,,,,,
2012-07-25T08:00:00.000+08:00,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year,LLY,https://www.benzinga.com/news/12/07/2773666/eli-lilly-says-will-buy-back-420m-shares-by-the-end-of-the-year,Paul Quintaro,,,,,,
2012-07-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2772930/financial-breakfast-morning-news-summary-for-july-25-2012,James Hunter,,,,,,
2012-07-25T08:00:00.000+08:00,"Benzinga Market Primer, Wednesday July 25",LLY,https://www.benzinga.com/markets/bonds/12/07/2772668/benzinga-market-primer-wednesday-july-25,Matthew Kanterman,,,,,,
2012-07-25T08:00:00.000+08:00,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est,LLY,https://www.benzinga.com/news/earnings/12/07/2772602/eli-lilly-reports-q2-eps-0-83-vs-0-77-est-revenues-5-6b-vs-5-59b-est,Allie Wickman,,,,,,
2012-07-25T08:00:00.000+08:00,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading,LLY,https://www.benzinga.com/news/12/07/2772595/us-stock-futures-mixed-apple-shares-drop-in-pre-market-trading,Monica Gerson,,,,,,
2012-07-25T08:00:00.000+08:00,Earnings Scheduled For July 25,LLY,https://www.benzinga.com/news/earnings/12/07/2772332/earnings-scheduled-for-july-25,Monica Gerson,,,,,,
2012-07-27T08:00:00.000+08:00,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/07/2782644/update-morgan-stanley-raises-pt-on-eli-lily-co-from-39-t,Viktor Puskorius,,,,,,
2012-07-27T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2781737/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,,,
2012-07-30T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 30, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2785682/financial-breakfast-morning-news-summary-for-july-30-2012,James Hunter,,,,,,
2012-07-30T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785603/benzingas-top-downgrades,Lisa Levin,,,,,,
2012-07-30T08:00:00.000+08:00,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT from $37 to $35",LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785370/jefferies-company-downgrades-eli-lilly-from-hold-to-underpe,Juan Lopez,,,,,,
2012-08-07T08:00:00.000+08:00,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group",LLY,https://www.benzinga.com/news/12/08/2810951/update-lilly-says-fewer-forteo-patients-had-worsening-back-pain-says-had-9-deaths,Paul Quintaro,,,,,,
2012-08-07T08:00:00.000+08:00,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures,LLY,https://www.benzinga.com/news/12/08/2810908/lilly-announces-study-results-regarding-postmenopausal-women-with-back-pain-cause,Paul Quintaro,,,,,,
2012-08-07T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/08/2810517/benzingas-top-pre-market-losers,Lisa Levin,,,,,,
2012-08-12T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/08/2825817/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,,,
2012-08-17T08:00:00.000+08:00,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets,LLY,https://www.benzinga.com/news/12/08/2842042/fda-approves-prescribing-eli-lillys-tradjenta-tablets,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,Eli Lilly Alzheimer's Drug Misses Goals,LLY,https://www.benzinga.com/news/12/08/2858605/eli-lilly-alzheimers-drug-misses-goals,Brett Callwood,,,,,,
2012-08-24T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent,LLY,https://www.benzinga.com/news/12/08/2858432/u-s-court-of-appeals-upholds-validity-of-lillys-alimta-compound-patent,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2858334/credit-suisse-upgrades-eli-lilly-co-from-neutral-to-outperfor,Juan Lopez,,,,,,
2012-08-24T08:00:00.000+08:00,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg,LLY,https://www.benzinga.com/news/12/08/2858324/teva-loses-bid-to-invalidate-patent-on-lilys-alimata-drug-bloomberg,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends,LLY,https://www.benzinga.com/news/12/08/2858142/update-eli-lillys-conference-call-on-solanezumab-ends,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial View,LLY,https://www.benzinga.com/news/12/08/2858011/update-eli-lilly-says-doesnt-see-solanezumab-results-affecting-financial-view,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,Jefferies Maintains Underperform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2857961/jefferies-maintains-underperform-on-eli-lilly,Joe Young,,,,,,
2012-08-24T08:00:00.000+08:00,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease",LLY,https://www.benzinga.com/news/12/08/2857769/lilly-rises-9-5-pre-market-as-alzheimers-drug-fails-to-meet-primary-endpoints-but,Charles Gross,,,,,,
2012-08-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/08/2857750/benzingas-top-pre-market-gainers,Lisa Levin,,,,,,
2012-08-24T08:00:00.000+08:00,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial,LLY,https://www.benzinga.com/news/12/08/2857688/eli-lilly-announces-negative-results-of-solanezumab-phase-3-trial,Paul Quintaro,,,,,,
2012-08-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2857613/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2012-08-24T08:00:00.000+08:00,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease,LLY,https://www.benzinga.com/news/12/08/2857568/eli-lilly-and-company-announces-top-line-results-on-solanezumab-phase-3-clinical-,Charles Gross,,,,,,
2012-08-27T08:00:00.000+08:00,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure,LLY,https://www.benzinga.com/news/12/08/2860547/daiichi-sankyo-and-lilly-announce-trilogy-acs-results-regarding-effient-prasugrel,Charles Gross,,,,,,
2012-08-28T08:00:00.000+08:00,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864257/atlantic-equities-upgrades-eli-lilly-from-underweight-to-over,Juan Lopez,,,,,,
2012-08-28T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864233/benzingas-top-upgrades,Lisa Levin,,,,,,
2012-08-28T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2864109/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2012-08-29T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2869106/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,,,
2012-08-29T08:00:00.000+08:00,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged",LLY,https://www.benzinga.com/news/12/08/2868041/lilly-stops-phase-3-development-on-schizophrenia-treatment-sees-0-02-charge-forec,Paul Quintaro,,,,,,
2012-08-29T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/08/2867719/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,,,
2012-09-05T08:00:00.000+08:00,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2884564/sanford-c-bernstein-upgraded-eli-lilly-from-market-perfor,Juan Lopez,,,,,,
2012-09-06T08:00:00.000+08:00,Seven Cheap Large-Caps Yielding Over 4%,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/09/2889501/seven-cheap-large-caps-yielding-over-4,Scott Rubin,,,,,,
2012-09-06T08:00:00.000+08:00,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival,LLY,https://www.benzinga.com/news/12/09/2888379/eli-lilly-says-phase-iii-study-on-pointbreak-did-not-meet-primary-endpoint-of-imp,Eddie Staley,,,,,,
2012-09-14T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/09/2912158/update-goldman-sachs-reiterates-sell-rating-raises-pt-on,Dwight Einhorn,,,,,,
2012-09-14T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2910893/goldman-sachs-maintains-eli-lilly-at-sell-raises-pt-from-,Juan Lopez,,,,,,
2012-09-21T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2930331/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-42-to-4,Juan Lopez,,,,,,
2012-09-21T08:00:00.000+08:00,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union,LLY,https://www.benzinga.com/news/12/09/2930030/cialis-tablets-recommended-for-approval-for-the-treatment-of-the-signs-and-sympto,Eddie Staley,,,,,,
2012-09-26T08:00:00.000+08:00,McCormick Appoints Jacques Tapiero to Board of Directors,LLY,https://www.benzinga.com/news/12/09/2941278/mccormick-appoints-jacques-tapiero-to-board-of-directors,Eddie Staley,,,,,,
2012-09-29T08:00:00.000+08:00,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer,LLY,https://www.benzinga.com/news/12/09/2952144/lilly-presents-phase-ii-results-for-monoclonal-antibody-ramucirumab-in-lung-cance,Charles Gross,,,,,,
2012-10-01T08:00:00.000+08:00,Deutsche Bank Suspends Coverage on Eli Lilly &,LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2956750/deutsche-bank-suspends-coverage-on-eli-lilly,Juan Lopez,,,,,,
2012-10-01T08:00:00.000+08:00,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/12/10/2955561/eli-lilly-releases-data-from-phase-2-ramucirumab-trials-says-indicate-may-be-bene,Paul Quintaro,,,,,,
2012-10-02T08:00:00.000+08:00,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance,LLY,https://www.benzinga.com/news/12/10/2958910/from-earlier-lilly-and-boehringer-say-linagliptin-treatment-shows-significance,Paul Quintaro,,,,,,
2012-10-02T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2958453/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2012-10-02T08:00:00.000+08:00,Eli Lilly Reports on SGLT-2 Trials,LLY,https://www.benzinga.com/news/12/10/2958278/eli-lilly-reports-on-sglt-2-trials,Charles Gross,,,,,,
2012-10-08T08:00:00.000+08:00,Hearing BMO Making Cautious Comments on Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2975769/hearing-bmo-making-cautious-comments-on-lilly,Charles Gross,,,,,,
2012-10-08T08:00:00.000+08:00,Lilly Hits $50 Following Positive Phase 3 Results,LLY,https://www.benzinga.com/news/12/10/2975649/lilly-hits-50-following-positive-phase-3-results,Charles Gross,,,,,,
2012-10-08T08:00:00.000+08:00,"Lilly Hits 52-Week High on Phase 3 Results, $49.38",LLY,https://www.benzinga.com/news/12/10/2975518/lilly-hits-52-week-high-on-phase-3-results-49-38,Charles Gross,,,,,,
2012-10-08T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant,LLY,https://www.benzinga.com/news/12/10/2975514/eli-lilly-reports-phase-3-results-of-solanezumab-decline-in-expedition1-study-not,Paul Quintaro,,,,,,
2012-10-08T08:00:00.000+08:00,Lilly Spiking Higher,LLY,https://www.benzinga.com/news/12/10/2975513/lilly-spiking-higher,Charles Gross,,,,,,
2012-10-08T08:00:00.000+08:00,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide,LLY,https://www.benzinga.com/news/12/10/2974797/eli-lilly-says-ending-partnership-with-amylin-wasnt-easy-broad-diabetes-pipeline-,Paul Quintaro,,,,,,
2012-10-09T08:00:00.000+08:00,Part I: Must Know ETFs For Q3 Earnings,LLY,https://www.benzinga.com/markets/bonds/12/10/2979411/part-i-must-know-etfs-for-q3-earnings,ETF Professor,,,,,,
2012-10-09T08:00:00.000+08:00,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2979535/update-goldman-sachs-upgrades-eli-lilly-co-to-neutral-on,David Johnson,,,,,,
2012-10-09T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2978995/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-45-to-4,Juan Lopez,,,,,,
2012-10-09T08:00:00.000+08:00,Lilly Crosses $52 on Heavy Volume,LLY,https://www.benzinga.com/news/12/10/2978551/lilly-crosses-52-on-heavy-volume,Charles Gross,,,,,,
2012-10-09T08:00:00.000+08:00,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80",LLY,https://www.benzinga.com/news/12/10/2978519/lilly-hits-52-week-high-following-mondays-positive-phase-3-results-51-80,Charles Gross,,,,,,
2012-10-09T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2977465/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,,,
2012-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977429/benzingas-top-upgrades,Monica Gerson,,,,,,
2012-10-09T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977094/goldman-sachs-upgrades-eli-lilly-from-sell-to-neutral-raises-,Juan Lopez,,,,,,
2012-10-11T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2985584/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,,,
2012-10-12T08:00:00.000+08:00,Cowen Downgrades Eli Lilly & from Neutral to Underperform,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/10/2989837/cowen-downgrades-eli-lilly-from-neutral-to-underperform,Paul Quintaro,,,,,,
2012-10-12T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2989403/jefferies-company-maintains-eli-lilly-at-underperform-rai,Juan Lopez,,,,,,
2012-10-15T08:00:00.000+08:00,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid,LLY,https://www.benzinga.com/news/12/10/2994551/lilly-announces-new-data-further-exploring-mechanistic-differences-between-forteo,Eddie Staley,,,,,,
2012-10-15T08:00:00.000+08:00,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2994017/leerink-swan-upgrades-eli-lilly-from-market-perform-to-outper,Paul Quintaro,,,,,,
2012-10-15T08:00:00.000+08:00,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment,LLY,https://www.benzinga.com/news/12/10/2993329/lilly-announces-ramucirumab-showed-prolonged-progression-free-survival-in-gastric,Paul Quintaro,,,,,,
2012-10-17T08:00:00.000+08:00,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients,LLY,https://www.benzinga.com/node/3003546,Eddie Staley,,,,,,
2012-10-19T08:00:00.000+08:00,Amyvid Recommended for Approval in Europe,LLY,https://www.benzinga.com/news/12/10/3010245/amyvid-recommended-for-approval-in-europe,Paul Quintaro,,,,,,
2012-10-19T08:00:00.000+08:00,EU Recommends Approval of Lilly's Brain Plaque Test,LLY,https://www.benzinga.com/news/12/10/3009806/eu-recommends-approval-of-lillys-brain-plaque-test,Eddie Staley,,,,,,
2012-10-22T08:00:00.000+08:00,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug,LLY,https://www.benzinga.com/news/12/10/3013941/eli-lilly-says-got-positive-data-for-phase-iii-on-type-2-diabetes-drug,Paul Quintaro,,,,,,
2012-10-22T08:00:00.000+08:00,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/10/3013699/lilly-diabetes-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-t,Eddie Staley,,,,,,
2012-10-22T08:00:00.000+08:00,Earnings Expectations for the Week of October 22,LLY,https://www.benzinga.com/news/earnings/12/10/3012252/earnings-expectations-for-the-week-of-october-22,Nelson Hem,,,,,,
2012-10-23T08:00:00.000+08:00,Eli Lilly Releases Data From Two Retrospective Studies,LLY,https://www.benzinga.com/news/12/10/3018695/eli-lilly-releases-data-from-two-retrospective-studies,Eddie Staley,,,,,,
2012-10-23T08:00:00.000+08:00,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT,LLY,https://www.benzinga.com/news/12/10/3018685/new-retrospective-studies-of-hospital-readmission-rates-for-subsequent-heart-atta,Paul Quintaro,,,,,,
2012-10-24T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Downbeat Q3 Profit,LLY,https://www.benzinga.com/news/earnings/12/10/3020117/update-eli-lilly-posts-downbeat-q3-profit,Lisa Levin,,,,,,
2012-10-24T08:00:00.000+08:00,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est,LLY,https://www.benzinga.com/news/earnings/12/10/3020018/eli-lilly-reports-q3-eps-0-79-vs-0-83-est-revenues-5-62b-vs-5-62b-est,Allie Wickman,,,,,,
2012-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2012",LLY,https://www.benzinga.com/news/earnings/12/10/3019635/earnings-scheduled-for-october-24-2012,Monica Gerson,,,,,,
2012-10-25T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/10/3027401/short-interest-swings-in-biotech-stocks-biib-gild-vvus,Nelson Hem,,,,,,
2012-10-26T08:00:00.000+08:00,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/3030232/bmo-capital-markets-maintains-eli-lilly-at-market-perform,Juan Lopez,,,,,,
2012-10-30T08:00:00.000+08:00,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations,LLY,https://www.benzinga.com/news/12/10/3038947/lilly-to-announce-expansion-of-indianapolis-insulin-manufacturing-operations,Paul Quintaro,,,,,,
2012-10-30T08:00:00.000+08:00,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/10/3037813/european-commission-approves-lillys-cialis-for-benign-prostatic-hyperplasia,Charles Gross,,,,,,
2012-11-09T08:00:00.000+08:00,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases,LLY,https://www.benzinga.com/news/12/11/3075054/lilly-to-present-phase-ii-rheumatoid-arthritis-and-biomarker-data-at-acr-for-two-,Paul Quintaro,,,,,,
2012-11-13T08:00:00.000+08:00,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials",LLY,https://www.benzinga.com/news/12/11/3086353/lilly-and-incyte-announce-additional-phase-iib-baricitinib-data-advance-into-phas,Eddie Staley,,,,,,
2012-11-21T08:00:00.000+08:00,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment,LLY,https://www.benzinga.com/news/12/11/3111645/eli-lillys-tabalumab-receives-orphan-drug-designation-for-multiple-myeloma-treatm,Paul Quintaro,,,,,,
2012-11-29T08:00:00.000+08:00,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3132161/citi-reiterates-buy-on-eli-lilly-and-company-maintains-55-00-pt,Paul Quintaro,,,,,,
2012-11-30T08:00:00.000+08:00,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3135439/citigroup-initiates-coverage-on-eli-lilly-and-company-at-buy-annoucnes-55-00-pt,Paul Quintaro,,,,,,
2012-12-10T08:00:00.000+08:00,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3159940/three-more-defensive-stock-picks-for-2013-lly-pfe-vtr,Nelson Hem,,,,,,
2012-12-12T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3167675/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,,,
2012-12-12T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/12/3166290/benzingas-top-pre-market-losers,Lisa Levin,,,,,,
2012-12-12T08:00:00.000+08:00,Eli Lilly Discusses Next Steps for Solanezumab,LLY,https://www.benzinga.com/news/12/12/3166274/eli-lilly-discusses-next-steps-for-solanezumab,Paul Quintaro,,,,,,
2012-12-12T08:00:00.000+08:00,Lilly Provides Update on Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/12/12/3165927/lilly-provides-update-on-solanezumab-phase-3-study,Charles Gross,,,,,,
2012-12-13T08:00:00.000+08:00,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share",LLY,https://www.benzinga.com/news/12/12/3170277/eli-lilly-reaffirms-fy12-outlook-sees-q4-charge-of-20-35m-pretax-or-0-02share,Paul Quintaro,,,,,,
2012-12-17T08:00:00.000+08:00,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend",LLY,https://www.benzinga.com/news/12/12/3180346/eli-lilly-authorizes-1-5b-buyback-plan-declares-0-49share-qtr-dividend,Paul Quintaro,,,,,,
2012-12-18T08:00:00.000+08:00,"Benzinga Market Primer, Tuesday, December 18",LLY,https://www.benzinga.com/news/12/12/3181502/benzinga-market-primer-tuesday-december-18,Sam Mattera,,,,,,
2012-12-20T08:00:00.000+08:00,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case,LLY,https://www.benzinga.com/news/12/12/3191061/eli-lilly-to-pay-29-4m-to-settle-sec-foreign-bribery-case,Paul Quintaro,,,,,,
2013-01-04T08:00:00.000+08:00,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher,LLY,https://www.benzinga.com/news/13/01/3215088/eli-lilly-offers-solid-fy13-eps-outlook-shares-slightly-higher,Paul Quintaro,,,,,,
2013-01-07T08:00:00.000+08:00,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00",LLY,https://www.benzinga.com/news/13/01/3220708/ubs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-51-00,Juan Lopez,,,,,,
2013-01-07T08:00:00.000+08:00,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3219991/update-bmo-capital-markets-reiterates-market-perform-rat,Dwight Einhorn,,,,,,
2013-01-07T08:00:00.000+08:00,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog",LLY,https://www.benzinga.com/news/13/01/3218919/eli-lilly-reassumes-sole-worldwide-development-commercialization-role-for-novel-b,Paul Quintaro,,,,,,
2013-01-07T08:00:00.000+08:00,"Stocks To Watch For January 7, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3217926/stocks-to-watch-for-january-7-2013,Monica Gerson,,,,,,
2013-01-08T08:00:00.000+08:00,Goldman Sachs and Others That May Beat Earnings,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3225028/goldman-sachs-and-others-that-may-beat-earnings,Nelson Hem,,,,,,
2013-01-09T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3229062/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,,,
2013-01-09T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00",LLY,https://www.benzinga.com/news/13/01/3228628/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-60-00,Juan Lopez,,,,,,
2013-01-15T08:00:00.000+08:00,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's,LLY,https://www.benzinga.com/news/13/01/3245709/lilys-amyvid-approved-in-eu-for-patients-with-cognitive-impairment-being-evaluate,Paul Quintaro,,,,,,
2013-01-16T08:00:00.000+08:00,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3248011/update-jefferies-company-reiterates-underperform-rating-,Dwight Einhorn,,,,,,
2013-01-16T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00",LLY,https://www.benzinga.com/news/13/01/3247857/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-43-00,Juan Lopez,,,,,,
2013-01-17T08:00:00.000+08:00,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT",LLY,https://www.benzinga.com/news/13/01/3251597/clsa-initiates-coverage-on-eli-lilly-and-company-at-sell-announces-47-00-pt,Juan Lopez,,,,,,
2013-01-25T08:00:00.000+08:00,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report",LLY,https://www.benzinga.com/news/earnings/13/01/3276171/the-week-ahead-earnings-from-facebook-ford-caterpillar-us-jobs-report,Sam Mattera,,,,,,
2013-01-26T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3276790/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,,,
2013-01-29T08:00:00.000+08:00,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,LLY,https://www.benzinga.com/news/13/01/3284158/novo-spokesperson-says-will-introduce-tresiba-in-some-eu-countries-in-first-half-,Paul Quintaro,,,,,,
2013-01-29T08:00:00.000+08:00,Lilly Planning Five New Drug Regulatory Filings in 2013,LLY,https://www.benzinga.com/news/13/01/3283502/lilly-planning-five-new-drug-regulatory-filings-in-2013,Paul Quintaro,,,,,,
2013-01-29T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast",LLY,https://www.benzinga.com/news/earnings/13/01/3282838/update-eli-lilly-posts-upbeat-q4-profit-lifts-fy13-forecast,Lisa Levin,,,,,,
2013-01-29T08:00:00.000+08:00,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est,LLY,https://www.benzinga.com/news/earnings/13/01/3282458/eli-lilly-co-reports-q4-eps-of-0-85-vs-0-82-est-revenue-5-96b-vs-5-78b-e,Charles Gross,,,,,,
2013-01-29T08:00:00.000+08:00,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data",LLY,https://www.benzinga.com/news/13/01/3282302/us-stock-futures-slightly-lower-ahead-of-ford-earnings-consumer-confidence-data,Monica Gerson,,,,,,
2013-01-29T08:00:00.000+08:00,"Earnings Scheduled For January 29, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3282117/earnings-scheduled-for-january-29-2013,Monica Gerson,,,,,,
2013-01-30T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3289155/update-goldman-sachs-reiterates-neutral-rating-raises-pt,Dwight Einhorn,,,,,,
2013-01-30T08:00:00.000+08:00,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3288937/update-citigroup-raises-eli-lilly-pt-to-60-on-eli-lilly-,David Johnson,,,,,,
2013-01-30T08:00:00.000+08:00,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00",LLY,https://www.benzinga.com/news/13/01/3288031/goldman-sachs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-56-00,Juan Lopez,,,,,,
2013-01-30T08:00:00.000+08:00,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00",LLY,https://www.benzinga.com/news/13/01/3288015/citigroup-maintains-buy-on-eli-lilly-and-company-raises-pt-to-60-00,Juan Lopez,,,,,,
2013-02-06T08:00:00.000+08:00,Eli Lilly Re-testing Breakout Over $53.50,LLY,https://www.benzinga.com/trading-ideas/dividends/13/02/3311390/eli-lilly-re-testing-breakout-over-53-50,Zack Armstrong,,,,,,
2013-02-07T08:00:00.000+08:00,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab,LLY,https://www.benzinga.com/news/13/02/3313229/eli-lilly-discontinues-phase-3-rheumatoid-arthritis-program-for-tabalumab,Paul Quintaro,,,,,,
2013-02-20T08:00:00.000+08:00,Eli Lilly Continues Advance After Breakout Over $54 Resistance,LLY,https://www.benzinga.com/trading-ideas/technicals/13/02/3349768/eli-lilly-continues-advance-after-breakout-over-54-resistance,Zack Armstrong,,,,,,
2013-02-27T08:00:00.000+08:00,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares,LLY,https://www.benzinga.com/news/13/02/3373257/eli-lilly-issues-statement-related-to-intention-to-cancel-listing-of-london-stock,Paul Quintaro,,,,,,
2013-02-27T08:00:00.000+08:00,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3372680/update-credit-suisse-raises-pt-to-68-on-eli-lilly-on-pat,David Johnson,,,,,,
2013-02-28T08:00:00.000+08:00,"If The Market Falls, Try These Low Beta ETFs",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3379576/if-the-market-falls-try-these-low-beta-etfs,ETF Professor,,,,,,
2013-03-01T08:00:00.000+08:00,Eli Lilly Files Automatic Mixed Securities Shelf,LLY,https://www.benzinga.com/news/13/03/3381184/eli-lilly-files-automatic-mixed-securities-shelf,Paul Quintaro,,,,,,
2013-03-05T08:00:00.000+08:00,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3391697/eli-lilly-breaks-out-over-55-resistance-to-continue-uptrend-m,Zack Armstrong,,,,,,
2013-03-05T08:00:00.000+08:00,Eli Lilly Sets Date for '13 Diabetes Pipeline Update,LLY,https://www.benzinga.com/news/13/03/3389836/eli-lilly-sets-date-for-13-diabetes-pipeline-update,Paul Quintaro,,,,,,
2013-03-11T08:00:00.000+08:00,Are Scientists Edging Closer to a Cure for Alzheimer's?,LLY,https://www.benzinga.com/news/13/03/3404085/are-scientists-edging-closer-to-a-cure-for-alzheimers,Tim Parker,,,,,,
2013-03-14T08:00:00.000+08:00,Magnet Trades: The Case of Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3417945/magnet-trades-the-case-of-eli-lilly,Dennis Dick,,,,,,
2013-03-18T08:00:00.000+08:00,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia,LLY,https://www.benzinga.com/news/13/03/3424958/lilly-says-new-study-of-cialis-met-primary-endpoint-in-men-with-lower-urinary-tra,Paul Quintaro,,,,,,
2013-03-22T08:00:00.000+08:00,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3439970/eli-lilly-fails-at-55-75-resistance-20-ema-support-lower-at-5,Zack Armstrong,,,,,,
2013-03-25T08:00:00.000+08:00,This Dead Money Sector is Leading the S&P This Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3442563/this-dead-money-sector-is-leading-the-s-p-this-year,Tim Parker,,,,,,
2013-03-26T08:00:00.000+08:00,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares,LLY,https://www.benzinga.com/news/13/03/3447546/eli-lilly-isues-statement-re-intention-to-cancel-listing-of-shares,Paul Quintaro,,,,,,
2013-03-26T08:00:00.000+08:00,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin",LLY,https://www.benzinga.com/news/13/03/3447482/ema-accepts-marketing-authorization-app-for-boehringer-lilly-empagliflozin,Paul Quintaro,,,,,,
2013-04-02T08:00:00.000+08:00,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops,LLY,https://www.benzinga.com/news/13/04/3463492/eli-lilly-working-with-indianapolis-officials-for-proposal-to-invest-added-180m-i,Paul Quintaro,,,,,,
2013-04-03T08:00:00.000+08:00,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3468447/eli-lilly-attempting-to-breakout-over-57-resistance-rsi-overb,Zack Armstrong,,,,,,
2013-04-09T08:00:00.000+08:00,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3483196/eli-lilly-rejects-57-25-resistance-20-ema-support-lower-at-56,Zack Armstrong,,,,,,
2013-04-10T08:00:00.000+08:00,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3486693/update-jefferies-raises-pt-on-eli-lilly-co-as-least-pref,Dwight Einhorn,,,,,,
2013-04-10T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00",LLY,https://www.benzinga.com/news/13/04/3485535/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-44-00,Juan Lopez,,,,,,
2013-04-11T08:00:00.000+08:00,ETF Showdown: A Pharma Fight,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3491090/etf-showdown-a-pharma-fight,ETF Professor,,,,,,
2013-04-11T08:00:00.000+08:00,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st,LLY,https://www.benzinga.com/news/13/04/3491071/ap-reporting-eli-lilly-planning-to-cut-hundreds-from-us-sales-force-by-july-1st,Paul Quintaro,,,,,,
2013-04-16T08:00:00.000+08:00,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/04/3499958/lilly-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-type-2-dia,Paul Quintaro,,,,,,
2013-04-17T08:00:00.000+08:00,Lilly Buys Novel Tau Tangle Diagnostic Progra,LLY,https://www.benzinga.com/news/13/04/3503556/lilly-buys-novel-tau-tangle-diagnostic-progra,Paul Quintaro,,,,,,
2013-04-19T08:00:00.000+08:00,"Weekly Preview: Earnings Season Continues, Apple In Focus",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3512062/weekly-preview-earnings-season-continues-apple-in-focus,Matthew Kanterman,,,,,,
2013-04-21T08:00:00.000+08:00,Earnings Expectations for the Week of April 22,LLY,https://www.benzinga.com/news/earnings/13/04/3514067/earnings-expectations-for-the-week-of-april-22,Nelson Hem,,,,,,
2013-04-23T08:00:00.000+08:00,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected",LLY,https://www.benzinga.com/news/earnings/13/04/3521186/eli-lilly-earnings-preview-eps-sales-growth-expected,Nelson Hem,,,,,,
2013-04-24T08:00:00.000+08:00,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support,LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3525181/eli-lilly-approaching-the-april-19th-low-of-56-37-currently-s,bret.kenwell@benzinga.com,,,,,,
2013-04-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est,LLY,https://www.benzinga.com/news/earnings/13/04/3523672/eli-lilly-and-company-reports-q1-eps-of-1-14-vs-1-05-est-revenue-of-5-60,Charles Gross,,,,,,
2013-04-24T08:00:00.000+08:00,US Stock Futures Up Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/04/3523632/us-stock-futures-up-ahead-of-earnings,Monica Gerson,,,,,,
2013-04-24T08:00:00.000+08:00,"Stocks To Watch For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523445/stocks-to-watch-for-april-24-2013,Monica Gerson,,,,,,
2013-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523440/earnings-scheduled-for-april-24-2013,Monica Gerson,,,,,,
2013-04-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, April 25",LLY,https://www.benzinga.com/markets/bonds/13/04/3528251/benzinga-market-primer-thursday-april-25,Matthew Kanterman,,,,,,
2013-05-06T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3560669/benzingas-top-pre-market-losers,Lisa Levin,,,,,,
2013-05-10T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3578792/benzingas-top-pre-market-losers,Monica Gerson,,,,,,
2013-05-10T08:00:00.000+08:00,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma,LLY,https://www.benzinga.com/news/13/05/3578660/lilly-announces-enzastaurin-phase-iii-study-did-not-meet-primary-endpoint-in-diff,Eddie Staley,,,,,,
2013-05-10T08:00:00.000+08:00,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook,LLY,https://www.benzinga.com/news/13/05/3578633/lilly-says-enzastaurin-phase-iii-did-not-meet-primary-endpoint-reaffirms-outlook,Paul Quintaro,,,,,,
2013-05-14T08:00:00.000+08:00,"PreMarket Info Recap for May 14, 2013",LLY,https://www.benzinga.com/news/13/05/3587360/premarket-info-recap-for-may-14-2013,PreMarketInfo,,,,,,
2013-05-14T08:00:00.000+08:00,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected,LLY,https://www.benzinga.com/news/13/05/3587273/eli-lillly-says-ceo-john-lechleiters-surgery-went-as-expected,Paul Quintaro,,,,,,
2013-05-18T08:00:00.000+08:00,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/05/3601714/u-s-steel-genomic-health-and-other-stocks-insiders-are-buying,Nelson Hem,,,,,,
2013-05-28T08:00:00.000+08:00,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/05/3624587/update-jefferies-upgrades-eli-lilly-to-hold-raises-pt-fo,Dwight Einhorn,,,,,,
2013-05-28T08:00:00.000+08:00,"PreMarket Info Recap for May 28, 2013",LLY,https://www.benzinga.com/news/earnings/13/05/3624297/premarket-info-recap-for-may-28-2013,PreMarketInfo,,,,,,
2013-05-28T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00",LLY,https://www.benzinga.com/news/13/05/3623663/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-49-00,Juan Lopez,,,,,,
2013-05-29T08:00:00.000+08:00,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT",LLY,https://www.benzinga.com/news/13/05/3630415/suntrust-robinson-humphrey-initiates-coverage-on-eli-lilly-and-company-at-buy-ann,Paul Quintaro,,,,,,
2013-05-29T08:00:00.000+08:00,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis,LLY,https://www.benzinga.com/news/13/05/3628114/new-data-on-forteo-teriparatide-rdna-origin-injection-show-increased-bone-mineral,Eddie Staley,,,,,,
2013-06-02T08:00:00.000+08:00,"CVR Energy, Warner Chilcott and Other Top Performers in May",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/06/3639582/cvr-energy-warner-chilcott-and-other-top-performers-in-may,Nelson Hem,,,,,,
2013-06-03T08:00:00.000+08:00,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint,LLY,https://www.benzinga.com/news/13/06/3641076/lilly-announces-pronounce-trial-did-not-meet-primary-superiority-endpoint,Paul Quintaro,,,,,,
2013-06-06T08:00:00.000+08:00,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)",LLY,https://www.benzinga.com/news/13/06/3653822/drug-company-profits-set-to-increase-from-additions-to-dsm-5,Jim Probasco,,,,,,
2013-06-13T08:00:00.000+08:00,UPDATE: Lilly Doesn't See Charge as Material,LLY,https://www.benzinga.com/news/13/06/3675179/update-lilly-doesnt-see-charge-as-material,Paul Quintaro,,,,,,
2013-06-13T08:00:00.000+08:00,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge",LLY,https://www.benzinga.com/news/13/06/3675176/lilly-issues-release-voluntarily-terminates-phase-ii-study-of-ly2886721-says-deci,Paul Quintaro,,,,,,
2013-06-13T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/06/3672822/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2013-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/13/06/3672609/lilly-incyte-announce-baricitinib-efficacy-and-safety-data-from-phase-2b-jada-stu,Charles Gross,,,,,,
2013-06-19T08:00:00.000+08:00,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name,LLY,https://www.benzinga.com/news/13/06/3690486/eli-lilly-issues-alert-for-two-illegal-scans-involving-co-name,Paul Quintaro,,,,,,
2013-06-20T08:00:00.000+08:00,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets",LLY,https://www.benzinga.com/press-releases/13/06/3693429/boehringer-ingelheim-pharmaceuticals-inc-and-eli-lilly-and-company-anno,James Hunt,,,,,,
2013-06-22T08:00:00.000+08:00,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function",LLY,https://www.benzinga.com/news/13/06/3698004/phase-3-study-shows-empagliflozin-significantly-reduced-blood-glucose-in-adults-w,Charles Gross,,,,,,
2013-06-22T08:00:00.000+08:00,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/06/3698001/lilly-announces-phase-3-data-show-empagliflozin-plus-insulin-significantly-reduce,Charles Gross,,,,,,
2013-06-25T08:00:00.000+08:00,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin",LLY,https://www.benzinga.com/news/13/06/3703663/boehringer-lilly-offer-results-of-cv-post-hoc-meta-analysis-examining-cv-events-i,Paul Quintaro,,,,,,
2013-07-03T08:00:00.000+08:00,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/13/07/3727699/lilly-to-host-call-discussing-trial-design-of-new-solanezumab-phase-3-study,Paul Quintaro,,,,,,
2013-07-16T08:00:00.000+08:00,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3756698/eli-lilly-tries-again-with-alzheimers-drug-as-the-race-f,Jim Probasco,,,,,,
2013-07-16T08:00:00.000+08:00,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy,LLY,https://www.benzinga.com/news/13/07/3755577/new-study-shows-men-taking-cialis-tadalafil-tablets-once-daily-returned-to-normal,James Hunt,,,,,,
2013-07-17T08:00:00.000+08:00,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year",LLY,https://www.benzinga.com/news/13/07/3761161/bloomberg-reporting-eli-lilly-spokesperson-says-to-freeze-worker-exec-pay-this-ye,Paul Quintaro,,,,,,
2013-07-19T08:00:00.000+08:00,Weekly Preview: Earnings Season Kicks Into Hyperdrive,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3767719/weekly-preview-earnings-season-kicks-into-hyperdrive,Matthew Kanterman,,,,,,
2013-07-22T08:00:00.000+08:00,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)",LLY,https://www.benzinga.com/news/earnings/13/07/3769106/earnings-expectations-for-the-week-of-july-22-aapl-gm-mcd-nflx,Nelson Hem,,,,,,
2013-07-23T08:00:00.000+08:00,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly,LLY,https://www.benzinga.com/news/13/07/3776476/transition-therapeutics-enters-osteoarthritis-license-and-collaboration-agreement,James Hunt,,,,,,
2013-07-24T08:00:00.000+08:00,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!",LLY,https://www.benzinga.com/news/earnings/13/07/3778890/benzingas-premarket-info-recap-for-july-24-2013-ford-and-general-motors-,PreMarketInfo,,,,,,
2013-07-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/07/3778530/benzingas-top-pre-market-gainers,Lisa Levin,,,,,,
2013-07-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/07/3778160/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,,,
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est,LLY,https://www.benzinga.com/news/13/07/3778051/eli-lilly-and-company-raises-fy2013-eps-guidance-from-3-82-3-97-to-4-05-4-15-vs-3,Paul Quintaro,,,,,,
2013-07-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook",LLY,https://www.benzinga.com/news/earnings/13/07/3778038/update-eli-lilly-posts-31-rise-in-q2-profit-lifts-full-year-outlook,Lisa Levin,,,,,,
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777867/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est-revenue-of-5-92,Charles Gross,,,,,,
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777866/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est,Charles Gross,,,,,,
2013-07-24T08:00:00.000+08:00,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat",LLY,https://www.benzinga.com/markets/bonds/13/07/3777693/benzinga-market-primer-wednesday-july-24-apple-earnings-beat,Matthew Kanterman,,,,,,
2013-07-24T08:00:00.000+08:00,US Stock Futures Rise After Upbeat Apple Results,LLY,https://www.benzinga.com/news/13/07/3777812/us-stock-futures-rise-after-upbeat-apple-results,Monica Gerson,,,,,,
2013-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/07/3777589/earnings-scheduled-for-july-24-2013,Monica Gerson,,,,,,
2013-07-25T08:00:00.000+08:00,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00",LLY,https://www.benzinga.com/news/13/07/3783085/barclays-maintains-equal-weight-on-eli-lilly-and-company-raises-pt-to-58-00,Juan Lopez,,,,,,
2013-07-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",LLY,https://www.benzinga.com/markets/bonds/13/07/3782015/benzinga-market-primer-thursday-july-25-futures-lower-after-technical-br,Matthew Kanterman,,,,,,
2013-08-13T08:00:00.000+08:00,Eli Lilly Soaring After Positive Cancer Drug Data (LLY),LLY,https://www.benzinga.com/news/13/08/3834345/eli-lilly-soaring-after-positive-cancer-drug-data-lly,Tim Parker,,,,,,
2013-08-13T08:00:00.000+08:00,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX",LLY,https://www.benzinga.com/news/13/08/3834157/notable-stocks-trading-ex-dividend-today-dupont-kroger-eli-lilly-microsoft-tjx,Paul Quintaro,,,,,,
2013-08-13T08:00:00.000+08:00,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint,LLY,https://www.benzinga.com/news/13/08/3833989/lilly-reports-phase-iii-necitumumab-study-met-primary-endpoint,Paul Quintaro,,,,,,
2013-08-15T08:00:00.000+08:00,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control,LLY,https://www.benzinga.com/news/13/08/3842282/linagliptin-demonstrated-significant-hba1c-reduction-in-elderly-people-with-type-,James Hunt,,,,,,
2013-08-22T08:00:00.000+08:00,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes,LLY,https://www.benzinga.com/news/13/08/3857382/eli-lilly-accused-of-bribing-doctors-in-china-wantchinatimes,Charles Gross,,,,,,
2013-08-28T08:00:00.000+08:00,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology,LLY,https://www.benzinga.com/news/13/08/3871986/immunogen-shares-charge-higher-following-news-of-deal-with-lilly-for-tap-technolo,Paul Quintaro,,,,,,
2013-08-28T08:00:00.000+08:00,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly,LLY,https://www.benzinga.com/news/13/08/3871979/update-immuogen-may-get-up-to-200-5m-under-deal-with-eli-lilly,Paul Quintaro,,,,,,
2013-08-28T08:00:00.000+08:00,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology,LLY,https://www.benzinga.com/news/13/08/3871972/form-8-k-shows-immunogen-entered-into-license-deal-with-eli-lilly-for-targeted-an,Paul Quintaro,,,,,,
2013-08-29T08:00:00.000+08:00,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes",LLY,https://www.benzinga.com/news/13/08/3874797/humana-lilly-collaborate-on-research-to-improve-health-care-outcomes,Charles Gross,,,,,,
2013-09-12T08:00:00.000+08:00,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting,LLY,https://www.benzinga.com/markets/bonds/13/09/3907246/benzinga-market-primer-thursday-september-12-kerry-and-lavrov-discuss-th,Laura Brodbeck,,,,,,
2013-09-17T08:00:00.000+08:00,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting,LLY,https://www.benzinga.com/news/13/09/3918659/lilly-to-present-data-across-diabetes-portfolio-at-49th-european-association-for-,Paul Quintaro,,,,,,
2013-09-26T08:00:00.000+08:00,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators,LLY,https://www.benzinga.com/news/13/09/3944283/lilly-shows-investigational-dulaglutide-resulted-in-improved-indicators,Paul Quintaro,,,,,,
2013-09-26T08:00:00.000+08:00,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944264/lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ramucir,Paul Quintaro,,,,,,
2013-09-26T08:00:00.000+08:00,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944254/eli-lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ram,Paul Quintaro,,,,,,
2013-09-28T08:00:00.000+08:00,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid",LLY,https://www.benzinga.com/news/13/09/3949927/lilly-disappointed-in-medicare-decision-to-deny-appropriate-patient-access-to-bet,Charles Gross,,,,,,
2013-09-30T08:00:00.000+08:00,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents,LLY,https://www.benzinga.com/news/13/09/3951685/eli-lilly-says-disappointed-in-medicares-decision-to-deny-patient-access-to-beta-,Paul Quintaro,,,,,,
2013-10-02T08:00:00.000+08:00,Pharmaceutical Industry Expected To Collect Billions From Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/10/3959811/pharmaceutical-industry-expected-to-collect-billions-from-oba,James Ha,,,,,,
2013-10-03T08:00:00.000+08:00,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound",LLY,https://www.benzinga.com/markets/commodities/13/10/3964446/premarket-info-recap-for-october-3-2013-quiet-markets-range-bound,PreMarketInfo,,,,,,
2013-10-03T08:00:00.000+08:00,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend",LLY,https://www.benzinga.com/news/13/10/3963817/lilly-reaffirms-outlook-will-buyback-up-to-5b-in-shares-maintaining-dividend,Paul Quintaro,,,,,,
2013-10-08T08:00:00.000+08:00,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",LLY,https://www.benzinga.com/analyst-ratings/price-target/13/10/3976494/credit-suisse-starts-pfizer-bristol-myers-abbvie-allergan,Paul Quintaro,,,,,,
2013-10-10T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company to Sell,LLY,https://www.benzinga.com/news/13/10/3981556/edward-jones-upgrades-eli-lilly-and-company-to-sell,Paul Quintaro,,,,,,
2013-10-11T08:00:00.000+08:00,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable,LLY,https://www.benzinga.com/news/13/10/3985376/fitch-affirms-eli-lilly-rating-raises-outlook-from-negative-to-stable,Paul Quintaro,,,,,,
2013-10-11T08:00:00.000+08:00,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00",LLY,https://www.benzinga.com/news/13/10/3984953/jefferies-downgrades-eli-lilly-and-company-to-underperform-lowers-pt-to-40-00,Paul Quintaro,,,,,,
2013-10-11T08:00:00.000+08:00,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End",LLY,https://www.benzinga.com/news/earnings/13/10/3984727/market-primer-friday-october-11-budget-showdown-could-be-nearing-its-end,Laura Brodbeck,,,,,,
2013-10-20T08:00:00.000+08:00,Earnings Expectations For The Week Of October 21: The Crunch Is On,LLY,https://www.benzinga.com/news/earnings/13/10/4004935/earnings-expectations-for-the-week-of-october-21-the-crunch-is-on,Nelson Hem,,,,,,
2013-10-23T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/10/4014409/benzingas-top-pre-market-gainers,Monica Gerson,,,,,,
2013-10-23T08:00:00.000+08:00,US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/10/4014076/us-stock-futures-down-ahead-of-earnings,Monica Gerson,,,,,,
2013-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Q3 Profit Drops 9.3%,LLY,https://www.benzinga.com/news/earnings/13/10/4014069/update-eli-lilly-q3-profit-drops-9-3,Monica Gerson,,,,,,
2013-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est,LLY,https://www.benzinga.com/news/earnings/13/10/4013863/eli-lilly-and-company-reports-q3-eps-of-1-11-vs-1-04-est-revenue-of-5-77,Charles Gross,,,,,,
2013-10-23T08:00:00.000+08:00,FDA Grants Priority Review to Lilly's Ramucirumab,LLY,https://www.benzinga.com/news/13/10/4013862/fda-grants-priority-review-to-lillys-ramucirumab,Charles Gross,,,,,,
2013-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013617/earnings-scheduled-for-october-23-2013,Monica Gerson,,,,,,
2013-10-23T08:00:00.000+08:00,"Stocks To Watch For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013609/stocks-to-watch-for-october-23-2013,Monica Gerson,,,,,,
2013-10-24T08:00:00.000+08:00,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT",LLY,https://www.benzinga.com/news/13/10/4019636/mkm-partners-upgrades-eli-lilly-and-company-to-buy-maintains-59-00-pt,Paul Quintaro,,,,,,
2013-10-25T08:00:00.000+08:00,UPDATE: FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022594/update-fda-approves-addition-to-cialis-product-label,Eddie Staley,,,,,,
2013-10-25T08:00:00.000+08:00,Elli Lilly Says FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022566/elli-lilly-says-fda-approves-addition-to-cialis-product-label,Paul Quintaro,,,,,,
2013-11-11T08:00:00.000+08:00,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/11/4068825/update-goldman-sachs-downgrades-eli-lilly-company-on-rel,Dwight Einhorn,,,,,,
2013-11-11T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/13/11/4068178/benzingas-top-downgrades,Monica Gerson,,,,,,
2013-11-11T08:00:00.000+08:00,US Stock Futures Mixed After Friday Rally,LLY,https://www.benzinga.com/news/13/11/4068007/us-stock-futures-mixed-after-friday-rally,Monica Gerson,,,,,,
2013-11-11T08:00:00.000+08:00,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00",LLY,https://www.benzinga.com/news/13/11/4067895/goldman-sachs-downgrades-eli-lilly-and-company-to-sell-lowers-pt-to-48-00,Juan Lopez,,,,,,
2013-11-14T08:00:00.000+08:00,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit",LLY,https://www.benzinga.com/news/13/11/4080047/actavis-confirms-patent-challenge-of-generic-axiron-says-lilly-filed-suit,Paul Quintaro,,,,,,
2013-11-14T08:00:00.000+08:00,US Stock Futures Mixed Ahead of Economic Data,LLY,https://www.benzinga.com/news/13/11/4079696/us-stock-futures-mixed-ahead-of-economic-data,Monica Gerson,,,,,,
2013-11-14T08:00:00.000+08:00,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity,LLY,https://www.benzinga.com/news/13/11/4079436/lilly-to-invest-700m-to-enhance-global-insulin-manufacturing-capacity,Charles Gross,,,,,,
2013-11-18T08:00:00.000+08:00,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds,LLY,https://www.benzinga.com/news/13/11/4087478/qiagen-announces-agreement-to-develop-molecular-companion-diagnostic-paired-with-,Charles Gross,,,,,,
2013-12-03T08:00:00.000+08:00,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",LLY,https://www.benzinga.com/news/13/12/4125553/bloomberg-reporting-merck-eli-lilly-rumored-to-be-interested-in-novartis-veterina,Paul Quintaro,,,,,,
2013-12-05T08:00:00.000+08:00,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share",LLY,https://www.benzinga.com/news/13/12/4131925/lilly-reports-edivoxetine-did-not-meet-primary-endpoint-expecting-q4-charge-0-01s,Paul Quintaro,,,,,,
2013-12-11T08:00:00.000+08:00,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules,LLY,https://www.benzinga.com/news/13/12/4148698/citron-pharma-launches-generic-cymbalta-delayed-release-capsules,Charles Gross,,,,,,
2013-12-11T08:00:00.000+08:00,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta,LLY,https://www.benzinga.com/news/13/12/4148557/fda-approves-first-generic-versions-of-antidepressant-drug-cymbalta,Charles Gross,,,,,,
2013-12-13T08:00:00.000+08:00,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment,LLY,https://www.benzinga.com/news/13/12/4153669/immunogen-reporting-that-lilly-may-extend-its-pact-with-added-payment,Paul Quintaro,,,,,,
2013-12-20T08:00:00.000+08:00,US Stock Futures Gain Ahead Of GDP Data,LLY,https://www.benzinga.com/news/13/12/4172260/us-stock-futures-gain-ahead-of-gdp-data,Monica Gerson,,,,,,
2013-12-20T08:00:00.000+08:00,"PeptiDream Announces Collaboration, License Agreement with Lilly",LLY,https://www.benzinga.com/news/13/12/4172061/peptidream-announces-collaboration-license-agreement-with-lilly,Charles Gross,,,,,,
2014-01-07T08:00:00.000+08:00,Market Wrap For January 7: Markets Reverse 3-Day Slump,LLY,https://www.benzinga.com/news/14/01/4199997/market-wrap-for-january-7-markets-reverse-3-day-slump,Jayson Derrick,,,,,,
2014-01-07T08:00:00.000+08:00,Lilly Commited To Maintaining Dividend at Least at Current Level,LLY,https://www.benzinga.com/news/14/01/4197465/lilly-commited-to-maintaining-dividend-at-least-at-current-level,Charles Gross,,,,,,
2014-01-07T08:00:00.000+08:00,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85,LLY,https://www.benzinga.com/news/earnings/14/01/4197456/eli-lilly-reconfirms-2013-expectations-sees-2014-eps-2-77-2-85,Charles Gross,,,,,,
2014-01-08T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT",LLY,https://www.benzinga.com/news/14/01/4201935/bmo-capital-downgrades-eli-lilly-and-company-to-underperform-maintains-50-00-pt,Juan Lopez,,,,,,
2014-01-10T08:00:00.000+08:00,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00",LLY,https://www.benzinga.com/news/14/01/4208858/barclays-downgrades-eli-lilly-and-company-to-underweight-lowers-pt-to-51-00,Paul Quintaro,,,,,,
2014-01-13T08:00:00.000+08:00,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics,LLY,https://www.benzinga.com/news/14/01/4216815/lilly-acquires-cgrp-antibody-for-migraine-prevention-from-arteaus-therapeutics,Charles Gross,,,,,,
2014-01-16T08:00:00.000+08:00,Is The Market On Drugs?,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4230084/is-the-market-on-drugs,PreMarketInfo,,,,,,
2014-01-22T08:00:00.000+08:00,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly",LLY,https://www.benzinga.com/news/14/01/4244358/uk-daily-mail-reports-aria-approached-by-big-pharma-including-lilly,Charles Gross,,,,,,
2014-01-23T08:00:00.000+08:00,Top Trending Tickers On StockTwits For January 23,LLY,https://www.benzinga.com/news/14/01/4246422/top-trending-tickers-on-stocktwits-for-january-23,Jayson Derrick,,,,,,
2014-01-24T08:00:00.000+08:00,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight,LLY,https://www.benzinga.com/news/earnings/14/01/4250770/benzinga-weekly-preview-tech-sector-to-steal-the-spotlight,Laura Brodbeck,,,,,,
2014-01-24T08:00:00.000+08:00,Ariad Shares Continue to Surge Amidst Buyout Rumors,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/01/4250914/ariad-shares-continue-to-surge-amidst-buyout-rumors,Erika Janowicz,,,,,,
2014-01-27T08:00:00.000+08:00,"Benzinga's M&A Chatter for Monday January 27, 2014",LLY,https://www.benzinga.com/news/14/01/4255409/benzingas-m-a-chatter-for-monday-january-27-2014,Charles Gross,,,,,,
2014-01-28T08:00:00.000+08:00,Tug Of War In Ariad Pharmaceuticals,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4259051/tug-of-war-in-ariad-pharmaceuticals,PreMarketInfo,,,,,,
2014-01-30T08:00:00.000+08:00,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights",LLY,https://www.benzinga.com/news/14/01/4268760/sanofi-files-suit-in-us-to-defend-lantus-lantus-solostar-patent-rights,Charles Gross,,,,,,
2014-01-30T08:00:00.000+08:00,Market Wrap For January 30: Markets Focus on Good News,LLY,https://www.benzinga.com/news/14/01/4268577/market-wrap-for-january-30-markets-focus-on-good-news,Jayson Derrick,,,,,,
2014-01-30T08:00:00.000+08:00,Eli Lilly Declines,LLY,https://www.benzinga.com/trading-ideas/technicals/14/01/4268039/eli-lilly-declines,Hal Lindon,,,,,,
2014-01-30T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Drop In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/14/01/4266060/update-eli-lilly-posts-drop-in-q4-profit,Monica Gerson,,,,,,
2014-01-30T08:00:00.000+08:00,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion",LLY,https://www.benzinga.com/news/earnings/14/01/4265520/premarket-primer-thursday-january-30-fed-cut-stimulus-by-further-10-bill,Laura Brodbeck,,,,,,
2014-01-30T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est",LLY,https://www.benzinga.com/news/earnings/14/01/4265698/eli-lilly-reports-q4-adjusted-eps-of-0-74-inline-revenue-of-5-81b-vs-5-4,Charles Gross,,,,,,
2014-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2014",LLY,https://www.benzinga.com/news/earnings/14/01/4265509/earnings-scheduled-for-january-30-2014,Monica Gerson,,,,,,
2014-01-31T08:00:00.000+08:00,Market Wrap For January 31: Markets End January On Sour Note,LLY,https://www.benzinga.com/news/14/01/4272196/market-wrap-for-january-31-markets-end-january-on-sour-note,Jayson Derrick,,,,,,
2014-01-31T08:00:00.000+08:00,Pfizer vs. Eli Lilly - Which Is The Better Investment?,LLY,https://www.benzinga.com/markets/14/01/4269947/pfizer-vs-eli-lily-which-is-the-better-investment,Tabitha Jean Naylor,,,,,,
2014-01-31T08:00:00.000+08:00,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe",LLY,https://www.benzinga.com/news/earnings/14/01/4269864/premarket-primer-friday-january-31-emerging-market-turmoil-spills-over-i,Laura Brodbeck,,,,,,
2014-02-19T08:00:00.000+08:00,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak",LLY,https://www.benzinga.com/news/14/02/4321856/market-wrap-for-february-19-stocks-close-lower-nasdaq-ends-winning-streak,Jayson Derrick,,,,,,
2014-02-19T08:00:00.000+08:00,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival,LLY,https://www.benzinga.com/news/14/02/4319425/eli-lilly-reports-ramucirumab-phase-iii-met-primary-endpoint-of-overall-survival,Paul Quintaro,,,,,,
2014-02-24T08:00:00.000+08:00,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis,LLY,https://www.benzinga.com/news/14/02/4336478/elanco-announces-agreement-to-acquire-lohmann-animal-health-lowers-fy-2014-earnin,Eddie Staley,,,,,,
2014-02-25T08:00:00.000+08:00,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint",LLY,https://www.benzinga.com/news/14/02/4340847/lillys-once-weekly-dulaglutide-shows-non-inferiority-to-liraglutide-hits-primary-,Paul Quintaro,,,,,,
2014-03-04T08:00:00.000+08:00,Biotechs vs. Pharmaceuticals: What's the Difference?,LLY,https://www.benzinga.com/general/education/14/03/4361845/biotechs-vs-pharmaceuticals-whats-the-difference,Tim Parker,,,,,,
2014-03-05T08:00:00.000+08:00,Lilly Announces FDA Complete Response Letter for Empagliflozin,LLY,https://www.benzinga.com/news/14/03/4366791/lilly-announces-fda-complete-response-letter-for-empagliflozin,Charles Gross,,,,,,
2014-03-12T08:00:00.000+08:00,Eli Lilly Range Bound,LLY,https://www.benzinga.com/trading-ideas/technicals/14/03/4386031/eli-lilly-range-bound,Hal Lindon,,,,,,
2014-03-31T08:00:00.000+08:00,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022,LLY,https://www.benzinga.com/news/14/03/4434125/update-court-upholds-validity-of-lillys-alimta-patent-through-2022,Charles Gross,,,,,,
2014-03-31T08:00:00.000+08:00,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers,LLY,https://www.benzinga.com/news/14/03/4434070/federal-judge-upholds-eli-lillys-alimta-cancer-drug-patent-had-been-challenged-by,Charles Gross,,,,,,
2014-04-01T08:00:00.000+08:00,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke,LLY,https://www.benzinga.com/news/14/04/4437774/market-wrap-for-april-1-s-p-500-hitting-new-all-time-high-not-an-april-fools-joke,Jayson Derrick,,,,,,
2014-04-01T08:00:00.000+08:00,Moody's Says Alimta Patent Ruling Credit Positive for Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4437053/moodys-says-alimta-patent-ruling-credit-positive-for-lil,Charles Gross,,,,,,
2014-04-01T08:00:00.000+08:00,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US",LLY,https://www.benzinga.com/news/14/04/4436074/eli-lilly-expands-authorized-generic-deals-with-prasco-will-market-authorized-gen,Paul Quintaro,,,,,,
2014-04-01T08:00:00.000+08:00,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4435425/update-bank-of-america-reiterates-on-eli-lilly-and-co-fo,Dwight Einhorn,,,,,,
2014-04-01T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00",LLY,https://www.benzinga.com/news/14/04/4435148/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-69-00,Juan Lopez,,,,,,
2014-04-03T08:00:00.000+08:00,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days,LLY,https://www.benzinga.com/news/14/04/4445359/market-wrap-for-april-3-markets-winning-streak-fails-to-extend-to-five-days,Jayson Derrick,,,,,,
2014-04-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4444982/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,,,
2014-04-03T08:00:00.000+08:00,UPDATE: Cowen & Company Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4444784/update-cowen-company-upgrades-eli-lilly,Kurt Zuschlag,,,,,,
2014-04-03T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4443242/benzingas-top-upgrades,Monica Gerson,,,,,,
2014-04-03T08:00:00.000+08:00,"Cowen &amp; Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00",LLY,https://www.benzinga.com/news/14/04/4443166/cowen-amp-company-upgrades-eli-lilly-and-company-to-outperform-raises-pt-to-68-00,Juan Lopez,,,,,,
2014-04-06T08:00:00.000+08:00,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014,LLY,https://www.benzinga.com/news/14/04/4449061/lilly-to-present-early-stage-data-targeting-key-cancer-pathways-at-aacr-2014,Charles Gross,,,,,,
2014-04-08T08:00:00.000+08:00,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins,LLY,https://www.benzinga.com/news/14/04/4455649/market-wrap-for-april-8-markets-bounce-higher-as-earnings-season-begins,Jayson Derrick,,,,,,
2014-04-08T08:00:00.000+08:00,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454915/fitch-says-lillys-ratings-intact-following-9b-actos-jury,Charles Gross,,,,,,
2014-04-08T08:00:00.000+08:00,UPDATE: BMO Capital Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454720/update-bmo-capital-upgrades-eli-lilly,Kurt Zuschlag,,,,,,
2014-04-08T08:00:00.000+08:00,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down. weird',LLY,https://www.benzinga.com/news/14/04/4454213/mark-schoenebaum-tweet-lly-will-owe-nothing-in-this-lost-court-case-they-are-inde,Charles Gross,,,,,,
2014-04-08T08:00:00.000+08:00,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses",LLY,https://www.benzinga.com/news/14/04/4454028/lilly-issues-response-to-verdict-in-case-of-terrence-allen-et-al-v-takeda-says-li,Paul Quintaro,,,,,,
2014-04-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4453756/benzingas-top-upgrades,Monica Gerson,,,,,,
2014-04-08T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00",LLY,https://www.benzinga.com/news/14/04/4453341/bmo-capital-upgrades-eli-lilly-and-company-to-market-perform-raises-pt-to-62-00,Hal Lindon,,,,,,
2014-04-08T08:00:00.000+08:00,Takeda Responds to $6B Verdict in Diabetes Drug Case,LLY,https://www.benzinga.com/news/14/04/4453097/takeda-responds-to-6b-verdict-in-diabetes-drug-case,Charles Gross,,,,,,
2014-04-08T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/14/04/4452855/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,,,
2014-04-09T08:00:00.000+08:00,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4457085/anne-marie-baiynd-tweets-careful-with-lly-looks-like-it-,David Johnson,,,,,,
2014-04-10T08:00:00.000+08:00,Eli Lilly to Report First Quarter Results April 24th Before Market Open,LLY,https://www.benzinga.com/news/earnings/14/04/4462889/eli-lilly-to-report-first-quarter-results-april-24th-before-market-open,David Johnson,,,,,,
2014-04-14T08:00:00.000+08:00,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",LLY,https://www.benzinga.com/news/14/04/4469346/market-wrap-for-april-14-markets-surge-on-positive-retail-data-citi-earnings,Jayson Derrick,,,,,,
2014-04-14T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4469026/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-04-14T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00",LLY,https://www.benzinga.com/news/14/04/4467649/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-54-00,Hal Lindon,,,,,,
2014-04-17T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/trading-ideas/technicals/14/04/4480002/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-04-21T08:00:00.000+08:00,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy,LLY,https://www.benzinga.com/news/14/04/4485121/update-lillys-cyramza-is-first-fda-approved-treatment-for-advanced-gastric-cancer,Charles Gross,,,,,,
2014-04-21T08:00:00.000+08:00,FDA Approves Cyramza for Stomach Cancer,LLY,https://www.benzinga.com/news/14/04/4484605/fda-approves-cyramza-for-stomach-cancer,Charles Gross,,,,,,
2014-04-21T08:00:00.000+08:00,"No Legwork Mondays – Takeda, Eli Lilly And Actos",LLY,https://www.benzinga.com/markets/14/04/4470420/no-legwork-mondays-takeda-eli-lilly-and-actos,Tabitha Jean Naylor,,,,,,
2014-04-22T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday April 22, 2014",LLY,https://www.benzinga.com/news/14/04/4489040/benzingas-m-a-chatter-for-tuesday-april-22-2014,Charles Gross,,,,,,
2014-04-22T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,LLY,https://www.benzinga.com/news/14/04/4486136/us-stock-futures-edge-higher-ahead-of-mcdonalds-earnings,Monica Gerson,,,,,,
2014-04-22T08:00:00.000+08:00,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash,LLY,https://www.benzinga.com/news/14/04/4485754/lilly-to-acquire-novartis-animal-health-for-approximately-5-4b-in-cash,Charles Gross,,,,,,
2014-04-23T08:00:00.000+08:00,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",LLY,https://www.benzinga.com/news/earnings/14/04/4492955/market-wrap-for-april-23-s-p-500-ends-winning-streak-apple-announces-7-f,Jayson Derrick,,,,,,
2014-04-23T08:00:00.000+08:00,MKM Partners Downgrades Eli Lilly and Company to Neutral,LLY,https://www.benzinga.com/news/14/04/4490412/mkm-partners-downgrades-eli-lilly-and-company-to-neutral,Paul Quintaro,,,,,,
2014-04-24T08:00:00.000+08:00,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,LLY,https://www.benzinga.com/news/14/04/4497474/market-wrap-for-april-24-apples-smashing-earnings-overshadowed-by-ukraine-concern,Jayson Derrick,,,,,,
2014-04-24T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est",LLY,https://www.benzinga.com/news/earnings/14/04/4494361/eli-lilly-reports-q1-adjusted-eps-of-0-70-inline-revenue-of-4-68b-vs-4-7,Charles Gross,,,,,,
2014-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/04/4494236/earnings-scheduled-for-april-24-2014,Monica Gerson,,,,,,
2014-04-29T08:00:00.000+08:00,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting,LLY,https://www.benzinga.com/news/14/04/4509591/market-wrap-for-april-29-dow-approaches-record-highs-despite-ongoing-ukraine-tens,Jayson Derrick,,,,,,
2014-05-09T08:00:00.000+08:00,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case,LLY,https://www.benzinga.com/news/14/05/4544324/lilly-strongly-disagrees-with-courts-ruling-in-brazil-labor-case,Charles Gross,,,,,,
2014-05-09T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4543359/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,,,
2014-05-12T08:00:00.000+08:00,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry,LLY,https://www.benzinga.com/news/14/05/4548238/google-celebrates-dorothy-hodgkin-her-contributions-to-chemistry,Erika Janowicz,,,,,,
2014-05-12T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546503/update-eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargi,Hal Lindon,,,,,,
2014-05-12T08:00:00.000+08:00,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546488/eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargine-in-h,Paul Quintaro,,,,,,
2014-05-14T08:00:00.000+08:00,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity,LLY,https://www.benzinga.com/news/14/05/4556838/lilly-says-abemaciclib-in-phase-1-study-demonstrated-single-agent-activity,Paul Quintaro,,,,,,
2014-05-14T08:00:00.000+08:00,"Stocks To Watch For May 14, 2014",LLY,https://www.benzinga.com/trading-ideas/technicals/14/05/4552883/stocks-to-watch-for-may-14-2014,António Costa,,,,,,
2014-05-15T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4560138/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,,,
2014-05-15T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Positive Results,LLY,https://www.benzinga.com/news/14/05/4560136/eli-lilly-announces-linagliptin-positive-results,Hal Lindon,,,,,,
2014-05-22T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4578583/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-05-27T08:00:00.000+08:00,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide,LLY,https://www.benzinga.com/news/14/05/4586375/eli-lilly-announces-will-hold-investor-web-call-on-jun-16th-to-discuss-phase-iii-,Hal Lindon,,,,,,
2014-05-28T08:00:00.000+08:00,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis",LLY,https://www.benzinga.com/news/14/05/4587949/sanofi-lilly-announce-licensing-agreement-for-nonprescription-cialis,Charles Gross,,,,,,
2014-05-30T08:00:00.000+08:00,US Stock Futures Edge Lower Ahead Of Consumer Spending Report,LLY,https://www.benzinga.com/news/14/05/4596217/us-stock-futures-edge-lower-ahead-of-consumer-spending-report,Monica Gerson,,,,,,
2014-05-30T08:00:00.000+08:00,QIAGEN Announces Collaboration with Lilly,LLY,https://www.benzinga.com/news/14/05/4595994/qiagen-announces-collaboration-with-lilly,Charles Gross,,,,,,
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602067/premarket-prep-technical-update-eli-lilly-finding-resistance-at,Hal Lindon,,,,,,
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602065/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,,,
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602063/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,,,
2014-06-02T08:00:00.000+08:00,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4600908/update-morgan-stanley-reiterates-on-eli-lilly-co-on-lack,Dwight Einhorn,,,,,,
2014-06-02T08:00:00.000+08:00,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers,LLY,https://www.benzinga.com/news/14/06/4600494/lilly-reports-increased-access-to-clinical-trials-data-for-qualified-researchers,Hal Lindon,,,,,,
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?,LLY,https://www.benzinga.com/news/14/06/4606298/asco-meeting-day-3-do-more-treatments-equal-a-longer-life,Erika Janowicz,,,,,,
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,LLY,https://www.benzinga.com/news/14/06/4606039/asco-meeting-day-2-promising-results-from-jnjs-imbruvica-targeted-therapy,Erika Janowicz,,,,,,
2014-06-11T08:00:00.000+08:00,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss",LLY,https://www.benzinga.com/news/earnings/14/06/4626985/market-wrap-for-june-11-momentum-hit-dow-suffers-triple-digit-loss,Jayson Derrick,,,,,,
2014-06-11T08:00:00.000+08:00,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/14/06/4624966/eli-lilly-announces-top-line-results-oh-phase-iii-hepatocellular-carcinoma-trial-,Paul Quintaro,,,,,,
2014-06-14T08:00:00.000+08:00,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action,LLY,https://www.benzinga.com/news/14/06/4633691/lilly-announces-new-data-on-basal-insulin-peglispro-shows-novel-mechanism-of-acti,Charles Gross,,,,,,
2014-06-14T08:00:00.000+08:00,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus®,LLY,https://www.benzinga.com/news/14/06/4633690/studies-show-ly2963016-from-lilly-and-boehringer-ingelheim-has-similar-safety-and,Charles Gross,,,,,,
2014-06-15T08:00:00.000+08:00,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials,LLY,https://www.benzinga.com/news/14/06/4633912/lilly-reports-empagliflozinlinagliptin-combination-tablet-showed-reduction-in-blo,Charles Gross,,,,,,
2014-06-20T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4650060/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-06-25T08:00:00.000+08:00,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4658975/bernstein-analysts-say-a-hostile-deal-with-eli-lilly-is-,Paul Quintaro,,,,,,
2014-06-27T08:00:00.000+08:00,CHMP Issues Positive Report For Lilly's Insulin Glargine Product,LLY,https://www.benzinga.com/news/14/06/4666384/chmp-issues-positive-report-for-lillys-insulin-glargine-product,Paul Quintaro,,,,,,
2014-07-02T08:00:00.000+08:00,Barclays Downgrades Pharmaceutical Sector,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4678189/barclays-downgrades-pharmaceutical-sector,John Seward,,,,,,
2014-07-02T08:00:00.000+08:00,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4677379/update-barclays-upgrades-eli-lilly-despite-sector-downgr,Eric Niederer,,,,,,
2014-07-02T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/07/4677107/benzingas-top-upgrades,Monica Gerson,,,,,,
2014-07-02T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00",LLY,https://www.benzinga.com/news/14/07/4676712/barclays-upgrades-eli-lilly-and-company-to-equal-weight-raises-pt-to-63-00,Paul Quintaro,,,,,,
2014-07-07T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/health-care/14/07/4684198/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,,,
2014-07-14T08:00:00.000+08:00,Dow Sets New Intraday High; Citigroup Impresses With Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4700510/dow-sets-new-intraday-high-citigroup-impresses-with-earn,Jayson Derrick,,,,,,
2014-07-15T08:00:00.000+08:00,Benzinga's Top #PreMarket Gainers,LLY,https://www.benzinga.com/news/14/07/4702184/benzingas-top-premarket-gainers,Monica Gerson,,,,,,
2014-07-15T08:00:00.000+08:00,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings,LLY,https://www.benzinga.com/news/14/07/4701903/us-stock-futures-mostly-higher-ahead-of-goldman-sachs-earnings,Monica Gerson,,,,,,
2014-07-15T08:00:00.000+08:00,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4701527/new-data-shows-cognitive-impairment-precedes-and-predicts-subsequent-functional-i,Charles Gross,,,,,,
2014-07-16T08:00:00.000+08:00,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4705758/new-study-shows-beta-amyloid-imaging-is-associated-with-altered-diagnosis-and-man,Eddie Staley,,,,,,
2014-07-16T08:00:00.000+08:00,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies,LLY,https://www.benzinga.com/news/14/07/4705393/lilly-and-immunocore-enter-immunotherapy-agreement-to-co-discover-and-co-develop-,Eddie Staley,,,,,,
2014-07-17T08:00:00.000+08:00,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results",LLY,https://www.benzinga.com/news/14/07/4707388/alzheimers-rates-falling-but-pharmas-search-for-a-cure-yields-no-results,Bruce Kennedy,,,,,,
2014-07-18T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4713478/premarket-prep-technical-update-eli-lilly-trading-sharply-highe,Hal Lindon,,,,,,
2014-07-24T08:00:00.000+08:00,Thursday Morning Earnings Reports,LLY,https://www.benzinga.com/news/earnings/14/07/4727432/thursday-morning-earnings-reports,Ali Berri,,,,,,
2014-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est,LLY,https://www.benzinga.com/news/earnings/14/07/4726147/eli-lilly-and-company-reports-q2-adjusted-eps-of-0-68-vs-0-65-est-revenu,Charles Gross,,,,,,
2014-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/07/4725954/earnings-scheduled-for-july-24-2014,Monica Gerson,,,,,,
2014-07-29T08:00:00.000+08:00,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties,LLY,https://www.benzinga.com/news/earnings/14/07/4739183/stocks-lower-as-earnings-season-takes-back-seat-to-geopolitical-uncertai,Jayson Derrick,,,,,,
2014-07-31T08:00:00.000+08:00,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble,LLY,https://www.benzinga.com/news/earnings/14/07/4748027/dow-suffers-300-point-drop-s-p-500-and-nasdaq-also-tumble,Jayson Derrick,,,,,,
2014-07-31T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4747319/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,,,
2014-08-01T08:00:00.000+08:00,UPDATE: Tigress Initiates Coverage On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/initiation/14/08/4750945/update-tigress-initiates-coverage-on-eli-lilly,Ali Berri,,,,,,
2014-08-01T08:00:00.000+08:00,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy,LLY,https://www.benzinga.com/news/14/08/4750777/tigress-financial-initiates-coverage-on-eli-lilly-and-company-at-buy,Paul Quintaro,,,,,,
2014-08-02T08:00:00.000+08:00,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes,LLY,https://www.benzinga.com/news/14/08/4751561/fda-approves-jardiance-rempagliflozin-tablets-for-adults-withtype-2-diabetes,Charles Gross,,,,,,
2014-08-05T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/08/4757856/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,,,
2014-08-11T08:00:00.000+08:00,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,LLY,https://www.benzinga.com/news/earnings/14/08/4772254/markets-marginally-higher-on-light-volume-and-encouraging-geopolitical-d,Jayson Derrick,,,,,,
2014-08-18T08:00:00.000+08:00,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar,LLY,https://www.benzinga.com/news/14/08/4787801/eli-lilly-reports-fda-granting-of-tentative-approval-for-basaglar,Paul Quintaro,,,,,,
2014-08-21T08:00:00.000+08:00,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives,LLY,https://www.benzinga.com/news/14/08/4795075/lillys-ixekizumab-met-all-primary-and-key-secondary-objectives,Charles Gross,,,,,,
2014-08-21T08:00:00.000+08:00,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/14/08/4795074/lillys-ixekizumab-found-superior-to-etanercept-placebo-in-phase-3-trial-met-all-p,Paul Quintaro,,,,,,
2014-08-26T08:00:00.000+08:00,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804308/new-type-2-diabetes-treatment-jardiance-tablets-for-adults-now-available-in-u-s-p,Eddie Staley,,,,,,
2014-08-26T08:00:00.000+08:00,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804300/eli-lilly-reports-new-type-2-diabetes-treatment-jardiance-tabs-now-available-in-u,Paul Quintaro,,,,,,
2014-08-27T08:00:00.000+08:00,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,LLY,https://www.benzinga.com/news/earnings/14/08/4809313/markets-little-changed-in-low-volume-and-slow-news-ahead-of-long-weekend,Jayson Derrick,,,,,,
2014-08-27T08:00:00.000+08:00,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/08/4808422/deutsche-bank-eli-lilly-at-critical-stage-in-its-journey,Jayson Derrick,,,,,,
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",LLY,https://www.benzinga.com/news/14/08/4808624/deutsche-bank-starts-pfizer-lilly-at-buy-merck-bristol-myers-at-hold,Paul Quintaro,,,,,,
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT",LLY,https://www.benzinga.com/news/14/08/4807106/deutsche-bank-initiates-coverage-on-eli-lilly-and-company-at-buy-announces-71-00-,Paul Quintaro,,,,,,
2014-09-04T08:00:00.000+08:00,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015",LLY,https://www.benzinga.com/news/14/09/4825118/lillys-basal-insulin-peglispro-demonstrated-hba1c-superiority-against-lantus-in-p,Charles Gross,,,,,,
2014-09-08T08:00:00.000+08:00,What Is A High Risk Market?,LLY,https://www.benzinga.com/general/education/14/09/4829252/what-is-a-high-risk-market,Jim Probasco,,,,,,
2014-09-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival,LLY,https://www.benzinga.com/news/14/09/4845416/lilly-announces-cyramza-phase-iii-second-line-colorectal-cancer-trial-meets-prima,Eddie Staley,,,,,,
2014-09-16T08:00:00.000+08:00,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed",LLY,https://www.benzinga.com/news/14/09/4853617/denovo-biopharma-reports-purchase-of-enzastaurin-from-eli-lilly-includes-rights-t,Paul Quintaro,,,,,,
2014-09-16T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones",LLY,https://www.benzinga.com/news/14/09/4851833/eli-lilly-astrazeneca-report-alliance-to-co-develop-potential-treatment-for-alzhe,Paul Quintaro,,,,,,
2014-09-17T08:00:00.000+08:00,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone",LLY,https://www.benzinga.com/news/14/09/4856827/lipocine-inc-halted-feds-eye-safety-efficacy-of-testosterone,John Seward,,,,,,
2014-09-18T08:00:00.000+08:00,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg,LLY,https://www.benzinga.com/news/14/09/4861043/lilly-wins-approval-from-fda-for-diabetes-treatment-trulicity-bloomberg,Paul Quintaro,,,,,,
2014-09-18T08:00:00.000+08:00,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients,LLY,https://www.benzinga.com/news/14/09/4859270/eli-lilly-reports-cyramza-in-combo-with-paclitaxel-showed-significant-improvement,Paul Quintaro,,,,,,
2014-09-22T08:00:00.000+08:00,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio",LLY,https://www.benzinga.com/news/14/09/4865236/dyax-offers-highlights-of-recent-progress-in-licensing-funded-research-portfolio,Paul Quintaro,,,,,,
2014-10-02T08:00:00.000+08:00,Markets Little Changed Ahead Of Friday's Jobs Report,LLY,https://www.benzinga.com/news/earnings/14/10/4895753/markets-little-changed-ahead-of-fridays-jobs-report,Jayson Derrick,,,,,,
2014-10-02T08:00:00.000+08:00,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data,LLY,https://www.benzinga.com/news/14/10/4894006/eli-lilly-will-discontinue-tabalumab-development-of-efficacy-data,Paul Quintaro,,,,,,
2014-10-02T08:00:00.000+08:00,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT",LLY,https://www.benzinga.com/news/14/10/4893395/guggenheim-securities-initiates-coverage-on-eli-lilly-and-company-at-buy-announce,Paul Quintaro,,,,,,
2014-10-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4897896/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-10-10T08:00:00.000+08:00,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation,LLY,https://www.benzinga.com/news/14/10/4914018/eli-lillys-olaratumab-wins-fda-orphan-drug-designation,Paul Quintaro,,,,,,
2014-10-13T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00",LLY,https://www.benzinga.com/news/14/10/4916681/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-70-00,Eddie Staley,,,,,,
2014-10-16T08:00:00.000+08:00,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site,LLY,https://www.benzinga.com/news/14/10/4929458/update-lilly-to-initiate-efforts-to-sell-guayama-site,Paul Quintaro,,,,,,
2014-10-16T08:00:00.000+08:00,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations,LLY,https://www.benzinga.com/news/14/10/4929452/lilly-announces-plan-to-realign-puerto-rico-manufacturing-operations,Paul Quintaro,,,,,,
2014-10-19T08:00:00.000+08:00,Benzinga Weekly Preview: Earnings Season Is In Full Swing,LLY,https://www.benzinga.com/news/earnings/14/10/4931957/benzinga-weekly-preview-earnings-season-is-in-full-swing,Laura Brodbeck,,,,,,
2014-10-21T08:00:00.000+08:00,FDA Accepts Filing Of A NDA For Empagliflozin,LLY,https://www.benzinga.com/news/14/10/4938737/fda-accepts-filing-of-a-nda-for-empagliflozin,Hal Lindon,,,,,,
2014-10-22T08:00:00.000+08:00,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit,LLY,https://www.benzinga.com/news/14/10/4945173/canda-nk-2-files-motion-to-dismiss-patent-infringement-suit,Eddie Staley,,,,,,
2014-10-22T08:00:00.000+08:00,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement",LLY,https://www.benzinga.com/news/14/10/4944856/lilly-zymeworks-announce-expansion-of-strategic-licensing-and-collaboration-agree,Eddie Staley,,,,,,
2014-10-23T08:00:00.000+08:00,"US Stock Futures Rise Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/14/10/4946403/us-stock-futures-rise-ahead-of-earnings-economic-data,Monica Gerson,,,,,,
2014-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Lower Q3 Profit,LLY,https://www.benzinga.com/news/earnings/14/10/4946310/update-eli-lilly-posts-lower-q3-profit,Monica Gerson,,,,,,
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42,LLY,https://www.benzinga.com/news/14/10/4946098/eli-lilly-and-company-sees-fy2014-eps-2-34-2-42,Paul Quintaro,,,,,,
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est,LLY,https://www.benzinga.com/news/earnings/14/10/4946070/eli-lilly-and-company-reports-q3-eps-of-0-66-vs-0-69-est-revenue-of-4-88,Paul Quintaro,,,,,,
2014-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2014",LLY,https://www.benzinga.com/news/earnings/14/10/4945866/earnings-scheduled-for-october-23-2014,Monica Gerson,,,,,,
2014-10-24T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4951251/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,,,
2014-10-27T08:00:00.000+08:00,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda",LLY,https://www.benzinga.com/news/14/10/4955900/lilly-responds-to-decision-in-case-of-terrence-allen-et-al-v-takeda,Charles Gross,,,,,,
2014-10-27T08:00:00.000+08:00,UPDATE: Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M,LLY,https://www.benzinga.com/news/14/10/4955077/update-judge-cut-9b-award-to-eli-lilly-takeda-pharma-to-36-8m,Paul Quintaro,,,,,,
2014-10-27T08:00:00.000+08:00,"Takeda, Lilly Receive $9B Actos Award To $36.8M",LLY,https://www.benzinga.com/news/14/10/4955072/takeda-lilly-receive-9b-actos-award-to-36-8m,Paul Quintaro,,,,,,
2014-10-27T08:00:00.000+08:00,Virbac to Acquire US Veterinary Assets from Eli Lilly,LLY,https://www.benzinga.com/news/14/10/4952719/virbac-to-acquire-us-veterinary-assets-from-eli-lilly,Charles Gross,,,,,,
2014-10-29T08:00:00.000+08:00,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing",LLY,https://www.benzinga.com/news/14/10/4963437/eli-lilly-recently-filed-10-q-seeing-fy14-eps-expected-in-2-36-2-44-range-amid-re,Paul Quintaro,,,,,,
2014-10-29T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries",LLY,https://www.benzinga.com/news/14/10/4961487/lilly-boehringer-ingelheim-changing-structure-of-diabetes-alliance-in-certain-cou,Charles Gross,,,,,,
2014-11-03T08:00:00.000+08:00,Credit Suisse Raises Eli Lilly Price Target,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/11/4975142/credit-suisse-raises-eli-lilly-price-target,James McIntosh,,,,,,
2014-11-05T08:00:00.000+08:00,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer,LLY,https://www.benzinga.com/news/14/11/4984623/fda-approves-ramcirumab-in-combination-with-paclitaxel-for-gastric-cancer,Paul Quintaro,,,,,,
2014-11-11T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5000617/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,,,
2014-11-17T08:00:00.000+08:00,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes",LLY,https://www.benzinga.com/news/14/11/5016446/eli-lilly-reports-new-retrospective-data-showed-empagliflozin-reduced-a1c-body-we,Paul Quintaro,,,,,,
2014-11-21T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5030739/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,,,
2014-11-24T08:00:00.000+08:00,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.,LLY,https://www.benzinga.com/news/14/11/5034405/from-13g-eli-lilly-company-reports-9-1-stake-in-coherus-biosciences-inc,Paul Quintaro,,,,,,
2014-12-01T08:00:00.000+08:00,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH,LLY,https://www.benzinga.com/news/14/12/5045611/lilly-announces-co-astrazeneca-report-enrollment-of-first-patient-into-amaranth,Paul Quintaro,,,,,,
2014-12-02T08:00:00.000+08:00,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate,LLY,https://www.benzinga.com/news/14/12/5049674/zosano-pharma-and-eli-lilly-and-company-enter-into-exclusive-licensing-agreement-,Eddie Staley,,,,,,
2014-12-04T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00",LLY,https://www.benzinga.com/news/14/12/5056734/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-5-00,Eddie Staley,,,,,,
2014-12-08T08:00:00.000+08:00,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration",LLY,https://www.benzinga.com/news/14/12/5063097/eli-lilly-anthem-inc-and-healthcore-create-research-collaboration,Hal Lindon,,,,,,
2014-12-09T08:00:00.000+08:00,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint",LLY,https://www.benzinga.com/news/14/12/5066369/lilly-incyte-announce-phase-3-trial-of-baricitinib-in-moderate-to-severe-rheumato,Charles Gross,,,,,,
2014-12-11T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00",LLY,https://www.benzinga.com/news/14/12/5074029/morgan-stanley-upgrades-eli-lilly-and-company-to-overweight-raises-pt-to-85-00,Eddie Staley,,,,,,
2014-12-12T08:00:00.000+08:00,UPDATE: FDA Expands Approval For Cyramza,LLY,https://www.benzinga.com/news/14/12/5077610/update-fda-expands-approval-for-cyramza,Paul Quintaro,,,,,,
2014-12-12T08:00:00.000+08:00,Eli Lilly's Cyramza Receives Expanded FDA Approval,LLY,https://www.benzinga.com/news/14/12/5077608/eli-lillys-cyramza-receives-expanded-fda-approval,Paul Quintaro,,,,,,
2014-12-15T08:00:00.000+08:00,Lilly Announces Dividend Increase From $0.49 To $0.50/share,LLY,https://www.benzinga.com/news/14/12/5081768/lilly-announces-dividend-increase-from-0-49-to-0-50share,Hal Lindon,,,,,,
2014-12-16T08:00:00.000+08:00,7 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/14/12/5082669/7-stocks-you-should-be-watching-today,Monica Gerson,,,,,,
2014-12-19T08:00:00.000+08:00,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro",LLY,https://www.benzinga.com/news/14/12/5095540/lilly-adocia-announce-alliance-to-co-develop-biochaperone-lispro,Charles Gross,,,,,,
2014-12-22T08:00:00.000+08:00,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA,LLY,https://www.benzinga.com/news/14/12/5100018/ftc-places-conditions-on-lillys-proposed-deal-to-divest-sentinel-to-virbac-sa,Paul Quintaro,,,,,,
2015-01-01T08:00:00.000+08:00,Lilly Completes Acquisition of Novartis Animal Health,LLY,https://www.benzinga.com/news/15/01/5114528/lilly-completes-acquisition-of-novartis-animal-health,Charles Gross,,,,,,
2015-01-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5116117/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,,,
2015-01-02T08:00:00.000+08:00,US Stock Futures Surge Ahead Of Manufacturing Data,LLY,https://www.benzinga.com/news/15/01/5115018/us-stock-futures-surge-ahead-of-manufacturing-data,Monica Gerson,,,,,,
2015-01-06T08:00:00.000+08:00,Fast Money Halftime Report Final Trade From January 6,LLY,https://www.benzinga.com/media/cnbc/15/01/5124655/fast-money-halftime-report-final-trade-from-january-6,Craig Jones,,,,,,
2015-01-07T08:00:00.000+08:00,4 Stocks Trending On Social Media This Wednesday,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5127925/4-stocks-trending-on-social-media-this-wednesday,Garrett Cook,,,,,,
2015-01-07T08:00:00.000+08:00,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook,LLY,https://www.benzinga.com/news/15/01/5126839/eli-lilly-moves-higher-following-fy-2014-2015-outlook,Kevin Riley,,,,,,
2015-01-07T08:00:00.000+08:00,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est.",LLY,https://www.benzinga.com/news/15/01/5126972/from-eli-lilly-guidance-conference-call-mgmt-still-expecting-fy14-sales-in-19-4-1,Paul Quintaro,,,,,,
2015-01-07T08:00:00.000+08:00,Benzinga's Top #PreMarket Losers,LLY,https://www.benzinga.com/news/15/01/5126569/benzingas-top-premarket-losers,Monica Gerson,,,,,,
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2014 EPS $2.72-2.80,LLY,https://www.benzinga.com/news/15/01/5126307/eli-lilly-sees-fy2014-eps-2-72-2-80,Eddie Staley,,,,,,
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B,LLY,https://www.benzinga.com/news/15/01/5126305/eli-lilly-sees-fy2015-eps-3-10-3-20-sees-sales-20-30b-20-80b,Eddie Staley,,,,,,
2015-01-08T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5131996/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,,,
2015-01-08T08:00:00.000+08:00,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5131674/deutsche-bank-stifel-differ-on-outlook-for-eli-lilly,Kevin Riley,,,,,,
2015-01-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130698/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-01-08T08:00:00.000+08:00,Jefferies Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130413/jefferies-upgrades-eli-lilly-to-buy,Monica Gerson,,,,,,
2015-01-08T08:00:00.000+08:00,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5130061/update-deutsche-bank-downgrades-eli-lilly-on-positive-ou,Dwight Einhorn,,,,,,
2015-01-08T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00",LLY,https://www.benzinga.com/news/15/01/5129698/jefferies-upgrades-eli-lilly-to-buy-raises-pt-to-80-00,Charles Gross,,,,,,
2015-01-08T08:00:00.000+08:00,Deutsche Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/15/01/5129666/deutsche-bank-downgrades-eli-lilly-to-hold,Charles Gross,,,,,,
2015-01-09T08:00:00.000+08:00,Bank of America Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5133767/bank-of-america-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,,,
2015-01-12T08:00:00.000+08:00,'FDA stops import of Lilly's Cialis from Australia',LLY,https://www.benzinga.com/news/15/01/5140427/fda-stops-import-of-lillys-cialis-from-australia,Paul Quintaro,,,,,,
2015-01-12T08:00:00.000+08:00,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies",LLY,https://www.benzinga.com/media/cnbc/15/01/5138491/eil-lilly-ceo-talks-new-product-launches-pricing-pressure-from-other-compan,Ritesh Anan,,,,,,
2015-01-12T08:00:00.000+08:00,FDA Issues Import Block On Eli Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138518/fda-issues-import-block-on-eli-lillys-cialis,Kevin Riley,,,,,,
2015-01-12T08:00:00.000+08:00,FDA issues Import Block Alert On Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138494/fda-issues-import-block-alert-on-lillys-cialis,Paul Quintaro,,,,,,
2015-01-12T08:00:00.000+08:00,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5136446/biotechs-presenting-at-the-j-p-morgan-healthcare-conference-d,Kyle Dennis,,,,,,
2015-01-12T08:00:00.000+08:00,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A Deals',LLY,https://www.benzinga.com/news/15/01/5138448/from-cnbc-eli-lilly-ceo-anticipates-2015-drug-price-increases-remains-interested-,Paul Quintaro,,,,,,
2015-01-12T08:00:00.000+08:00,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate",LLY,https://www.benzinga.com/media/cnbc/15/01/5135993/fast-money-picks-for-january-12-twitter-eli-lilly-lions-gate,Craig Jones,,,,,,
2015-01-13T08:00:00.000+08:00,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',LLY,https://www.benzinga.com/opinion/15/01/5141858/notes-from-the-street-flashback-oil-going-to-200barrel,Kenny Polcari,,,,,,
2015-01-13T08:00:00.000+08:00,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial,LLY,https://www.benzinga.com/news/15/01/5141737/merck-and-eli-lilly-announce-agreement-for-collaboration-on-cancer-clinical-trial,Paul Quintaro,,,,,,
2015-01-15T08:00:00.000+08:00,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5151534/here-is-goldman-sachs-potential-pair-trade-for-2-drug-gi,Javier Hasse,,,,,,
2015-01-15T08:00:00.000+08:00,10 Biotech Stories You Might've Missed This Week,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5151323/10-biotech-stories-you-mightve-missed-this-week,Kyle Dennis,,,,,,
2015-01-15T08:00:00.000+08:00,Goldman Sachs Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5149456/goldman-sachs-upgrades-eli-lilly-to-neutral,Paul Quintaro,,,,,,
2015-01-30T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline",LLY,https://www.benzinga.com/news/earnings/15/01/5195086/update-eli-lilly-posts-upbeat-q4-profit-sales-decline,Monica Gerson,,,,,,
2015-01-30T08:00:00.000+08:00,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B",LLY,https://www.benzinga.com/news/15/01/5194897/eli-lilly-guides-fy-2015-lower-expects-19-5b-to-20b,Paul Quintaro,,,,,,
2015-01-30T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.75, $0.73 Est",LLY,https://www.benzinga.com/news/earnings/15/01/5194894/eli-lilly-q4-eps-0-75-0-73-est,Paul Quintaro,,,,,,
2015-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2015",LLY,https://www.benzinga.com/news/earnings/15/01/5194708/earnings-scheduled-for-january-30-2015,Monica Gerson,,,,,,
2015-01-30T08:00:00.000+08:00,10 Must Watch Stocks for Today,LLY,https://www.benzinga.com/news/earnings/15/01/5194673/10-must-watch-stocks-for-today,Monica Gerson,,,,,,
2015-02-02T08:00:00.000+08:00,UBS: Eli Lilly's 'Outlook Continuing To Improve',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5200436/ubs-eli-lillys-outlook-continuing-to-improve,Anthony Sanfilippo,,,,,,
2015-02-02T08:00:00.000+08:00,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/02/5199947/lilly-announces-fda-approves-first-in-class-glyxambi-tablets-for-adults-with-type,Charles Gross,,,,,,
2015-02-02T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar,LLY,https://www.benzinga.com/media/cnbc/15/02/5198463/eli-lilly-ceo-explains-the-reasons-behind-not-changing-2015-guidance-on-bac,Ritesh Anan,,,,,,
2015-02-05T08:00:00.000+08:00,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/02/5214143/ipo-alert-biotech-investors-should-watch-advanced-accelerator,Charles Enser,,,,,,
2015-02-06T08:00:00.000+08:00,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",LLY,https://www.benzinga.com/general/education/15/02/5220037/after-a-blockbuster-2014-what-will-2015-hold-for-pharmaceutical-m-a,Steve Sapletal,,,,,,
2015-02-11T08:00:00.000+08:00,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable",LLY,https://www.benzinga.com/news/15/02/5231133/update-lilly-says-china-parts-of-asia-most-profitable-of-emerging-markets-parts-o,Charles Gross,,,,,,
2015-02-11T08:00:00.000+08:00,Lilly Says Still Room to Grow Business in China,LLY,https://www.benzinga.com/news/15/02/5231123/lilly-says-still-room-to-grow-business-in-china,Charles Gross,,,,,,
2015-02-11T08:00:00.000+08:00,Lilly Currently Presenting at Leerink Global Healthcare Conference,LLY,https://www.benzinga.com/news/15/02/5231099/lilly-currently-presenting-at-leerink-global-healthcare-conference,Charles Gross,,,,,,
2015-02-19T08:00:00.000+08:00,Lilly Provides Phase 3 Trial Update On Evacetrapib,LLY,https://www.benzinga.com/news/15/02/5255050/lilly-provides-phase-3-trial-update-on-evacetrapib,Hal Lindon,,,,,,
2015-02-23T08:00:00.000+08:00,5 'Key Pipeline Catalysts' To Watch At Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5266196/5-key-pipeline-catalysts-to-watch-at-eli-lilly,Monica Gerson,,,,,,
2015-02-23T08:00:00.000+08:00,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies,LLY,https://www.benzinga.com/news/15/02/5263752/lilly-announces-delay-in-submission-for-basal-insulin-peglispro-to-regulatory-age,Hal Lindon,,,,,,
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro,LLY,https://www.benzinga.com/news/15/02/5263713/eli-lilly-reports-delay-on-regulatory-submission-timing-for-basal-insulin-peglisp,Paul Quintaro,,,,,,
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity,LLY,https://www.benzinga.com/news/15/02/5263220/eli-lilly-reports-baricitinib-found-superior-to-placebo-for-reducing-ra-disease-a,Paul Quintaro,,,,,,
2015-02-23T08:00:00.000+08:00,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study",LLY,https://www.benzinga.com/news/15/02/5263188/lilly-incyte-report-baricitinib-superior-to-placebo-in-reducing-ra-disease-activi,Charles Gross,,,,,,
2015-03-03T08:00:00.000+08:00,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.,LLY,https://www.benzinga.com/general/biotech/15/03/5292109/denovo-biopharma-announces-it-has-exclusively-licensed-pomaglumetad-me,Hal Lindon,,,,,,
2015-03-06T08:00:00.000+08:00,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/15/03/5304800/german-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Eddie Staley,,,,,,
2015-03-10T08:00:00.000+08:00,8 Healthcare Names Cowen & Co Are Talking About,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5315206/8-healthcare-names-cowen-co-are-talking-about,Monica Gerson,,,,,,
2015-03-19T08:00:00.000+08:00,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy",LLY,https://www.benzinga.com/news/15/03/5340194/eli-lilly-hanmi-report-exclusive-license-deal-for-development-commercialization-o,Paul Quintaro,,,,,,
2015-03-20T08:00:00.000+08:00,Eli Lilly Just Unveiled A Major Biotech Collaboration In China,LLY,https://www.benzinga.com/general/biotech/15/03/5344535/eli-lilly-just-unveiled-a-major-biotech-collaboration-in-china,John Seward,,,,,,
2015-03-20T08:00:00.000+08:00,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+",LLY,https://www.benzinga.com/news/15/03/5343870/update-lilly-says-innovent-will-get-upfront-payment-of-56m-could-get-future-payme,Paul Quintaro,,,,,,
2015-03-20T08:00:00.000+08:00,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World,LLY,https://www.benzinga.com/news/15/03/5343861/lilly-and-innovent-biologics-announce-a-strategic-alliance-to-bring-potential-onc,Eddie Staley,,,,,,
2015-03-23T08:00:00.000+08:00,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5349889/analyst-heres-why-eli-lilly-is-worth-more-than-it-used-t,Monica Gerson,,,,,,
2015-03-23T08:00:00.000+08:00,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed",LLY,https://www.benzinga.com/news/15/03/5349188/fda-concludes-2-year-zyprexa-relprevv-review-of-two-deaths-related-to-schizophren,Paul Quintaro,,,,,,
2015-03-23T08:00:00.000+08:00,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab",LLY,https://www.benzinga.com/news/15/03/5348944/pfizer-lilly-to-resume-phase-3-chronic-pain-program-for-tanezumab,Paul Quintaro,,,,,,
2015-03-23T08:00:00.000+08:00,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5348881/suntrust-names-eli-lilly-merck-bristol-myers-as-favorite,Mark Meadows,,,,,,
2015-03-23T08:00:00.000+08:00,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab",LLY,https://www.benzinga.com/news/15/03/5347402/pfizer-eli-lilly-announce-preparing-of-resumption-for-phase-3-chronic-pain-progra,Paul Quintaro,,,,,,
2015-03-27T08:00:00.000+08:00,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin",LLY,https://www.benzinga.com/news/15/03/5362511/ema-recommends-approval-of-eli-lilly-boehringer-ingelheims-empagliflozin-plus-met,Charles Gross,,,,,,
2015-04-01T08:00:00.000+08:00,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law,LLY,https://www.benzinga.com/news/15/04/5374706/8-companies-that-are-fighting-indianas-religious-freedom-law,Laura Brodbeck,,,,,,
2015-04-13T08:00:00.000+08:00,7 Trends Drug Investors Should Know,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5403186/7-trends-drug-investors-should-know,John Seward,,,,,,
2015-04-14T08:00:00.000+08:00,Morgan Stanley's Major Pharma Q1 Preview,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5407829/morgan-stanleys-major-pharma-q1-preview,Kevin Riley,,,,,,
2015-04-15T08:00:00.000+08:00,SunTrust's Latest Comments On Merck,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5411600/suntrusts-latest-comments-on-merck,Jayson Derrick,,,,,,
2015-04-16T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales",LLY,https://www.benzinga.com/news/15/04/5415298/lilly-bristol-myers-squibb-restructure-erbitux-pact-in-north-america-lilly-gets-f,Paul Quintaro,,,,,,
2015-04-20T08:00:00.000+08:00,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis,LLY,https://www.benzinga.com/news/15/04/5421562/lillys-ixekizumab-meets-primary-endpoint-in-a-phase-3-study-investigating-treatme,Hal Lindon,,,,,,
2015-04-22T08:00:00.000+08:00,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting,LLY,https://www.benzinga.com/news/15/04/5430900/eli-lilly-partner-deciphera-pharma-announces-data-highlighting-kinase-inhibitor-p,Paul Quintaro,,,,,,
2015-04-23T08:00:00.000+08:00,"US Stock Futures Down Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/04/5435801/us-stock-futures-down-ahead-of-earnings-economic-data,Monica Gerson,,,,,,
2015-04-23T08:00:00.000+08:00,Eli Lilly Tops Q1 Views,LLY,https://www.benzinga.com/news/earnings/15/04/5435387/eli-lilly-tops-q1-views,Monica Gerson,,,,,,
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $4.65B vs $4.62B est,LLY,https://www.benzinga.com/news/15/04/5435084/lilly-q1-eps-4-65b-vs-4-62b-est,Paul Quintaro,,,,,,
2015-04-23T08:00:00.000+08:00,Lilly Confirms FY Guidance,LLY,https://www.benzinga.com/news/15/04/5435081/lilly-confirms-fy-guidance,Paul Quintaro,,,,,,
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $0.87 vs $0.77 est,LLY,https://www.benzinga.com/news/earnings/15/04/5435079/lilly-q1-eps-0-87-vs-0-77-est,Paul Quintaro,,,,,,
2015-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/04/5434811/earnings-scheduled-for-april-23-2015,Monica Gerson,,,,,,
2015-04-24T08:00:00.000+08:00,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/15/04/5442461/lillys-cyramza-receives-approval-for-use-with-folfiri-in-second-line-treatment-of,Paul Quintaro,,,,,,
2015-04-24T08:00:00.000+08:00,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind,LLY,https://www.benzinga.com/media/cnbc/15/04/5438000/eli-lilly-cfo-solid-underlying-performance-despite-fx-headwind,Ritesh Anan,,,,,,
2015-04-24T08:00:00.000+08:00,BMO's Updated Eli Lilly Model Following Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5441265/bmos-updated-eli-lilly-model-following-earnings,Javier Hasse,,,,,,
2015-04-28T08:00:00.000+08:00,BofA Sees Many Catalysts On Eli Lilly's Horizon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5453175/bofa-sees-many-catalysts-on-eli-lillys-horizon,Monica Gerson,,,,,,
2015-04-29T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5456013/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5455619/citigroup-upgrades-eli-lilly-to-buy,Monica Gerson,,,,,,
2015-04-29T08:00:00.000+08:00,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers,LLY,https://www.benzinga.com/general/biotech/15/04/5451948/ipo-outlook-colucid-offers-hope-for-migraine-sufferers,Charles Enser,,,,,,
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/04/5454745/citigroup-upgrades-eli-lilly-to-buy,Hal Lindon,,,,,,
2015-05-01T08:00:00.000+08:00,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73,LLY,https://www.benzinga.com/news/15/05/5468614/shares-of-lilly-spike-lower-momentarily-to-71-25-before-rebounding-to-73,Paul Quintaro,,,,,,
2015-05-01T08:00:00.000+08:00,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly,LLY,https://www.benzinga.com/news/15/05/5467343/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-lilly,Charles Gross,,,,,,
2015-05-05T08:00:00.000+08:00,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5476290/credit-suisse-we-prefer-pfizer-bristol-over-pharma-peers,Mark Meadows,,,,,,
2015-05-11T08:00:00.000+08:00,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies",LLY,https://www.benzinga.com/news/15/05/5498678/lilly-biontech-announce-research-collaboration-on-novel-cancer-immunotherapies,Charles Gross,,,,,,
2015-05-12T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016,LLY,https://www.benzinga.com/news/15/05/5501447/lilly-announces-cash-tender-offer-for-up-to-1-6aggregate-principal-amount-of-its-,Eddie Staley,,,,,,
2015-05-14T08:00:00.000+08:00,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies",LLY,https://www.benzinga.com/news/15/05/5509634/lilly-sanford-burnham-collaborate-to-investigate-immunological-therapies,Charles Gross,,,,,,
2015-05-27T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Humalog,LLY,https://www.benzinga.com/news/15/05/5543248/eli-lilly-announces-fda-approves-humalog,Hal Lindon,,,,,,
2015-05-27T08:00:00.000+08:00,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/15/05/5542840/lilly-to-present-new-clinical-data-at-75th-american-diabetes-association-scientif,Eddie Staley,,,,,,
2015-05-28T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data,LLY,https://www.benzinga.com/news/15/05/5548917/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-iii-data,Paul Quintaro,,,,,,
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Results Of Cash Tender Offer,LLY,https://www.benzinga.com/news/15/05/5547402/eli-lilly-reports-results-of-cash-tender-offer,Hal Lindon,,,,,,
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities,LLY,https://www.benzinga.com/news/15/05/5547396/eli-lilly-reports-will-present-cyramza-data-at-asco-meeting-will-submit-to-japane,Paul Quintaro,,,,,,
2015-05-29T08:00:00.000+08:00,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors",LLY,https://www.benzinga.com/news/15/05/5551419/lilly-astrazeneca-to-partner-on-immuno-oncology-combination-clinical-trial-in-sol,Hal Lindon,,,,,,
2015-06-01T08:00:00.000+08:00,16 Biotech Stocks Moving Off The ASCO Conference,LLY,https://www.benzinga.com/general/biotech/15/06/5557758/16-biotech-stocks-moving-off-the-asco-conference,Javier Hasse,,,,,,
2015-06-04T08:00:00.000+08:00,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology,LLY,https://www.benzinga.com/news/15/06/5568186/lilly-to-report-pivotal-phase-3-study-results-for-investigational-psoriasis-treat,Hal Lindon,,,,,,
2015-06-07T08:00:00.000+08:00,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks,LLY,https://www.benzinga.com/news/15/06/5573876/lily-presents-study-indicating-once-weekly-trulicity-more-effective-than-once-dai,Charles Gross,,,,,,
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573869/lillys-basal-insulin-peglispro-shows-superiority-to-glargine-in-reducing-hba1c-in,Charles Gross,,,,,,
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573867/lillys-basal-insulin-peglispro-studies-demonstrate-superiority-to-glargine-in-peo,Charles Gross,,,,,,
2015-06-08T08:00:00.000+08:00,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5576612/this-technology-could-disrupt-u-s-pharma-stocks-credit-s,John Seward,,,,,,
2015-06-08T08:00:00.000+08:00,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5575490/new-data-show-enhanced-effects-of-lillys-once-weekly-trulicity-dulaglutide-to-lan,Hal Lindon,,,,,,
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to All-Time High,LLY,https://www.benzinga.com/news/15/06/5581168/lily-shares-spike-to-all-time-high,Charles Gross,,,,,,
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active,LLY,https://www.benzinga.com/news/15/06/5580891/lily-shares-spike-to-high-weekly-jun-12-79-5-call-active,Charles Gross,,,,,,
2015-06-10T08:00:00.000+08:00,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment",LLY,https://www.benzinga.com/news/15/06/5584295/studies-report-psoriasis-patients-achieved-significant-levels-of-skin-clearance-i,Paul Quintaro,,,,,,
2015-06-10T08:00:00.000+08:00,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis,LLY,https://www.benzinga.com/news/15/06/5582938/lilly-and-incyte-unveil-detailed-data-on-two-pivotal-studies-of-baricitinib-in-rh,Eddie Staley,,,,,,
2015-06-10T08:00:00.000+08:00,Fast Money Picks For June 10,LLY,https://www.benzinga.com/media/cnbc/15/06/5582100/fast-money-picks-for-june-10,Craig Jones,,,,,,
2015-06-12T08:00:00.000+08:00,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price,LLY,https://www.benzinga.com/news/15/06/5591696/update-alzheimers-association-says-release-of-data-under-embargo-to-conference-pa,Charles Gross,,,,,,
2015-06-12T08:00:00.000+08:00,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters,LLY,https://www.benzinga.com/news/15/06/5591693/alzheimers-group-says-may-not-offer-early-look-at-highly-sought-data-on-lilly-dru,Charles Gross,,,,,,
2015-06-16T08:00:00.000+08:00,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5599077/new-report-abbvie-is-jefferies-top-global-pharma-stock,Wayne Duggan,,,,,,
2015-06-17T08:00:00.000+08:00,The Note Moving Pharma Giants Today,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5603207/the-note-moving-pharma-giants-today,John Seward,,,,,,
2015-06-17T08:00:00.000+08:00,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study,LLY,https://www.benzinga.com/news/15/06/5602740/lillys-investigational-migraine-prevention-medicine-met-primary-endpoint-in-a-pha,Hal Lindon,,,,,,
2015-06-17T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/06/5602006/benzingas-top-initiations,Lisa Levin,,,,,,
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer",LLY,https://www.benzinga.com/news/15/06/5601491/eli-lilly-dana-farber-announce-research-collaboration-for-new-medicines-to-fight-,Hal Lindon,,,,,,
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy",LLY,https://www.benzinga.com/news/15/06/5601453/eli-lilly-sara-cannon-research-institute-enter-collaboration-to-develop-investiga,Hal Lindon,,,,,,
2015-06-17T08:00:00.000+08:00,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT",LLY,https://www.benzinga.com/news/15/06/5600995/piper-jaffray-initiates-coverage-on-eli-lilly-at-overweight-announces-97-00-pt,Eddie Staley,,,,,,
2015-06-18T08:00:00.000+08:00,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5606161/eli-lilly-price-target-hiked-to-92-at-argus-heres-why,Jim Swanson,,,,,,
2015-06-19T08:00:00.000+08:00,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology,LLY,https://www.benzinga.com/news/15/06/5608057/cyramza-hepatocellular-carcinoma-data-published-by-the-lancet-oncology,Hal Lindon,,,,,,
2015-06-22T08:00:00.000+08:00,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5612627/ken-langones-top-stock-picks-schlumberger-eli-lilly-and-,Ritesh Anan,,,,,,
2015-06-24T08:00:00.000+08:00,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5621334/sales-of-this-eli-lilly-drug-could-nearly-double-wall-st,Jim Swanson,,,,,,
2015-06-25T08:00:00.000+08:00,Eli Lilly Shares Go Parabolic,LLY,https://www.benzinga.com/trading-ideas/technicals/15/06/5625001/eli-lilly-shares-go-parabolic,Joel Elconin,,,,,,
2015-06-25T08:00:00.000+08:00,Bank of America Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/06/5623660/bank-of-america-upgrades-eli-lilly-to-buy,Hal Lindon,,,,,,
2015-06-25T08:00:00.000+08:00,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit,LLY,https://www.benzinga.com/news/15/06/5623532/eli-lilly-announces-uk-court-has-ruled-in-favor-of-co-in-alimta-vitamin-regimen-p,Paul Quintaro,,,,,,
2015-06-29T08:00:00.000+08:00,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma",LLY,https://www.benzinga.com/news/15/06/5631264/lilly-immunocore-report-immunotherapy-based-clinical-trial-collaboration-in-melan,Hal Lindon,,,,,,
2015-07-03T08:00:00.000+08:00,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5647375/aaic-is-coming-heres-what-to-expect-biogen-and-eli-lilly,Zoheb Sait,,,,,,
2015-07-07T08:00:00.000+08:00,Fast Money Picks For July 7,LLY,https://www.benzinga.com/media/cnbc/15/07/5651262/fast-money-picks-for-july-7,Craig Jones,,,,,,
2015-07-09T08:00:00.000+08:00,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review",LLY,https://www.benzinga.com/news/15/07/5661905/eli-lilly-issues-statement-regarding-fda-panel-review-of-necitumumab-encouraged-b,Paul Quintaro,,,,,,
2015-07-09T08:00:00.000+08:00,Fast Money Picks For July 9,LLY,https://www.benzinga.com/media/cnbc/15/07/5659284/fast-money-picks-for-july-9,Craig Jones,,,,,,
2015-07-13T08:00:00.000+08:00,Stocks Hitting 52-Week Highs,LLY,https://www.benzinga.com/news/15/07/5667030/stocks-hitting-52-week-highs,Lisa Levin,,,,,,
2015-07-15T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/15/07/5673731/benzingas-top-downgrades,Lisa Levin,,,,,,
2015-07-15T08:00:00.000+08:00,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5673474/morgan-stanley-cuts-eli-lilly-says-downgraded-not-relate,Paul Quintaro,,,,,,
2015-07-15T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equalweight,LLY,https://www.benzinga.com/news/15/07/5672850/morgan-stanley-downgrades-eli-lilly-to-equalweight,Hal Lindon,,,,,,
2015-07-20T08:00:00.000+08:00,Has Eli Lilly Found A Cure For Alzheimer's?,LLY,https://www.benzinga.com/news/15/07/5683636/has-eli-lilly-found-a-cure-for-alzheimers,Laura Brodbeck,,,,,,
2015-07-20T08:00:00.000+08:00,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5684214/stifel-jmp-securities-discuss-what-to-expect-from-aaic-c,Jayson Derrick,,,,,,
2015-07-21T08:00:00.000+08:00,New Alzheimer's Trials Could Produce The Most Important Drugs In History,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5689606/new-alzheimers-trials-could-produce-the-most-important-d,Leigh Drogen,,,,,,
2015-07-21T08:00:00.000+08:00,Fast Money Picks For July 21,LLY,https://www.benzinga.com/media/cnbc/15/07/5686983/fast-money-picks-for-july-21,Craig Jones,,,,,,
2015-07-22T08:00:00.000+08:00,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693254/whats-coming-for-large-cap-pharma-stocks-this-earnings-s,Wayne Duggan,,,,,,
2015-07-22T08:00:00.000+08:00,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5694244/did-mcdonalds-caterpillar-amazon-lose-sizzle-to-strong-d,TD Ameritrade,,,,,,
2015-07-22T08:00:00.000+08:00,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693489/evercore-isis-mark-schoenebaum-new-eli-lilly-data-increm,Monica Gerson,,,,,,
2015-07-22T08:00:00.000+08:00,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692153/data-using-new-delayed-start-methodology-suggested-benefit-of-early-treatment-wit,Eddie Staley,,,,,,
2015-07-22T08:00:00.000+08:00,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692146/data-utilizing-new-delayed-start-methodology-suggested-benefit-of-early-treatment,Hal Lindon,,,,,,
2015-07-23T08:00:00.000+08:00,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5698873/analysts-key-takeaways-from-eli-lilly-bristol-myer-squib,Jayson Derrick,,,,,,
2015-07-23T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat,LLY,https://www.benzinga.com/general/biotech/15/07/5697796/eli-lilly-ceo-explains-the-reasons-behind-the-0-16-eps-beat,Santhosh Naikar,,,,,,
2015-07-23T08:00:00.000+08:00,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters,LLY,https://www.benzinga.com/news/15/07/5697835/lilly-ceo-says-bubble-in-prices-of-smaller-biotech-cos-reuters,Charles Gross,,,,,,
2015-07-23T08:00:00.000+08:00,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.,LLY,https://www.benzinga.com/news/15/07/5696333/eli-lilly-sees-fy15-adj-eps-3-20-3-30-vs-3-18-est,Paul Quintaro,,,,,,
2015-07-23T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B",LLY,https://www.benzinga.com/news/earnings/15/07/5696332/eli-lilly-reports-q1-adj-eps-0-90-vs-est-0-74-sales-4-98b-vs-est-4-91b,Eddie Staley,,,,,,
2015-07-23T08:00:00.000+08:00,"Earnings Scheduled For July 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/07/5696128/earnings-scheduled-for-july-23-2015,Monica Gerson,,,,,,
2015-07-27T08:00:00.000+08:00,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16,LLY,https://www.benzinga.com/news/15/07/5704861/lilly-issues-update-on-evacetrapib-phase-3-trial-last-patient-visit-in-accelerate,Paul Quintaro,,,,,,
2015-08-15T08:00:00.000+08:00,Here's A Look At Eli Lilly's Future Pipeline,LLY,https://www.benzinga.com/general/biotech/15/08/5767069/heres-a-look-at-eli-lillys-future-pipeline,Zoheb Sait,,,,,,
2015-08-16T08:00:00.000+08:00,Eli Lilly CEO: Recent Events In China Don't Change Much,LLY,https://www.benzinga.com/general/biotech/15/08/5767116/eli-lilly-ceo-recent-events-in-china-dont-change-much,Ritesh Anan,,,,,,
2015-08-20T08:00:00.000+08:00,Benzinga's Volume Movers,LLY,https://www.benzinga.com/news/15/08/5780843/benzingas-volume-movers,Lisa Levin,,,,,,
2015-08-20T08:00:00.000+08:00,Lily +3% on Positive Jardiance Results,LLY,https://www.benzinga.com/news/15/08/5780049/lily-3-on-positive-jardiance-results,Charles Gross,,,,,,
2015-08-20T08:00:00.000+08:00,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events,LLY,https://www.benzinga.com/news/15/08/5779292/jardiance-demonstrated-cardiovascular-risk-reduction-in-people-with-type-2-diabet,Hal Lindon,,,,,,
2015-08-25T08:00:00.000+08:00,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/15/08/5791011/u-s-district-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patent,Paul Quintaro,,,,,,
2015-08-27T08:00:00.000+08:00,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes,LLY,https://www.benzinga.com/news/15/08/5796737/u-s-fda-approves-synjardy-tablets-for-adults-with-type-2-diabetes,Hal Lindon,,,,,,
2015-08-27T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/08/5796522/benzingas-top-initiations,Lisa Levin,,,,,,
2015-08-27T08:00:00.000+08:00,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/08/5795879/berenberg-initiates-coverage-on-eli-lilly-at-buy-announces-100-00-pt,Paul Quintaro,,,,,,
2015-09-15T08:00:00.000+08:00,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters,LLY,https://www.benzinga.com/news/15/09/5838008/eli-lilly-says-abasaglar-showed-similar-safety-to-lantus-reuters,Paul Quintaro,,,,,,
2015-09-17T08:00:00.000+08:00,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke",LLY,https://www.benzinga.com/news/15/09/5847206/boehringer-ingelheim-pharma-eli-lilly-announce-jardiance-significantly-reduced-ri,Paul Quintaro,,,,,,
2015-09-18T08:00:00.000+08:00,Bank Of America: New Eli Lilly Data Is 'Game-Changing',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849914/bank-of-america-new-eli-lilly-data-is-game-changing,Jayson Derrick,,,,,,
2015-09-18T08:00:00.000+08:00,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849393/eli-lillys-home-run-is-jardiance-says-morgan-stanley,J.D. Singh,,,,,,
2015-09-21T08:00:00.000+08:00,"Forget The 2016 Election Candidates, CEOs Are Driving Change",LLY,https://www.benzinga.com/news/15/09/5851638/forget-the-2016-election-candidates-ceos-are-driving-change,Laura Brodbeck,,,,,,
2015-09-28T08:00:00.000+08:00,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential",LLY,https://www.benzinga.com/news/15/09/5868975/lilly-sanofi-reach-settlement-agreement-on-insulin-glargine-litigation-in-u-s-lil,Hal Lindon,,,,,,
2015-09-28T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial,LLY,https://www.benzinga.com/news/15/09/5868322/lillys-cyramza-ramucirumab-significantly-improves-progression-free-survival-in-ph,Paul Quintaro,,,,,,
2015-09-29T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/15/09/5872882/stocks-hitting-52-week-lows,Lisa Levin,,,,,,
2015-09-29T08:00:00.000+08:00,Morning Market Losers,LLY,https://www.benzinga.com/news/15/09/5872776/morning-market-losers,Lisa Levin,,,,,,
2015-09-29T08:00:00.000+08:00,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results,LLY,https://www.benzinga.com/news/15/09/5871582/eli-lilly-and-incyte-announce-positive-top-line-phase-3-baricitnib-results,Paul Quintaro,,,,,,
2015-10-01T08:00:00.000+08:00,10 Defensive Stock Ideas From Bank Of America,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5881648/10-defensive-stock-ideas-from-bank-of-america,Jayson Derrick,,,,,,
2015-10-02T08:00:00.000+08:00,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters,LLY,https://www.benzinga.com/news/15/10/5884154/us-insurers-cautious-on-lillys-diabetes-drug-jardiance-reuters,Charles Gross,,,,,,
2015-10-08T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer,LLY,https://www.benzinga.com/news/15/10/5897301/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6,Paul Quintaro,,,,,,
2015-10-09T08:00:00.000+08:00,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed,LLY,https://www.benzinga.com/news/15/10/5902720/lilly-acquires-phase-iii-intranasal-glucagon-from-locemia-solutions-terms-not-dis,Hal Lindon,,,,,,
2015-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/10/5901507/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-10-09T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5901399/credit-suisse-upgrades-eli-lilly-likes-jardiance-for-sho,Monica Gerson,,,,,,
2015-10-09T08:00:00.000+08:00,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00",LLY,https://www.benzinga.com/news/15/10/5901004/credit-suisse-upgrades-eli-lilly-to-outperform-raises-pt-to-105-00,Paul Quintaro,,,,,,
2015-10-11T08:00:00.000+08:00,"Lilly, Innovent Biologics Expand Their Strategic Alliance",LLY,https://www.benzinga.com/news/15/10/5903735/lilly-innovent-biologics-expand-their-strategic-alliance,Charles Gross,,,,,,
2015-10-12T08:00:00.000+08:00,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905636/update-chardans-amusa-highlights-bull-vs-bear-case-for-e,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905630/chardan-capitals-amusa-on-esperion-following-evacetrapib,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,LLY,https://www.benzinga.com/general/biotech/15/10/5905059/eli-lilly-discontinues-evacetrapib-investors-move-bets-to-alternatives,Wayne Duggan,,,,,,
2015-10-12T08:00:00.000+08:00,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi",LLY,https://www.benzinga.com/movers/15/10/5904624/regeneron-trading-up-to-517share-up-2-6-premarket-on-eli-lilly-evacetraqib-deve,Hal Lindon,,,,,,
2015-10-12T08:00:00.000+08:00,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904582/update-shares-of-esperion-therapeutics-trading-up-14-following-discontinuation-of,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49",LLY,https://www.benzinga.com/movers/15/10/5904581/update-shares-of-eli-lilly-trading-down-8-now-under-80-at-79-49,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904572/thestreets-adam-feuerstein-recently-tweets-watch-espr-on-the-heels-of-eli-lilly-d,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib",LLY,https://www.benzinga.com/movers/15/10/5904564/esperion-shares-trading-higher-to-28-50share-up-14-9-premarket-following-eli-li,Hal Lindon,,,,,,
2015-10-12T08:00:00.000+08:00,Shares of Eli Lilly Resume; Now Trading Down ~$83,LLY,https://www.benzinga.com/news/15/10/5904561/shares-of-eli-lilly-resume-now-trading-down-83,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax,LLY,https://www.benzinga.com/news/15/10/5904548/update-eli-lilly-evacetraqib-devlopment-discontinuation-expected-to-result-in-q4-,Hal Lindon,,,,,,
2015-10-12T08:00:00.000+08:00,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings",LLY,https://www.benzinga.com/news/15/10/5904540/update-eli-discontinuing-evacetraqib-development-due-to-low-probability-of-study-,Hal Lindon,,,,,,
2015-10-12T08:00:00.000+08:00,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy",LLY,https://www.benzinga.com/news/15/10/5904532/update-lilly-will-terminate-phase-3-trial-of-evacetrapib-cites-insufficient-effic,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,Lilly Announces Will Discontinue Development of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904443/lilly-announces-will-discontinue-development-of-evacetrapib,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,LLY,https://www.benzinga.com/general/biotech/15/10/5904403/watching-volatility-in-other-big-pharma-names-amid-eli-lilly-halt,Hal Lindon,,,,,,
2015-10-12T08:00:00.000+08:00,Eli Lilly Shares Halted News Pending,LLY,https://www.benzinga.com/news/15/10/5904398/eli-lilly-shares-halted-news-pending,Paul Quintaro,,,,,,
2015-10-12T08:00:00.000+08:00,US Stock Futures Flat Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/15/10/5904212/us-stock-futures-flat-ahead-of-fed-speakers,Monica Gerson,,,,,,
2015-10-13T08:00:00.000+08:00,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5907490/jmp-analyst-says-eli-lillys-cetp-failure-positive-for-es,Hal Lindon,,,,,,
2015-10-13T08:00:00.000+08:00,US Stock Futures Down; JPMorgan Earnings In Focus,LLY,https://www.benzinga.com/news/15/10/5907418/us-stock-futures-down-jpmorgan-earnings-in-focus,Monica Gerson,,,,,,
2015-10-13T08:00:00.000+08:00,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms",LLY,https://www.benzinga.com/news/15/10/5907277/lilly-and-imaginab-announce-preclinical-immuno-oncology-collaboration-no-terms,Paul Quintaro,,,,,,
2015-10-13T08:00:00.000+08:00,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector,LLY,https://www.benzinga.com/media/cnbc/15/10/5906585/fast-money-traders-share-their-thoughts-on-eli-lilly-and-and-the-restaurant,Craig Jones,,,,,,
2015-10-13T08:00:00.000+08:00,Fast Money Picks For October 13,LLY,https://www.benzinga.com/media/cnbc/15/10/5906571/fast-money-picks-for-october-13,Craig Jones,,,,,,
2015-10-14T08:00:00.000+08:00,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/15/10/5911779/new-type-2-diabetes-treatment-synjardy-tablets-now-available-in-u-s-pharmacies,Hal Lindon,,,,,,
2015-10-14T08:00:00.000+08:00,Incyte and Eli Lilly Announce Baricitnib Results,LLY,https://www.benzinga.com/news/15/10/5911278/incyte-and-eli-lilly-announce-baricitnib-results,Paul Quintaro,,,,,,
2015-10-18T08:00:00.000+08:00,Google Stands Out Amid Low Earnings Expectations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5922170/google-stands-out-amid-low-earnings-expectations,Nelson Hem,,,,,,
2015-10-20T08:00:00.000+08:00,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment,LLY,https://www.benzinga.com/news/15/10/5927985/yabao-pharmaceuticals-enters-2nd-innovative-collaboration-with-eli-lilly-and-comp,Hal Lindon,,,,,,
2015-10-21T08:00:00.000+08:00,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings",LLY,https://www.benzinga.com/trading-ideas/previews/15/10/5932997/global-growth-temperature-likely-captured-in-caterpillar-mcdona,The Ticker Tape,,,,,,
2015-10-21T08:00:00.000+08:00,Lilly supports global Dementia Discovery Fund,LLY,https://www.benzinga.com/news/15/10/5930964/lilly-supports-global-dementia-discovery-fund,Paul Quintaro,,,,,,
2015-10-22T08:00:00.000+08:00,"US Stock Futures Gain Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/10/5935702/us-stock-futures-gain-ahead-of-earnings-economic-data,Monica Gerson,,,,,,
2015-10-22T08:00:00.000+08:00,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast",LLY,https://www.benzinga.com/news/earnings/15/10/5935628/eli-lilly-posts-upbeat-q3-earnings-raises-forecast,Monica Gerson,,,,,,
2015-10-22T08:00:00.000+08:00,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B",LLY,https://www.benzinga.com/news/15/10/5935490/eli-lilly-raises-fy-2015-eps-3-40-3-45-vs-est-3-28-had-seen-3-20-3-30-revs-19-7b-,Paul Quintaro,,,,,,
2015-10-22T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est",LLY,https://www.benzinga.com/news/earnings/15/10/5935489/eli-lilly-q3-eps-0-89-vs-0-75-est-revenue-4-96b-vs-4-99b-est,Paul Quintaro,,,,,,
2015-10-22T08:00:00.000+08:00,"Earnings Scheduled For October 22, 2015",LLY,https://www.benzinga.com/news/earnings/15/10/5935259/earnings-scheduled-for-october-22-2015,Monica Gerson,,,,,,
2015-10-27T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data,LLY,https://www.benzinga.com/press-releases/15/10/5945308/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-3-data,Paul Quintaro,,,,,,
2015-11-06T08:00:00.000+08:00,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'",LLY,https://www.benzinga.com/news/15/11/5966759/eli-lilly-spokesperson-confirms-disclosure-of-doj-inquiry-was-in-filing-a-week-ag,Paul Quintaro,,,,,,
2015-11-06T08:00:00.000+08:00,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old",LLY,https://www.benzinga.com/news/15/11/5966717/eli-lilly-moving-off-doj-inquiry-but-news-is-old,Javier Hasse,,,,,,
2015-11-06T08:00:00.000+08:00,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers,LLY,https://www.benzinga.com/exclusives/15/11/5966728/eli-lilly-spokesperson-says-will-soon-be-providing-statement-related-to-doj,Paul Quintaro,,,,,,
2015-11-06T08:00:00.000+08:00,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago,LLY,https://www.benzinga.com/news/15/11/5966680/bz-note-eli-lilly-comments-on-doj-inquiry-on-wholesalers-came-from-10-q-filed-on-,Paul Quintaro,,,,,,
2015-11-06T08:00:00.000+08:00,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session",LLY,https://www.benzinga.com/movers/15/11/5966637/update-eli-lilly-shares-plunge-1-over-last-few-mins-stock-now-down-2-5-for-sess,Paul Quintaro,,,,,,
2015-11-06T08:00:00.000+08:00,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ,LLY,https://www.benzinga.com/news/15/11/5966636/lilly-says-doj-conducting-inquiry-of-agreements-with-wholesalers-dj,Charles Gross,,,,,,
2015-11-06T08:00:00.000+08:00,Eli Lilly Shares Falling,LLY,https://www.benzinga.com/movers/15/11/5966633/eli-lilly-shares-falling,Hal Lindon,,,,,,
2015-11-07T08:00:00.000+08:00,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA",LLY,https://www.benzinga.com/news/15/11/5967515/lilly-incyte-announce-data-demonstrate-baricitinib-superiority-to-adalimumab-in-i,Charles Gross,,,,,,
2015-11-08T08:00:00.000+08:00,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares",LLY,https://www.benzinga.com/news/15/11/5967717/ignyta-acquires-exclusive-rights-to-taladegib-oncology-program-from-lilly-for-2m-,Charles Gross,,,,,,
2015-11-09T08:00:00.000+08:00,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo",LLY,https://www.benzinga.com/news/15/11/5969221/update-eli-lilly-release-shows-new-data-on-jardiance-showed-reduction-to-risk-of-,Paul Quintaro,,,,,,
2015-11-09T08:00:00.000+08:00,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline,LLY,https://www.benzinga.com/news/15/11/5969217/new-jardiance-data-show-improved-cv-outcomes-regardless-of-heart-failure-status-a,Hal Lindon,,,,,,
2015-11-10T08:00:00.000+08:00,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China",LLY,https://www.benzinga.com/news/15/11/5972639/wuxi-lilly-report-strategic-collaboration-to-develop-novel-therapeutic-in-china,Paul Quintaro,,,,,,
2015-11-16T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/11/5979841/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-11-16T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00",LLY,https://www.benzinga.com/news/15/11/5979322/bmo-capital-upgrades-eli-lilly-to-outperform-raises-pt-to-100-00,Paul Quintaro,,,,,,
2015-11-19T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of Jobless Claims Report,LLY,https://www.benzinga.com/news/earnings/15/11/5990030/us-stock-futures-edge-higher-ahead-of-jobless-claims-report,Monica Gerson,,,,,,
2015-11-19T08:00:00.000+08:00,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,LLY,https://www.benzinga.com/news/15/11/5989132/lilly-and-merck-expand-immuno-oncology-collaboration-with-phase-iii-nonsquamous-n,Eddie Staley,,,,,,
2015-11-24T08:00:00.000+08:00,Eli Lilly Release Confirms FDA Approval If Portrazza,LLY,https://www.benzinga.com/news/15/11/5999325/eli-lilly-release-confirms-fda-approval-if-portrazza,Eddie Staley,,,,,,
2015-11-24T08:00:00.000+08:00,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ,LLY,https://www.benzinga.com/news/15/11/5999047/fda-approves-eli-lillys-portrazza-to-treat-advanced-squamous-non-small-cell-lung-,Hal Lindon,,,,,,
2015-11-30T08:00:00.000+08:00,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/11/6007462/health-canada-approves-jardiance-empagliflozin-tablets-for-adults-with-type-2-dia,Eddie Staley,,,,,,
2015-12-01T08:00:00.000+08:00,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/news/15/12/6013131/new-data-show-lillys-once-weekly-trulicity-is-effective-as-add-on-treatment-to-su,Hal Lindon,,,,,,
2015-12-01T08:00:00.000+08:00,Barclays' Biopharmaceuticals Blueprint For 2016,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6011335/barclays-biopharmaceuticals-blueprint-for-2016,Jayson Derrick,,,,,,
2015-12-01T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6011813/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-12-01T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00",LLY,https://www.benzinga.com/news/15/12/6010816/barclays-upgrades-eli-lilly-to-overweight-raises-pt-to-95-00,Charles Gross,,,,,,
2015-12-04T08:00:00.000+08:00,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question,LLY,https://www.benzinga.com/news/15/12/6022625/cautious-stock-rebound-as-jobs-data-delivers-but-wages-still-in-question,The Ticker Tape,,,,,,
2015-12-04T08:00:00.000+08:00,Lilly Ends Basal Insulin Peglispro Development Program,LLY,https://www.benzinga.com/news/15/12/6021994/lilly-ends-basal-insulin-peglispro-development-program,Eddie Staley,,,,,,
2015-12-07T08:00:00.000+08:00,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6026272/eli-lilly-could-make-a-lot-more-from-alzheimers-drug-tha,Monica Gerson,,,,,,
2015-12-07T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6025991/benzingas-top-upgrades,Lisa Levin,,,,,,
2015-12-07T08:00:00.000+08:00,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00",LLY,https://www.benzinga.com/news/15/12/6025218/deutsche-bank-upgrades-eli-lilly-to-buy-raises-to-99-00,Paul Quintaro,,,,,,
2015-12-08T08:00:00.000+08:00,Eli Lilly Increases Dividend From $0.50 To $0.51/Share,LLY,https://www.benzinga.com/news/15/12/6029081/eli-lilly-increases-dividend-from-0-50-to-0-51share,Hal Lindon,,,,,,
2015-12-10T08:00:00.000+08:00,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration,LLY,https://www.benzinga.com/news/15/12/6036228/eli-lilly-and-merk-announces-expansion-of-immuno-oncology-collaboration,Paul Quintaro,,,,,,
2015-12-12T08:00:00.000+08:00,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6041783/major-pharma-group-outlook-in-2016-fundamentals-to-outwe,Jennifer Lynn,,,,,,
2015-12-17T08:00:00.000+08:00,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6057167/shares-of-eli-lilly-up-0-6-after-credit-suisse-adds-to-f,Paul Quintaro,,,,,,
2015-12-18T08:00:00.000+08:00,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061206/3-biotechs-atlantic-equities-loves-and-1-its-avoiding,Javier Hasse,,,,,,
2015-12-18T08:00:00.000+08:00,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/12/6060358/atlantic-equities-initiates-coverage-on-eli-lilly-at-overweight-announces-100-00-,Paul Quintaro,,,,,,
2015-12-18T08:00:00.000+08:00,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA,LLY,https://www.benzinga.com/news/15/12/6060080/lillys-lung-cancer-drug-necitumumab-receives-positive-opinion-from-ema,Charles Gross,,,,,,
2015-12-19T08:00:00.000+08:00,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061487/credit-suisse-offers-2016-u-s-large-cap-pharma-outlook,Jayson Derrick,,,,,,
2015-12-21T08:00:00.000+08:00,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets",LLY,https://www.benzinga.com/news/15/12/6064738/update-halozyme-says-will-receive-initial-25m-payment-followed-by-milestone-payme,Paul Quintaro,,,,,,
2015-12-21T08:00:00.000+08:00,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly",LLY,https://www.benzinga.com/news/15/12/6064722/halozyme-reports-entering-of-global-collab-licensing-deal-with-lilly,Paul Quintaro,,,,,,
2015-12-23T08:00:00.000+08:00,Not All Of Clinton's Policies Are Bad For Pharmaceuticals,LLY,https://www.benzinga.com/general/biotech/15/12/6070719/not-all-of-clintons-policies-are-bad-for-pharmaceuticals,Laura Brodbeck,,,,,,
2015-12-28T08:00:00.000+08:00,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075841/eli-lillys-2016-guidance-released-next-week-could-disapp,Jim Swanson,,,,,,
2015-12-28T08:00:00.000+08:00,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075811/leerinks-fernandez-on-eli-lilly-ahead-of-expected-fy16-g,Paul Quintaro,,,,,,
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance,LLY,https://www.benzinga.com/news/16/01/6110639/eli-lilly-shares-lower-following-weaker-than-expected-2016-guidance,Jayson Derrick,,,,,,
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook,LLY,https://www.benzinga.com/news/16/01/6110210/eli-lilly-shares-trading-down-2-to-81-following-weaker-than-expected-fy16-outlook,Paul Quintaro,,,,,,
2016-01-05T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est.",LLY,https://www.benzinga.com/news/16/01/6109863/update-eli-lilly-sees-fy16-adj-eps-3-45-3-55-vs-3-65-est-sales-20-2b-20-7b-vs-21-,Paul Quintaro,,,,,,
2016-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.,LLY,https://www.benzinga.com/news/16/01/6109861/update-eli-lilly-reaffirms-fy15-adj-eps-outlook-3-40-3-45-vs-3-44-est,Paul Quintaro,,,,,,
2016-01-05T08:00:00.000+08:00,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance,LLY,https://www.benzinga.com/news/16/01/6109858/eli-lilly-issues-update-to-fy15-outlook-offers-fy16-guidance,Paul Quintaro,,,,,,
2016-01-11T08:00:00.000+08:00,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed",LLY,https://www.benzinga.com/news/16/01/6133603/insulet-enters-agreement-with-eli-lilly-for-omnipod-delivery-of-u200-concentrated,Hal Lindon,,,,,,
2016-01-15T08:00:00.000+08:00,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6146521/argus-reiterates-93-target-on-eli-lilly-highlights-stron,Jim Swanson,,,,,,
2016-01-19T08:00:00.000+08:00,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ,LLY,https://www.benzinga.com/news/16/01/6151234/eli-lilly-reiterates-fy15-guidance-of-3-45-3-55-vs-est-3-43-dj,Hal Lindon,,,,,,
2016-01-19T08:00:00.000+08:00,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA",LLY,https://www.benzinga.com/news/16/01/6151199/eli-lilly-incyte-report-submission-of-nda-for-oral-once-daily-baricitinib-for-tre,Paul Quintaro,,,,,,
2016-01-21T08:00:00.000+08:00,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen,LLY,https://www.benzinga.com/news/16/01/6159361/u-s-food-and-drug-administration-approves-humulin-r-u-500-kwikpen,Hal Lindon,,,,,,
2016-01-25T08:00:00.000+08:00,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?",LLY,https://www.benzinga.com/news/earnings/16/01/6166994/jnj-kicks-off-health-care-earnings-what-about-deals-buybacks,The Ticker Tape,,,,,,
2016-01-25T08:00:00.000+08:00,US Big Pharma: What To Watch For In Q4 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6166545/us-big-pharma-what-to-watch-for-in-q4-results,Wayne Duggan,,,,,,
2016-01-25T08:00:00.000+08:00,"Stock Marquee Crowded With Oil, Apple, And The Fed",LLY,https://www.benzinga.com/news/earnings/16/01/6166641/stock-marquee-crowded-with-oil-apple-and-the-fed,The Ticker Tape,,,,,,
2016-01-25T08:00:00.000+08:00,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance,LLY,https://www.benzinga.com/news/16/01/6166052/eli-lilly-reports-fda-acceptance-of-filing-of-cv-outcomes-data-for-jardiance,Paul Quintaro,,,,,,
2016-01-27T08:00:00.000+08:00,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool",LLY,https://www.benzinga.com/news/16/01/6174360/lilly-roche-diagnostics-to-partner-on-alzheimers-disease-adjunct-diagnostic-tool,Hal Lindon,,,,,,
2016-01-28T08:00:00.000+08:00,Earnings Recap For January 28,LLY,https://www.benzinga.com/news/earnings/16/01/6182803/earnings-recap-for-january-28,Javier Hasse,,,,,,
2016-01-28T08:00:00.000+08:00,Eli Lilly Punished For Inline Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/01/6180042/eli-lilly-punished-for-inline-report,Joel Elconin,,,,,,
2016-01-28T08:00:00.000+08:00,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est",LLY,https://www.benzinga.com/news/16/01/6177562/eli-lilly-sees-fy-eps-2-83-to-2-93-est-vs-3-43-est-revenue-20-2b-to-20-7b-vs-20-8,Paul Quintaro,,,,,,
2016-01-28T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est",LLY,https://www.benzinga.com/news/earnings/16/01/6177559/eli-lilly-q4-eps-0-78-vs-0-78-est-revenue-5-38b-vs-5-32b-est,Paul Quintaro,,,,,,
2016-01-28T08:00:00.000+08:00,"Earnings Scheduled For January 28, 2016",LLY,https://www.benzinga.com/news/earnings/16/01/6177199/earnings-scheduled-for-january-28-2016,Monica Gerson,,,,,,
2016-02-05T08:00:00.000+08:00,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6221815/credit-suisse-global-focus-list-update-toyota-out-agnico,Wayne Duggan,,,,,,
2016-02-08T08:00:00.000+08:00,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6228983/most-of-credit-suisses-top-investment-ideas-for-2016-in-,Amy Weingarden,,,,,,
2016-02-12T08:00:00.000+08:00,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015",LLY,https://www.benzinga.com/general/hedge-funds/16/02/6254781/13g-filing-shows-eli-lilly-holder-primecap-mgmt-co-holds-amended-5,Paul Quintaro,,,,,,
2016-02-12T08:00:00.000+08:00,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol,LLY,https://www.benzinga.com/news/16/02/6254773/eli-lilly-announces-alimta-not-infringed-by-actavis-marketing-pemetrexed-trometam,Hal Lindon,,,,,,
2016-02-16T08:00:00.000+08:00,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6307372/biotech-conference-suggests-tempering-expectations-for-e,Rebecca Sheppard,,,,,,
2016-02-22T08:00:00.000+08:00,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/16/02/6501807/eli-lilly-files-auto-shelf-for-mixed-offering-size-not-disclosed,Paul Quintaro,,,,,,
2016-02-22T08:00:00.000+08:00,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints",LLY,https://www.benzinga.com/news/16/02/6495221/radius-health-shares-up-29-following-data-from-amgen-ucbs-romosozumab-showing-fai,Paul Quintaro,,,,,,
2016-02-26T08:00:00.000+08:00,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍,LLY,https://www.benzinga.com/news/16/02/6692644/ema-recommends-against-approval-of-eli-lillys-psoriasis-treatment-lxekizumab,Charles Gross,,,,,,
2016-03-01T08:00:00.000+08:00,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th,LLY,https://www.benzinga.com/news/16/03/6760428/lilly-to-present-phase-3-ixekizumab-data-at-74th-aad-conference-taking-place-mar-,Hal Lindon,,,,,,
2016-03-02T08:00:00.000+08:00,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @ ASK $1.15: 1050 traded vs 0 OI: $73.54 Ref,LLY,https://www.benzinga.com/markets/options/16/03/6785516/option-alert-lly-fri-48-70-0-puts-wkly-sweep-1050-ask-1-15-1050-traded,Charles Gross,,,,,,
2016-03-03T08:00:00.000+08:00,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/6796936/bernstein-cuts-lly-fy-2017-eps-from-4-23-to-4-07-cuts-nv,Paul Quintaro,,,,,,
2016-03-07T08:00:00.000+08:00,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/03/7325981/eli-lilly-studies-show-ixekizumab-improved-work-productivity-for-patients-w-moder,Paul Quintaro,,,,,,
2016-03-07T08:00:00.000+08:00,PeptiDream to License PDPS Technology to Lilly,LLY,https://www.benzinga.com/news/16/03/7203359/peptidream-to-license-pdps-technology-to-lilly,Charles Gross,,,,,,
2016-03-14T08:00:00.000+08:00,Adocia & Lilly Announce Topline Results: 'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose',LLY,https://www.benzinga.com/news/16/03/7706809/adocia-lilly-announce-topline-results-biochaperone-lispro-u100-demonstrated-a-sta,Paul Quintaro,,,,,,
2016-03-14T08:00:00.000+08:00,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes,LLY,https://www.benzinga.com/news/16/03/7706801/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1b-study-of-repea,Charles Gross,,,,,,
2016-03-15T08:00:00.000+08:00,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition",LLY,https://www.benzinga.com/news/16/03/7712214/lilly-announces-change-to-primary-endpoint-of-expedition3-study-instead-of-co-pri,Hal Lindon,,,,,,
2016-03-17T08:00:00.000+08:00,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @ ASK $2.76: 1500 traded vs 55 OI: Earnings 4/26 Before Open $69.58 Ref,LLY,https://www.benzinga.com/markets/options/16/03/7728081/option-alert-lly-may16-70-0-calls-sweep-1500-ask-2-76-1500-traded-vs-5,Charles Gross,,,,,,
2016-03-22T08:00:00.000+08:00,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.',LLY,https://www.benzinga.com/news/16/03/7746881/adam-feuerstein-tweets-lly-fda-approves-ixekizumab-to-treat-adults-with-moderate-,Paul Quintaro,,,,,,
2016-03-28T08:00:00.000+08:00,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading",LLY,https://www.benzinga.com/news/16/03/7764033/biopharma-names-lly-pfe-mrk-and-more-popping-higher-following-reports-china-fda-t,Paul Quintaro,,,,,,
2016-03-29T08:00:00.000+08:00,Citi Downgrades Novartis Following SAG Investigation,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7769264/citi-downgrades-novartis-following-sag-investigation,Manikandan Raman,,,,,,
2016-03-31T08:00:00.000+08:00,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients,LLY,https://www.benzinga.com/news/16/03/7785232/eli-lillys-says-accaha-u-s-guideline-says-its-reasonable-to-chosose-effient-over-,Hal Lindon,,,,,,
2016-03-31T08:00:00.000+08:00,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint",LLY,https://www.benzinga.com/news/16/03/7782201/eli-lilly-phase-3-show-baricitinib-treatment-with-patients-in-rheumatoid-arthriti,Hal Lindon,,,,,,
2016-04-04T08:00:00.000+08:00,This Data Signals The End For Merck's Anacetrapib,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7796690/this-data-signals-the-end-for-mercks-anacetrapib,Monica Gerson,,,,,,
2016-04-06T08:00:00.000+08:00,SocGen Picks New Favorites In Big Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7810497/socgen-picks-new-favorites-in-big-pharma,Manikandan Raman,,,,,,
2016-04-06T08:00:00.000+08:00,Societe Generale Initiates Coverage on Eli Lilly at Hold,LLY,https://www.benzinga.com/news/16/04/7810187/societe-generale-initiates-coverage-on-eli-lilly-at-hold,Eddie Staley,,,,,,
2016-04-06T08:00:00.000+08:00,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",LLY,https://www.benzinga.com/news/16/04/7808622/incyte-acquires-rights-to-devlop-and-commercialize-ruxolitinib-from-lilly-will-ma,Hal Lindon,,,,,,
2016-04-06T08:00:00.000+08:00,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,LLY,https://www.benzinga.com/news/16/04/7808154/who-says-number-of-adults-with-diabetes-has-quadrupled-since-1980-afp,Charles Gross,,,,,,
2016-04-08T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data",LLY,https://www.benzinga.com/news/16/04/7818685/eli-lilly-astrazeneca-report-continuation-of-pivotal-trial-for-people-with-early-,Paul Quintaro,,,,,,
2016-04-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher,LLY,https://www.benzinga.com/news/earnings/16/04/7852329/mid-afternoon-market-update-chiasma-tumbles-following-fda-review-cvent-s,Lisa Levin,,,,,,
2016-04-18T08:00:00.000+08:00,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat,LLY,https://www.benzinga.com/news/earnings/16/04/7851616/mid-day-market-update-us-stocks-turn-positive-hasbro-shares-gain-followi,Lisa Levin,,,,,,
2016-04-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations,LLY,https://www.benzinga.com/news/earnings/16/04/7850856/mid-morning-market-update-markets-open-lower-morgan-stanley-q1-profit-be,Monica Gerson,,,,,,
2016-04-18T08:00:00.000+08:00,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development,LLY,https://www.benzinga.com/news/16/04/7849507/transition-therapeutics-says-partner-eli-lily-will-not-advance-tt401-into-phase-3,Hal Lindon,,,,,,
2016-04-19T08:00:00.000+08:00,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure,LLY,https://www.benzinga.com/news/16/04/7854782/eli-lilly-and-boehringer-reveals-study-on-jardiance-for-treatment-heart-failure,R. Chandrasekaran,,,,,,
2016-04-19T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Announce Jardiance to be Studied to Treat People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/16/04/7854602/lilly-boehringer-ingelheim-announce-jardiance-to-be-studied-to-treatment-people-w,Charles Gross,,,,,,
2016-04-25T08:00:00.000+08:00,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector",LLY,https://www.benzinga.com/general/biotech/16/04/7881082/aratana-eli-lilly-team-create-watershed-contract-for-pet-biotech-secto,Nicholas Donato,,,,,,
2016-04-25T08:00:00.000+08:00,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M",LLY,https://www.benzinga.com/news/16/04/7880194/aratana-elanco-announce-global-strategic-collaboration-45-up-front-payment-to-ara,Paul Quintaro,,,,,,
2016-04-25T08:00:00.000+08:00,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly",LLY,https://www.benzinga.com/news/16/04/7880126/transition-therapeutics-reports-dosing-of-first-patient-in-phase-2-study-of-drug-,Paul Quintaro,,,,,,
2016-04-25T08:00:00.000+08:00,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7878887/the-heart-of-major-pharma-q1-earnings-season-eli-lilly-a,Wayne Duggan,,,,,,
2016-04-25T08:00:00.000+08:00,"The Market In 5 Minutes: Monday, April 25, 2016",LLY,https://www.benzinga.com/news/16/04/7877761/the-market-in-5-minutes-monday-april-25-2016,Benzinga Newsdesk,,,,,,
2016-04-26T08:00:00.000+08:00,10 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/04/7883462/10-stocks-moving-in-tuesdays-pre-market-session,Monica Gerson,,,,,,
2016-04-26T08:00:00.000+08:00,Eli Lilly's Q1 EPS Disappoints,LLY,https://www.benzinga.com/news/earnings/16/04/7882697/eli-lillys-q1-eps-disappoints,R. Chandrasekaran,,,,,,
2016-04-26T08:00:00.000+08:00,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est",LLY,https://www.benzinga.com/news/16/04/7882567/eli-lilly-raises-fy-2016-guidance-sees-eps-3-50-to-3-60-vs-3-54-est-revenue-20-6b,Paul Quintaro,,,,,,
2016-04-26T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est",LLY,https://www.benzinga.com/news/earnings/16/04/7882563/eli-lilly-q1-eps-0-83-vs-0-85-est-revenue-4-87b-vs-4-82b-est,Paul Quintaro,,,,,,
2016-04-26T08:00:00.000+08:00,"Keep an Eye on These 12 Stocks for April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882108/keep-an-eye-on-these-12-stocks-for-april-26-2016,Monica Gerson,,,,,,
2016-04-26T08:00:00.000+08:00,"Earnings Scheduled For April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882015/earnings-scheduled-for-april-26-2016,Monica Gerson,,,,,,
2016-04-27T08:00:00.000+08:00,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes",LLY,https://www.benzinga.com/news/16/04/7891650/adocia-lilly-reportpositive-topline-results-from-a-phase-1b-study-of-repeated-adm,Paul Quintaro,,,,,,
2016-05-02T08:00:00.000+08:00,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/05/7915217/eli-lillys-taltz-now-available-in-the-u-s-for-the-treatment-of-moderate-to-severe,Paul Quintaro,,,,,,
2016-05-02T08:00:00.000+08:00,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36,LLY,https://www.benzinga.com/news/16/05/7914112/geoinvesting-says-anavex-life-sciences-stock-has-a-book-value-of-just-0-36,Jayson Derrick,,,,,,
2016-05-04T08:00:00.000+08:00,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma",LLY,https://www.benzinga.com/news/16/05/7927630/fda-grants-priority-review-for-lillys-olaratumab-an-investigational-medicine-for-,Paul Quintaro,,,,,,
2016-05-10T08:00:00.000+08:00,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares,LLY,https://www.benzinga.com/news/16/05/7959917/fda-says-will-add-new-warning-to-labels-for-all-olanzapine-containing-products-wa,Paul Quintaro,,,,,,
2016-05-11T08:00:00.000+08:00,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7966287/jefferies-updates-price-targets-in-global-pharma-sees-ri,Wayne Duggan,,,,,,
2016-05-11T08:00:00.000+08:00,The Market In 5 Minutes: Don't Stop Me Now,LLY,https://www.benzinga.com/news/16/05/7965189/the-market-in-5-minutes-dont-stop-me-now,Benzinga News Desk,,,,,,
2016-05-17T08:00:00.000+08:00,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7997997/fitch-says-drug-approvals-are-driving-targeted-acquisiti,Dhiraj Surapaneni,,,,,,
2016-05-17T08:00:00.000+08:00,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say",LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/05/7996612/eli-lilly-now-a-strong-buy-run-up-to-continue-vetr-top-raters,Javier Hasse,,,,,,
2016-05-18T08:00:00.000+08:00,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio",LLY,https://www.benzinga.com/news/16/05/8001681/lilly-highlights-asco-data-underscores-co-s-diverse-oncology-pipeline-portfolio,Paul Quintaro,,,,,,
2016-05-19T08:00:00.000+08:00,JPMorgan's Take On Big Pharma's New ASCO Abstracts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8006813/jpmorgans-take-on-big-pharmas-new-asco-abstracts,Wayne Duggan,,,,,,
2016-05-23T08:00:00.000+08:00,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target",LLY,https://www.benzinga.com/node/8017397,Andrew Efimoff,,,,,,
2016-05-24T08:00:00.000+08:00,Eli Lilly Says It Will Launch 20 New Products Through 2023,LLY,https://www.benzinga.com/general/biotech/16/05/8023341/eli-lilly-says-it-will-launch-20-new-products-through-2023,Jayson Derrick,,,,,,
2016-05-24T08:00:00.000+08:00,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years,LLY,https://www.benzinga.com/news/16/05/8022495/eli-lilly-offers-outline-of-potential-to-launch-20-new-products-in-10-years,Paul Quintaro,,,,,,
2016-05-31T08:00:00.000+08:00,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed",LLY,https://www.benzinga.com/news/16/05/8049442/adocia-lilly-reports-positive-topline-results-from-phase-1-study-of-biochaperone-,Paul Quintaro,,,,,,
2016-05-31T08:00:00.000+08:00,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/16/05/8049224/eli-lilly-gets-fda-approval-for-its-jentadueto-xr-for-adults-with-type,R. Chandrasekaran,,,,,,
2016-05-31T08:00:00.000+08:00,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/05/8048674/u-s-fda-approves-once-daily-jentadueto-xr-tablets-for-adults-with-type-2-diabetes,Paul Quintaro,,,,,,
2016-06-03T08:00:00.000+08:00,Negative Alimta News Disappointing For Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8068589/negative-alimta-news-disappointing-for-eli-lilly,Manikandan Raman,,,,,,
2016-06-03T08:00:00.000+08:00,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",LLY,https://www.benzinga.com/news/16/06/8068298/ouch-jobs-report-miss-sends-rate-hike-odds-down-raises-questions,The Ticker Tape,,,,,,
2016-06-03T08:00:00.000+08:00,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office",LLY,https://www.benzinga.com/news/16/06/8067849/eli-lilly-shares-selling-off-hearing-cos-patent-on-alimta-to-be-reviewed-at-us-pa,Paul Quintaro,,,,,,
2016-06-03T08:00:00.000+08:00,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8067770/morgan-stanley-negative-on-eli-lilly-says-negative-alimt,Paul Quintaro,,,,,,
2016-06-05T08:00:00.000+08:00,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16,LLY,https://www.benzinga.com/news/16/06/8071138/lilly-announces-encouraging-data-of-early-phase-immuno-oncology-studies-of-alimta,Charles Gross,,,,,,
2016-06-06T08:00:00.000+08:00,4 Key Takeaways From ASCO,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8076107/4-key-takeaways-from-asco,Javier Hasse,,,,,,
2016-06-07T08:00:00.000+08:00,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA",LLY,https://www.benzinga.com/news/16/06/8077730/eli-lilly-reports-results-of-clinical-patient-reported-outcomes-data-for-bariciti,Paul Quintaro,,,,,,
2016-06-08T08:00:00.000+08:00,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks,LLY,https://www.benzinga.com/news/16/06/8090415/studies-demonstrate-lillys-taltz-ixekizumab-maintained-or-achieved-high-levels-of,Paul Quintaro,,,,,,
2016-06-08T08:00:00.000+08:00,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @ ASK $0.13: 900 traded vs 320 OI: Earnings 7/26 Before Open $74.80 Ref,LLY,https://www.benzinga.com/markets/options/16/06/8089044/option-alert-lly-fri-610-76-5-calls-wkly-sweep-801-ask-0-13-900-traded,Charles Gross,,,,,,
2016-06-09T08:00:00.000+08:00,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results,LLY,https://www.benzinga.com/news/16/06/8091888/eli-lilly-and-incyte-say-two-phase-3-trials-for-arthritis-have-positive-results,Paul Quintaro,,,,,,
2016-06-12T08:00:00.000+08:00,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/06/8101683/lilly-announces-new-jardiance-data-show-reduced-risk-for-cardiovascular-death-was,Charles Gross,,,,,,
2016-06-12T08:00:00.000+08:00,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/16/06/8101680/lilly-presents-new-data-showing-once-weekly-trulicity-in-combination-with-insulin,Charles Gross,,,,,,
2016-06-12T08:00:00.000+08:00,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment,LLY,https://www.benzinga.com/news/16/06/8101559/lilly-announces-new-study-results-show-tradjenta-reduces-blood-sugar-in-adults-wi,Charles Gross,,,,,,
2016-06-13T08:00:00.000+08:00,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8105042/suntrust-highlights-upcoming-pharma-calendar-favorite-na,Amy Weingarden,,,,,,
2016-06-14T08:00:00.000+08:00,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/16/06/8111785/german-supreme-court-grants-lilly-appeal-in-alimta-vitamin-regimen-patent-lawsuit,Charles Gross,,,,,,
2016-06-14T08:00:00.000+08:00,Jefferies Shares Pharma Stock Catalyst Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8110237/jefferies-shares-pharma-stock-catalyst-outlook,Javier Hasse,,,,,,
2016-06-14T08:00:00.000+08:00,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease,LLY,https://www.benzinga.com/news/16/06/8108899/eli-lilly-says-jardiance-significantly-reduced-risk-of-progressive-kidney-disease,Paul Quintaro,,,,,,
2016-06-21T08:00:00.000+08:00,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/06/8135931/eli-lilly-canada-granted-approval-for-taltz-in-treatment-of-moderate-to-severe-pl,Eddie Staley,,,,,,
2016-06-30T08:00:00.000+08:00,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company",LLY,https://www.benzinga.com/news/16/06/8170340/regen-biopharma-inc-enters-into-open-innovation-drug-discovery-program-agreement-,Paul Quintaro,,,,,,
2016-07-06T08:00:00.000+08:00,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co.",LLY,https://www.benzinga.com/news/16/07/8189473/watch-for-near-term-profit-taking-in-lilly-shares-following-spike-higher-as-trade,Paul Quintaro,,,,,,
2016-07-06T08:00:00.000+08:00,Eli Lilly Shares Spiking Higher,LLY,https://www.benzinga.com/movers/16/07/8189464/eli-lilly-shares-spiking-higher,Paul Quintaro,,,,,,
2016-07-13T08:00:00.000+08:00,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer,LLY,https://www.benzinga.com/news/16/07/8212419/eli-lilly-reports-clinical-trial-collaboration-deal-with-ingelheim-for-metastatic,Paul Quintaro,,,,,,
2016-07-18T08:00:00.000+08:00,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/07/8227554/bmo-analysts-say-mercks-fundamentals-dont-justify-its-va,Manikandan Raman,,,,,,
2016-07-19T08:00:00.000+08:00,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults,LLY,https://www.benzinga.com/general/biotech/16/07/8231550/eli-lilly-gets-fda-expanded-indication-for-type-2-diabetes-treatment-s,R. Chandrasekaran,,,,,,
2016-07-19T08:00:00.000+08:00,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults,LLY,https://www.benzinga.com/news/16/07/8231138/eli-lilly-reports-u-s-fda-expands-indication-for-type-2-diabetes-treatment-synjar,Paul Quintaro,,,,,,
2016-07-25T08:00:00.000+08:00,Can MCD Feed Higher Sales with More than Breakfast?,LLY,https://www.benzinga.com/news/earnings/16/07/8253048/can-mcd-feed-higher-sales-with-more-than-breakfast,The Ticker Tape,,,,,,
2016-07-25T08:00:00.000+08:00,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap",LLY,https://www.benzinga.com/news/earnings/16/07/8252276/week-ahead-its-not-just-earnings-this-time-as-gdp-fed-also-on-tap,The Ticker Tape,,,,,,
2016-07-26T08:00:00.000+08:00,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/07/8259383/technical-alert-eli-lilly-unchanged-after-wild-ride-following,Eddie Staley,,,,,,
2016-07-26T08:00:00.000+08:00,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est",LLY,https://www.benzinga.com/news/16/07/8256302/lilly-sees-fy-2016-eps-3-50-to-3-60-vs-3-56-est-revenue-20-6b-to-21-1b-vs-20-9b-e,Paul Quintaro,,,,,,
2016-07-26T08:00:00.000+08:00,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est",LLY,https://www.benzinga.com/news/earnings/16/07/8256298/lilly-q2-eps-0-86-vs-0-86-est-revenue-5-4b-vs-5-2b-est,Paul Quintaro,,,,,,
2016-07-26T08:00:00.000+08:00,"Earnings Scheduled For July 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/07/8255995/earnings-scheduled-for-july-26-2016,Monica Gerson,,,,,,
2016-07-27T08:00:00.000+08:00,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease,LLY,https://www.benzinga.com/news/16/07/8267566/new-studies-suggest-relationship-between-tau-pathology-and-progression-of-alzheim,Paul Quintaro,,,,,,
2016-07-27T08:00:00.000+08:00,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position",LLY,https://www.benzinga.com/news/16/07/8262781/john-lechleiter-to-step-down-from-lilly-ceo-david-ricks-to-take-position,Paul Quintaro,,,,,,
2016-07-28T08:00:00.000+08:00,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York,LLY,https://www.benzinga.com/news/16/07/8273137/update-lilly-in-10q-says-received-civil-investigative-demand-from-u-s-attorneys-o,Charles Gross,,,,,,
2016-07-28T08:00:00.000+08:00,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ",LLY,https://www.benzinga.com/news/16/07/8273124/eli-lilly-says-doj-requested-documents-information-relating-to-relationships-with,Charles Gross,,,,,,
2016-08-10T08:00:00.000+08:00,Lilly Volume Spike,LLY,https://www.benzinga.com/news/16/08/8332627/lilly-volume-spike,Charles Gross,,,,,,
2016-08-10T08:00:00.000+08:00,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met,LLY,https://www.benzinga.com/news/16/08/8330854/eli-lilly-update-on-monarch-2-phase-3-trial-recommended-to-continue-as-planned-by,Paul Quintaro,,,,,,
2016-08-11T08:00:00.000+08:00,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/16/08/8337214/lilly-announces-health-canada-approves-new-indication-for-jardiance-tablets-for-a,Charles Gross,,,,,,
2016-08-22T08:00:00.000+08:00,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293,LLY,https://www.benzinga.com/news/16/08/8376571/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293,Paul Quintaro,,,,,,
2016-08-29T08:00:00.000+08:00,Novogen Names Gordon Hirsch as Chief Medical Officer,LLY,https://www.benzinga.com/news/16/08/8399344/novogen-names-gordon-hirsch-as-chief-medical-officer,Charles Gross,,,,,,
2016-08-30T08:00:00.000+08:00,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8405933/janney-initiates-galapagos-at-buy-sees-fair-value-of-sha,Manikandan Raman,,,,,,
2016-09-06T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint. 99%! Yowza.",LLY,https://www.benzinga.com/news/16/09/8425884/adam-feuerstein-adamfeuerstein-tweet-lly-cowen-analyst-steve-scala-goes-all-in-on,Charles Gross,,,,,,
2016-09-07T08:00:00.000+08:00,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7",LLY,https://www.benzinga.com/media/cnbc/16/09/8428800/apple-eli-lilly-u-s-steel-fast-money-picks-for-september-7,Craig Jones,,,,,,
2016-09-08T08:00:00.000+08:00,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8436629/new-upside-potential-drives-jpmorgans-eli-lilly-upgrade,Manikandan Raman,,,,,,
2016-09-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8435965/benzingas-top-upgrades,Monica Gerson,,,,,,
2016-09-08T08:00:00.000+08:00,The Market In 5 Minutes: iPhone 7 Arrives,LLY,https://www.benzinga.com/news/16/09/8435362/the-market-in-5-minutes-iphone-7-arrives,Benzinga News Desk,,,,,,
2016-09-08T08:00:00.000+08:00,JP Morgan Upgrades Eli Lilly to Overweight,LLY,https://www.benzinga.com/news/16/09/8434693/jp-morgan-upgrades-eli-lilly-to-overweight,Paul Quintaro,,,,,,
2016-09-16T08:00:00.000+08:00,3 Pharma Companies Receive Positive EU Opinions,LLY,https://www.benzinga.com/general/biotech/16/09/8465083/3-pharma-companies-receive-positive-eu-opinions,R. Chandrasekaran,,,,,,
2016-09-16T08:00:00.000+08:00,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/09/8464972/eli-lilly-reports-chmp-recommended-approval-of-co-s-olaratumab-in-combo-with-doxo,Paul Quintaro,,,,,,
2016-09-20T08:00:00.000+08:00,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8479674/some-traders-attributing-after-hours-upside-in-clovis-to,Paul Quintaro,,,,,,
2016-09-20T08:00:00.000+08:00,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors",LLY,https://www.benzinga.com/node/8478906,Paul Quintaro,,,,,,
2016-09-20T08:00:00.000+08:00,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest,LLY,https://www.benzinga.com/news/16/09/8478767/traders-attributing-spike-higher-in-clovis-oncology-to-unconfirmed-chatter-of-lil,Paul Quintaro,,,,,,
2016-09-21T08:00:00.000+08:00,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio,LLY,https://www.benzinga.com/node/8482768,Joel Elconin,,,,,,
2016-09-21T08:00:00.000+08:00,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",LLY,https://www.benzinga.com/news/16/09/8480831/the-market-in-5-minutes-were-waiting-for-you-mrs-yellen,Benzinga News Desk,,,,,,
2016-09-21T08:00:00.000+08:00,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8480898/clovis-upgraded-at-credit-suisse-following-acquisition-r,Monica Gerson,,,,,,
2016-09-26T08:00:00.000+08:00,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8494801/vtv-therapeutics-shares-initiated-with-buy-rating-13-tar,Manikandan Raman,,,,,,
2016-09-26T08:00:00.000+08:00,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly,LLY,https://www.benzinga.com/news/16/09/8494523/cerecor-reports-acquisition-of-tarp-8-ampa-receptor-antagonist-from-eli-lilly,Paul Quintaro,,,,,,
2016-09-26T08:00:00.000+08:00,First Trust Gets Smart With New Sector ETFs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/16/09/8493047/first-trust-gets-smart-with-new-sector-etfs,ETF Professor,,,,,,
2016-09-27T08:00:00.000+08:00,The Drug Price Increase Debate: Separating The Winners From The Losers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499775/goldman-on-the-drug-price-increase-debate-separating-the,Jim Swanson,,,,,,
2016-09-27T08:00:00.000+08:00,7 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/09/8499957/7-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,,,
2016-09-27T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8499491/benzingas-top-upgrades,Monica Gerson,,,,,,
2016-09-27T08:00:00.000+08:00,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed",LLY,https://www.benzinga.com/news/16/09/8499111/the-market-in-5-minutes-debates-oil-keep-stocks-mixed,Benzinga News Desk,,,,,,
2016-09-27T08:00:00.000+08:00,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499117/lilly-is-entering-a-period-of-accelerated-growth-goldman,Monica Gerson,,,,,,
2016-09-27T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/09/8498946/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-economic-data,Monica Gerson,,,,,,
2016-09-27T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00",LLY,https://www.benzinga.com/news/16/09/8498722/goldman-sachs-upgrades-eli-lilly-to-buy-raises-pt-to-95-00,Paul Quintaro,,,,,,
2016-10-03T08:00:00.000+08:00,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521018/in-one-experts-view-eli-lillys-alzheimer-drug-trial-has-,Wayne Duggan,,,,,,
2016-10-03T08:00:00.000+08:00,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521040/a-possible-trading-opportunity-presents-itself-in-biogen,Manikandan Raman,,,,,,
2016-10-05T08:00:00.000+08:00,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8532707/anavex-life-sciences-joins-the-club-of-stocks-moving-hig,Jayson Derrick,,,,,,
2016-10-05T08:00:00.000+08:00,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M",LLY,https://www.benzinga.com/news/16/10/8531059/eli-lilly-announces-elanco-us-subsidiary-has-entered-deal-to-buy-boehringer-ingel,Paul Quintaro,,,,,,
2016-10-09T08:00:00.000+08:00,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016,LLY,https://www.benzinga.com/news/16/10/8544704/new-data-on-the-combination-of-lillys-alimta-and-mercks-keytruda-show-a-near-doub,Charles Gross,,,,,,
2016-10-17T08:00:00.000+08:00,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative,LLY,https://www.benzinga.com/news/16/10/8568461/lilly-partners-with-the-national-cancer-institute-to-accelerate-cancer-research-t,Paul Quintaro,,,,,,
2016-10-18T08:00:00.000+08:00,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8572794/ac-immune-is-an-alzheimers-pure-play-with-a-lot-on-the-l,Shanthi Rexaline,,,,,,
2016-10-19T08:00:00.000+08:00,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/10/8578952/hearing-fda-has-granted-accelerated-approval-for-eli-lillys-lartruvo-with-doxorub,Paul Quintaro,,,,,,
2016-10-21T08:00:00.000+08:00,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,LLY,https://www.benzinga.com/general/biotech/16/10/8588232/are-the-drugs-working-pharma-giants-eli-lilly-and-merck-to-update-inve,The Ticker Tape,,,,,,
2016-10-25T08:00:00.000+08:00,6 Big Pharma Companies Left To Report September Quarterly Figures,LLY,https://www.benzinga.com/general/biotech/16/10/8597972/6-big-pharma-companies-left-to-report-september-quarterly-figures,R. Chandrasekaran,,,,,,
2016-10-25T08:00:00.000+08:00,Epic Earnings: Many US Companies Beating Expectations As Season Continues,LLY,https://www.benzinga.com/news/earnings/16/10/8598230/epic-earnings-many-us-companies-beating-expectations-as-season-continues,The Ticker Tape,,,,,,
2016-10-25T08:00:00.000+08:00,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",LLY,https://www.benzinga.com/news/16/10/8595821/the-market-in-5-minutes-ua-gm-p-g-earnings-on-the-streets-mind,Benzinga News Desk,,,,,,
2016-10-25T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus",LLY,https://www.benzinga.com/news/earnings/16/10/8596085/a-peek-into-the-markets-u-s-stock-futures-rise-gm-apple-earnings-in-focu,Monica Gerson,,,,,,
2016-10-25T08:00:00.000+08:00,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est",LLY,https://www.benzinga.com/news/16/10/8595669/eli-lilly-maintains-fy-2016-eps-guidance-raises-revenue-outlook-from-20-6b-21-1b-,Paul Quintaro,,,,,,
2016-10-25T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est",LLY,https://www.benzinga.com/news/earnings/16/10/8595665/eli-lilly-q3-eps-0-88-vs-0-96-est-revenue-5-19b-vs-5-28b-est,Paul Quintaro,,,,,,
2016-10-25T08:00:00.000+08:00,12 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/16/10/8595352/12-stocks-you-should-be-watching-today,Monica Gerson,,,,,,
2016-10-25T08:00:00.000+08:00,"Earnings Scheduled For October 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/10/8595305/earnings-scheduled-for-october-25-2016,Monica Gerson,,,,,,
2016-10-26T08:00:00.000+08:00,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8603593/following-q3-results-heres-where-eli-lilly-investors-foc,R. Chandrasekaran,,,,,,
2016-11-01T08:00:00.000+08:00,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.",LLY,https://www.benzinga.com/general/biotech/16/11/8631548/senator-bernie-sanders-tweets-people-are-dying-or-getting-sicker-becau,Paul Quintaro,,,,,,
2016-11-02T08:00:00.000+08:00,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo",LLY,https://www.benzinga.com/news/16/11/8638669/eli-lilly-incyte-reports-new-data-from-pivotal-ra-beacon-study-showing-significan,Paul Quintaro,,,,,,
2016-11-03T08:00:00.000+08:00,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively",LLY,https://www.benzinga.com/general/biotech/16/11/8639557/palatins-female-arousal-drug-data-impresses-investors-react-positively,Manikandan Raman,,,,,,
2016-11-09T08:00:00.000+08:00,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",LLY,https://www.benzinga.com/movers/16/11/8672426/pharma-stocks-up-post-election-ariad-16-infinity-up-13-allergan-progenics-endo-,Paul Quintaro,,,,,,
2016-11-09T08:00:00.000+08:00,Biotech Is Getting A Big Boost Following Clinton's Loss,LLY,https://www.benzinga.com/general/biotech/16/11/8671658/biotech-is-getting-a-big-boost-following-clintons-loss,R. Chandrasekaran,,,,,,
2016-11-10T08:00:00.000+08:00,"10 Notable Stocks Trading Ex-Dividend Friday, November 11",LLY,https://www.benzinga.com/news/dividends/16/11/8681027/10-notable-stocks-trading-ex-dividend-friday-november-11,Lisa Levin,,,,,,
2016-11-11T08:00:00.000+08:00,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price",LLY,https://www.benzinga.com/news/16/11/8686688/traders-attributing-drop-in-eli-lilly-to-humana-dropping-humalog-insulin-from-201,Paul Quintaro,,,,,,
2016-11-13T08:00:00.000+08:00,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline,LLY,https://www.benzinga.com/news/16/11/8688398/lilly-announces-jardiance-consistently-reduced-the-risk-of-cardiovascular-death-i,Charles Gross,,,,,,
2016-11-14T08:00:00.000+08:00,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes",LLY,https://www.benzinga.com/news/16/11/8691085/eli-lilly-incyte-corp-report-ra-beam-and-ra-build-patients-early-response-to-bari,Paul Quintaro,,,,,,
2016-11-21T08:00:00.000+08:00,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943,LLY,https://www.benzinga.com/news/16/11/8723017/intelgenx-technologies-reports-signing-of-term-sheet-for-eli-lilly-to-license-tad,Paul Quintaro,,,,,,
2016-11-22T08:00:00.000+08:00,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",LLY,https://www.benzinga.com/news/16/11/8728289/quintilesims-forms-new-collaboration-with-bristol-myers-squibb-lilly-merck-kgaa-d,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,A Tough Day For Some Biotech Bulls,LLY,https://www.benzinga.com/general/biotech/16/11/8735459/a-tough-day-for-some-biotech-bulls,Wayne Duggan,,,,,,
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,LLY,https://www.benzinga.com/general/biotech/16/11/8735076/eli-lillys-solanezumab-failure-alzheimers-treatment-space-feels-afters,Bryan Finnigan,,,,,,
2016-11-23T08:00:00.000+08:00,18 Biggest Mid-Day Losers For Wednesday,LLY,https://www.benzinga.com/news/16/11/8735535/18-biggest-mid-day-losers-for-wednesday,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8735421/baird-analayst-says-no-change-to-axovant-sciences-on-lil,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,LLY,https://www.benzinga.com/news/earnings/16/11/8735174/mid-day-market-update-eli-lilly-tumbles-after-alzheimers-study-fails-to-,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/16/11/8734565/stocks-hitting-52-week-lows,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.,LLY,https://www.benzinga.com/news/16/11/8734422/adam-feuerstein-tweets-check-out-af-biotech-tweets-laying-out-bear-thesis-on-prta,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,LLY,https://www.benzinga.com/news/earnings/16/11/8734398/mid-morning-market-update-markets-mostly-lower-deere-tops-q4-views,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",LLY,https://www.benzinga.com/news/16/11/8734362/biotech-down-in-early-trading-pdl-biopharma-15-eli-lilly-13-biogen-6-cellectis-in,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Neurotrope Issues Statement On Eli Lilly's Solanezumab,LLY,https://www.benzinga.com/news/16/11/8734206/neurotrope-issues-statement-on-eli-lillys-solanezumab,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734123/credit-suisse-says-hard-to-get-strong-read-through-concl,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734116/jp-morgan-highlighting-downside-in-biogen-shares-this-mo,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure Is Bad News For Biogen,LLY,https://www.benzinga.com/general/biotech/16/11/8733840/eli-lillys-solanezumab-failure-is-bad-news-for-biogen,Shanthi Rexaline,,,,,,
2016-11-23T08:00:00.000+08:00,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734021/ac-immune-shares-down-20-amid-concerning-alzheimer-drug-,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733961/morgan-stanley-calling-for-biogen-to-end-the-day-flat-to,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733897/raymond-james-out-saying-they-would-be-buyers-of-biogen-,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,20 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/11/8733809/20-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes",LLY,https://www.benzinga.com/news/earnings/16/11/8733667/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data-f,Lisa Levin,,,,,,
2016-11-23T08:00:00.000+08:00,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals,LLY,https://www.benzinga.com/news/16/11/8733559/eli-lilly-plunges-15-after-alzheimers-study-fails-to-meet-goals,Manikandan Raman,,,,,,
2016-11-23T08:00:00.000+08:00,Can You Guess This Chart?,LLY,https://www.benzinga.com/general/16/11/8733554/can-you-guess-this-chart,Benzinga News Desk,,,,,,
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB",LLY,https://www.benzinga.com/news/16/11/8733507/adam-feuerstein-tweets-worst-thing-lly-gamed-sola-study-to-win-but-still-failed-b,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/16/11/8733456/lilly-15-premarket-64-75-following-report-that-solanezumab-did-not-meet-primary-e,Charles Gross,,,,,,
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later.",LLY,https://www.benzinga.com/news/16/11/8733438/adam-feuerstein-adamfeuerstein-tweet-lly-alzheimers-drug-fails-key-clinical-trial,Charles Gross,,,,,,
2016-11-23T08:00:00.000+08:00,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09,LLY,https://www.benzinga.com/news/16/11/8733380/update-lilly-expedition-3-study-outcome-expected-to-result-in-q4-charge-of-150m-o,Paul Quintaro,,,,,,
2016-11-23T08:00:00.000+08:00,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/16/11/8733377/lilly-announces-top-line-results-of-solanezumab-phase-3-clinical-trial-did-not-me,Paul Quintaro,,,,,,
2016-11-25T08:00:00.000+08:00,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8739191/aside-from-the-recent-drug-failure-what-else-is-happenin,Manikandan Raman,,,,,,
2016-11-25T08:00:00.000+08:00,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8738941/reasons-to-be-optimistic-on-biogens-alzheimers-treatment,Manikandan Raman,,,,,,
2016-11-25T08:00:00.000+08:00,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/16/11/8739094/atlantic-equities-earlier-downgraded-eli-lilly-to-neutral,Paul Quintaro,,,,,,
2016-11-25T08:00:00.000+08:00,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,LLY,https://www.benzinga.com/news/16/11/8738744/the-market-in-5-minutes-black-friday-closes-shortened-trading-week,Benzinga News Desk,,,,,,
2016-11-25T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/16/11/8738935/benzingas-top-downgrades,Lisa Levin,,,,,,
2016-11-25T08:00:00.000+08:00,Experts React To Concerning Alzheimer's News From Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8736227/experts-react-to-concerning-alzheimers-news-from-lilly,Shanthi Rexaline,,,,,,
2016-11-25T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday,LLY,https://www.benzinga.com/news/earnings/16/11/8738678/a-peek-into-the-markets-u-s-stock-futures-gain-on-black-friday,Lisa Levin,,,,,,
2016-11-25T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00",LLY,https://www.benzinga.com/news/16/11/8738593/bmo-capital-downgrades-eli-lilly-to-market-perform-lowers-target-to-64-00,Paul Quintaro,,,,,,
2016-11-25T08:00:00.000+08:00,"Must Watch Stocks for November 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/11/8738412/must-watch-stocks-for-november-25-2016,Lisa Levin,,,,,,
2016-11-29T08:00:00.000+08:00,The Difference Between Shareholders And Stakeholders,LLY,https://www.benzinga.com/general/education/16/11/8739519/the-difference-between-shareholders-and-stakeholders,Shanthi Rexaline,,,,,,
2016-12-01T08:00:00.000+08:00,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",LLY,https://www.benzinga.com/news/16/12/8758294/forbes-healthcare-summit-concludes-today-presenters-include-express-scripts-aller,Hal Lindon,,,,,,
2016-12-02T08:00:00.000+08:00,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/12/8765387/eli-lilly-shares-spike-higher-as-fda-has-approved-jardiance-to-reduce-cv-death-in,Paul Quintaro,,,,,,
2016-12-02T08:00:00.000+08:00,Lilly Pops to High of $67.45 on Volume,LLY,https://www.benzinga.com/movers/16/12/8765378/lilly-pops-to-high-of-67-45-on-volume,Charles Gross,,,,,,
2016-12-02T08:00:00.000+08:00,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST",LLY,https://www.benzinga.com/news/16/12/8764556/eli-lilly-confirms-it-will-provide-updated-guidance-in-conf-call-dec-15-10am-est,Hal Lindon,,,,,,
2016-12-05T08:00:00.000+08:00,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,LLY,https://www.benzinga.com/general/biotech/16/12/8771991/pressure-biosciences-ceo-on-biological-samples-its-all-about-how-you-b,Javier Hasse,,,,,,
2016-12-07T08:00:00.000+08:00,What If Trump Keeps Badmouthing Drug Pricing?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8781602/what-if-trump-keeps-badmouthing-drug-pricing,Wayne Duggan,,,,,,
2016-12-07T08:00:00.000+08:00,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",LLY,https://www.benzinga.com/movers/16/12/8780747/pfizer-j-j-other-big-pharma-names-dip-lower-just-after-the-open,Paul Quintaro,,,,,,
2016-12-08T08:00:00.000+08:00,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment,LLY,https://www.benzinga.com/news/16/12/8785679/update-lilly-trial-met-primary-endpoint-of-ki67-expression-reduction-after-2-week,Paul Quintaro,,,,,,
2016-12-08T08:00:00.000+08:00,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer,LLY,https://www.benzinga.com/news/16/12/8785672/lilly-presents-neomonarch-phase-2-data-on-abemaciclib-in-early-stage-breast-cance,Paul Quintaro,,,,,,
2016-12-09T08:00:00.000+08:00,AstraZeneca Higher Off Drug News And Upgrade,LLY,https://www.benzinga.com/general/biotech/16/12/8791572/astrazeneca-higher-off-drug-news-and-upgrade,Joel Elconin,,,,,,
2016-12-09T08:00:00.000+08:00,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,LLY,https://www.benzinga.com/news/fda/16/12/8790139/eli-lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-tre,Paul Quintaro,,,,,,
2016-12-09T08:00:00.000+08:00,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met,LLY,https://www.benzinga.com/news/16/12/8789840/lilly-announces-detailed-results-of-solanezumab-phase-3-expedition3-study-at-ctad,Charles Gross,,,,,,
2016-12-12T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/16/12/8799284/eli-lilly-raises-qtr-dividend-from-0-51-to-0-52share,Paul Quintaro,,,,,,
2016-12-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes",LLY,https://www.benzinga.com/news/16/12/8798038/eli-lilly-boehringer-ingelheim-report-fda-approved-synjardy-xr-tablets-for-adults,Paul Quintaro,,,,,,
2016-12-12T08:00:00.000+08:00,What We Know About Trump's Potential Pick To Head The FDA,LLY,https://www.benzinga.com/news/16/12/8797598/what-we-know-about-trumps-potential-pick-to-head-the-fda,Javier Hasse,,,,,,
2016-12-12T08:00:00.000+08:00,AC Immune Out Positive On Crenezumab; What Does It Mean?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8795639/ac-immune-out-positive-on-crenezumab-what-does-it-mean,Jayson Derrick,,,,,,
2016-12-13T08:00:00.000+08:00,Heads Up! These 4 Companies Issuing Guidance This Week,LLY,https://www.benzinga.com/news/16/12/8802471/heads-up-these-4-companies-issuing-guidance-this-week,Jayson Derrick,,,,,,
2016-12-13T08:00:00.000+08:00,Lilly Announces Program to Provide Insulin at Discounted Prices,LLY,https://www.benzinga.com/news/16/12/8800170/lilly-announces-program-to-provide-insulin-at-discounted-prices,Paul Quintaro,,,,,,
2016-12-15T08:00:00.000+08:00,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8811408/the-week-in-guidance-4-companies-that-gave-investors-the,Jayson Derrick,,,,,,
2016-12-15T08:00:00.000+08:00,18 Biggest Mid-Day Gainers For Thursday,LLY,https://www.benzinga.com/news/16/12/8811357/18-biggest-mid-day-gainers-for-thursday,Lisa Levin,,,,,,
2016-12-15T08:00:00.000+08:00,Hearing Eli Lilly Added To Conviction Buy List At Goldman,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8810923/hearing-eli-lilly-added-to-conviction-buy-list-at-goldma,Hal Lindon,,,,,,
2016-12-15T08:00:00.000+08:00,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales,LLY,https://www.benzinga.com/general/biotech/16/12/8810424/eli-lilly-cfo-says-they-do-not-see-u-s-healthcare-reform-changes-impac,Paul Quintaro,,,,,,
2016-12-15T08:00:00.000+08:00,"Eli Lilly Announces Guidance, U.S. Insulin Release",LLY,https://www.benzinga.com/news/16/12/8809798/eli-lilly-announces-guidance-u-s-insulin-release,Jayson Derrick,,,,,,
2016-12-15T08:00:00.000+08:00,Eli Lilly Holding Guidance Call Today 10am EST,LLY,https://www.benzinga.com/news/16/12/8809617/eli-lilly-holding-guidance-call-today-10am-est,Hal Lindon,,,,,,
2016-12-15T08:00:00.000+08:00,18 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/12/8809586/18-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,,,
2016-12-15T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/12/8809350/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data,Lisa Levin,,,,,,
2016-12-15T08:00:00.000+08:00,Eli Lilly's Basaglar Now Available in US,LLY,https://www.benzinga.com/news/16/12/8809127/eli-lillys-basaglar-now-available-in-us,Paul Quintaro,,,,,,
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est,LLY,https://www.benzinga.com/news/16/12/8809025/eli-lilly-and-company-common-stock-sees-fy2017-eps-4-05-4-15-vs-3-97-est,Paul Quintaro,,,,,,
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est,LLY,https://www.benzinga.com/news/16/12/8809024/eli-lilly-and-company-common-stock-sees-fy2016-eps-3-50-3-60-vs-3-52-est,Paul Quintaro,,,,,,
2016-12-16T08:00:00.000+08:00,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death",LLY,https://www.benzinga.com/news/16/12/8816793/eli-lilly-boehringer-welcome-new-recommendation-for-jardiance-tablets-includes-ne,Paul Quintaro,,,,,,
2016-12-16T08:00:00.000+08:00,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated",LLY,https://www.benzinga.com/news/16/12/8816202/eli-lilly-biochaperone-lispro-u100-and-humalog-showed-similar-safety-result-well-,Paul Quintaro,,,,,,
2016-12-16T08:00:00.000+08:00,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814910/eli-lillys-guidance-supported-by-short-term-boosts-not-b,Jayson Derrick,,,,,,
2016-12-16T08:00:00.000+08:00,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage",LLY,https://www.benzinga.com/news/16/12/8814600/the-market-in-5-minutes-adobe-oracle-take-the-earnings-stage,Benzinga News Desk,,,,,,
2016-12-16T08:00:00.000+08:00,7 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/12/8815159/7-biggest-price-target-changes-for-friday,Lisa Levin,,,,,,
2016-12-16T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00",LLY,https://www.benzinga.com/news/16/12/8814369/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-82-00,Paul Quintaro,,,,,,
2016-12-19T08:00:00.000+08:00,Jefferies' 2017 Global Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820515/jefferies-2017-global-pharma-outlook,Jim Swanson,,,,,,
2016-12-23T08:00:00.000+08:00,6 Worst Biotech Stocks Of 2016,LLY,https://www.benzinga.com/general/biotech/16/12/8832621/6-worst-biotech-stocks-of-2016,Shanthi Rexaline,,,,,,
2016-12-27T08:00:00.000+08:00,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,LLY,https://www.benzinga.com/general/biotech/16/12/8843728/expect-availability-of-biogens-newly-approved-spinraza-in-just-one-wee,Manikandan Raman,,,,,,
2016-12-28T08:00:00.000+08:00,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal",LLY,https://www.benzinga.com/news/16/12/8847178/ftc-will-require-boehringer-ingelheim-to-make-divestitures-to-eli-lilly-bayer-ag-,Hal Lindon,,,,,,
2016-12-28T08:00:00.000+08:00,A Preview Of January PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/16/12/8844162/a-preview-of-january-pdufa-dates,Shanthi Rexaline,,,,,,
2017-01-04T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets",LLY,https://www.benzinga.com/news/fda/17/01/8868086/eli-lilly-boehringer-ingelheim-announce-fda-approval-of-snda-to-include-landm,Paul Quintaro,,,,,,
2017-01-05T08:00:00.000+08:00,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration,LLY,https://www.benzinga.com/news/17/01/8870150/zymeworks-announces-successful-achievement-of-research-milestone-with-lilly-in-bi,Charles Gross,,,,,,
2017-01-06T08:00:00.000+08:00,The MedTech Group: 2017 Top Picks And Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8877727/the-medtech-group-2017-top-picks-and-catalysts,Jim Swanson,,,,,,
2017-01-11T08:00:00.000+08:00,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed",LLY,https://www.benzinga.com/news/17/01/8893616/lilly-and-merck-expand-immuno-oncology-collaboration-financial-terms-not-disclose,Paul Quintaro,,,,,,
2017-01-12T08:00:00.000+08:00,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",LLY,https://www.benzinga.com/news/legal/17/01/8900010/eli-lilly-releases-pr-on-earlier-report-says-u-s-court-of-appeals-rules-in-,Paul Quintaro,,,,,,
2017-01-12T08:00:00.000+08:00,Teva 'Disappointed' In Court's Patent Decision,LLY,https://www.benzinga.com/news/17/01/8899847/teva-disappointed-in-courts-patent-decision,Elizabeth Balboa,,,,,,
2017-01-12T08:00:00.000+08:00,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @ ASK $0.54: 740 traded vs 16k OI: Earnings 1/31 Before Open $76.22 Ref,LLY,https://www.benzinga.com/news/17/01/8899699/option-alert-lilly-jan-75-0-puts-sweep-710-ask-0-54-740-traded-vs-16k-oi-earnings,Charles Gross,,,,,,
2017-01-12T08:00:00.000+08:00,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case,LLY,https://www.benzinga.com/news/legal/17/01/8899681/u-s-appeals-court-rules-for-eli-lilly-against-teva-in-alimta-patent-case,Paul Quintaro,,,,,,
2017-01-13T08:00:00.000+08:00,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months",LLY,https://www.benzinga.com/general/biotech/17/01/8906996/eli-lilly-and-incyte-report-fda-has-extended-review-period-for-baricit,Hal Lindon,,,,,,
2017-01-13T08:00:00.000+08:00,7 Biotech Catalysts Remaining In January,LLY,https://www.benzinga.com/general/biotech/17/01/8905085/7-biotech-catalysts-remaining-in-january,Manikandan Raman,,,,,,
2017-01-13T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Friday Trade,LLY,https://www.benzinga.com/markets/options/17/01/8903595/watch-these-5-huge-put-purchases-in-friday-trade,Lisa Levin,,,,,,
2017-01-17T08:00:00.000+08:00,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8911012/barictinib-fda-delay-only-a-short-term-setback-for-eli-l,Manikandan Raman,,,,,,
2017-01-17T08:00:00.000+08:00,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8910538/incyte-pdufa-date-pushed-back-jmp-discusses-impact,Jim Swanson,,,,,,
2017-01-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast,LLY,https://www.benzinga.com/news/earnings/17/01/8918930/mid-afternoon-market-update-crude-oil-down-2-5-gigamon-shares-drop-after,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,15 Biggest Mid-Day Gainers For Wednesday,LLY,https://www.benzinga.com/news/17/01/8918442/15-biggest-mid-day-gainers-for-wednesday,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble,LLY,https://www.benzinga.com/news/earnings/17/01/8918328/mid-day-market-update-colucid-jumps-on-acquisition-news-pearson-shares-t,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views,LLY,https://www.benzinga.com/news/earnings/17/01/8917585/mid-morning-market-update-markets-mixed-goldman-sachs-profit-beats-views,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld",LLY,https://www.benzinga.com/news/17/01/8916391/the-market-in-5-minutes-goldman-sachs-chelsea-manning-and-jerry-seinfeld,Benzinga News Desk,,,,,,
2017-01-18T08:00:00.000+08:00,18 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/01/8916687/18-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech",LLY,https://www.benzinga.com/news/earnings/17/01/8916454/a-peek-into-the-markets-u-s-stock-futures-edge-higher-ahead-of-economic-,Lisa Levin,,,,,,
2017-01-18T08:00:00.000+08:00,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash,LLY,https://www.benzinga.com/news/m-a/17/01/8916178/colucid-pharma-to-be-acquired-by-eli-lilly-for-46-50share-cash,Paul Quintaro,,,,,,
2017-01-24T08:00:00.000+08:00,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis",LLY,https://www.benzinga.com/news/17/01/8941384/elanco-animal-health-a-division-of-eli-lilly-and-aratana-announces-galliprant-ava,Paul Quintaro,,,,,,
2017-01-25T08:00:00.000+08:00,Which Pharma Players Dominate The Lung Cancer Space?,LLY,https://www.benzinga.com/general/biotech/17/01/8945361/which-pharma-players-dominate-the-lung-cancer-space,Shanthi Rexaline,,,,,,
2017-01-26T08:00:00.000+08:00,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label,LLY,https://www.benzinga.com/news/fda/17/01/8950019/eli-lilly-reports-jardiance-is-first-type-2-diabetes-medicine-in-eu-to-includ,Paul Quintaro,,,,,,
2017-01-29T08:00:00.000+08:00,"Barron's Sees Dow At 30,000",LLY,https://www.benzinga.com/media/barrons/17/01/8961927/barrons-sees-dow-at-30-000,Nelson Hem,,,,,,
2017-01-30T08:00:00.000+08:00,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin",LLY,https://www.benzinga.com/movers/17/01/8966334/recent-weakness-in-eli-lilly-novo-nordisk-sanofi-due-to-new-york-times-reportin,Paul Quintaro,,,,,,
2017-01-30T08:00:00.000+08:00,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,LLY,https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al,Taylor Cox,,,,,,
2017-01-30T08:00:00.000+08:00,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8965539/a-mixed-bag-of-earnings-ahead-eli-lilly-pfizer-exxon-mob,The Ticker Tape,,,,,,
2017-01-30T08:00:00.000+08:00,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8964318/mixing-it-up-markets-await-host-of-economic-data-key-ear,The Ticker Tape,,,,,,
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light",LLY,https://www.benzinga.com/news/17/01/8972532/eli-lilly-ceo-says-too-early-to-say-if-amyloid-beta-hypothesis-for-alzheihmers-is,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward",LLY,https://www.benzinga.com/news/17/01/8972494/eli-lilly-ceo-says-president-trump-didnt-get-into-collaborative-policy-detail-in-,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call,LLY,https://www.benzinga.com/news/17/01/8972402/eli-lilly-says-quarterly-rev-growth-led-by-volume-on-conf-call,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.,LLY,https://www.benzinga.com/news/17/01/8972323/us-commercial-news-managing-editor-mandy-jackson-tweets-lly-terminated-expedition,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'",LLY,https://www.benzinga.com/general/biotech/17/01/8971909/president-trump-doubles-down-on-healthcare-criticism-says-drug-prices-,Jayson Derrick,,,,,,
2017-01-31T08:00:00.000+08:00,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8971667/fed-meeting-starts-today-but-focus-remains-on-key-earnin,The Ticker Tape,,,,,,
2017-01-31T08:00:00.000+08:00,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations",LLY,https://www.benzinga.com/general/politics/17/01/8971432/cnbcs-meg-tirrell-tweets-lly-ceo-tells-trump-tax-deregulation-could-r,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer",LLY,https://www.benzinga.com/news/17/01/8970347/the-market-in-5-minutes-under-armours-miss-apples-q1-primer,Benzinga News Desk,,,,,,
2017-01-31T08:00:00.000+08:00,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses",LLY,https://www.benzinga.com/general/biotech/17/01/8970589/healthcare-q4-eli-lilly-beats-pfizer-misses,Jayson Derrick,,,,,,
2017-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus,LLY,https://www.benzinga.com/news/earnings/17/01/8970273/a-peek-into-the-markets-u-s-stock-futures-down-apple-earnings-in-focus,Lisa Levin,,,,,,
2017-01-31T08:00:00.000+08:00,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.,LLY,https://www.benzinga.com/news/guidance/17/01/8969884/lilly-reaffirms-fy17-adj-eps-outlook-4-05-4-15-vs-4-10-est,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est.",LLY,https://www.benzinga.com/news/earnings/17/01/8969882/eli-lilly-reports-q4-eps-0-95-vs-0-98-est-sales-5-761b-vs-5-55b-est,Paul Quintaro,,,,,,
2017-01-31T08:00:00.000+08:00,15 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/17/01/8969608/15-stocks-you-should-be-watching-today,Lisa Levin,,,,,,
2017-01-31T08:00:00.000+08:00,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary,LLY,https://www.benzinga.com/news/17/01/8969579/jaguar-animal-health-60-premarket-0-85-after-announcement-of-deal-with-lilly-subs,Charles Gross,,,,,,
2017-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2017",LLY,https://www.benzinga.com/news/earnings/17/01/8969578/earnings-scheduled-for-january-31-2017,Lisa Levin,,,,,,
2017-01-31T08:00:00.000+08:00,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M",LLY,https://www.benzinga.com/news/17/01/8969575/jaguar-animal-health-elanco-announce-global-collaboration-for-development-co-prom,Charles Gross,,,,,,
2017-02-02T08:00:00.000+08:00,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta,LLY,https://www.benzinga.com/news/legal/17/02/8985156/eli-lilly-reprots-japan-ip-high-court-rules-in-favor-in-invalidation-trials,Paul Quintaro,,,,,,
2017-02-08T08:00:00.000+08:00,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/02/9010327/eli-lilly-reports-trulicity-label-updated-to-include-use-in-combo-with-basal-insu,Paul Quintaro,,,,,,
2017-02-13T08:00:00.000+08:00,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment",LLY,https://www.benzinga.com/news/17/02/9037913/update-eli-lilly-says-as-a-result-of-olumiant-approval-by-ec-incyte-becomes-eligi,Paul Quintaro,,,,,,
2017-02-13T08:00:00.000+08:00,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA,LLY,https://www.benzinga.com/news/17/02/9037900/eli-lilly-reports-ec-approved-once-daily-olumiant-tablets-for-treatment-of-adults,Paul Quintaro,,,,,,
2017-02-15T08:00:00.000+08:00,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine,LLY,https://www.benzinga.com/general/biotech/17/02/9056642/eli-lilly-incyte-announce-addl-results-from-pivotal-ra-beam-study-in-n,Hal Lindon,,,,,,
2017-02-16T08:00:00.000+08:00,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",LLY,https://www.benzinga.com/general/biotech/17/02/9061803/after-merck-stops-study-what-remains-of-the-alzheimers-drug-pipeline,Taylor Cox,,,,,,
2017-02-16T08:00:00.000+08:00,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team,LLY,https://www.benzinga.com/general/politics/17/02/9054755/border-tax-polarizes-u-s-companies-as-exporters-take-side-with-trump-,Shanthi Rexaline,,,,,,
2017-02-24T08:00:00.000+08:00,Carl Icahn's Track Record In Big Pharma,LLY,https://www.benzinga.com/general/biotech/17/02/9084990/carl-icahns-track-record-in-big-pharma,Shanthi Rexaline,,,,,,
2017-03-03T08:00:00.000+08:00,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/17/03/9125280/chi-med-announces-positive-top-line-results-for-fresco-phase-iii-pivotal-registra,Charles Gross,,,,,,
2017-03-05T08:00:00.000+08:00,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/fintech/17/03/9131060/new-head-to-head-data-shows-significantly-higher-response-rates-for-lillys-tal,Charles Gross,,,,,,
2017-03-07T08:00:00.000+08:00,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",LLY,https://www.benzinga.com/news/events/17/03/9138971/cowen-annual-healthcare-conference-continues-today-presenters-include-regu,Hal Lindon,,,,,,
2017-03-16T08:00:00.000+08:00,Lilly Drops to Low of $84.16 on Volume,LLY,https://www.benzinga.com/movers/17/03/9181306/lilly-drops-to-low-of-84-16-on-volume,Charles Gross,,,,,,
2017-03-17T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'",LLY,https://www.benzinga.com/news/fda/17/03/9184772/eli-lilly-boehringer-ingelheim-report-emperor-hf-clinical-trial-program-will-,Paul Quintaro,,,,,,
2017-03-20T08:00:00.000+08:00,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9182637/leerink-presents-your-2017-biopharma-catalyst-tracker,Shanthi Rexaline,,,,,,
2017-03-20T08:00:00.000+08:00,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival,LLY,https://www.benzinga.com/news/17/03/9189873/eli-lilly-announces-monarch-2-trial-of-abemaciclib-met-primary-endpoint-of-progre,Paul Quintaro,,,,,,
2017-03-23T08:00:00.000+08:00,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly",LLY,https://www.benzinga.com/news/17/03/9210145/ignyta-announces-exploration-of-strategic-options-for-taladegib-enalbed-by-new-li,Hal Lindon,,,,,,
2017-03-24T08:00:00.000+08:00,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017,LLY,https://www.benzinga.com/news/17/03/9212125/eli-lilly-announces-plans-to-invest-850m-in-u-s-operations-in-2017,Paul Quintaro,,,,,,
2017-03-28T08:00:00.000+08:00,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?",LLY,https://www.benzinga.com/news/17/03/9224070/if-gender-confirmation-becomes-a-legal-human-right-which-corporations-could-benef,Elizabeth Balboa,,,,,,
2017-03-28T08:00:00.000+08:00,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent,LLY,https://www.benzinga.com/news/17/03/9223249/intelgenx-reports-eli-lilly-granted-co-versafilm-an-exclusive-license-for-tadalaf,Paul Quintaro,,,,,,
2017-03-31T08:00:00.000+08:00,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing,LLY,https://www.benzinga.com/news/insider-trades/17/03/9242733/eli-lilly-endowment-reports-open-market-sale-of-210k-shares-of-com,Paul Quintaro,,,,,,
2017-04-05T08:00:00.000+08:00,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'",LLY,https://www.benzinga.com/general/biotech/17/04/9264950/eli-lilly-spokesperson-asked-if-3-month-delay-in-baricitinib-pdufa-dat,Hal Lindon,,,,,,
2017-04-07T08:00:00.000+08:00,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements,LLY,https://www.benzinga.com/news/17/04/9276350/fda-warns-of-dangerous-hidden-ingredient-in-5-otc-male-sexual-enhancement-supplem,Wayne Duggan,,,,,,
2017-04-12T08:00:00.000+08:00,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9293543/healthcare-sector-earnings-making-a-comeback-in-q1-2017,The Ticker Tape,,,,,,
2017-04-12T08:00:00.000+08:00,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?,LLY,https://www.benzinga.com/news/fda/17/04/9293422/endpoint-reporter-john-carroll-tweets-lly-spokesperson-says-they-are-not-disc,Hal Lindon,,,,,,
2017-04-14T08:00:00.000+08:00,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade",LLY,https://www.benzinga.com/news/earnings/17/04/9302180/lilly-reaffirms-financial-guidance-for-2017-mid-term-guidance-for-remain,Charles Gross,,,,,,
2017-04-14T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib",LLY,https://www.benzinga.com/news/earnings/17/04/9302178/lilly-incyte-announce-fda-issues-crl-for-baricitinib,Charles Gross,,,,,,
2017-04-17T08:00:00.000+08:00,15 Biggest Mid-Day Losers For Monday,LLY,https://www.benzinga.com/news/17/04/9306429/15-biggest-mid-day-losers-for-monday,Lisa Levin,,,,,,
2017-04-17T08:00:00.000+08:00,Hearing Leerink Defending Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9305474/hearing-leerink-defending-eli-lilly,Hal Lindon,,,,,,
2017-04-17T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9305337/benzingas-top-upgrades-downgrades-for-april-17-2017,Lisa Levin,,,,,,
2017-04-17T08:00:00.000+08:00,20 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/04/9304944/20-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,,,
2017-04-17T08:00:00.000+08:00,BMO Capital Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/17/04/9304923/bmo-capital-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,,,
2017-04-17T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/17/04/9304915/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Paul Quintaro,,,,,,
2017-04-17T08:00:00.000+08:00,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant",LLY,https://www.benzinga.com/news/17/04/9304475/eli-lilly-4-7-premarket-81-88-incyte-12-7-123-fda-on-friday-declined-to-approve-l,Charles Gross,,,,,,
2017-04-20T08:00:00.000+08:00,What Would A $5.8 Billion NIH Cut Look Like? Devastation,LLY,https://www.benzinga.com/news/17/04/9308625/what-would-a-5-8-billion-nih-cut-look-like-devastation,Elizabeth Balboa,,,,,,
2017-04-24T08:00:00.000+08:00,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9336445/earnings-caterpillar-lockheed-martin-and-eli-lilly-repor,The Ticker Tape,,,,,,
2017-04-24T08:00:00.000+08:00,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/04/9333621/eli-lilly-announces-phase-3-study-comparing-abemaciclib-in-combination-with-a,Paul Quintaro,,,,,,
2017-04-25T08:00:00.000+08:00,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,LLY,https://www.benzinga.com/general/biotech/17/04/9341495/mark-your-calendar-for-these-days-in-may-to-play-the-volatility-around,Shanthi Rexaline,,,,,,
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339031/eli-lilly-reaffirms-fy-2017-sales-guidance-sees-21-8b-to-22-3b-vs-22-1b-,Paul Quintaro,,,,,,
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339030/eli-lilly-reaffirms-fy-2017-adj-eps-guidance-sees-4-05-to-4-15-vs-4-11-e,Paul Quintaro,,,,,,
2017-04-25T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est",LLY,https://www.benzinga.com/news/earnings/17/04/9339029/eli-lilly-q1-eps-0-98-vs-0-96-est-sales-5-23b-vs-5-21b-est,Paul Quintaro,,,,,,
2017-04-25T08:00:00.000+08:00,"15 Stocks To Watch For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338686/15-stocks-to-watch-for-april-25-2017,Lisa Levin,,,,,,
2017-04-25T08:00:00.000+08:00,"Earnings Scheduled For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338633/earnings-scheduled-for-april-25-2017,Lisa Levin,,,,,,
2017-04-27T08:00:00.000+08:00,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9356865/analyst-sees-eli-lilly-fairly-valued-at-81-per-share-dow,Jayson Derrick,,,,,,
2017-04-27T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9356456/benzingas-top-upgrades-downgrades-for-april-27-2017,Lisa Levin,,,,,,
2017-04-27T08:00:00.000+08:00,Argus Research Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/17/04/9355322/argus-research-downgrades-eli-lilly-to-hold,Paul Quintaro,,,,,,
2017-05-01T08:00:00.000+08:00,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs",LLY,https://www.benzinga.com/news/17/05/9377236/10-k-just-recently-out-from-eli-lilly-shows-co-received-cid-from-state-of-washing,Paul Quintaro,,,,,,
2017-05-01T08:00:00.000+08:00,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga",LLY,https://www.benzinga.com/news/events/17/05/9375749/companies-holding-shareholder-meetings-today-include-american-express-dish,Hal Lindon,,,,,,
2017-05-04T08:00:00.000+08:00,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward",LLY,https://www.benzinga.com/news/17/05/9400795/incyte-lilly-disagree-with-fda-crl-for-baricitinib-expects-lilly-to-engage-with-f,Charles Gross,,,,,,
2017-05-12T08:00:00.000+08:00,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,LLY,https://www.benzinga.com/news/17/05/9452714/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-th,Charles Gross,,,,,,
2017-05-16T08:00:00.000+08:00,Benzinga's Option Alert Recap From May 16,LLY,https://www.benzinga.com/news/17/05/9476376/benzingas-option-alert-recap-from-may-16,Javier Hasse,,,,,,
2017-05-16T08:00:00.000+08:00,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @ ASK $1.008: 4230 traded vs 2903 OI: Earnings 7/25 Before Open $78.97 Ref,LLY,https://www.benzinga.com/markets/options/17/05/9474601/option-alert-lilly-jun-77-5-puts-sweep-1000-ask-1-008-4230-traded-vs-2,Charles Gross,,,,,,
2017-05-17T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Wednesday Trade,LLY,https://www.benzinga.com/markets/options/17/05/9477836/watch-these-5-huge-put-purchases-in-wednesday-trade,Lisa Levin,,,,,,
2017-05-23T08:00:00.000+08:00,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9506563/zymeworks-early-but-compelling-data-large-biopharma-part,Ezra Schwarzbaum,,,,,,
2017-05-25T08:00:00.000+08:00,A Look At Nvidia's Largest Shareholders And What Their Presence Means,LLY,https://www.benzinga.com/trading-ideas/long-ideas/17/05/9514507/a-look-at-nvidias-largest-shareholders-and-what-their-presenc,Wayne Duggan,,,,,,
2017-05-30T08:00:00.000+08:00,Monday's Market In 5 Minutes,LLY,https://www.benzinga.com/news/17/05/9534287/mondays-market-in-5-minutes,Benzinga News Desk,,,,,,
2017-05-31T08:00:00.000+08:00,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands",LLY,https://www.benzinga.com/news/events/17/05/9542289/bernstein-strategic-decisions-conference-begins-today-presenters-include-e,Hal Lindon,,,,,,
2017-05-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book,LLY,https://www.benzinga.com/news/earnings/17/05/9541176/a-peek-into-the-markets-u-s-stock-futures-up-ahead-of-beige-book,Lisa Levin,,,,,,
2017-05-31T08:00:00.000+08:00,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/05/9540920/eli-lilly-phase-3-range-urothelial-cancer-trial-of-cyramza-meets-primary-endp,Paul Quintaro,,,,,,
2017-06-01T08:00:00.000+08:00,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates",LLY,https://www.benzinga.com/news/17/06/9548231/eli-lilly-announces-derica-rice-to-retire-as-cfo-co-is-considering-internal-exter,Paul Quintaro,,,,,,
2017-06-03T08:00:00.000+08:00,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17,LLY,https://www.benzinga.com/news/17/06/9560837/lilly-announces-initiation-of-monarche-global-phase-3-study-of-abemaciclib-as-adj,Charles Gross,,,,,,
2017-06-08T08:00:00.000+08:00,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data,LLY,https://www.benzinga.com/17/06/9583782/abbvie-abbv-announced-positive-phase-iii-ra-candidate-data,Zacks,,,,,,
2017-06-08T08:00:00.000+08:00,Teva Migraine Candidate Succeeds in Second Phase III Study,LLY,https://www.benzinga.com/17/06/9583468/teva-migraine-candidate-succeeds-in-second-phase-iii-study,Zacks,,,,,,
2017-06-08T08:00:00.000+08:00,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists,LLY,https://www.benzinga.com/news/17/06/9581590/eli-lilly-to-collaborate-with-keybioscince-on-dual-amylin-calcitonin-receptor-ago,Paul Quintaro,,,,,,
2017-06-09T08:00:00.000+08:00,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program,LLY,https://www.benzinga.com/news/17/06/9587690/eli-lilly-and-the-international-diabetes-federation-announce-second-phase-of-brid,Paul Quintaro,,,,,,
2017-06-11T08:00:00.000+08:00,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS,LLY,https://www.benzinga.com/news/17/06/9592931/lilly-announces-results-showing-galcanezumab-significantly-reduces-number-of-migr,Charles Gross,,,,,,
2017-06-12T08:00:00.000+08:00,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,LLY,https://www.benzinga.com/17/06/9598892/novartis-presents-positive-data-on-car-t-cell-therapy-drug,Zacks,,,,,,
2017-06-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease",LLY,https://www.benzinga.com/news/fda/17/06/9594198/eli-lilly-boehringer-ingelheim-announce-plans-to-conduct-new-large-clinical-o,Hal Lindon,,,,,,
2017-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017",LLY,https://www.benzinga.com/news/17/06/9604917/lilly-incyte-announce-presentation-of-new-data-on-olumiant-in-ra-taltz-in-psa-at-,Charles Gross,,,,,,
2017-06-13T08:00:00.000+08:00,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'",LLY,https://www.benzinga.com/news/fda/17/06/9602969/update-lilly-says-analysis-of-12-500-adults-with-type-2-diabetes-from-19-stud,Paul Quintaro,,,,,,
2017-06-13T08:00:00.000+08:00,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile,LLY,https://www.benzinga.com/news/fda/17/06/9602960/eli-lilly-reports-jardiance-analysis-reinforces-established-safety-profile,Paul Quintaro,,,,,,
2017-06-13T08:00:00.000+08:00,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda,LLY,https://www.benzinga.com/17/06/9601762/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda,Zacks,,,,,,
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601421/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,,,
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601422/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,,,
2017-06-13T08:00:00.000+08:00,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation",LLY,https://www.benzinga.com/news/fda/17/06/9600523/pfizer-eli-lilly-report-tanezumab-received-fda-fast-track-designation,Paul Quintaro,,,,,,
2017-06-14T08:00:00.000+08:00,Pfizer & Lilly Get Fast Track Designation for Pain Candidate,LLY,https://www.benzinga.com/17/06/9608357/pfizer-lilly-get-fast-track-designation-for-pain-candidate,Zacks,,,,,,
2017-06-14T08:00:00.000+08:00,"Company News for June 14, 2017",LLY,https://www.benzinga.com/17/06/9608119/company-news-for-june-14-2017,Zacks,,,,,,
2017-06-15T08:00:00.000+08:00,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy",LLY,https://www.benzinga.com/trading-ideas/technicals/17/06/9615279/regeneron-lower-day-after-8-k-filing-increased-competition-fo,Joel Elconin,,,,,,
2017-06-15T08:00:00.000+08:00,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?,LLY,https://www.benzinga.com/17/06/9615572/why-is-immunogen-imgn-stock-up-131-this-year,Zacks,,,,,,
2017-06-15T08:00:00.000+08:00,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors",LLY,https://www.benzinga.com/news/fda/17/06/9613634/eli-lillys-talz-showed-significant-improvements-in-disease-signs-symptoms-at-,Hal Lindon,,,,,,
2017-06-16T08:00:00.000+08:00,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends",LLY,https://www.benzinga.com/17/06/9621758/dow-30-stock-roundup-ge-appoints-flannery-as-ceo-utx-cat-hike-dividends,Zacks,,,,,,
2017-06-16T08:00:00.000+08:00,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused",LLY,https://www.benzinga.com/17/06/9618359/pharma-stock-roundup-j-j-lilly-present-data-merck-keytruda-study-enrolment-paused,Zacks,,,,,,
2017-06-16T08:00:00.000+08:00,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017",LLY,https://www.benzinga.com/news/17/06/9617421/lilly-incyte-announce-results-from-long-term-extension-of-phase-3-studies-show-tr,Charles Gross,,,,,,
2017-06-18T08:00:00.000+08:00,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in Treatment Of UC in Pediatric Patients,LLY,https://www.benzinga.com/news/17/06/9622743/eli-lilly-receives-fda-orphan-designation-for-humanized-immunoglobulin-g4-variant,Charles Gross,,,,,,
2017-06-21T08:00:00.000+08:00,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M U.S. Capital Investment In 2017,LLY,https://www.benzinga.com/news/17/06/9636480/eli-lilly-unveils-expanded-biotechnology-center-in-san-diego-as-part-of-850m-u-s-,Paul Quintaro,,,,,,
2017-06-22T08:00:00.000+08:00,Why You Should Add Novo Nordisk Stock to Your Portfolio,LLY,https://www.benzinga.com/17/06/9642489/why-you-should-add-novo-nordisk-stock-to-your-portfolio,Zacks,,,,,,
2017-06-22T08:00:00.000+08:00,Merck's Keytruda on a Roll: Can it Retain the Momentum?,LLY,https://www.benzinga.com/17/06/9642216/mercks-keytruda-on-a-roll-can-it-retain-the-momentum,Zacks,,,,,,
2017-06-26T08:00:00.000+08:00,Attention To Details: Neos' ADHD Portfolio,LLY,https://www.benzinga.com/general/biotech/17/06/9634178/attention-to-details-neos-adhd-portfolio,Shanthi Rexaline,,,,,,
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652391/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,,,
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652392/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,,,
2017-06-26T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly",LLY,https://www.benzinga.com/media/cnbc/17/06/9650666/jim-cramer-shares-his-thoughts-on-helmerich-payne-tailored-brands-and-eli-l,Craig Jones,,,,,,
2017-06-28T08:00:00.000+08:00,Alder's Shares Dip Despite Positive Migraine Trial Results,LLY,https://www.benzinga.com/17/06/9665252/alders-shares-dip-despite-positive-migraine-trial-results,Zacks,,,,,,
2017-06-28T08:00:00.000+08:00,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study,LLY,https://www.benzinga.com/17/06/9664402/mercks-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study,Zacks,,,,,,
2017-07-03T08:00:00.000+08:00,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte,LLY,https://www.benzinga.com/news/17/07/9681307/update-lilly-says-japanese-marketing-authorization-of-olumiant-triggered-15m-mile,Paul Quintaro,,,,,,
2017-07-03T08:00:00.000+08:00,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant,LLY,https://www.benzinga.com/news/17/07/9681304/eli-lilly-and-incyte-announce-japans-ministry-of-health-grants-marketing-approval,Paul Quintaro,,,,,,
2017-07-06T08:00:00.000+08:00,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,LLY,https://www.benzinga.com/general/biotech/17/07/9745996/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies,Zacks,,,,,,
2017-07-07T08:00:00.000+08:00,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal",LLY,https://www.benzinga.com/news/17/07/9749773/uk-supreme-court-rules-in-favor-of-eli-lillys-alimta-vitamin-regimen-patents-also,Paul Quintaro,,,,,,
2017-07-10T08:00:00.000+08:00,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer,LLY,https://www.benzinga.com/news/17/07/9756000/eli-lillys-abemaciclib-is-granted-priority-review-by-the-fda-for-the-treatment-of,Paul Quintaro,,,,,,
2017-07-12T08:00:00.000+08:00,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018",LLY,https://www.benzinga.com/news/17/07/9768420/lilly-reaches-settlement-agreement-in-u-s-cialis-patent-litigation-cialis-exclusi,Paul Quintaro,,,,,,
2017-07-13T08:00:00.000+08:00,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",LLY,https://www.benzinga.com/movers/17/07/9775206/shares-of-eli-lilly-astrazeneca-merck-gilead-abbvie-other-large-cap-biotech-spi,Paul Quintaro,,,,,,
2017-07-13T08:00:00.000+08:00,6 Biggest Price Target Changes For Thursday,LLY,https://www.benzinga.com/analyst-ratings/price-target/17/07/9773573/6-biggest-price-target-changes-for-thursday,Lisa Levin,,,,,,
2017-07-13T08:00:00.000+08:00,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13",LLY,https://www.benzinga.com/media/cnbc/17/07/9771620/delta-united-eli-lilly-general-electric-fast-money-picks-for-july-13,Craig Jones,,,,,,
2017-07-18T08:00:00.000+08:00,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas",LLY,https://www.benzinga.com/news/fda/17/07/9788329/adimab-reports-deal-with-eli-lilly-to-transfer-co-s-platform-to-lilly-for-dis,Paul Quintaro,,,,,,
2017-07-24T08:00:00.000+08:00,2 Ways To Trade This Week's Healthcare Earnings,LLY,https://www.benzinga.com/news/earnings/17/07/9776865/2-ways-to-trade-this-weeks-healthcare-earnings,ETF Professor,,,,,,
2017-07-24T08:00:00.000+08:00,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358,LLY,https://www.benzinga.com/news/17/07/9810074/eli-lilly-and-nektar-therapeutics-to-partner-for-development-and-commercializatio,Paul Quintaro,,,,,,
2017-07-25T08:00:00.000+08:00,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est.",LLY,https://www.benzinga.com/news/guidance/17/07/9815351/eli-lilly-raises-fy-2017-guidance-sees-eps-4-10-4-20-from-4-05-4-15-vs-4,Paul Quintaro,,,,,,
2017-07-25T08:00:00.000+08:00,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est.",LLY,https://www.benzinga.com/news/earnings/17/07/9815349/eli-lilly-q2-eps-1-11-vs-1-05-est-sales-5-82b-vs-5-60b-est,Paul Quintaro,,,,,,
2017-07-25T08:00:00.000+08:00,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017,LLY,https://www.benzinga.com/news/17/07/9815321/eli-lilly-and-incytes-re-submission-of-a-new-drug-application-to-the-fda-will-be-,Paul Quintaro,,,,,,
2017-07-25T08:00:00.000+08:00,"12 Stocks To Watch For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815117/12-stocks-to-watch-for-july-25-2017,Lisa Levin,,,,,,
2017-07-25T08:00:00.000+08:00,"Earnings Scheduled For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815114/earnings-scheduled-for-july-25-2017,Lisa Levin,,,,,,
2017-07-26T08:00:00.000+08:00,Zoetis Investors May Need Patience To See Bull Thesis Play Out,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824398/zoetis-investors-may-need-patience-to-see-bull-thesis-pl,Jayson Derrick,,,,,,
2017-07-26T08:00:00.000+08:00,"Intense Competition Pressures Eli Lilly, Leerink Downgrades",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824628/intense-competition-pressures-eli-lilly-leerink-downgrad,Merrick Weingarten,,,,,,
2017-07-26T08:00:00.000+08:00,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824125/19-upside-predicted-for-biogen-goldman-upgrades-on-stren,Mark Fritz,,,,,,
2017-07-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/07/9823964/benzingas-top-upgrades-downgrades-for-july-26-2017,Lisa Levin,,,,,,
2017-07-26T08:00:00.000+08:00,Leerink Swann Downgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/17/07/9822845/leerink-swann-downgrades-eli-lilly-to-market-perform,Paul Quintaro,,,,,,
2017-07-27T08:00:00.000+08:00,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows",LLY,https://www.benzinga.com/general/biotech/17/07/9832748/on-wisconsin-university-wins-half-billion-in-iphone-patent-suit-anothe,Mark Fritz,,,,,,
2017-07-27T08:00:00.000+08:00,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals",LLY,https://www.benzinga.com/general/biotech/17/07/9827012/samsung-amazon-everyone-is-getting-into-pharmaceuticals,Elizabeth Balboa,,,,,,
2017-07-28T08:00:00.000+08:00,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products,LLY,https://www.benzinga.com/news/17/07/9841215/eli-lilly-says-california-and-florida-ags-have-requested-info-on-co-s-insulin-pro,Hal Lindon,,,,,,
2017-08-04T08:00:00.000+08:00,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN,LLY,https://www.benzinga.com/news/fda/17/08/9879323/eli-lilly-reports-results-from-second-phase-3-study-of-lasmiditan-for-acute-t,Paul Quintaro,,,,,,
2017-08-14T08:00:00.000+08:00,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly,LLY,https://www.benzinga.com/news/17/08/9926914/13f-from-farallon-capital-shows-liquidated-1-6m-share-stake-in-eli-lilly,Paul Quintaro,,,,,,
2017-08-16T08:00:00.000+08:00,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results,LLY,https://www.benzinga.com/news/17/08/9940712/shares-of-lilly-fall-on-positive-novo-nordisk-sustain-7-trial-results,Charles Gross,,,,,,
2017-08-30T08:00:00.000+08:00,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle",LLY,https://www.benzinga.com/news/fda/17/08/9994372/update-lilly-incyte-expect-fda-to-classify-nda-for-baricitinib-as-class-i-res,Paul Quintaro,,,,,,
2017-08-30T08:00:00.000+08:00,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18",LLY,https://www.benzinga.com/news/17/08/9994366/eli-lilly-incyte-report-will-resubmit-nda-for-baricitinib-before-end-of-jan-18,Paul Quintaro,,,,,,
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax",LLY,https://www.benzinga.com/news/guidance/17/09/10026977/update-eli-lilly-sees-incurring-1-2b-pre-tax-charge-related-to-streamli,Paul Quintaro,,,,,,
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs",LLY,https://www.benzinga.com/news/17/09/10026973/update-eli-lilly-says-streamlining-of-operations-will-impact-8-of-workforce-or-a,Paul Quintaro,,,,,,
2017-09-07T08:00:00.000+08:00,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M",LLY,https://www.benzinga.com/news/17/09/10026965/eli-lilly-unveils-actions-to-streamline-operations-sees-annualized-savings-of-50,Paul Quintaro,,,,,,
2017-09-08T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'",LLY,https://www.benzinga.com/news/17/09/10032182/update-eli-lilly-says-galcanezumab-showed-statistically-significant-reduction-in,Paul Quintaro,,,,,,
2017-09-08T08:00:00.000+08:00,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine",LLY,https://www.benzinga.com/news/fda/17/09/10032176/eli-lilly-reports-treatment-with-self-administered-galcanezumab-for-up-to-12,Paul Quintaro,,,,,,
2017-09-09T08:00:00.000+08:00,What Pharmaceuticals Spend On Lobbying To Influence Trump,LLY,https://www.benzinga.com/general/biotech/17/09/10008324/what-pharmaceuticals-spend-on-lobbying-to-influence-trump,Elizabeth Balboa,,,,,,
2017-09-09T08:00:00.000+08:00,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017,LLY,https://www.benzinga.com/news/17/09/10037098/data-showing-lillys-lasmiditan-significantly-reduces-pain-in-patients-with-migra,Charles Gross,,,,,,
2017-09-10T08:00:00.000+08:00,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017,LLY,https://www.benzinga.com/news/17/09/10037266/lilly-announces-presentation-of-phase-3-range-data-for-cyramza-demonstrating-sup,Charles Gross,,,,,,
2017-09-11T08:00:00.000+08:00,Array BioPharma And Others Shine At The ESMO 2017 Congress,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10040619/array-biopharma-and-others-shine-at-the-esmo-2017-congr,Wayne Duggan,,,,,,
2017-09-12T08:00:00.000+08:00,This Analyst Predicts Bullish Growth Outlook For Incyte,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10044788/this-analyst-predicts-bullish-growth-outlook-for-incyte,Shanthi Rexaline,,,,,,
2017-09-12T08:00:00.000+08:00,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/09/10043829/eli-lilly-says-jardiance-tablets-reduced-the-risk-of-cardiovascular-death-in-peo,Paul Quintaro,,,,,,
2017-09-14T08:00:00.000+08:00,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/17/09/10057182/eli-lillys-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-,Paul Quintaro,,,,,,
2017-09-19T08:00:00.000+08:00,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",LLY,https://www.benzinga.com/news/17/09/10074065/wall-streets-m-a-chatter-from-september-18-walgreesn-rite-aid-northrup-grumman-o,Charles Gross,,,,,,
2017-09-20T08:00:00.000+08:00,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10080961/johnson-johnson-downgraded-on-hefty-valuation-compared-,Jayson Derrick,,,,,,
2017-09-28T08:00:00.000+08:00,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct.",LLY,https://www.benzinga.com/news/17/09/10117028/eli-lilly-has-said-list-price-for-its-new-breast-cancer-treatment-verzenio-will-,Paul Quintaro,,,,,,
2017-10-05T08:00:00.000+08:00,Eli Lilly Shares Spike On Patent Victory,LLY,https://www.benzinga.com/news/17/10/10147611/eli-lilly-shares-spike-on-patent-victory,Elizabeth Balboa,,,,,,
2017-10-05T08:00:00.000+08:00,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/17/10/10147909/eli-lilly-reports-us-pto-ruled-in-favor-of-co-s-alimta-vitamin-regimen-patent,Paul Quintaro,,,,,,
2017-10-05T08:00:00.000+08:00,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta,LLY,https://www.benzinga.com/news/legal/17/10/10147144/update-scribd-reports-eli-lilly-prevails-in-ipr-review-of-209-patent-for-a,Hal Lindon,,,,,,
2017-10-05T08:00:00.000+08:00,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision,LLY,https://www.benzinga.com/news/rumors/17/10/10147127/watching-shares-of-eli-lilly-as-traders-pass-unconfirmed-chatter-of-favor,Hal Lindon,,,,,,
2017-10-06T08:00:00.000+08:00,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'",LLY,https://www.benzinga.com/general/biotech/17/10/10150151/teva-pharmaceuticals-responds-to-patent-office-decision-in-eli-lillys,Hal Lindon,,,,,,
2017-10-09T08:00:00.000+08:00,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,LLY,https://www.benzinga.com/general/biotech/17/10/10156660/health-care-sector-back-in-focus-in-congress-ahead-of-q3-earnings-res,JJ Kinahan,,,,,,
2017-10-10T08:00:00.000+08:00,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/10/10160332/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings,Zacks,,,,,,
2017-10-10T08:00:00.000+08:00,7 Catalysts For Eli Lilly Over The Next Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10159795/7-catalysts-for-eli-lilly-over-the-next-year,Shanthi Rexaline,,,,,,
2017-10-10T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 10, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10159397/benzingas-top-upgrades-downgrades-for-october-10-2017,Lisa Levin,,,,,,
2017-10-10T08:00:00.000+08:00,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits",LLY,https://www.benzinga.com/news/17/10/10158860/the-market-in-5-minutes-nvidias-drive-russia-and-cryptos-and-carbon-emission-lim,Benzinga News Desk,,,,,,
2017-10-10T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/17/10/10158201/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-fed-speakers,Lisa Levin,,,,,,
2017-10-10T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'",LLY,https://www.benzinga.com/news/fda/17/10/10158024/update-eli-lilly-says-analysis-of-the-secondary-study-endpoints-of-both-pfs-,Paul Quintaro,,,,,,
2017-10-10T08:00:00.000+08:00,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival',LLY,https://www.benzinga.com/news/fda/17/10/10158021/eli-lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verz,Paul Quintaro,,,,,,
2017-10-10T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/17/10/10157951/credit-suisse-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,,,
2017-10-12T08:00:00.000+08:00,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/17/10/10170118/eli-lilly-granted-priority-review-for-verzenio-for-advanced-breast-cancer,Paul Quintaro,,,,,,
2017-10-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",LLY,https://www.benzinga.com/general/biotech/17/10/10175753/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-eli,Zacks,,,,,,
2017-10-16T08:00:00.000+08:00,Eli Lilly Gives an Update on its CYRAMZA Trial,LLY,https://www.benzinga.com/news/17/10/10180082/eli-lilly-gives-an-update-on-its-cyramza-trial,Paul Quintaro,,,,,,
2017-10-18T08:00:00.000+08:00,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10192709/boosted-by-keytruda-citi-upgrades-merck-to-buy-for-the-,Jayson Derrick,,,,,,
2017-10-18T08:00:00.000+08:00,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines",LLY,https://www.benzinga.com/news/17/10/10191892/eli-lilly-curevac-report-global-collaboration-for-development-of-mrna-cancer-vac,Paul Quintaro,,,,,,
2017-10-20T08:00:00.000+08:00,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday,LLY,https://www.benzinga.com/news/earnings/17/10/10206691/upcoming-earnings-heavy-equipment-maker-caterpillar-and-pharma-giant-el,JJ Kinahan,,,,,,
2017-10-23T08:00:00.000+08:00,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10211724/buy-sierra-oncology-ahead-of-a-2018-full-of-catalysts,Shanthi Rexaline,,,,,,
2017-10-23T08:00:00.000+08:00,The Week Ahead: Earnings Season Starts In Earnest,LLY,https://www.benzinga.com/news/17/10/10210048/the-week-ahead-earnings-season-starts-in-earnest,Brent Slava,,,,,,
2017-10-23T08:00:00.000+08:00,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis,LLY,https://www.benzinga.com/news/17/10/10209639/eli-lilly-announces-a-72m-investment-in-insulin-manufacturing-in-indianapolis,Paul Quintaro,,,,,,
2017-10-24T08:00:00.000+08:00,14 Technical Levels Discussed On Tuesday's PreMarket Prep,LLY,https://www.benzinga.com/trading-ideas/technicals/17/10/10217298/14-technical-levels-discussed-on-tuesdays-premarket-prep,Spencer Israel,,,,,,
2017-10-24T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus",LLY,https://www.benzinga.com/news/17/10/10215835/a-peek-into-the-markets-u-s-stock-futures-gain-mcdonalds-general-motors-earnings,Lisa Levin,,,,,,
2017-10-24T08:00:00.000+08:00,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale",LLY,https://www.benzinga.com/news/17/10/10215500/eli-lilly-says-it-is-considering-strategic-alternatives-for-its-elanco-animal-he,Paul Quintaro,,,,,,
2017-10-24T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est.",LLY,https://www.benzinga.com/news/earnings/17/10/10215495/eli-lilly-q3-eps-1-05-vs-1-03-est-sales-5-66b-vs-5-52b-est,Paul Quintaro,,,,,,
2017-10-24T08:00:00.000+08:00,"12 Stocks To Watch For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215244/12-stocks-to-watch-for-october-24-2017,Lisa Levin,,,,,,
2017-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215183/earnings-scheduled-for-october-24-2017,Lisa Levin,,,,,,
2017-10-25T08:00:00.000+08:00,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10225463/evercore-out-with-a-note-saying-teva-is-suing-eli-lilly,Paul Quintaro,,,,,,
2017-11-08T08:00:00.000+08:00,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark,LLY,https://www.benzinga.com/news/fda/17/11/10745999/eli-lilly-says-taltz-demonstrated-improvement-in-psoriatic-arthritis-for-pat,Paul Quintaro,,,,,,
2017-11-09T08:00:00.000+08:00,Pharma ETFs Down Post Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/11/10757139/pharma-etfs-down-post-q3-earnings,Zacks,,,,,,
2017-11-10T08:00:00.000+08:00,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures,LLY,https://www.benzinga.com/general/biotech/17/11/10763761/eli-lilly-thursday-reported-positive-new-data-on-forteo-showing-stati,Hal Lindon,,,,,,
2017-11-13T08:00:00.000+08:00,Stocks Going Ex Dividend The Third Week of November,LLY,https://www.benzinga.com/news/17/11/10766231/stocks-going-ex-dividend-the-third-week-of-november,Fred Fuld,,,,,,
2017-11-14T08:00:00.000+08:00,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?,LLY,https://www.benzinga.com/news/17/11/10780202/who-is-the-former-pharma-exec-trump-nominated-to-lead-hhs,Jayson Derrick,,,,,,
2017-11-21T08:00:00.000+08:00,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00",LLY,https://www.benzinga.com/news/17/11/10819373/morgan-stanley-earlier-maintained-equal-weight-rating-on-eli-lilly-raised-price-,Paul Quintaro,,,,,,
2017-11-21T08:00:00.000+08:00,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem,LLY,https://www.benzinga.com/news/17/11/10817894/dexcom-reports-development-agreement-with-lilly-to-integrate-dexcom-cgm-into-con,Eddie Staley,,,,,,
2017-11-27T08:00:00.000+08:00,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7,LLY,https://www.benzinga.com/markets/options/17/11/10833716/lilly-option-alert-dec-15-81-calls-sweep-27-at-the-ask-639-3-847-vs-0,Charles Gross,,,,,,
2017-12-01T08:00:00.000+08:00,Eli Lilly Receives FDA Approval For Taltz,LLY,https://www.benzinga.com/general/biotech/17/12/10862229/eli-lilly-receives-fda-approval-for-taltz,Hal Lindon,,,,,,
2017-12-04T08:00:00.000+08:00,Eli Lilly's Taltz Gets Approval For Label Expansion in US,LLY,https://www.benzinga.com/general/biotech/17/12/10866077/eli-lillys-taltz-gets-approval-for-label-expansion-in-us,Zacks,,,,,,
2017-12-06T08:00:00.000+08:00,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition",LLY,https://www.benzinga.com/news/contracts/17/12/10878747/juno-therapeutics-signs-licensing-agreements-with-lilly-oncotracker-an,Eddie Staley,,,,,,
2017-12-08T08:00:00.000+08:00,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival",LLY,https://www.benzinga.com/news/fda/17/12/10893730/eli-lilly-reports-top-line-results-from-cyramza-phase-3-study-met-endpoint-o,Paul Quintaro,,,,,,
2017-12-11T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/17/12/10899169/eli-lilly-raises-qtr-dividend-from-0-52share-to-0-5625share,Hal Lindon,,,,,,
2017-12-11T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/17/12/10895964/a-peek-into-the-markets-u-s-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,,,
2017-12-11T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults,LLY,https://www.benzinga.com/news/fda/17/12/10895775/eli-lilly-reports-fda-accepted-bla-for-galcanezumab-review-for-prevention-of,Paul Quintaro,,,,,,
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est,LLY,https://www.benzinga.com/news/17/12/10907977/eli-lilly-sees-fy2018-eps-4-60-4-70-vs-4-64-est-sees-sales-23-0b-23-50b-vs-23-10,Hal Lindon,,,,,,
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est,LLY,https://www.benzinga.com/news/17/12/10907976/eli-lilly-sees-fy2017-eps-4-15-4-25-vs-4-21-est,Hal Lindon,,,,,,
2017-12-14T08:00:00.000+08:00,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line",LLY,https://www.benzinga.com/general/biotech/17/12/10915878/eli-lilly-issues-guidance-for-2018-new-drugs-to-drive-top-line,Zacks,,,,,,
2017-12-15T08:00:00.000+08:00,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",LLY,https://www.benzinga.com/media/cnbc/17/12/10919102/lightning-round-jim-cramer-shares-his-thoughts-on-t-mobile-electronic-arts,Craig Jones,,,,,,
2017-12-18T08:00:00.000+08:00,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit,LLY,https://www.benzinga.com/news/17/12/10927456/eli-lilly-shares-volatile-over-last-few-mins-as-traders-circulate-chatter-co-hir,Paul Quintaro,,,,,,
2017-12-19T08:00:00.000+08:00,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides,LLY,https://www.benzinga.com/news/17/12/10931579/entrega-to-receive-5m-investment-from-lilly-to-advance-proprietary-oral-delivery,Charles Gross,,,,,,
2017-12-20T08:00:00.000+08:00,3 Biotech Pipeline Areas To Keep An Eye On In 2018,LLY,https://www.benzinga.com/general/biotech/17/12/10939349/3-biotech-pipeline-areas-to-keep-an-eye-on-in-2018,Zacks,,,,,,
2017-12-21T08:00:00.000+08:00,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding",LLY,https://www.benzinga.com/news/17/12/10938703/peta-leverages-shareholder-power-calls-on-seaworld-to-end-all-animal-breeding,Elizabeth Balboa,,,,,,
2018-01-04T08:00:00.000+08:00,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",LLY,https://www.benzinga.com/general/biotech/18/01/10985998/goldman-sachs-healthcare-ceos-unscripted-conference-taking-place-toda,Hal Lindon,,,,,,
2018-01-05T08:00:00.000+08:00,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/10995058/argus-shares-eli-lillys-optimism-upgrades-to-buy,Elizabeth Balboa,,,,,,
2018-01-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/10993786/benzingas-top-upgrades-downgrades-for-january-5-2018,Lisa Levin,,,,,,
2018-01-05T08:00:00.000+08:00,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/01/10993723/eli-lilly-to-report-q4-earnings-on-wed-jan-31-before-market-open,Paul Quintaro,,,,,,
2018-01-05T08:00:00.000+08:00,Argus Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/18/01/10993237/argus-upgrades-eli-lilly-to-buy,Eddie Staley,,,,,,
2018-01-08T08:00:00.000+08:00,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area,LLY,https://www.benzinga.com/general/biotech/18/01/11000497/alzheimers-takes-another-hit-as-pfizer-ends-research-in-the-area,Zacks,,,,,,
2018-01-08T08:00:00.000+08:00,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In",LLY,https://www.benzinga.com/news/18/01/11001477/the-week-ahead-conferences-take-center-stage-earnings-begin-to-trickle-in,Taylor Cox,,,,,,
2018-01-11T08:00:00.000+08:00,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April",LLY,https://www.benzinga.com/general/biotech/18/01/11021042/bz-note-eli-lillys-pdufa-date-for-amemaciclib-monarch-1-2-estimated-a,Hal Lindon,,,,,,
2018-01-16T08:00:00.000+08:00,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11034244/eli-lillys-risks-could-be-underappreciated-goldman-sach,Jayson Derrick,,,,,,
2018-01-16T08:00:00.000+08:00,Goldman Sachs Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/01/11032947/goldman-sachs-downgrades-eli-lilly-to-neutral,Eddie Staley,,,,,,
2018-01-16T08:00:00.000+08:00,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health,LLY,https://www.benzinga.com/news/contracts/18/01/11032593/innventure-and-eli-lillys-elanco-announce-strategic-initiative-to-comm,Eddie Staley,,,,,,
2018-01-19T08:00:00.000+08:00,The Top 10 Value Stocks In The S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/01/11053516/the-top-10-value-stocks-in-the-s-p-500,Matt Hogan - Finbox.io,,,,,,
2018-01-20T08:00:00.000+08:00,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More",LLY,https://www.benzinga.com/trading-ideas/18/01/11057025/benzingas-weekly-bulls-bears-apple-eli-lilly-ge-nike-and-more,Nelson Hem,,,,,,
2018-01-22T08:00:00.000+08:00,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11059871/eli-lillys-challenges-leaves-credit-suisse-with-a-sour-,Jayson Derrick,,,,,,
2018-01-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/11059799/benzingas-top-upgrades-downgrades-for-january-22-2018,Lisa Levin,,,,,,
2018-01-22T08:00:00.000+08:00,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl",LLY,https://www.benzinga.com/news/18/01/11058793/the-market-in-5-minutes-celgene-buys-juno-netflix-earnings-preview-eagles-and-pa,Benzinga Newsdesk,,,,,,
2018-01-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas,LLY,https://www.benzinga.com/news/18/01/11058673/eli-lilly-announces-fda-approval-of-credelio-to-treat-and-protect-against-ticks-,Paul Quintaro,,,,,,
2018-01-22T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/18/01/11058296/credit-suisse-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,,,
2018-01-25T08:00:00.000+08:00,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis,LLY,https://www.benzinga.com/news/18/01/11077489/lilly-receives-eu-marketing-authorisation-for-taltz-for-the-treatment-of-active-,Charles Gross,,,,,,
2018-01-26T08:00:00.000+08:00,Jefferies On Gilead: 'We See Better Days Ahead',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11087168/jefferies-on-gilead-we-see-better-days-ahead,Elizabeth Balboa,,,,,,
2018-01-29T08:00:00.000+08:00,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines",LLY,https://www.benzinga.com/news/earnings/18/01/11094350/the-week-ahead-big-tech-earnings-fed-rate-decision-likely-to-dominate-h,Taylor Cox,,,,,,
2018-01-29T08:00:00.000+08:00,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11093344/analyst-radius-health-could-advance-50-with-osteoporosi,Shanthi Rexaline,,,,,,
2018-01-29T08:00:00.000+08:00,"PFE, LLY, MRK Write Up 'Scripts For Q4",LLY,https://www.benzinga.com/news/earnings/18/01/11094446/pfe-lly-mrk-write-up-scripts-for-q4,JJ Kinahan,,,,,,
2018-01-29T08:00:00.000+08:00,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data",LLY,https://www.benzinga.com/news/earnings/18/01/11093826/fed-earnings-are-meaty-filling-between-slices-of-job-price-data,JJ Kinahan,,,,,,
2018-01-30T08:00:00.000+08:00,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses,LLY,https://www.benzinga.com/news/18/01/11101992/hang-on-rate-fears-in-focus-as-futures-point-lower-after-mondays-big-losses,JJ Kinahan,,,,,,
2018-01-31T08:00:00.000+08:00,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life",LLY,https://www.benzinga.com/news/earnings/18/01/11109382/treasury-bounce-boeing-results-appear-to-give-slumping-market-new-life,JJ Kinahan,,,,,,
2018-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus,LLY,https://www.benzinga.com/news/18/01/11107803/a-peek-into-the-markets-u-s-stock-futures-rise-fed-decision-in-focus,Lisa Levin,,,,,,
2018-01-31T08:00:00.000+08:00,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance",LLY,https://www.benzinga.com/news/guidance/18/01/11107399/eli-lilly-raises-fy18-adj-eps-guidance-from-4-60-4-70-to-4-81-4-91-vs-4,Paul Quintaro,,,,,,
2018-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est.",LLY,https://www.benzinga.com/news/earnings/18/01/11107398/eli-lilly-reports-q4-adj-eps-1-14-vs-1-07-est-sales-6-16b-vs-5-94b-est,Paul Quintaro,,,,,,
2018-01-31T08:00:00.000+08:00,"15 Stocks To Watch For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107068/15-stocks-to-watch-for-january-31-2018,Lisa Levin,,,,,,
2018-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107039/earnings-scheduled-for-january-31-2018,Lisa Levin,,,,,,
2018-02-07T08:00:00.000+08:00,Array's Melanoma Combo Shows Positive Overall Survival Data,LLY,https://www.benzinga.com/general/biotech/18/02/11150091/arrays-melanoma-combo-shows-positive-overall-survival-data,Zacks,,,,,,
2018-02-08T08:00:00.000+08:00,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,LLY,https://www.benzinga.com/general/biotech/18/02/11011808/the-alzheimers-drug-pipeline-high-failure-rates-in-research-on-an-inc,Shanthi Rexaline,,,,,,
2018-02-13T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls,LLY,https://www.benzinga.com/news/18/02/11184126/a-peek-into-the-markets-u-s-stock-futures-down-crude-oil-falls,Lisa Levin,,,,,,
2018-02-13T08:00:00.000+08:00,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints,LLY,https://www.benzinga.com/news/18/02/11183860/eli-lilly-says-its-top-line-phase-3-study-of-taltz-met-the-primary-and-all-key-s,Paul Quintaro,,,,,,
2018-02-22T08:00:00.000+08:00,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat",LLY,https://www.benzinga.com/news/18/02/11242697/eli-lilly-shares-near-session-highs-up-0-4-traders-circulating-takeover-chatter-,Paul Quintaro,,,,,,
2018-02-26T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'",LLY,https://www.benzinga.com/news/fda/18/02/11262614/update-eli-lilly-says-new-indication-based-on-monarch-3-trial-can-help-more-,Paul Quintaro,,,,,,
2018-02-26T08:00:00.000+08:00,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/18/02/11262599/eli-lilly-reports-received-added-fda-approval-for-verzenio-as-initial-treatm,Paul Quintaro,,,,,,
2018-02-26T08:00:00.000+08:00,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/02/11256652/eli-lillys-says-trulicity-in-combination-with-an-sglt-2-inhibitor-improves-blood,Paul Quintaro,,,,,,
2018-02-27T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/02/11265713/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,,,
2018-03-06T08:00:00.000+08:00,Dear Activists: Buying Stock Can Effect More Change Than Selling It,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/03/11291102/dear-activists-buying-stock-can-effect-more-change-than-sell,Elizabeth Balboa,,,,,,
2018-03-06T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials,LLY,https://www.benzinga.com/news/18/03/11311288/boehringer-ingelheim-and-eli-lilly-expand-their-heart-failure-program-for-jardia,Hal Lindon,,,,,,
2018-03-07T08:00:00.000+08:00,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11320275/height-casts-65-odds-that-congress-rolls-back-pharma-di,Elizabeth Balboa,,,,,,
2018-03-14T08:00:00.000+08:00,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14",LLY,https://www.benzinga.com/media/18/03/11356773/citigroup-eli-lilly-square-target-fast-money-picks-for-march-14,Craig Jones,,,,,,
2018-03-15T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Merck, Five Below And More",LLY,https://www.benzinga.com/media/18/03/11364192/jim-cramer-shares-his-thoughts-on-merck-five-below-and-more,Craig Jones,,,,,,
2018-03-20T08:00:00.000+08:00,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,LLY,https://www.benzinga.com/general/biotech/18/03/11390687/checking-in-on-the-healthcare-sector-ahead-of-q1-earnings-season,JJ Kinahan,,,,,,
2018-04-03T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/04/11422065/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-,Shanthi Rexaline,,,,,,
2018-04-04T08:00:00.000+08:00,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/04/11472753/eli-lilly-to-report-q1-earnings-on-tues-apr-24-before-market-open,Paul Quintaro,,,,,,
2018-04-04T08:00:00.000+08:00,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2",LLY,https://www.benzinga.com/news/contracts/18/04/11467583/update-as-a-result-of-lillys-transaction-the-co-will-incur-an-acquired,Eddie Staley,,,,,,
2018-04-04T08:00:00.000+08:00,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon",LLY,https://www.benzinga.com/news/contracts/18/04/11467581/lilly-sigilon-therapeutics-report-strategic-partnership-to-develop-enc,Eddie Staley,,,,,,
2018-04-04T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival,LLY,https://www.benzinga.com/news/18/04/11467482/lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-and-,Eddie Staley,,,,,,
2018-04-04T08:00:00.000+08:00,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly,LLY,https://www.benzinga.com/news/contracts/18/04/11467361/terns-pharmaceutical-acquires-global-exclusive-rights-to-develop-and-c,Eddie Staley,,,,,,
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Analyst Calls From April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11516373/benzingas-top-analyst-calls-from-april-13-2018,Bill Haddad,,,,,,
2018-04-13T08:00:00.000+08:00,BMO's Bearish Stance On Eli Lilly Comes To An End,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11515585/bmos-bearish-stance-on-eli-lilly-comes-to-an-end,Jayson Derrick,,,,,,
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11515178/benzingas-top-upgrades-downgrades-for-april-13-2018,Lisa Levin,,,,,,
2018-04-13T08:00:00.000+08:00,BMO Capital Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/18/04/11514504/bmo-capital-upgrades-eli-lilly-to-market-perform,Eddie Staley,,,,,,
2018-04-16T08:00:00.000+08:00,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More",LLY,https://www.benzinga.com/trading-ideas/18/04/11519182/benzingas-bulls-bears-of-the-week-caterpillar-facebook-starbucks-tesla-,Nelson Hem,,,,,,
2018-04-19T08:00:00.000+08:00,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose",LLY,https://www.benzinga.com/news/fda/18/04/11542112/fda-staff-review-of-eli-lillys-rheumatoid-arthritis-treatment-says-supportiv,Paul Quintaro,,,,,,
2018-04-20T08:00:00.000+08:00,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/general/biotech/18/04/11552703/eli-lilly-reports-addl-toplien-results-from-cyramza-phase-3-range-stu,Hal Lindon,,,,,,
2018-04-20T08:00:00.000+08:00,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",LLY,https://www.benzinga.com/general/biotech/18/04/11545276/the-week-ahead-in-biotech-pdufa-dates-ipos-and-more,Shanthi Rexaline,,,,,,
2018-04-23T08:00:00.000+08:00,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11560145/top-ideas-from-the-2018-sohn-conference-box-bitcoin-facebook,Elizabeth Balboa,,,,,,
2018-04-23T08:00:00.000+08:00,Earnings Preview: Verizon And AT&T Report Q1 Results This Week,LLY,https://www.benzinga.com/news/earnings/18/04/11559193/earnings-preview-verizon-and-at-t-report-q1-results-this-week,JJ Kinahan,,,,,,
2018-04-23T08:00:00.000+08:00,"Upcoming Earnings: CAT, LLY And BA Report This Week",LLY,https://www.benzinga.com/news/earnings/18/04/11558746/upcoming-earnings-cat-lly-and-ba-report-this-week,JJ Kinahan,,,,,,
2018-04-23T08:00:00.000+08:00,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer",LLY,https://www.benzinga.com/news/18/04/11558189/from-sohn-conference-ecor1s-noodleman-on-ascendis-pharma-highlighted-10-potentia,Paul Quintaro,,,,,,
2018-04-23T08:00:00.000+08:00,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",LLY,https://www.benzinga.com/news/earnings/18/04/11557960/the-week-ahead-sohn-conference-fang-earnings-docusign-ipo,Taylor Cox,,,,,,
2018-04-23T08:00:00.000+08:00,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today,LLY,https://www.benzinga.com/general/biotech/18/04/11556096/reminder-eli-lilly-and-incyte-have-fda-adcom-meeting-for-baricitinib-,Hal Lindon,,,,,,
2018-04-24T08:00:00.000+08:00,19 Companies Google Could Buy With Its $102 Billion In Cash,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11567157/19-companies-google-could-buy-with-its-102-billion-in-cash,Elizabeth Balboa,,,,,,
2018-04-24T08:00:00.000+08:00,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11565763/goldman-sachs-neutral-on-alder-biopharma-as-launch-of-m,Elizabeth Balboa,,,,,,
2018-04-24T08:00:00.000+08:00,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs",LLY,https://www.benzinga.com/news/18/04/11565365/eli-lilly-says-it-is-looking-to-do-more-deals-in-oncology-including-immuno-oncol,Eddie Staley,,,,,,
2018-04-24T08:00:00.000+08:00,28 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/04/11563983/28-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,,,
2018-04-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est.",LLY,https://www.benzinga.com/news/guidance/18/04/11563044/update-eli-lilly-raises-fy18-adj-eps-outlook-from-4-81-4-91-to-5-10-5-2,Paul Quintaro,,,,,,
2018-04-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Outlook,LLY,https://www.benzinga.com/news/guidance/18/04/11563041/eli-lilly-raises-fy18-outlook,Paul Quintaro,,,,,,
2018-04-24T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est.",LLY,https://www.benzinga.com/news/earnings/18/04/11563040/eli-lilly-q1-adj-eps-1-34-beats-1-14-est-sales-5-7b-beats-5-49b-est,Paul Quintaro,,,,,,
2018-04-24T08:00:00.000+08:00,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018,LLY,https://www.benzinga.com/news/18/04/11562844/lilly-reports-galcanezumab-significantly-reduced-monthly-migraine-headache-days-,Charles Gross,,,,,,
2018-04-24T08:00:00.000+08:00,"12 Stocks To Watch For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562671/12-stocks-to-watch-for-april-24-2018,Lisa Levin,,,,,,
2018-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562595/earnings-scheduled-for-april-24-2018,Lisa Levin,,,,,,
2018-04-24T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA",LLY,https://www.benzinga.com/news/18/04/11562553/lilly-incyte-announce-fda-advisory-committee-recommends-approval-of-baricitinib-,Charles Gross,,,,,,
2018-04-25T08:00:00.000+08:00,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease,LLY,https://www.benzinga.com/news/18/04/11571630/eli-lilly-and-nccd-of-china-collaborate-to-advance-care-for-people-living-with-d,Paul Quintaro,,,,,,
2018-05-07T08:00:00.000+08:00,What's In Store For Radius Health In Q1 Earnings?,LLY,https://www.benzinga.com/general/biotech/18/05/11656510/whats-in-store-for-radius-health-in-q1-earnings,Zacks,,,,,,
2018-05-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide,LLY,https://www.benzinga.com/news/18/05/11688608/mid-afternoon-market-update-prestige-brands-gains-on-earnings-beat-mdc-partners-,Lisa Levin,,,,,,
2018-05-10T08:00:00.000+08:00,40 Stocks Moving In Thursday's Mid-Day Session,LLY,https://www.benzinga.com/news/18/05/11687704/40-stocks-moving-in-thursdays-mid-day-session,Lisa Levin,,,,,,
2018-05-10T08:00:00.000+08:00,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge,LLY,https://www.benzinga.com/news/18/05/11687433/mid-day-market-update-dow-rises-150-points-hudson-technologies-shares-plunge,Lisa Levin,,,,,,
2018-05-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views,LLY,https://www.benzinga.com/news/18/05/11686239/mid-morning-market-update-markets-open-higher-markets-magna-tops-q1-views,Lisa Levin,,,,,,
2018-05-10T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",LLY,https://www.benzinga.com/general/biotech/18/05/11682938/benzingas-daily-biotech-pulse-armo-skyrockets-on-eli-lilly-deal-akcea,Shanthi Rexaline,,,,,,
2018-05-10T08:00:00.000+08:00,32 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/05/11684612/32-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,,,
2018-05-10T08:00:00.000+08:00,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B,LLY,https://www.benzinga.com/news/18/05/11684092/lilly-announces-agreement-to-acquire-armo-biosciences-for-50share-or-1-6b,Eddie Staley,,,,,,
2018-05-11T08:00:00.000+08:00,55 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/18/05/11693478/55-biggest-movers-from-yesterday,Lisa Levin,,,,,,
2018-05-11T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B,LLY,https://www.benzinga.com/news/m-a/18/05/11693426/update-eli-lilly-announces-tender-offer-for-hbm-portfolio-company-armo-biosc,Charles Gross,,,,,,
2018-05-14T08:00:00.000+08:00,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01",LLY,https://www.benzinga.com/news/m-a/18/05/11702671/eli-lilly-to-buy-aurka-pharma-for-110m-upfront-payment-plus-eligibility-to-r,Benzinga Newsdesk,,,,,,
2018-05-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label,LLY,https://www.benzinga.com/news/18/05/11755511/eli-lilly-announces-fda-approval-for-its-taltz-to-include-psoriasis-involving-th,Benzinga Newsdesk,,,,,,
2018-05-22T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area,LLY,https://www.benzinga.com/news/18/05/11755507/lillys-taltz-ixekizumab-receives-first-u-s-fda-approval-for-label-update-to-incl,Benzinga Newsdesk,,,,,,
2018-06-01T08:00:00.000+08:00,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant,LLY,https://www.benzinga.com/news/fda/18/06/11814901/eli-lilly-pr-confirms-earlier-news-of-fda-approval-for-olumiant,Eddie Staley,,,,,,
2018-06-01T08:00:00.000+08:00,Eli Lilly And Co.'s Olumiant Wins FDA Approval,LLY,https://www.benzinga.com/news/fda/18/06/11814500/eli-lilly-and-co-s-olumiant-wins-fda-approval,Eddie Staley,,,,,,
2018-06-01T08:00:00.000+08:00,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5,LLY,https://www.benzinga.com/news/18/06/11812268/eli-lilly-says-will-present-new-data-evaluating-mirikizumab-fro-treatment-of-mod,Paul Quintaro,,,,,,
2018-06-03T08:00:00.000+08:00,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,LLY,https://www.benzinga.com/general/biotech/18/06/11806828/the-week-ahead-in-biotech-asco-presentations-dominate-the-headlines,Shanthi Rexaline,,,,,,
2018-06-04T08:00:00.000+08:00,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",LLY,https://www.benzinga.com/news/18/06/11821277/donald-trump-tweets-we-had-repeal-replace-done-and-the-saving-to-our-country-of-,Benzinga Newsdesk,,,,,,
2018-06-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018,LLY,https://www.benzinga.com/news/fda/18/06/11830896/update-eli-lilly-reports-will-initiate-phase-3-trial-in-moderate-to-severe-u,Benzinga Newsdesk,,,,,,
2018-06-05T08:00:00.000+08:00,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo",LLY,https://www.benzinga.com/news/fda/18/06/11830886/eli-lilly-offers-new-safety-efficacy-data-from-phase-2-study-evaluating-miri,Benzinga Newsdesk,,,,,,
2018-06-05T08:00:00.000+08:00,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression",LLY,https://www.benzinga.com/general/biotech/18/06/11828515/fda-expands-eli-lillys-alimta-pemetrexed-label-to-include-combination,Benzinga Newsdesk,,,,,,
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care",LLY,https://www.benzinga.com/general/biotech/18/06/11848847/eli-lilly-ceo-calls-for-uniform-prices-better-use-of-technology-in-he,Dustin Blitchok,,,,,,
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly",LLY,https://www.benzinga.com/news/18/06/11847698/lilly-ceo-ricks-when-asked-if-co-will-participate-in-right-to-try-initiative-tel,Benzinga Newsdesk,,,,,,
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'",LLY,https://www.benzinga.com/news/18/06/11847458/lilly-ceo-ricks-positive-on-jp-morgan-berkshire-amazon-health-care-coalition-say,Benzinga Newsdesk,,,,,,
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors",LLY,https://www.benzinga.com/news/18/06/11847379/eli-lilly-ceo-david-ricks-currently-speaking-at-detroit-economic-club-highlights,Benzinga Newsdesk,,,,,,
2018-06-08T08:00:00.000+08:00,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",LLY,https://www.benzinga.com/general/biotech/18/06/11853189/pharma-stock-roundup-merck-eli-lilly-abbvie-and-more,Zacks,,,,,,
2018-06-08T08:00:00.000+08:00,"The Market In 5 Minutes: China, ZTE, McDonald's And More",LLY,https://www.benzinga.com/news/18/06/11852066/the-market-in-5-minutes-china-zte-mcdonalds-and-more,Benzinga Newsdesk,,,,,,
2018-06-08T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 8, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11852140/benzingas-top-upgrades-downgrades-for-june-8-2018,Lisa Levin,,,,,,
2018-06-08T08:00:00.000+08:00,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target",LLY,https://www.benzinga.com/news/18/06/11851455/cantor-fitzgerald-initiates-coverage-on-eli-lilly-with-overweight-rating-announc,Benzinga Newsdesk,,,,,,
2018-06-11T08:00:00.000+08:00,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine",LLY,https://www.benzinga.com/news/18/06/11857880/eli-lilly-division-elanco-animal-health-introduces-new-respiratory-prrs-vaccine,Benzinga Newsdesk,,,,,,
2018-06-11T08:00:00.000+08:00,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older,LLY,https://www.benzinga.com/news/fda/18/06/11857852/eli-lilly-reports-its-elanco-animal-health-unit-received-licensing-of-prevac,Benzinga Newsdesk,,,,,,
2018-06-12T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",LLY,https://www.benzinga.com/general/biotech/18/06/11863705/benzingas-daily-biotech-pulse-galmed-rips-higher-on-positive-nash-dat,Shanthi Rexaline,,,,,,
2018-06-12T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat",LLY,https://www.benzinga.com/news/18/06/11863702/eli-lilly-astrazeneca-discontinuing-global-phase-3-clinical-trials-of-lanabecest,Benzinga Newdesk,,,,,,
2018-06-13T08:00:00.000+08:00,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting,LLY,https://www.benzinga.com/news/18/06/11876187/pop-star-pink-confronts-seaworld-on-petas-behalf-during-shareholder-meeting,Elizabeth Balboa,,,,,,
2018-06-21T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84",LLY,https://www.benzinga.com/news/18/06/11913332/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-84,Vick Meyer,,,,,,
2018-06-22T08:00:00.000+08:00,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires",LLY,https://www.benzinga.com/news/18/06/11923238/update-in-separate-decision-june-15th-district-court-ruled-in-favor-of-eli-lilly,Benzinga Newsdesk,,,,,,
2018-06-22T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/18/06/11923214/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-,Benzinga Newsdesk,,,,,,
2018-06-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11920459/benzingas-top-upgrades-downgrades-for-june-22-2018,Lisa Levin,,,,,,
2018-06-22T08:00:00.000+08:00,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk",LLY,https://www.benzinga.com/markets/cryptocurrency/18/06/11920224/the-market-in-5-minutes-stress-test-results-more-trade-talks-v,Benzinga Newsdesk,,,,,,
2018-06-22T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/18/06/11919824/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,,,
2018-06-22T08:00:00.000+08:00,DZ Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/06/11919663/dz-bank-downgrades-eli-lilly-to-hold,Benzinga Newsdesk,,,,,,
2018-06-23T08:00:00.000+08:00,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018,LLY,https://www.benzinga.com/news/18/06/11925333/lilly-announces-investigational-doses-of-once-weekly-trulicity-show-promise-in-d,Benzinga Newdesk,,,,,,
2018-06-23T08:00:00.000+08:00,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors,LLY,https://www.benzinga.com/news/18/06/11925321/lily-announces-jardiance-reduced-risk-of-kidney-disease-progression-in-adults-wi,Benzinga Newdesk,,,,,,
2018-06-23T08:00:00.000+08:00,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/06/11925320/lilly-announces-new-data-presented-at-ada2018-reinforce-potential-of-ultra-rapid,Benzinga Newdesk,,,,,,
2018-06-25T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin,LLY,https://www.benzinga.com/news/18/06/11927084/boehringer-ingelheim-and-lilly-report-ease-phase-iii-program-met-primary-endpoin,Benzinga Newsdesk,,,,,,
2018-06-27T08:00:00.000+08:00,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality,LLY,https://www.benzinga.com/news/18/06/11945795/eli-lilly-reports-intended-brand-name-for-episodic-cluster-headache-treatment-ap,Benzinga Newsdesk,,,,,,
2018-06-27T08:00:00.000+08:00,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint,LLY,https://www.benzinga.com/general/biotech/18/06/11945793/eli-lilly-announces-results-of-phase-3-study-of-emgailty-which-met-pr,Benzinga Newsdesk,,,,,,
2018-06-28T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",LLY,https://www.benzinga.com/general/biotech/18/06/11947397/benzingas-daily-biotech-pulse-eli-lilly-edge-therapeutics-bioxcel-rep,Shanthi Rexaline,,,,,,
2018-06-28T08:00:00.000+08:00,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study,LLY,https://www.benzinga.com/news/18/06/11948093/eli-lilly-reports-taltz-met-primary-and-secondary-endpoints-in-a-phase-3-study,Benzinga Newsdesk,,,,,,
2018-06-29T08:00:00.000+08:00,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co.",LLY,https://www.benzinga.com/news/fda/18/06/11956348/update-lilly-will-engage-40k-people-with-migraine-in-us-over-next-2-years-wi,Benzinga Newsdesk,,,,,,
2018-06-29T08:00:00.000+08:00,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine",LLY,https://www.benzinga.com/news/fda/18/06/11956347/eli-lilly-reports-initiation-of-overcome-study-to-advance-understanding-of-b,Benzinga Newsdesk,,,,,,
2018-07-05T08:00:00.000+08:00,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,LLY,https://www.benzinga.com/general/biotech/18/07/11955951/a-look-at-biotech-in-2018-and-the-biggest-catalysts-coming-up-in-the-,Shanthi Rexaline,,,,,,
2018-07-09T08:00:00.000+08:00,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,LLY,https://www.benzinga.com/news/earnings/18/07/11994014/health-care-sector-outlook-checking-in-ahead-of-q2-earnings-reports,JJ Kinahan,,,,,,
2018-07-17T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12032289/stocks-that-made-new-52-week-highs-today-include-citrix-trip,Benzinga Newsdesk,,,,,,
2018-07-18T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12039238/stocks-that-made-new-52-week-highs-today-include-alphabet-bo,Benzinga Newsdesk,,,,,,
2018-07-18T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/07/12035427/benzingas-daily-biotech-pulse-novartis-earnings-j-js-hiv-cocktail-cle,Shanthi Rexaline,,,,,,
2018-07-18T08:00:00.000+08:00,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints",LLY,https://www.benzinga.com/news/18/07/12035761/pfizer-eli-lilly-report-phase-3-trial-of-tanezumab-met-all-thre-co-primary-endpo,Benzinga_Newsdesk,,,,,,
2018-07-19T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint,LLY,https://www.benzinga.com/news/18/07/12043218/boehringer-ingelheim-and-lilly-announce-tradjentas-carmelina-outcome-trial-meets,Benzinga_Newsdesk,,,,,,
2018-07-19T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80",LLY,https://www.benzinga.com/news/18/07/12043200/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-80,Vick Meyer,,,,,,
2018-07-19T08:00:00.000+08:00,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease",LLY,https://www.benzinga.com/news/18/07/12042569/eli-lilly-reports-once-weekly-trulicity-label-updated-to-include-data-showing-be,Benzinga Newsdesk,,,,,,
2018-07-20T08:00:00.000+08:00,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet,LLY,https://www.benzinga.com/general/biotech/18/07/12050508/eli-lilly-and-incyte-late-thursday-announced-study-results-showing-be,Benzinga Newsdesk,,,,,,
2018-07-22T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12038223/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-resu,Shanthi Rexaline,,,,,,
2018-07-23T08:00:00.000+08:00,Eli Lilly's Q2 Earnings Preview,LLY,https://www.benzinga.com/news/earnings-previews/18/07/12059076/eli-lillys-earnings-preview,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,Earnings Season Optimism Seems To Help Lift Market,LLY,https://www.benzinga.com/news/earnings/18/07/12065019/earnings-season-optimism-seems-to-help-lift-market,JJ Kinahan,,,,,,
2018-07-24T08:00:00.000+08:00,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs",LLY,https://www.benzinga.com/news/18/07/12064280/from-eli-lilly-q2-earnings-conference-call-co-says-it-is-preparing-for-all-scena,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/07/12064091/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,,,
2018-07-24T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",LLY,https://www.benzinga.com/general/biotech/18/07/12061774/benzingas-daily-biotech-pulse-celgenes-lymphoma-trial-meets-endpoint-,Shanthi Rexaline,,,,,,
2018-07-24T08:00:00.000+08:00,25 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/07/12063230/25-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,,,
2018-07-24T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/07/12062662/a-peek-into-the-markets-us-stock-futures-rise-ahead-of-earnings,Lisa Levin,,,,,,
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.,LLY,https://www.benzinga.com/news/18/07/12062340/eli-lilly-raises-fy18-sales-outlook-from-23-7b-24-2b-to-24-0b-24-5b-vs-23-99b-es,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.,LLY,https://www.benzinga.com/news/18/07/12062329/eli-lilly-raises-fy18-adj-eps-outlook-from-5-10-5-20-to-5-40-5-50-vs-5-15-est,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,Eli Lilly Revises FY18 Outlook,LLY,https://www.benzinga.com/news/18/07/12062324/eli-lilly-revises-fy18-outlook,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate",LLY,https://www.benzinga.com/news/earnings/18/07/12062321/eli-lilly-q2-adj-eps-1-50-beats-1-30-estimate-sales-6-36b-beat-6-05b-es,Benzinga Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018",LLY,https://www.benzinga.com/news/18/07/12062312/lilly-to-separate-elanco-animal-health-with-ipo-offering-is-expected-to-represen,Benzinga_Newsdesk,,,,,,
2018-07-24T08:00:00.000+08:00,"12 Stocks To Watch For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12062019/12-stocks-to-watch-for-july-24-2018,Lisa Levin,,,,,,
2018-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12061930/earnings-scheduled-for-july-24-2018,Lisa Levin,,,,,,
2018-07-25T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073985/stocks-that-made-new-52-week-highs-earlier-include-adobe-s-p,Benzinga Newsdesk,,,,,,
2018-07-25T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 24th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073898/stocks-which-set-new-52-week-high-yesterday-july-24th,Benzinga Newsdesk,,,,,,
2018-07-25T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90",LLY,https://www.benzinga.com/news/18/07/12072711/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-90,Vick Meyer,,,,,,
2018-07-25T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86",LLY,https://www.benzinga.com/news/18/07/12072560/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-86,Vick Meyer,,,,,,
2018-07-25T08:00:00.000+08:00,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report",LLY,https://www.benzinga.com/news/earnings/18/07/12072376/concerns-about-trade-picture-overshadowing-earnings-as-gm-boeing-report,JJ Kinahan,,,,,,
2018-07-25T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/07/12072351/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,,,
2018-07-25T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 25, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/07/12071901/benzingas-top-upgrades-downgrades-for-july-25-2018,Lisa Levin,,,,,,
2018-07-25T08:00:00.000+08:00,Berenberg Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/07/12071311/berenberg-downgrades-eli-lilly-to-hold,Benzinga_Newsdesk,,,,,,
2018-07-25T08:00:00.000+08:00,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110",LLY,https://www.benzinga.com/news/18/07/12070765/cantor-fitzgerald-maintains-overweight-on-eli-lilly-raises-price-target-to-110,Vick Meyer,,,,,,
2018-07-26T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 25th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12082507/stocks-which-set-new-52-week-high-yesterday-july-25th,Benzinga Newsdesk,,,,,,
2018-07-26T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",LLY,https://www.benzinga.com/general/biotech/18/07/12078445/benzingas-daily-biotech-pulse-biogen-ac-immune-slip-despite-positive-,Shanthi Rexaline,,,,,,
2018-07-27T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 26th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12091145/stocks-which-set-new-52-week-high-yesterday-july-26th,Benzinga Newsdesk,,,,,,
2018-07-28T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12083481/the-week-ahead-in-biotech-conferences-pdufa-dates-earnings-and-ipos,Shanthi Rexaline,,,,,,
2018-07-29T08:00:00.000+08:00,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More",LLY,https://www.benzinga.com/media/18/07/12095539/barrons-picks-and-pans-amazon-eli-lilly-fiat-chrysler-and-more,Nelson Hem,,,,,,
2018-07-30T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12100261/stocks-that-made-new-52-week-highs-so-far-today-include-amd-,Benzinga Newsdesk,,,,,,
2018-07-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, July 27th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12099824/stocks-which-set-new-52-week-high-friday-july-27th,Benzinga Newsdesk,,,,,,
2018-07-30T08:00:00.000+08:00,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute,LLY,https://www.benzinga.com/news/18/07/12096843/eli-lilly-announces-a-3-year-extension-of-its-cancer-research-collaboration-with,Benzinga Newsdesk,,,,,,
2018-07-31T08:00:00.000+08:00,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102",LLY,https://www.benzinga.com/news/18/07/12107653/morgan-stanley-maintains-equal-weight-on-eli-lilly-raises-price-target-to-102,Vick Meyer,,,,,,
2018-07-31T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 30th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12107459/stocks-which-set-new-52-week-high-yesterday-july-30th,Benzinga Newsdesk,,,,,,
2018-08-01T08:00:00.000+08:00,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119888/stocks-that-have-made-new-52-week-highs-thus-far-today-inclu,Benzinga Newsdesk,,,,,,
2018-08-01T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 31",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119145/stocks-which-set-new-52-week-high-yesterday-july-31,Benzinga Newsdesk,,,,,,
2018-08-01T08:00:00.000+08:00,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",LLY,https://www.benzinga.com/general/biotech/18/08/12114456/benzingas-biotech-pulse-pfizers-xeljanz-gets-eu-nod-newlink-losses-na,Shanthi Rexaline,,,,,,
2018-08-01T08:00:00.000+08:00,Dan Nathan Sees Unusual Options Activity In Eli Lilly,LLY,https://www.benzinga.com/markets/options/18/08/12113952/dan-nathan-sees-unusual-options-activity-in-eli-lilly,Craig Jones,,,,,,
2018-08-02T08:00:00.000+08:00,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit,LLY,https://www.benzinga.com/news/18/08/12134479/elanco-animal-health-f-1-shows-registration-for-100m-ipo-co-planning-to-list-on-,Benzinga Newsdesk,,,,,,
2018-08-02T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129601/stocks-that-made-new-52-week-highs-so-far-today-include-perk,Benzinga Newsdesk,,,,,,
2018-08-02T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 1st",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129448/stocks-which-set-new-52-week-high-yesterday-august-1st,Benzinga Newsdesk,,,,,,
2018-08-02T08:00:00.000+08:00,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",LLY,https://www.benzinga.com/general/biotech/18/08/12125416/the-daily-biotech-pulse-denalis-parkinsons-candidate-clears-early-sta,Shanthi Rexaline,,,,,,
2018-08-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12138981/stocks-which-set-new-52-week-high-yesterday-august-2nd,Benzinga Newsdesk,,,,,,
2018-08-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",LLY,https://www.benzinga.com/general/biotech/18/08/12136788/the-daily-biotech-pulse-zafgen-executive-departs-adamas-acceleron-acc,Shanthi Rexaline,,,,,,
2018-08-06T08:00:00.000+08:00,"Stocks Which Set New 52-Week Highs Friday, August 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12147637/stocks-which-set-new-52-week-highs-friday-august-3rd,Benzinga Newsdesk,,,,,,
2018-08-07T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12155877/stocks-that-made-new-52-week-highs-earlier-today-include-sl-,Benzinga Newsdesk,,,,,,
2018-08-07T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 6th",LLY,https://www.benzinga.com/trading-ideas/small-cap-analysis/18/08/12155686/stocks-which-set-new-52-week-high-yesterday-august-6,Benzinga Newsdesk,,,,,,
2018-08-07T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",LLY,https://www.benzinga.com/general/biotech/18/08/12152105/the-daily-biotech-pulse-fda-snub-for-gemphire-ligand-earnings-insmeds,Shanthi Rexaline,,,,,,
2018-08-08T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12165578/stocks-which-set-new-52-week-high-yesterday-august-7th,Benzinga Newsdesk,,,,,,
2018-08-08T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",LLY,https://www.benzinga.com/general/biotech/18/08/12162539/the-daily-biotech-pulse-fda-panel-backs-insmed-eidos-maiden-earnings-,Shanthi Rexaline,,,,,,
2018-08-13T08:00:00.000+08:00,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th",LLY,https://www.benzinga.com/news/18/08/12193922/stocks-that-will-be-trading-ex-dividend-tomorrow-august-14th,Benzinga Newsdesk,,,,,,
2018-08-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend Today, August 14th",LLY,https://www.benzinga.com/news/18/08/12199631/stocks-trading-ex-dividend-today-august-14th,Benzinga Newsdesk,,,,,,
2018-08-16T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12218948/stocks-that-made-new-52-week-highs-so-far-today-include-inge,Benzinga Newsdesk,,,,,,
2018-08-17T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 16th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12224603/stocks-which-set-new-52-week-high-yesterday-august-16th,Benzinga Newsdesk,,,,,,
2018-08-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",LLY,https://www.benzinga.com/general/biotech/18/08/12222856/the-daily-biotech-pulse-aveo-slips-on-stock-offering-fda-greenlights-,Shanthi Rexaline,,,,,,
2018-08-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",LLY,https://www.benzinga.com/general/biotech/18/08/12235573/the-daily-biotech-pulse-mercks-keytruda-secures-approval-for-expanded,Shanthi Rexaline,,,,,,
2018-08-25T08:00:00.000+08:00,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More",LLY,https://www.benzinga.com/media/18/08/12260491/barrons-picks-and-pans-electronic-arts-glaxosmithkline-microsoft-tesla-and-more,Nelson Hem,,,,,,
2018-08-27T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12264607/stocks-that-made-new-52-week-highs-so-far-today-include-ihs-,Benzinga Newsdesk,,,,,,
2018-08-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",LLY,https://www.benzinga.com/general/biotech/18/08/12267407/the-daily-biotech-pulse-regulatory-roadblock-for-akcea-ionis-affimeds,Shanthi Rexaline,,,,,,
2018-08-30T08:00:00.000+08:00,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest",LLY,https://www.benzinga.com/news/18/08/12285393/update-adocia-notes-eli-lilly-filed-counterclaims-against-co-seeking-188m-includ,luke@benzinga.com,,,,,,
2018-08-30T08:00:00.000+08:00,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B",LLY,https://www.benzinga.com/news/18/08/12285388/french-biopharma-co-focused-on-treatment-for-diabetes-etc-adocia-issues-press-re,luke@benzinga.com,,,,,,
2018-08-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/08/12265004/attention-biotech-investors-mark-your-calendar-for-these-september-pd,Shanthi Rexaline,,,,,,
2018-09-04T08:00:00.000+08:00,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform,LLY,https://www.benzinga.com/general/biotech/18/09/12302894/zymeworks-reports-ind-submission-milestone-achieved-in-eli-lilly-coll,Benzinga_Newsdesk,,,,,,
2018-09-05T08:00:00.000+08:00,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change,LLY,https://www.benzinga.com/news/18/09/12309274/eli-lilly-says-phase-3-results-in-flortaucipir-pet-imaging-agent-showed-that-flo,Benzinga_Newsdesk,,,,,,
2018-09-06T08:00:00.000+08:00,New Class of Migraine Drug Creates Four-Way Pharma Development Race,LLY,https://www.benzinga.com/general/biotech/18/09/12284580/new-class-of-migraine-drug-creates-four-way-pharma-development-race,Shanthi Rexaline,,,,,,
2018-09-06T08:00:00.000+08:00,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range,LLY,https://www.benzinga.com/news/18/09/12312848/eli-lillys-elanco-sets-ipo-of-62-9m-shares-in-20-23share-range,luke@benzinga.com,,,,,,
2018-09-07T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/09/12320597/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,,,
2018-09-10T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, September 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/09/12332289/stocks-which-set-new-52-week-high-friday-september-7th,Benzinga Newsdesk,,,,,,
2018-09-10T08:00:00.000+08:00,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya,LLY,https://www.benzinga.com/news/18/09/12328380/eli-lilly-initiates-ixora-r-head-to-head-clinical-trial-comparing-taltz-and-trem,Benzinga_Newsdesk,,,,,,
2018-09-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",LLY,https://www.benzinga.com/general/biotech/18/09/12333621/the-daily-biotech-pulse-advaxis-posts-narrower-loss-endocyte-announce,Shanthi Rexaline,,,,,,
2018-09-14T08:00:00.000+08:00,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion",LLY,https://www.benzinga.com/news/18/09/12355696/the-ipo-outlook-for-the-week-eventbrite-animal-health-and-luxury-fashion,Elizabeth Balboa,,,,,,
2018-09-16T08:00:00.000+08:00,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/09/12351792/the-week-ahead-in-biotech-sept-16-22-conferences-pdufa-dates-clinical,Shanthi Rexaline,,,,,,
2018-09-17T08:00:00.000+08:00,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12363642/credit-suisse-lifts-teva-price-target-says-execution-is,Shanthi Rexaline,,,,,,
2018-09-17T08:00:00.000+08:00,Teva's Preventive Migraine Treatment Approved By FDA,LLY,https://www.benzinga.com/general/biotech/18/09/12362386/tevas-preventive-migraine-treatment-approved-by-fda,Shanthi Rexaline,,,,,,
2018-09-18T08:00:00.000+08:00,10 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/09/12370398/10-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,,,
2018-09-18T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112",LLY,https://www.benzinga.com/news/18/09/12368272/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-112,Vick Meyer,,,,,,
2018-09-19T08:00:00.000+08:00,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'",LLY,https://www.benzinga.com/news/18/09/12379857/eli-lilly-and-company-subsidiary-elanco-prices-ipo-of-62-9m-shares-at-24share-sh,Benzinga_Newsdesk,,,,,,
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share,LLY,https://www.benzinga.com/news/18/09/12383300/elanco-animal-health-shares-indicated-26-on-750k-shares-ipo-priced-at-24share,Benzinga Newsdesk,,,,,,
2018-09-20T08:00:00.000+08:00,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",LLY,https://www.benzinga.com/general/biotech/18/09/12381811/the-daily-biotech-pulse-adverum-snags-fast-track-designation-crispr-t,Shanthi Rexaline,,,,,,
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Prices $62.9M Share IPO @$24/Share,LLY,https://www.benzinga.com/news/18/09/12381007/elanco-animal-health-prices-62-9m-share-ipo-24share,Charles Gross,,,,,,
2018-09-21T08:00:00.000+08:00,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12388457/lilly-receives-positive-chmp-opinion-for-emgality-for-the-prophylaxis-of-migrain,Benzinga_Newsdesk,,,,,,
2018-09-26T08:00:00.000+08:00,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12410874/jpmorgan-resumes-coverage-of-eli-lilly-one-of-the-best-,Shanthi Rexaline,,,,,,
2018-09-26T08:00:00.000+08:00,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target",LLY,https://www.benzinga.com/news/18/09/12412239/from-earlier-jp-morgan-reinstated-eli-lilly-at-overweight-announces-117-price-ta,Benzinga Newsdesk,,,,,,
2018-09-27T08:00:00.000+08:00,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12422436/lillys-emgality-receives-fda-approval-for-the-preventive-treatment-of-migraine-i,Charles Gross,,,,,,
2018-09-27T08:00:00.000+08:00,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug,LLY,https://www.benzinga.com/news/18/09/12420070/us-judge-has-dismissed-patent-suits-by-teva-against-eli-lilly-related-to-its-mig,Benzinga Newsdesk,,,,,,
2018-09-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron",LLY,https://www.benzinga.com/general/biotech/18/09/12415125/the-daily-biotech-pulse-hologic-goes-shopping-johnson-johnson-snaps-t,Shanthi Rexaline,,,,,,
2018-09-28T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/18/09/12423355/the-daily-biotech-pulse-fda-nods-for-adamis-eli-lilly-pfizer-spero-ob,Shanthi Rexaline,,,,,,
2018-10-01T08:00:00.000+08:00,Leerink: Improving Fundamentals Drive Teva Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12432584/leerink-improving-fundamentals-drive-teva-upgrade,Hannah Genig,,,,,,
2018-10-02T08:00:00.000+08:00,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/18/10/12439121/results-from-two-phase-3-studies-show-lillys-ultra-rapid-lispro-urli-,Benzinga_Newsdesk,,,,,,
2018-10-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12451979/stocks-which-set-new-52-week-high-yesterday-october-2nd,Benzinga Newsdesk,,,,,,
2018-10-03T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12450241/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,,,
2018-10-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12448229/the-daily-biotech-pulse-endologixs-q3-sales-obsevas-positive-trial-re,Shanthi Rexaline,,,,,,
2018-10-03T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/10/12448689/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,,,
2018-10-04T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12460628/stocks-that-made-new-52-week-highs-so-far-today-include-ball,Benzinga Newsdesk,,,,,,
2018-10-04T08:00:00.000+08:00,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.,LLY,https://www.benzinga.com/markets/wiim/18/10/12459709/eli-lilly-shares-are-up-2-8-to-111-68-after-the-company-earlier-reported,Benzinga_Newsdesk,,,,,,
2018-10-04T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12459146/stocks-which-set-new-52-week-high-yesterday-october-3rd,Benzinga Newsdesk,,,,,,
2018-10-04T08:00:00.000+08:00,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",LLY,https://www.benzinga.com/general/biotech/18/10/12455944/the-daily-biotech-pulse-atricures-guidance-guardant-health-and-kodiak,Shanthi Rexaline,,,,,,
2018-10-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint",LLY,https://www.benzinga.com/news/18/10/12456485/boehringer-ingelheim-eli-lilly-report-empagliflozin-in-phase-iii-trial-met-prima,Benzinga Newsdesk,,,,,,
2018-10-04T08:00:00.000+08:00,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes",LLY,https://www.benzinga.com/news/18/10/12456383/eli-lilly-reports-investigational-dual-gip-glp-1-receptor-agonist-showed-reducti,Benzinga Newsdesk,,,,,,
2018-10-05T08:00:00.000+08:00,3 Screens That Hint At Which Stocks May Outperform In Q4,LLY,https://www.benzinga.com/fintech/18/10/12465725/3-screens-that-hint-at-which-stocks-may-outperform-in-q4,Chris Dier-Scalise,,,,,,
2018-10-05T08:00:00.000+08:00,10 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12464630/10-biggest-price-target-changes-for-friday,Lisa Levin,,,,,,
2018-10-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12464568/benzingas-top-upgrades-downgrades-for-october-5-2018,Lisa Levin,,,,,,
2018-10-05T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 4th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12464408/stocks-which-set-new-52-week-high-yesterday-october-4th,Benzinga Newsdesk,,,,,,
2018-10-05T08:00:00.000+08:00,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",LLY,https://www.benzinga.com/general/biotech/18/10/12463117/the-daily-biotech-pulse-medicinova-gets-orphan-drug-status-kempharm-t,Shanthi Rexaline,,,,,,
2018-10-05T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130",LLY,https://www.benzinga.com/news/18/10/12463136/bmo-capital-upgrades-eli-lilly-to-outperform-raises-price-target-to-130,Benzinga Newsdesk,,,,,,
2018-10-08T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp.",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12472827/stocks-that-made-new-52-week-highs-so-far-today-include-amer,Benzinga Newsdesk,,,,,,
2018-10-09T08:00:00.000+08:00,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',LLY,https://www.benzinga.com/news/18/10/12478199/fda-commissioner-scott-gottlieb-issues-statement-on-new-efforts-to-advance-the-d,Benzinga Newsdesk,,,,,,
2018-10-09T08:00:00.000+08:00,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",LLY,https://www.benzinga.com/general/biotech/18/10/12474171/the-daily-biotech-pulse-affimeds-cancer-drug-placed-on-clinical-hold-,Shanthi Rexaline,,,,,,
2018-10-10T08:00:00.000+08:00,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12482335/the-daily-biotech-pulse-novartis-blood-disorder-drug-improves-patient,Shanthi Rexaline,,,,,,
2018-10-12T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/18/10/12498448/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,,,
2018-10-14T08:00:00.000+08:00,4 Major Market Opportunities For The Cannabis Industry,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12479521/4-major-market-opportunities-for-the-cannabis-industry,Hannah Genig,,,,,,
2018-10-14T08:00:00.000+08:00,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/10/12487249/the-week-ahead-in-biotech-esmo-conference-pdufa-dates-clinical-trial-,Shanthi Rexaline,,,,,,
2018-10-16T08:00:00.000+08:00,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices",LLY,https://www.benzinga.com/news/18/10/12515662/sanofi-novo-nordisk-lilly-shares-unaffected-amid-report-state-of-minnesota-filed,Benzinga Newsdesk,,,,,,
2018-10-22T08:00:00.000+08:00,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint',LLY,https://www.benzinga.com/news/18/10/12544009/eli-lilly-reports-results-for-2-phase-3-studies-of-taltz-in-ankylosing-spondylit,Benzinga Newsdesk,,,,,,
2018-10-22T08:00:00.000+08:00,A Preview Of Eli Lilly's Q3 Earnings,LLY,https://www.benzinga.com/news/earnings-previews/18/10/12543573/a-preview-of-eli-lillys-earnings,Benzinga Newsdesk,,,,,,
2018-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2018",LLY,https://www.benzinga.com/news/earnings/18/10/12546405/earnings-scheduled-for-october-23-2018,Lisa Levin,,,,,,
2018-10-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 24, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12557064/benzingas-top-upgrades-downgrades-for-october-24-2018,Lisa Levin,,,,,,
2018-10-24T08:00:00.000+08:00,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target",LLY,https://www.benzinga.com/news/18/10/12555261/wolfe-research-initiates-coverage-on-eli-lilly-with-peer-perform-rating-announce,Vick Meyer,,,,,,
2018-10-24T08:00:00.000+08:00,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",LLY,https://www.benzinga.com/news/18/10/12554734/pfizer-lilly-announce-complete-results-from-first-study-in-ongoing-phase-3-progr,Charles Gross,,,,,,
2018-10-29T08:00:00.000+08:00,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",LLY,https://www.benzinga.com/general/biotech/18/10/12582501/dicerna-soars-after-eli-lilly-invests-100m-in-licensing-research-deal,Shanthi Rexaline,,,,,,
2018-10-29T08:00:00.000+08:00,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain",LLY,https://www.benzinga.com/news/18/10/12580835/dicerna-pharma-announces-licensing-and-research-collaboration-with-eli-lilly-for,Benzinga Newsdesk,,,,,,
2018-10-30T08:00:00.000+08:00,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30",LLY,https://www.benzinga.com/media/18/10/12588760/eli-lilly-lowes-macys-xlu-fast-money-picks-for-october-30,Craig Jones,,,,,,
2018-10-31T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 31, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12601454/benzingas-top-upgrades-downgrades-for-october-31-2018,Lisa Levin,,,,,,
2018-10-31T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/10/12600305/credit-suisse-upgrades-eli-lilly-to-neutral,Vick Meyer,,,,,,
2018-11-01T08:00:00.000+08:00,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M,LLY,https://www.benzinga.com/news/18/11/12610119/siga-technologies-reports-sale-of-medical-countermeasures-priority-review-vouche,Charles Gross,,,,,,
2018-11-04T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/11/12615052/the-week-ahead-in-biotech-earnings-conferences-pdufa-dates-clinical-t,Shanthi Rexaline,,,,,,
2018-11-05T08:00:00.000+08:00,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure",LLY,https://www.benzinga.com/news/18/11/12634476/eli-lilly-nextcure-report-collaboration-to-discover-develop-novel-immuno-oncolog,Benzinga Newsdesk,,,,,,
2018-11-05T08:00:00.000+08:00,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.,LLY,https://www.benzinga.com/markets/wiim/18/11/12633381/eli-lilly-shares-are-trading-up-3-8-after-the-company-reported-positive-,Benzinga Newsdesk,,,,,,
2018-11-05T08:00:00.000+08:00,Eli Lilly Gets Ready For First Report Post-Elanco IPO,LLY,https://www.benzinga.com/news/earnings/18/11/12632088/eli-lilly-gets-ready-for-first-report-post-elanco-ipo,JJ Kinahan,,,,,,
2018-11-05T08:00:00.000+08:00,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/11/12631667/eli-lilly-says-trulicity-demonstrates-a-superior-reduction-of-cardiovascular-eve,Benzinga Newsdesk,,,,,,
2018-11-05T08:00:00.000+08:00,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing,LLY,https://www.benzinga.com/news/earnings/18/11/12630536/rally-fizzles-as-apples-guidance-seen-weak-mixed-signals-on-china-keep-,JJ Kinahan,,,,,,
2018-11-05T08:00:00.000+08:00,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use,LLY,https://www.benzinga.com/news/18/11/12628962/eli-lilly-announces-positive-early-results-from-a-study-of-the-first-5-years-of-,Benzinga Newsdesk,,,,,,
2018-11-06T08:00:00.000+08:00,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure,LLY,https://www.benzinga.com/news/earnings/18/11/12640101/long-wait-is-over-election-day-dawns-with-markets-under-light-pressure,JJ Kinahan,,,,,,
2018-11-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/11/12638083/a-peek-into-the-markets-us-stock-futures-drop-ahead-of-earnings,Lisa Levin,,,,,,
2018-11-06T08:00:00.000+08:00,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",LLY,https://www.benzinga.com/general/biotech/18/11/12637056/the-daily-biotech-pulse-eyepoint-licenses-eye-inflammation-drug-insys,Shanthi Rexaline,,,,,,
2018-11-06T08:00:00.000+08:00,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate,LLY,https://www.benzinga.com/news/18/11/12637390/update-eli-lilly-raises-fy18-adj-eps-guidance-from-5-40-5-50-to-5-55-5-60-vs-5-4,Benzinga Newsdesk,,,,,,
2018-11-06T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance",LLY,https://www.benzinga.com/news/earnings/18/11/12637388/eli-lilly-q3-eps-1-39-beats-1-36-estimate-sales-6-062b-beat-6-02b-estim,Benzinga Newsdesk,,,,,,
2018-11-06T08:00:00.000+08:00,"10 Stocks To Watch For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637058/10-stocks-to-watch-for-november-6-2018,Lisa Levin,,,,,,
2018-11-06T08:00:00.000+08:00,"Earnings Scheduled For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637030/earnings-scheduled-for-november-6-2018,Lisa Levin,,,,,,
2018-11-14T08:00:00.000+08:00,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache",LLY,https://www.benzinga.com/news/18/11/12694503/eli-lilly-reports-submission-of-new-drug-application-for-lasmiditan-for-acute-tr,Benzinga Newsdesk,,,,,,
2018-11-16T08:00:00.000+08:00,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources",LLY,https://www.benzinga.com/news/18/11/12715079/eli-lilly-considers-sale-of-china-assets-to-raise-cash-bloomberg-citing-sources,Benzinga Newsdesk,,,,,,
2018-11-26T08:00:00.000+08:00,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease,LLY,https://www.benzinga.com/general/biotech/18/11/12751645/expert-consensus-decision-pathway-issued-by-american-college-of-cardi,Benzinga Newsdesk,,,,,,
2018-11-26T08:00:00.000+08:00,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way",LLY,https://www.benzinga.com/news/18/11/12749682/data-dive-trade-talks-and-powell-busy-post-holiday-week-on-the-way,JJ Kinahan,,,,,,
2018-11-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/11/12749415/benzingas-top-upgrades-downgrades-for-november-26-2018,Lisa Levin,,,,,,
2018-11-26T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points",LLY,https://www.benzinga.com/news/18/11/12748416/a-peek-into-the-markets-us-stock-futures-surge-dow-futures-up-over-250-points,Lisa Levin,,,,,,
2018-11-26T08:00:00.000+08:00,Citigroup Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/11/12748319/citigroup-downgrades-eli-lilly-to-neutral,Benzinga Newsdesk,,,,,,
2018-11-29T08:00:00.000+08:00,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8,LLY,https://www.benzinga.com/news/18/11/12770572/eli-lilly-highlights-will-present-data-for-verzenio-at-san-antonio-breast-cancer,Benzinga Newsdesk,,,,,,
2018-11-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",LLY,https://www.benzinga.com/news/18/11/12779656/stocks-which-set-new-52-week-high-yesterday-thurs-nov-29-2018,Benzinga Newsdesk,,,,,,
2018-11-30T08:00:00.000+08:00,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",LLY,https://www.benzinga.com/general/biotech/18/11/12777751/the-daily-biotech-pulse-ec-nod-for-shire-mirati-gets-fda-clearance-fo,Shanthi Rexaline,,,,,,
2018-12-04T08:00:00.000+08:00,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details",LLY,https://www.benzinga.com/news/18/12/12795841/ahead-of-mid-week-pause-investors-fret-over-trade-pact-details,JJ Kinahan,,,,,,
2018-12-06T08:00:00.000+08:00,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",LLY,https://www.benzinga.com/general/biotech/18/12/12805307/the-daily-biotech-pulse-abbvie-halts-lung-cancer-trial-oncomed-merges,Shanthi Rexaline,,,,,,
2018-12-07T08:00:00.000+08:00,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",LLY,https://www.benzinga.com/markets/cannabis/18/12/12818199/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we,Javier Hasse,,,,,,
2018-12-12T08:00:00.000+08:00,Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position,LLY,https://www.benzinga.com/general/biotech/18/12/12836467/lilly-and-ac-immune-announce-license-and-collaboration-agreement-to-f,Benzinga Newsdesk,,,,,,
2018-12-13T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data",LLY,https://www.benzinga.com/news/18/12/12843937/a-peek-into-the-markets-us-stock-futures-edge-higher-ahead-of-jobless-claims-imp,Lisa Levin,,,,,,
2018-12-13T08:00:00.000+08:00,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus,LLY,https://www.benzinga.com/news/18/12/12843783/eli-lilly-reports-fast-track-designation-to-baricitinib-development-program-for-,Benzinga Newsdesk,,,,,,
2018-12-13T08:00:00.000+08:00,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease",LLY,https://www.benzinga.com/news/18/12/12843723/eli-lilly-announces-co-boehringer-ingelheim-partner-with-duke-clinical-research-,Benzinga Newsdesk,,,,,,
2018-12-14T08:00:00.000+08:00,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed",LLY,https://www.benzinga.com/news/18/12/12854132/eli-lilly-reports-purchase-of-pre-clinical-pain-program-from-hydra-biosciences-n,Benzinga Newsdesk,,,,,,
2018-12-14T08:00:00.000+08:00,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform,LLY,https://www.benzinga.com/news/18/12/12850880/eli-lilly-reports-expansion-of-collaboration-with-evidation-health-for-andromeda,Benzinga Newsdesk,,,,,,
2018-12-17T08:00:00.000+08:00,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.,LLY,https://www.benzinga.com/markets/wiim/18/12/12859979/health-insurers-and-healthcare-providers-are-trading-down-today-after-a-,Benzinga_Newsdesk,,,,,,
2018-12-17T08:00:00.000+08:00,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints",LLY,https://www.benzinga.com/news/18/12/12857511/eli-lilly-says-taltz-in-a-superiority-study-vs-abbvies-humira-in-patients-with-a,Benzinga Newsdesk,,,,,,
2018-12-18T08:00:00.000+08:00,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product",LLY,https://www.benzinga.com/news/18/12/12869690/update-aduro-will-be-eligible-for-development-commercial-milestones-up-to-620mpr,Benzinga Newsdesk,,,,,,
2018-12-18T08:00:00.000+08:00,UPDATE: Aduro To Receive Upfront Payment Of $12M,LLY,https://www.benzinga.com/news/18/12/12869687/update-aduro-to-receive-upfront-payment-of-12m,Benzinga Newsdesk,,,,,,
2018-12-18T08:00:00.000+08:00,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program",LLY,https://www.benzinga.com/news/18/12/12869683/eli-lilly-aduro-biotech-report-research-collaboration-exclusive-license-deal-for,Benzinga Newsdesk,,,,,,
2018-12-18T08:00:00.000+08:00,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients,LLY,https://www.benzinga.com/general/biotech/18/12/12864693/lilly-highlights-publication-of-analysis-showing-benefit-of-the-addit,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.,LLY,https://www.benzinga.com/markets/wiim/18/12/12874700/eli-lilly-shares-are-trading-up-after-the-company-reaffirmed-strong-guid,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",LLY,https://www.benzinga.com/general/biotech/18/12/12871984/the-daily-biotech-pulse-pfizer-glaxo-set-up-consumer-health-care-vent,Shanthi Rexaline,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate,LLY,https://www.benzinga.com/news/18/12/12872490/eli-lilly-reaffirms-fy18-sales-guidance-24-3b-24-5b-vs-24-43b-estimate,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate,LLY,https://www.benzinga.com/news/18/12/12872489/eli-lilly-sees-fy19-sales-25-3b-25-8b-vs-24-77b-estimate,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate,LLY,https://www.benzinga.com/news/18/12/12872478/eli-lilly-reaffirms-fy18-adj-eps-guidance-5-55-5-60-vs-5-58-estimate,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate,LLY,https://www.benzinga.com/news/18/12/12872475/eli-lilly-sees-fy19-adj-eps-5-90-6-vs-5-82-estimate,Benzinga Newsdesk,,,,,,
2018-12-19T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share,LLY,https://www.benzinga.com/news/18/12/12872448/eli-lilly-raises-qtr-dividend-from-0-5625-to-0-645share,Benzinga Newsdesk,,,,,,
2018-12-20T08:00:00.000+08:00,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake,LLY,https://www.benzinga.com/news/18/12/12884561/dicerna-pharma-13d-filing-from-eli-lilly-shows-new-8-6-stake,Benzinga Newsdesk,,,,,,
2018-12-20T08:00:00.000+08:00,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company,LLY,https://www.benzinga.com/news/18/12/12879162/chi-med-announces-amendment-to-the-2013-license-collaboration-agreement-on-fruqu,Charles Gross,,,,,,
2018-12-20T08:00:00.000+08:00,"Lilly's Shares Rise on Robust 2019 View, Dividend Hike",LLY,http://www.zacks.com/stock/news/343999/lillys-shares-rise-on-robust-2019-view-dividend-hike?cid=CS-BENZ-FT-343999,Zacks,,,,,,
2018-12-20T08:00:00.000+08:00,"Allergan Drops, Stops Textured Breast Implant Sales in Europe",LLY,http://www.zacks.com/stock/news/343980/allergan-drops-stops-textured-breast-implant-sales-in-europe?cid=CS-BENZ-FT-343980,Zacks,,,,,,
2018-12-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab",LLY,http://www.zacks.com/stock/news/343959/the-zacks-analyst-blog-highlights-eli-lilly-mitsubishi-ufj-thermo-fisher-oracle-and-ecolab?cid=CS-BENZ-FT-343959,Zacks,,,,,,
2018-12-21T08:00:00.000+08:00,Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study,LLY,http://www.zacks.com/stock/news/344168/pfizer-xtandi-succeeds-in-late-stage-prostate-cancer-study?cid=CS-BENZ-FT-344168,Zacks,,,,,,
2018-12-24T08:00:00.000+08:00,"Dividend Increases: December 17-21, 2018",LLY,https://seekingalpha.com/article/4229902-dividend-increases-december-17minus-21-2018?source=partner_benzinga,Seeking Alpha,,,,,,
2018-12-26T08:00:00.000+08:00,Bayer (BAYRY) Faces Generic Threat & Rising Competition,LLY,http://www.zacks.com/stock/news/344595/bayer-bayry-faces-generic-threat-rising-competition?cid=CS-BENZ-FT-344595,Zacks,,,,,,
2018-12-27T08:00:00.000+08:00,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma,LLY,https://www.benzinga.com/news/18/12/12902413/lilly-announces-chinas-nmpa-approves-innovents-anti-pd-1-antibody-tyvyt-for-hodg,Charles Gross,,,,,,
2018-12-27T08:00:00.000+08:00,Teva Stock Rises on Patent Settlement With Neos Therapeutics,LLY,http://www.zacks.com/stock/news/344759/teva-stock-rises-on-patent-settlement-with-neos-therapeutics?cid=CS-BENZ-FT-344759,Zacks,,,,,,
2018-12-27T08:00:00.000+08:00,"Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019",LLY,http://www.zacks.com/stock/news/344663/forget-jj-buy-these-3-big-drug-stocks-instead-in-2019?cid=CS-BENZ-FT-344663,Zacks,,,,,,
2018-12-29T08:00:00.000+08:00,Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019,LLY,https://www.benzinga.com/node/12911936,TalkMarkets,,,,,,
2018-12-31T08:00:00.000+08:00,"Centene finishes first, Coty last on S&P 500 for 2018",LLY,https://seekingalpha.com/news/3419833-centene-finishes-first-coty-last-s-and-p-500-2018?source=partner_benzinga,Seeking Alpha,,,,,,
2018-12-31T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/345212/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-345212,Zacks,,,,,,
2018-12-31T08:00:00.000+08:00,Adamis Pharma files U.S. marketing application for fast-dissolving sublingual tadalafil tablet for ED,LLY,https://seekingalpha.com/news/3419670-adamis-pharma-files-u-s-marketing-application-fast-dissolving-sublingual-tadalafil-tablet-ed?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-01T08:00:00.000+08:00,Biotech Bonanza: 2019 Outlook,LLY,https://www.benzinga.com/node/12916141,TalkMarkets,,,,,,
2019-01-02T08:00:00.000+08:00,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12918090/adamis-has-favorable-pipeline-setup-says-bullish-raymon,Shanthi Rexaline,,,,,,
2019-01-02T08:00:00.000+08:00,The Best Performing Stocks Of 2018,LLY,https://www.benzinga.com/node/12920772,TalkMarkets,,,,,,
2019-01-02T08:00:00.000+08:00,Drug makers OK with price inclusion in TV ads if done fairly,LLY,https://seekingalpha.com/news/3420056-drug-makers-ok-price-inclusion-tv-ads-done-fairly?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-02T08:00:00.000+08:00,Eli Lilly Looks To Newly Acquired Assets For Pain Market,LLY,https://seekingalpha.com/article/4231044-eli-lilly-looks-newly-acquired-assets-pain-market?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-02T08:00:00.000+08:00,5 Great S&P 500 Stocks to Buy in 2019,LLY,http://www.zacks.com/stock/news/345316/5-great-sp-500-stocks-to-buy-in-2019?cid=CS-BENZ-FT-345316,Zacks,,,,,,
2019-01-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily",LLY,http://www.zacks.com/stock/news/345489/the-zacks-analyst-blog-highlights-tripadvisor-advance-auto-red-hat-salesforce-and-eli-lily?cid=CS-BENZ-FT-345489,Zacks,,,,,,
2019-01-03T08:00:00.000+08:00,Japan OKs five new indications for Merck's Keytruda,LLY,https://seekingalpha.com/news/3420246-japan-oks-five-new-indications-mercks-keytruda?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-04T08:00:00.000+08:00,"Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate",LLY,http://www.zacks.com/stock/news/345809/pharma-stock-roundup-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate?cid=CS-BENZ-FT-345809,Zacks,,,,,,
2019-01-04T08:00:00.000+08:00,"Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration",LLY,http://www.zacks.com/stock/news/345747/nektar-imaginab-enter-into-immuno-oncology-collaboration?cid=CS-BENZ-FT-345747,Zacks,,,,,,
2019-01-06T08:00:00.000+08:00,"Dow Jones Futures: Stock Market Rally Picks Up Steam, But This Is Missing",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2019-stock-market-rally-top-stocks/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-01-07T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher,LLY,https://www.benzinga.com/news/19/01/12945702/mid-afternoon-market-update-dow-up-125-points-axsome-therapeutics-shares-spike-h,Lisa Levin,,,,,,
2019-01-07T08:00:00.000+08:00,42 Stocks Moving In Monday's Mid-Day Session,LLY,https://www.benzinga.com/news/19/01/12945226/42-stocks-moving-in-mondays-mid-day-session,Lisa Levin,,,,,,
2019-01-07T08:00:00.000+08:00,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble,LLY,https://www.benzinga.com/news/19/01/12944918/mid-day-market-update-luxoft-jumps-on-acquisition-news-pg-e-shares-tumble,Lisa Levin,,,,,,
2019-01-07T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views,LLY,https://www.benzinga.com/news/19/01/12943620/mid-morning-market-update-markets-mixed-commercial-metals-misses-q1-views,Lisa Levin,,,,,,
2019-01-07T08:00:00.000+08:00,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise,LLY,https://www.benzinga.com/general/biotech/19/01/12942435/eli-lilly-agrees-to-buy-loxo-for-8b-in-bid-to-expand-oncology-franchi,Shanthi Rexaline,,,,,,
2019-01-07T08:00:00.000+08:00,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019,LLY,https://www.benzinga.com/news/19/01/12942537/eli-lilly-says-it-will-limit-share-buybacks-to-3-5m-in-1h-2019,Benzinga Newsdesk,,,,,,
2019-01-07T08:00:00.000+08:00,21 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/12942028/21-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,,,
2019-01-07T08:00:00.000+08:00,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B,LLY,https://www.benzinga.com/news/19/01/12941025/loxo-oncology-to-be-acquired-by-eli-lilly-for-235share-cash-in-deal-worth-8b,Benzinga Newsdesk,,,,,,
2019-01-07T08:00:00.000+08:00,"Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. ...",LLY,http://www.gurufocus.com/news/796107/bragar-eagel--squire-pc-is-investigating-the-board-of-directors-of-loxo-oncology-inc-loxo-on-behalf-of-stockholders-and-encourages-loxo-investors-to-contact-the-firm,GuruFocus,,,,,,
2019-01-07T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/346099/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-346099,Zacks,,,,,,
2019-01-07T08:00:00.000+08:00,"Stock Market News: Nasdaq Leads Up Session, Helped By Biotech Stocks",LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-news-biotechs-amazon-netflix/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-01-07T08:00:00.000+08:00,Tech Stocks Set The Pace; This FANG Stock Is At A Critical Level,LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-stock-market-amazon-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-01-07T08:00:00.000+08:00,Eli Lilly to acquire Loxo Oncology for $8B,LLY,https://seekingalpha.com/news/3420898-eli-lilly-acquire-loxo-oncology-8b?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-07T08:00:00.000+08:00,3 Things To Watch For Monday In Biotech Land,LLY,https://seekingalpha.com/article/4231737-3-things-watch-monday-biotech-land?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-07T08:00:00.000+08:00,What The Celgene Deal Means For The Biotech Sector,LLY,https://seekingalpha.com/article/4231701-celgene-deal-means-biotech-sector?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-08T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",LLY,https://www.benzinga.com/general/biotech/19/01/12948270/the-daily-biotech-pulse-amgen-slashes-cholesterol-drug-device-prices-,Shanthi Rexaline,,,,,,
2019-01-08T08:00:00.000+08:00,65 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/19/01/12948364/65-biggest-movers-from-yesterday,Lisa Levin,,,,,,
2019-01-08T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO David Ricks presents at 37th Annual JPMorgan Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4232218-eli-lilly-company-lly-ceo-david-ricks-presents-37th-annual-jpmorgan-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-08T08:00:00.000+08:00,"Eli Lilly Buys Loxo, This Year Looks To Be An M&A Year To Never Forget",LLY,https://seekingalpha.com/article/4232154-eli-lilly-buys-loxo-year-looks-m-year-never-forget?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-08T08:00:00.000+08:00,Eli Lilly: Loxo To Drive Growth?,LLY,https://seekingalpha.com/article/4232119-eli-lilly-loxo-drive-growth?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-08T08:00:00.000+08:00,Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?,LLY,http://www.zacks.com/stock/news/346269/eli-lilly-lly-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-346269,Zacks,,,,,,
2019-01-08T08:00:00.000+08:00,Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo,LLY,http://www.zacks.com/stock/news/346271/lilly-offers-%248b-to-acquire-cancer-focused-small-biotech-loxo?cid=CS-BENZ-FT-346271,Zacks,,,,,,
2019-01-08T08:00:00.000+08:00,Crowded Cancer Space Triggers Big M&A Deals: More in Store?,LLY,http://www.zacks.com/stock/news/346265/crowded-cancer-space-triggers-big-ma-deals-more-in-store?cid=CS-BENZ-FT-346265,Zacks,,,,,,
2019-01-08T08:00:00.000+08:00,"Company News For Jan 8, 2019",LLY,http://www.zacks.com/stock/news/346224/company-news-for-jan-8-2019?cid=CS-BENZ-FT-346224,Zacks,,,,,,
2019-01-08T08:00:00.000+08:00,U.S.-China Wrap Up Trade Meeting (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4231992-u-s-china-wrap-trade-meeting-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-08T08:00:00.000+08:00,Wall Street Breakfast: U.S.-China Wrap Up Trade Meeting,LLY,https://seekingalpha.com/article/4231987-wall-street-breakfast-u-s-china-wrap-trade-meeting?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-09T08:00:00.000+08:00,Building A Bulletproof Portfolio Around Enbridge,LLY,https://seekingalpha.com/article/4232358-building-bulletproof-portfolio-around-enbridge?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo",LLY,http://www.zacks.com/stock/news/346426/the-zacks-analyst-blog-highlights-bristol-myers-celgene-lilly-and-glaxo?cid=CS-BENZ-FT-346426,Zacks,,,,,,
2019-01-09T08:00:00.000+08:00,NantKwest launches mid-stage study of triplet therapy for rare skin cancer,LLY,https://seekingalpha.com/news/3421732-nantkwest-launches-mid-stage-study-triplet-therapy-rare-skin-cancer?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-09T08:00:00.000+08:00,Novartis' Crizanlizumab Gets Breakthrough Therapy Status,LLY,http://www.zacks.com/stock/news/346407/novartis-crizanlizumab-gets-breakthrough-therapy-status?cid=CS-BENZ-FT-346407,Zacks,,,,,,
2019-01-09T08:00:00.000+08:00,"Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, ...",LLY,http://www.gurufocus.com/news/797021/report-exploring-fundamental-drivers-behind-virtusa-eli-lilly-cree-newjersey-resources-getty-realty-and-pennantpark-investment--new-horizons-emerging-trends-and-upcoming-developments,GuruFocus,,,,,,
2019-01-09T08:00:00.000+08:00,Where Will M&A Strike Next Across Biotech?,LLY,https://seekingalpha.com/article/4232266-will-m-strike-next-across-biotech?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-10T08:00:00.000+08:00,2018 In The Numbers And What It Means For 2019 - Part I: Stocks,LLY,https://seekingalpha.com/article/4232736-2018-numbers-means-2019-part-stocks?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-10T08:00:00.000+08:00,Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting,LLY,http://www.zacks.com/stock/news/346748/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting?cid=CS-BENZ-FT-346748,Zacks,,,,,,
2019-01-10T08:00:00.000+08:00,Drug applications take back seat to safety surveillance at FDA during shutdown,LLY,https://seekingalpha.com/news/3421978-drug-applications-take-back-seat-safety-surveillance-fda-shutdown?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-11T08:00:00.000+08:00,4 Biotech Pipeline Areas To Keep An Eye On In 2019,LLY,https://www.benzinga.com/general/biotech/19/01/12970244/4-biotech-pipeline-areas-to-keep-an-eye-on-in-2019,Zacks,,,,,,
2019-01-11T08:00:00.000+08:00,5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019,LLY,http://www.zacks.com/stock/news/347065/5-reasons-why-investors-should-buy-novo-nordisk-nvo-in-2019?cid=CS-BENZ-FT-347065,Zacks,,,,,,
2019-01-11T08:00:00.000+08:00,Composite Rating For Eli Lilly Jumps To 98,LLY,http://www.investors.com/ibd-data-stories/composite-rating-for-eli-lilly-jumps-to-98/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-01-11T08:00:00.000+08:00,Dem lawmakers introduce bill to lower U.S. drug prices,LLY,https://seekingalpha.com/news/3422438-dem-lawmakers-introduce-bill-lower-u-s-drug-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-11T08:00:00.000+08:00,Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why,LLY,http://www.zacks.com/stock/news/347050/puma-biotech-pbyi-down-more-than-40-in-90-days-heres-why?cid=CS-BENZ-FT-347050,Zacks,,,,,,
2019-01-11T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet",LLY,http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-BENZ-FT-347005,Zacks,,,,,,
2019-01-11T08:00:00.000+08:00,4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019,LLY,http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-BENZ-FT-346884,Zacks,,,,,,
2019-01-12T08:00:00.000+08:00,"Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development",LLY,https://seekingalpha.com/article/4232947-alector-ipo-abbvie-helping-early-stage-development?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-13T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",LLY,https://www.benzinga.com/general/biotech/19/01/12960202/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials,Shanthi Rexaline,,,,,,
2019-01-14T08:00:00.000+08:00,"Merger Arbitrage Mondays - January 14, 2018",LLY,https://seekingalpha.com/article/4233349-merger-arbitrage-mondays-january-14-2018?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-14T08:00:00.000+08:00,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know,LLY,http://www.zacks.com/stock/news/347317/eli-lilly-lly-dips-more-than-broader-markets-what-you-should-know?cid=CS-BENZ-FT-347317,Zacks,,,,,,
2019-01-14T08:00:00.000+08:00,"Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene",LLY,https://seekingalpha.com/article/4233282-eli-lilly-loxo-make-sense-bristol-myers-celgene?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-14T08:00:00.000+08:00,Rep. Cummings opens investigation into drug prices,LLY,https://seekingalpha.com/news/3422823-rep-cummings-opens-investigation-drug-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-14T08:00:00.000+08:00,A Planned Spinoff Of Cancer Vaccines At Generex,LLY,https://seekingalpha.com/article/4233211-planned-spinoff-cancer-vaccines-generex?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-15T08:00:00.000+08:00,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding ...",LLY,http://www.gurufocus.com/news/800508/shareholder-alert-levi--korsinsky-llp-reminds-investors-of-an-investigation-regarding-whether-the-sale-of-loxo-oncology-inc-to-eli-lilly-and-company-is-fair-to-shareholders,GuruFocus,,,,,,
2019-01-15T08:00:00.000+08:00,FDA to beef up cell and gene therapy staff,LLY,https://seekingalpha.com/news/3423193-fda-beef-cell-gene-therapy-staff?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-15T08:00:00.000+08:00,FDA Commish touts advances/successes,LLY,https://seekingalpha.com/news/3423185-fda-commish-touts-advances-successes?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-15T08:00:00.000+08:00,Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer,LLY,http://www.zacks.com/stock/news/347471/bristol-myers-drug-combination-gets-eu-nod-for-renal-cancer?cid=CS-BENZ-FT-347471,Zacks,,,,,,
2019-01-16T08:00:00.000+08:00,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share,LLY,https://www.benzinga.com/news/19/01/12995122/eli-lilly-form-4-from-lilly-endowment-shows-open-market-sale-of-51-8k-shares-at-,Benzinga Newsdesk,,,,,,
2019-01-16T08:00:00.000+08:00,Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings,LLY,http://www.zacks.com/stock/news/347859/kitov-pharmas-stock-up-on-anti-cancer-candidate-findings?cid=CS-BENZ-FT-347859,Zacks,,,,,,
2019-01-16T08:00:00.000+08:00,Intrexon Signs Licensing Agreement with Next Green Wave,LLY,http://www.zacks.com/stock/news/347858/intrexon-signs-licensing-agreement-with-next-green-wave?cid=CS-BENZ-FT-347858,Zacks,,,,,,
2019-01-16T08:00:00.000+08:00,Hospitals squeezed by high drug costs,LLY,https://seekingalpha.com/news/3423552-hospitals-squeezed-high-drug-costs?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-16T08:00:00.000+08:00,Biopharma firms under pressure on Brexit uncertainty,LLY,https://seekingalpha.com/news/3423533-biopharma-firms-pressure-brexit-uncertainty?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-16T08:00:00.000+08:00,6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019,LLY,http://www.zacks.com/stock/news/347690/6-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2019?cid=CS-BENZ-FT-347690,Zacks,,,,,,
2019-01-17T08:00:00.000+08:00,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly,LLY,https://www.benzinga.com/news/19/01/13003543/zymeworks-to-receive-an-8m-milestone-payment-from-eli-lilly,Benzinga Newsdesk,,,,,,
2019-01-17T08:00:00.000+08:00,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform,LLY,https://www.benzinga.com/general/biotech/19/01/12998311/eli-lilly-and-ablexis-announces-expansion-of-non-exclusive-perpetual-,Benzinga Newsdesk,,,,,,
2019-01-17T08:00:00.000+08:00,Ligand (LGND) Takes a Hit on Citron's Negative Research Report,LLY,http://www.zacks.com/stock/news/348173/ligand-lgnd-takes-a-hit-on-citrons-negative-research-report?cid=CS-BENZ-FT-348173,Zacks,,,,,,
2019-01-17T08:00:00.000+08:00,Eli Lilly: An Update,LLY,https://seekingalpha.com/article/4233901-eli-lilly-update?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-18T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/01/13006253/eli-lilly-shares-are-trading-lower-after-the-company-announced-the-phase,Hal Lindon,,,,,,
2019-01-18T08:00:00.000+08:00,40 Stocks Moving In Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/13005824/40-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,,,
2019-01-18T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",LLY,https://www.benzinga.com/general/biotech/19/01/13004869/the-daily-biotech-pulse-regulatory-roadblock-for-immunomedics-adcom-s,Shanthi Rexaline,,,,,,
2019-01-18T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/19/01/13005404/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,,,
2019-01-18T08:00:00.000+08:00,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint,LLY,https://www.benzinga.com/news/19/01/13005262/eli-lillys-phase-3-study-of-lartruvo-did-not-meet-its-primary-endpoint,Benzinga Newsdesk,,,,,,
2019-01-18T08:00:00.000+08:00,Realty Income: Halftime Report,LLY,https://seekingalpha.com/article/4234336-realty-income-halftime-report?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-18T08:00:00.000+08:00,Eli Lilly to stop promoting Lartruvo after Phase 3 flop; shares down 3%,LLY,https://seekingalpha.com/news/3424279-eli-lilly-stop-promoting-lartruvo-phase-3-flop-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-18T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY",LLY,http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-BENZ-FT-348355,Zacks,,,,,,
2019-01-18T08:00:00.000+08:00,Lilly's olaratumab flunks late-stage soft tissue sarcoma study,LLY,https://seekingalpha.com/news/3424174-lillys-olaratumab-flunks-late-stage-soft-tissue-sarcoma-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-18T08:00:00.000+08:00,Zymeworks earns $8M milestone from licensee Lilly,LLY,https://seekingalpha.com/news/3424166-zymeworks-earns-8m-milestone-licensee-lilly?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-22T08:00:00.000+08:00,Johnson & Johnson Shares Fall on Disappointing —…–9 Outlook,LLY,http://www.gurufocus.com/news/803452/johnson--johnson-shares-fall-on-disappointing-2019-outlook-,GuruFocus,,,,,,
2019-01-22T08:00:00.000+08:00,"Company News For Jan 22, 2019",LLY,http://www.zacks.com/stock/news/348839/company-news-for-jan-22-2019?cid=CS-BENZ-FT-348839,Zacks,,,,,,
2019-01-23T08:00:00.000+08:00,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life,LLY,https://www.benzinga.com/general/biotech/19/01/13023766/european-medicines-agency-says-no-new-patients-should-start-treatment,Benzinga Newsdesk,,,,,,
2019-01-23T08:00:00.000+08:00,UBS Initiates Coverage On Eli Lilly with Buy Rating,LLY,https://www.benzinga.com/news/19/01/13023247/ubs-initiates-coverage-on-eli-lilly-with-buy-rating,Benzinga_Newsdesk,,,,,,
2019-01-23T08:00:00.000+08:00,5 Best Biotech Bets Likely to Outperform Estimates in Q4,LLY,http://www.zacks.com/stock/news/349155/5-best-biotech-bets-likely-to-outperform-estimates-in-q4?cid=CS-BENZ-FT-349155,Zacks,,,,,,
2019-01-23T08:00:00.000+08:00,UBS likes Lilly in premarket analyst action,LLY,https://seekingalpha.com/news/3425002-ubs-likes-lilly-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-23T08:00:00.000+08:00,6 Stocks to Prepare for a Global Economic Slowdown,LLY,http://www.zacks.com/stock/news/348943/6-stocks-to-prepare-for-a-global-economic-slowdown?cid=CS-BENZ-FT-348943,Zacks,,,,,,
2019-01-23T08:00:00.000+08:00,Teva up 3% premarket on bullish call at UBS,LLY,https://seekingalpha.com/news/3425050-teva-3-percent-premarket-bullish-call-ubs?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-23T08:00:00.000+08:00,Treatment with Lilly's Lartruvo to cease in Europe,LLY,https://seekingalpha.com/news/3425041-treatment-lillys-lartruvo-cease-europe?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-23T08:00:00.000+08:00,Insulin costs in U.S. doubled from 2012 - 2016,LLY,https://seekingalpha.com/news/3424992-insulin-costs-u-s-doubled-2012-2016?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-24T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13036569,TalkMarkets,,,,,,
2019-01-24T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13033560,TalkMarkets,,,,,,
2019-01-24T08:00:00.000+08:00,Early Q4 reports weigh on large cap drug makers,LLY,https://seekingalpha.com/news/3425685-early-q4-reports-weigh-large-cap-drug-makers?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-24T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston",LLY,http://www.zacks.com/stock/news/349486/the-zacks-analyst-blog-highlights-archer-daniels-midland-molina-healthcare-eli-lilly-spark-energy-and-lamb-weston?cid=CS-BENZ-FT-349486,Zacks,,,,,,
2019-01-24T08:00:00.000+08:00,Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids,LLY,http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-BENZ-FT-349470,Zacks,,,,,,
2019-01-25T08:00:00.000+08:00,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG",LLY,https://www.benzinga.com/news/19/01/13041549/cvs-says-puts-new-migraine-drugs-from-teva-and-eli-lilly-on-list-of-covered-medi,Benzinga Newsdesk,,,,,,
2019-01-25T08:00:00.000+08:00,Amgen's Aimovig reportedly excluded from CVS plans,LLY,https://seekingalpha.com/news/3426166-amgens-aimovig-reportedly-excluded-cvs-plans?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-25T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV",LLY,http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-BENZ-FT-349786,Zacks,,,,,,
2019-01-25T08:00:00.000+08:00,Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds,LLY,http://www.zacks.com/stock/news/349760/merck-kgaa-gives-vertex-rights-to-two-gene-editing-compounds?cid=CS-BENZ-FT-349760,Zacks,,,,,,
2019-01-27T08:00:00.000+08:00,AbbVie: Not Driving Via The Rearview Mirror,LLY,https://seekingalpha.com/article/4235824-abbvie-driving-via-rearview-mirror?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-28T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus",LLY,https://www.benzinga.com/news/19/01/13045164/a-peek-into-the-markets-us-stock-futures-down-caterpillar-earnings-in-focus,Lisa Levin,,,,,,
2019-01-28T08:00:00.000+08:00,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions,LLY,https://www.benzinga.com/news/19/01/13045031/111-and-eli-lilly-to-collaborate-on-pharmaceutical-distribution-with-a-focus-on-,Benzinga Newsdesk,,,,,,
2019-01-28T08:00:00.000+08:00,Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/350151/dr-reddys-rdy-to-report-q3-earnings-whats-in-store?cid=CS-BENZ-FT-350151,Zacks,,,,,,
2019-01-28T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update,LLY,https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-28T08:00:00.000+08:00,Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results,LLY,http://www.zacks.com/stock/news/350112/allergan-hikes-quarterly-dividend-by-28-ahead-of-q4-results?cid=CS-BENZ-FT-350112,Zacks,,,,,,
2019-01-28T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck",LLY,http://www.zacks.com/stock/news/350036/the-zacks-analyst-blog-highlights-jj-bristol-myers-lilly-abbvie-and-merck?cid=CS-BENZ-FT-350036,Zacks,,,,,,
2019-01-29T08:00:00.000+08:00,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks,LLY,https://www.benzinga.com/general/biotech/19/01/13053531/pfizer-and-lilly-announce-second-phase-3-study-of-tanezumab-in-osteoa,Benzinga Newsdesk,,,,,,
2019-01-29T08:00:00.000+08:00,Tiny Israeli firm touts cancer cure,LLY,https://seekingalpha.com/news/3427030-tiny-israeli-firm-touts-cancer-cure?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-29T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/350252/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-350252,Zacks,,,,,,
2019-01-29T08:00:00.000+08:00,Pfizer and Lilly's tanezumab successful in second late-stage study,LLY,https://seekingalpha.com/news/3426829-pfizer-lillys-tanezumab-successful-second-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-30T08:00:00.000+08:00,Stocks Going Ex-Dividend In February 2019,LLY,https://www.benzinga.com/node/13069106,TalkMarkets,,,,,,
2019-01-31T08:00:00.000+08:00,"Earnings, Volatility, Brexit Are Key Topics Heading Into February",LLY,https://www.benzinga.com/government/19/01/13077426/earnings-volatility-brexit-are-key-topics-heading-into-february,JJ Kinahan,,,,,,
2019-01-31T08:00:00.000+08:00,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer",LLY,https://www.benzinga.com/news/19/01/13071823/eli-lilly-reports-fda-expanded-alimtas-label-to-combine-keytruda-platinum-chemot,Benzinga Newsdesk,,,,,,
2019-01-31T08:00:00.000+08:00,J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study,LLY,http://www.zacks.com/stock/news/351417/jjs-erleada-meets-both-primary-endpoints-in-late-stage-study?cid=CS-BENZ-FT-351417,Zacks,,,,,,
2019-01-31T08:00:00.000+08:00,Entera Bio advancing osteoporosis candidate EB-613; shares up 3%,LLY,https://seekingalpha.com/news/3428239-entera-bio-advancing-osteoporosis-candidate-ebminus-613-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-31T08:00:00.000+08:00,Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?,LLY,http://www.zacks.com/stock/news/351124/eli-lilly-lly-q4-earnings-coming-up-whats-in-the-cards?cid=CS-BENZ-FT-351124,Zacks,,,,,,
2019-01-31T08:00:00.000+08:00,FDA OKs new use for Lilly's Alimta,LLY,https://seekingalpha.com/news/3428023-fda-oks-new-use-lillys-alimta?source=partner_benzinga,Seeking Alpha,,,,,,
2019-01-31T08:00:00.000+08:00,Another Alzheimer's Antibody Fails. There Will Be More,LLY,https://seekingalpha.com/article/4236924-another-alzheimers-antibody-fails-will?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-01T08:00:00.000+08:00,Trump At State Of The Union Will Ask For Drug Pricing Cuts,LLY,https://www.benzinga.com/news/19/02/13086160/trump-at-state-of-the-union-will-ask-for-drug-pricing-cuts,Benzinga Newsdesk,,,,,,
2019-02-01T08:00:00.000+08:00,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva",LLY,https://www.benzinga.com/general/health-care/19/02/13083644/optum-to-cover-amgen-eli-lilly-migraine-drugs-exclude-teva,Benzinga Newsdesk,,,,,,
2019-02-01T08:00:00.000+08:00,Pharma Catches Another Case Of M&A Fever,LLY,https://www.benzinga.com/general/biotech/19/02/13083455/pharma-catches-another-case-of-m-a-fever,Chris Dier-Scalise,,,,,,
2019-02-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant",LLY,https://www.benzinga.com/general/biotech/19/02/13080524/the-daily-biotech-pulse-merck-earnings-positive-relaunch-of-titans-op,Shanthi Rexaline,,,,,,
2019-02-01T08:00:00.000+08:00,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal",LLY,https://www.benzinga.com/news/19/02/13081295/eli-lilly-loxo-oncology-reports-expiration-of-hart-scott-rodino-antitrust-act-wa,Benzinga Newsdesk,,,,,,
2019-02-01T08:00:00.000+08:00,"Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-351653,Zacks,,,,,,
2019-02-01T08:00:00.000+08:00,"UnitedHealth's Optum to cover Amgen and Lilly migraine meds, Teva excluded",LLY,https://seekingalpha.com/news/3428735-unitedhealths-optum-cover-amgen-lilly-migraine-meds-teva-excluded?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-01T08:00:00.000+08:00,"Lilly (LLY) Hits 52-Week High, Can the Run Continue?",LLY,http://www.zacks.com/stock/news/351514/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-BENZ-FT-351514,Zacks,,,,,,
2019-02-01T08:00:00.000+08:00,"Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY",LLY,http://www.zacks.com/stock/news/351448/pharma-stock-roundup-q4-earnings-pipeline-updates-at-pfe-rhhby?cid=CS-BENZ-FT-351448,Zacks,,,,,,
2019-02-04T08:00:00.000+08:00,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints,LLY,https://www.benzinga.com/news/19/02/13089677/eli-lilly-announces-two-phase-3-trials-of-baricitinib-met-their-primary-endpoint,Benzinga Newsdesk,,,,,,
2019-02-04T08:00:00.000+08:00,Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy,LLY,http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-BENZ-FT-351848,Zacks,,,,,,
2019-02-04T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 4, 2019",LLY,https://seekingalpha.com/article/4237780-merger-arbitrage-mondays-february-4-2019?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/19/02/13098290/the-daily-biotech-pulse-gilead-earnings-codexis-sings-pact-with-merck,Shanthi Rexaline,,,,,,
2019-02-05T08:00:00.000+08:00,Selling Roche: Sector And Company-Specific Reasons,LLY,https://seekingalpha.com/article/4238279-selling-roche-sector-company-specific-reasons?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-05T08:00:00.000+08:00,Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer,LLY,http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-BENZ-FT-352085,Zacks,,,,,,
2019-02-05T08:00:00.000+08:00,Roche Submits sBLA to FDA for Label Expansion of Kadcyla,LLY,http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-BENZ-FT-352051,Zacks,,,,,,
2019-02-05T08:00:00.000+08:00,Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies,LLY,http://www.zacks.com/stock/news/351997/lilly-incytes-olumiant-meets-endpoint-in-eczema-studies?cid=CS-BENZ-FT-351997,Zacks,,,,,,
2019-02-05T08:00:00.000+08:00,Lilly's baricitinib successful in late-stage dermatitis studies,LLY,https://seekingalpha.com/news/3429471-lillys-baricitinib-successful-late-stage-dermatitis-studies?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed",LLY,https://www.benzinga.com/news/earnings/19/02/13111084/after-state-of-the-union-focus-turns-again-to-earnings-news-geopolitics,JJ Kinahan,,,,,,
2019-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",LLY,https://www.benzinga.com/general/biotech/19/02/13108115/the-daily-biotech-pulse-paratek-launches-antibiotic-in-us-eli-lilly-e,Shanthi Rexaline,,,,,,
2019-02-06T08:00:00.000+08:00,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est,LLY,https://www.benzinga.com/news/earnings/19/02/13108640/eli-lilly-guides-fy19-eps-of-5-55-5-65-vs-5-77-est-lowers-fy19-revenue-,Benzinga_Newsdesk,,,,,,
2019-02-06T08:00:00.000+08:00,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est.",LLY,https://www.benzinga.com/news/earnings/19/02/13108626/lilly-reports-q4-1-33share-vs-1-34-est-reports-q4-revenues-of-6-438-bln,Benzinga_Newsdesk,,,,,,
2019-02-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/earnings/19/02/13108605/a-peek-into-the-markets-us-stock-futures-down-ahead-of-earnings,Lisa Levin,,,,,,
2019-02-06T08:00:00.000+08:00,"13 Stocks To Watch For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108221/13-stocks-to-watch-for-february-6-2019,Lisa Levin,,,,,,
2019-02-06T08:00:00.000+08:00,"Earnings Scheduled For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108178/earnings-scheduled-for-february-6-2019,Lisa Levin,,,,,,
2019-02-06T08:00:00.000+08:00,This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag,LLY,http://www.investors.com/research/ibd-industry-themes/eli-lilly-earnings-eli-lilly-stock-glaxo-earnings-q4-2018/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-02-06T08:00:00.000+08:00,Array: Poised For Growth,LLY,https://seekingalpha.com/article/4238737-array-poised-growth?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,Lilly bails on BTK inhibitor LY3337641,LLY,https://seekingalpha.com/news/3430381-lilly-bails-btk-inhibitor-ly3337641?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,"Elanco down 5% after Q4 report, Lilly plan to divest remaining shares",LLY,https://seekingalpha.com/news/3430266-elanco-5-percent-q4-report-lilly-plan-divest-remaining-shares?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,"Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down",LLY,http://www.zacks.com/stock/news/352494/lilly-lly-lags-q4-earnings-lowers-2019-view-stock-down?cid=CS-BENZ-FT-352494,Zacks,,,,,,
2019-02-06T08:00:00.000+08:00,"Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View",LLY,http://www.zacks.com/stock/news/352407/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view?cid=CS-BENZ-FT-352407,Zacks,,,,,,
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company 2018 Q4 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4238540-eli-lilly-company-2018-q4-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-06T08:00:00.000+08:00,"Eli Lilly misses by $0.01, beats on revenue",LLY,https://seekingalpha.com/news/3430040-eli-lilly-misses-0_01-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-07T08:00:00.000+08:00,Vertex: Shareholders Might Have Reason To Breathe More Easily,LLY,https://seekingalpha.com/article/4239272-vertex-shareholders-might-reason-breathe-easily?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-07T08:00:00.000+08:00,Is Big Pharma Poised For A 2019 Buying Spree In Biotech Stocks?,LLY,http://www.investors.com/research/industry-snapshot/biotech-stocks-pharmaceutical-companies/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-02-07T08:00:00.000+08:00,Array BioPharma: Fairly Valued After Q2 Report,LLY,https://seekingalpha.com/article/4239030-array-biopharma-fairly-valued-q2-report?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-07T08:00:00.000+08:00,"Stock Market News For Feb 7, 2019",LLY,http://www.zacks.com/stock/news/352868/stock-market-news-for-feb-7-2019?cid=CS-BENZ-FT-352868,Zacks,,,,,,
2019-02-08T08:00:00.000+08:00,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health,LLY,https://www.benzinga.com/news/19/02/13127520/eli-lilly-reports-will-initiate-divestiture-of-its-remaining-interest-in-elanco-,Benzinga Newsdesk,,,,,,
2019-02-08T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13133347,TalkMarkets,,,,,,
2019-02-08T08:00:00.000+08:00,Incyte Down as FDA Extends Review Period of Jakafi for GVHD,LLY,http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-BENZ-FT-353405,Zacks,,,,,,
2019-02-08T08:00:00.000+08:00,Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition,LLY,https://seekingalpha.com/article/4239475-lilly-q4-looking-low-verzenio-sales-loxo-oncology-acquisition?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-08T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13131230,TalkMarkets,,,,,,
2019-02-08T08:00:00.000+08:00,The Diabetes Landscape Is Changing — Can This Stock Lead The Pack?,LLY,http://www.investors.com/research/the-new-america/diabetes-treatment-dexcom-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-02-08T08:00:00.000+08:00,Lilly launches exchange offer for Elanco shares,LLY,https://seekingalpha.com/news/3431261-lilly-launches-exchange-offer-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 11",LLY,https://www.benzinga.com/node/13144295,TalkMarkets,,,,,,
2019-02-11T08:00:00.000+08:00,Alkermes Is Still An Attractive Pick,LLY,https://seekingalpha.com/article/4239938-alkermes-still-attractive-pick?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-11T08:00:00.000+08:00,Regeneron: Cheap Enough To Look Past The Eylea Valley,LLY,https://seekingalpha.com/article/4239839-regeneron-cheap-enough-look-past-eylea-valley?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-11T08:00:00.000+08:00,Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake,LLY,http://www.zacks.com/stock/news/353577/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake?cid=CS-BENZ-FT-353577,Zacks,,,,,,
2019-02-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13155620,TalkMarkets,,,,,,
2019-02-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13152044,TalkMarkets,,,,,,
2019-02-12T08:00:00.000+08:00,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials,LLY,https://seekingalpha.com/news/3432086-boehringer-ingelheim-teams-ibm-explore-use-blockchain-clinical-trials?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-13T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13167628,TalkMarkets,,,,,,
2019-02-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13163977,TalkMarkets,,,,,,
2019-02-13T08:00:00.000+08:00,5 Tiny Biotech Stocks With Superb Growth Potential,LLY,http://www.zacks.com/stock/news/354140/5-tiny-biotech-stocks-with-superb-growth-potential?cid=CS-BENZ-FT-354140,Zacks,,,,,,
2019-02-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019",LLY,https://www.benzinga.com/news/19/02/13176454/stocks-trading-ex-dividend-for-thurs-feb-14-2019,Benzinga Newsdesk,,,,,,
2019-02-14T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'",LLY,https://www.benzinga.com/news/19/02/13170784/eli-lilly-boehringer-ingelheim-report-carolina-trial-of-tradjenta-met-primary-en,Benzinga Newsdesk,,,,,,
2019-02-14T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13182578,TalkMarkets,,,,,,
2019-02-14T08:00:00.000+08:00,"Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-354853,Zacks,,,,,,
2019-02-14T08:00:00.000+08:00,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings,LLY,http://www.zacks.com/stock/news/354851/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings?cid=CS-BENZ-FT-354851,Zacks,,,,,,
2019-02-14T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13177411,TalkMarkets,,,,,,
2019-02-14T08:00:00.000+08:00,"Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down",LLY,http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-BENZ-FT-354559,Zacks,,,,,,
2019-02-14T08:00:00.000+08:00,Eli Lilly and Boehringer Ingelheim's Tradjenta successful in CV outcomes study,LLY,https://seekingalpha.com/news/3433257-eli-lilly-boehringer-ingelheims-tradjenta-successful-cv-outcomes-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-15T08:00:00.000+08:00,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both",LLY,https://www.benzinga.com/general/biotech/19/02/13188321/bayer-to-obtain-full-rights-to-global-development-and-commercializati,Benzinga Newsdesk,,,,,,
2019-02-15T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 15",LLY,https://www.benzinga.com/node/13192791,TalkMarkets,,,,,,
2019-02-15T08:00:00.000+08:00,FDA creates new accelerated review pathway for generic drug applications,LLY,https://seekingalpha.com/news/3433986-fda-creates-new-accelerated-review-pathway-generic-drug-applications?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-15T08:00:00.000+08:00,Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/355111/alkermes-alks-q4-earnings-revenues-surpass-estimates?cid=CS-BENZ-FT-355111,Zacks,,,,,,
2019-02-15T08:00:00.000+08:00,Bayer in-licenses Loxo's Vitrakvi and LOXO-195,LLY,https://seekingalpha.com/news/3433965-bayer-licenses-loxos-vitrakvi-loxominus-195?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-15T08:00:00.000+08:00,Lilly finalizes Loxo buy,LLY,https://seekingalpha.com/news/3433947-lilly-finalizes-loxo-buy?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-15T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/355011/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-355011,Zacks,,,,,,
2019-02-18T08:00:00.000+08:00,Novo Nordisk: Solid Performance Marred By Currency Fluctuations,LLY,https://seekingalpha.com/article/4241865-novo-nordisk-solid-performance-marred-currency-fluctuations?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-18T08:00:00.000+08:00,How To Retire: Kill The TV,LLY,https://seekingalpha.com/article/4241728-retire-kill-tv?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable,LLY,https://www.benzinga.com/news/19/02/13203173/s-p-downgrades-eli-lilly-credit-rating-from-aa-to-a-outlook-raised-from-credit-w,Benzinga Newsdesk,,,,,,
2019-02-19T08:00:00.000+08:00,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/19/02/13202602/eli-lilly-files-for-mixed-shelf-offering-size-not-disclosed,Benzinga Newsdesk,,,,,,
2019-02-19T08:00:00.000+08:00,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018",LLY,https://www.benzinga.com/news/19/02/13201130/eli-lilly-10-k-just-recently-out-1-highlight-co-employed-38-680-employees-at-end,Benzinga Newsdesk,,,,,,
2019-02-19T08:00:00.000+08:00,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports",LLY,https://www.benzinga.com/general/biotech/19/02/13200385/supreme-court-rejects-marylands-bid-to-revive-a-law-aimed-at-preventi,Benzinga Newsdesk,,,,,,
2019-02-19T08:00:00.000+08:00,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/19/02/13197642/pfizer-and-lilly-announce-top-line-results-from-phase-3-study-of-tane,Benzinga Newsdesk,,,,,,
2019-02-19T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13204775,TalkMarkets,,,,,,
2019-02-19T08:00:00.000+08:00,Lilly files for mixed shelf offering,LLY,https://seekingalpha.com/news/3434620-lilly-files-mixed-shelf-offering?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,Lilly wins review of Teva migraine patents in U.S.,LLY,https://seekingalpha.com/news/3434551-lilly-wins-review-teva-migraine-patents-u-s?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,Maryland strikes out in reviving drug price-gouging law,LLY,https://seekingalpha.com/news/3434544-maryland-strikes-reviving-drug-price-gouging-law?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13202013,TalkMarkets,,,,,,
2019-02-19T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 18, 2019",LLY,https://seekingalpha.com/article/4242039-merger-arbitrage-mondays-february-18-2019?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo,LLY,http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-BENZ-FT-355437,Zacks,,,,,,
2019-02-19T08:00:00.000+08:00,Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why,LLY,http://www.zacks.com/stock/news/355423/mercks-mrk-stock-up-almost-50-in-a-year-heres-why?cid=CS-BENZ-FT-355423,Zacks,,,,,,
2019-02-19T08:00:00.000+08:00,Lilly and Pfizer's tanezumab successful in late-stage back pain study,LLY,https://seekingalpha.com/news/3434316-lilly-pfizers-tanezumab-successful-late-stage-back-pain-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-19T08:00:00.000+08:00,Teva: Reasons To Avoid It In Favor Of Innovative Biotechs,LLY,https://seekingalpha.com/article/4242001-teva-reasons-avoid-favor-innovative-biotechs?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-20T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13213916,TalkMarkets,,,,,,
2019-02-20T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13211402,TalkMarkets,,,,,,
2019-02-20T08:00:00.000+08:00,Allergan Responds to Investor's Call for CEO/Chair Role Split,LLY,http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-BENZ-FT-355578,Zacks,,,,,,
2019-02-20T08:00:00.000+08:00,Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study,LLY,http://www.zacks.com/stock/news/355538/pfizer-lillys-pain-candidate-succeeds-in-back-pain-study?cid=CS-BENZ-FT-355538,Zacks,,,,,,
2019-02-21T08:00:00.000+08:00,Merck To Buy Immune Design For $300M,LLY,https://www.benzinga.com/general/biotech/19/02/13218686/merck-to-buy-immune-design-for-300m,Shanthi Rexaline,,,,,,
2019-02-21T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13223942,TalkMarkets,,,,,,
2019-02-21T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13220998,TalkMarkets,,,,,,
2019-02-21T08:00:00.000+08:00,Philip Morris International: Halftime Report,LLY,https://seekingalpha.com/article/4242862-philip-morris-international-halftime-report?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-21T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/356081/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-356081,Zacks,,,,,,
2019-02-21T08:00:00.000+08:00,U.S. healthcare spending to rise 5.5% per annum over next decade,LLY,https://seekingalpha.com/news/3435547-u-s-healthcare-spending-rise-5_5-percent-per-annum-next-decade?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-22T08:00:00.000+08:00,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi",LLY,https://www.benzinga.com/news/19/02/13230342/us-senate-finance-committee-launches-bipartisan-investigation-into-rising-insuli,Benzinga Newsdesk,,,,,,
2019-02-22T08:00:00.000+08:00,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",LLY,https://www.benzinga.com/general/biotech/19/02/13225988/the-daily-biotech-pulse-biomarin-slips-on-earnings-therapeuticsmd-pos,Shanthi Rexaline,,,,,,
2019-02-22T08:00:00.000+08:00,Merck to Buy Immunotherapy Developer Immune Design for $300M,LLY,http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-BENZ-FT-356654,Zacks,,,,,,
2019-02-22T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb 22",LLY,https://www.benzinga.com/node/13230648,TalkMarkets,,,,,,
2019-02-22T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates",LLY,http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-BENZ-FT-356445,Zacks,,,,,,
2019-02-22T08:00:00.000+08:00,"New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, ...",LLY,http://www.gurufocus.com/news/820916/new-research-coverage-highlights-fedex-honeywell-international-nielsen-holdings-plc-changyou-jb-hunt-transport-services-and-eli-lilly--consolidated-revenues-company-growth-and-expectations-for-2019,GuruFocus,,,,,,
2019-02-22T08:00:00.000+08:00,"Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review",LLY,http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-BENZ-FT-356394,Zacks,,,,,,
2019-02-24T08:00:00.000+08:00,"Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers",LLY,http://www.gurufocus.com/news/821833/biogen-biomarin-lilly-and-bristolmyers-could-be-in-crosshairs-of-acquirers,GuruFocus,,,,,,
2019-02-25T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13240623,TalkMarkets,,,,,,
2019-02-25T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13238053,TalkMarkets,,,,,,
2019-02-25T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft",LLY,http://www.zacks.com/stock/news/356845/the-zacks-analyst-blog-highlights-walmart-pfizer-eli-lilly-merck-and-microsoft?cid=CS-BENZ-FT-356845,Zacks,,,,,,
2019-02-25T08:00:00.000+08:00,According To Sources: Scandal In The Chicken And Pork Industries (Podcast),LLY,https://seekingalpha.com/article/4243811-according-sources-scandal-chicken-pork-industries-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-26T08:00:00.000+08:00,FDA rejects Adamis Pharma's application for sublingual tadalafil; shares down 13% after hours,LLY,https://seekingalpha.com/news/3437549-fda-rejects-adamis-pharmas-application-sublingual-tadalafil-shares-13-percent-hours?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-26T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13251186,TalkMarkets,,,,,,
2019-02-26T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13248215,TalkMarkets,,,,,,
2019-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",LLY,https://www.benzinga.com/general/biotech/19/02/13254225/the-daily-biotech-pulse-fda-panel-vote-sinks-karyopharm-refuse-to-fil,Shanthi Rexaline,,,,,,
2019-02-27T08:00:00.000+08:00,Eli Lilly and Company (LLY) Management Presents at Leerink Partners Global Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4244976-eli-lilly-company-lly-management-presents-leerink-partners-global-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-27T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13261452,TalkMarkets,,,,,,
2019-02-27T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13258484,TalkMarkets,,,,,,
2019-02-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",LLY,https://www.benzinga.com/general/biotech/19/02/13265063/the-daily-biotech-pulse-bristol-myers-squibb-celgene-deal-faces-setba,Shanthi Rexaline,,,,,,
2019-02-28T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13273507,TalkMarkets,,,,,,
2019-02-28T08:00:00.000+08:00,Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates,LLY,http://www.zacks.com/stock/news/357341/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates?cid=CS-BENZ-FT-357341,Zacks,,,,,,
2019-02-28T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13270080,TalkMarkets,,,,,,
2019-02-28T08:00:00.000+08:00,Pfenex expands PF708 deal with Alvogen,LLY,https://seekingalpha.com/news/3438575-pfenex-expands-pf708-deal-alvogen?source=partner_benzinga,Seeking Alpha,,,,,,
2019-02-28T08:00:00.000+08:00,United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates,LLY,http://www.zacks.com/stock/news/357300/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-BENZ-FT-357300,Zacks,,,,,,
2019-03-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",LLY,https://www.benzinga.com/general/biotech/19/03/13276510/the-daily-biotech-pulse-puma-biotech-earnings-mersana-offering-orphan,Shanthi Rexaline,,,,,,
2019-03-01T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, March 1",LLY,https://www.benzinga.com/node/13284656,TalkMarkets,,,,,,
2019-03-01T08:00:00.000+08:00,Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/357476/radius-rdus-posts-narrower-q4-loss-on-robust-tymlos-sales?cid=CS-BENZ-FT-357476,Zacks,,,,,,
2019-03-01T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, March 1",LLY,https://www.benzinga.com/node/13281376,TalkMarkets,,,,,,
2019-03-01T08:00:00.000+08:00,Dividend Champions For March 2019,LLY,https://seekingalpha.com/article/4245611-dividend-champions-march-2019?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-04T08:00:00.000+08:00,Eli Lilly Announces the Launch of Lower Priced Insulin,LLY,https://www.benzinga.com/news/19/03/13287406/eli-lilly-announces-the-launch-of-lower-priced-insulin,Benzinga Newsdesk,,,,,,
2019-03-04T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 4",LLY,https://www.benzinga.com/node/13294376,TalkMarkets,,,,,,
2019-03-04T08:00:00.000+08:00,"\"Senate committee \"\"looking into\"\" high insulin prices\"",LLY,https://seekingalpha.com/news/3439568-senate-committee-looking-high-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-04T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 4",LLY,https://www.benzinga.com/node/13291619,TalkMarkets,,,,,,
2019-03-04T08:00:00.000+08:00,Lilly to launch lower-priced insulin in U.S.,LLY,https://seekingalpha.com/news/3439383-lilly-launch-lower-priced-insulin-u-s?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-05T08:00:00.000+08:00,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/03/13297342/lilly-receives-fda-priority-review-designation-for-emgality-injection-for-the-pr,Benzinga Newsdesk,,,,,,
2019-03-05T08:00:00.000+08:00,"If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?",LLY,https://seekingalpha.com/article/4246517-celgene-deal-fails-buy-bristol-myers-squibb?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-05T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 5",LLY,https://www.benzinga.com/node/13304453,TalkMarkets,,,,,,
2019-03-05T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 5",LLY,https://www.benzinga.com/node/13301692,TalkMarkets,,,,,,
2019-03-05T08:00:00.000+08:00,Lilly to Bring Half-Priced Version of Popular Humalog Insulin,LLY,http://www.zacks.com/stock/news/357718/lilly-to-bring-half-priced-version-of-popular-humalog-insulin?cid=CS-BENZ-FT-357718,Zacks,,,,,,
2019-03-05T08:00:00.000+08:00,Lilly nabs accelerated review for Emgality injection,LLY,https://seekingalpha.com/news/3439731-lilly-nabs-accelerated-review-emgality-injection?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-06T08:00:00.000+08:00,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary",LLY,https://www.benzinga.com/general/health-care/19/03/13312083/cigna-says-in-discussions-with-lilly-about-humalog-authorized-alt,Benzinga Newsdesk,,,,,,
2019-03-06T08:00:00.000+08:00,FDA Approves Major Novel Depression Drug For First Time In 3 Decades,LLY,https://www.benzinga.com/general/biotech/19/03/13309108/fda-approves-major-novel-depression-drug-for-first-time-in-3-decades,Shanthi Rexaline,,,,,,
2019-03-06T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, March 6",LLY,https://www.benzinga.com/node/13313973,TalkMarkets,,,,,,
2019-03-06T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 6",LLY,https://www.benzinga.com/node/13311573,TalkMarkets,,,,,,
2019-03-06T08:00:00.000+08:00,J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression,LLY,http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-BENZ-FT-357836,Zacks,,,,,,
2019-03-07T08:00:00.000+08:00,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco,LLY,https://www.benzinga.com/news/19/03/13316398/eli-lilly-reports-final-exchange-ratio-of-4-5121-shares-for-elanco,Benzinga Newsdesk,,,,,,
2019-03-07T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, March 7",LLY,https://www.benzinga.com/node/13323125,TalkMarkets,,,,,,
2019-03-07T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, March 7",LLY,https://www.benzinga.com/node/13320531,TalkMarkets,,,,,,
2019-03-07T08:00:00.000+08:00,Xeris: Looking For Entry Before PDUFA,LLY,https://seekingalpha.com/article/4246895-xeris-looking-entry-pdufa?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-07T08:00:00.000+08:00,"Allergan's Depression Candidate Fails in Studies, Stock Down",LLY,http://www.zacks.com/stock/news/358070/allergans-depression-candidate-fails-in-studies-stock-down?cid=CS-BENZ-FT-358070,Zacks,,,,,,
2019-03-07T08:00:00.000+08:00,Lilly announces final exchange offering for Elanco shares,LLY,https://seekingalpha.com/news/3440638-lilly-announces-final-exchange-offering-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-08T08:00:00.000+08:00,"Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",LLY,http://www.zacks.com/stock/news/358431/pharma-stock-roundup-fda-oks-jj-antidepressant-chmp-recommends-several-drugs?cid=CS-BENZ-FT-358431,Zacks,,,,,,
2019-03-08T08:00:00.000+08:00,"Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review",LLY,https://seekingalpha.com/article/4247372-biotech-analysis-central-pharma-news-evokes-mishap-immunogens-struggle-eli-lillys-priority?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-08T08:00:00.000+08:00,"Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat",LLY,http://www.zacks.com/stock/news/358423/celldex-cldx-q4-loss-narrower-than-expected-sales-beat?cid=CS-BENZ-FT-358423,Zacks,,,,,,
2019-03-08T08:00:00.000+08:00,Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/358352/lilly-lly-up-75-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-358352,Zacks,,,,,,
2019-03-11T08:00:00.000+08:00,Elanco Animal Health Begins Trading After Eli Lilly Split,LLY,https://www.benzinga.com/news/19/03/13335982/elanco-animal-health-begins-trading-after-eli-lilly-split,Jayson Derrick,,,,,,
2019-03-11T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents at Cowen and Company 39th Annual Health Care Conference (Transcript),LLY,https://seekingalpha.com/article/4247895-eli-lilly-company-lly-presents-cowen-company-39th-annual-health-care-conference-transcript?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 11",LLY,https://www.benzinga.com/node/13339349,TalkMarkets,,,,,,
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336924,TalkMarkets,,,,,,
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336925,TalkMarkets,,,,,,
2019-03-12T08:00:00.000+08:00,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/03/13344113/eli-lilly-could-sustain-industry-leading-growth-says-bu,Priya Nigam,,,,,,
2019-03-12T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",LLY,https://www.benzinga.com/general/biotech/19/03/13341010/the-daily-biotech-pulse-zafgen-wont-file-ind-for-metabolic-disorder-d,Shanthi Rexaline,,,,,,
2019-03-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/03/13341449/lilly-announces-cyramza-phase-3-relay-trial-met-primary-endpoint-in-p,Benzinga Newsdesk,,,,,,
2019-03-12T08:00:00.000+08:00,Eli Lilly (LLY) Flat As Market Gains: What You Should Know,LLY,http://www.zacks.com/stock/news/359060/eli-lilly-lly-flat-as-market-gains-what-you-should-know?cid=CS-BENZ-FT-359060,Zacks,,,,,,
2019-03-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 12",LLY,https://www.benzinga.com/node/13347950,TalkMarkets,,,,,,
2019-03-12T08:00:00.000+08:00,Trump 2020 drug pricing initiatives - part 2,LLY,https://seekingalpha.com/news/3441977-trump-2020-drug-pricing-initiatives-part-2?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-12T08:00:00.000+08:00,Trump aiming to rein in drug cost with range of proposals,LLY,https://seekingalpha.com/news/3441957-trump-aiming-rein-drug-cost-range-proposals?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 12",LLY,https://www.benzinga.com/node/13345182,TalkMarkets,,,,,,
2019-03-12T08:00:00.000+08:00,Allergan Announces FDA Acceptance of Migraine Candidate NDA,LLY,http://www.zacks.com/stock/news/358972/allergan-announces-fda-acceptance-of-migraine-candidate-nda?cid=CS-BENZ-FT-358972,Zacks,,,,,,
2019-03-12T08:00:00.000+08:00,Lilly's Cyramza shows positive effect in first-line lung cancer,LLY,https://seekingalpha.com/news/3441763-lillys-cyramza-shows-positive-effect-first-line-lung-cancer?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 13",LLY,https://www.benzinga.com/node/13353793,TalkMarkets,,,,,,
2019-03-13T08:00:00.000+08:00,Lilly's Cyramza Successful in Phase III First-Line NSCLC Study,LLY,http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-BENZ-FT-359294,Zacks,,,,,,
2019-03-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",LLY,https://www.benzinga.com/general/biotech/19/03/13357435/the-daily-biotech-pulse-arsanis-completes-x4-merger-ec-nod-for-roche-,Shanthi Rexaline,,,,,,
2019-03-15T08:00:00.000+08:00,Microsoft Portfolio: Halftime Report,LLY,https://seekingalpha.com/article/4249101-microsoft-portfolio-halftime-report?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-15T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others",LLY,http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-BENZ-FT-359854,Zacks,,,,,,
2019-03-19T08:00:00.000+08:00,IPO Update: Precision BioSciences Readies Plan For IPO,LLY,https://seekingalpha.com/article/4249820-ipo-update-precision-biosciences-readies-plan-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-19T08:00:00.000+08:00,Why The Future Looks Bright For Incyte Pharmaceuticals,LLY,http://www.investors.com/stock-lists/stock-spotlight/top-stocks-incyte-pharmaceuticals-biotech-sector/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-03-20T08:00:00.000+08:00,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US",LLY,https://www.benzinga.com/news/19/03/13393886/national-comprehensive-cancer-network-announces-its-oncology-research-program-el,Benzinga Newsdesk,,,,,,
2019-03-22T08:00:00.000+08:00,Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know,LLY,http://www.zacks.com/stock/news/363545/eli-lilly-lly-stock-moves-001-what-you-should-know?cid=CS-BENZ-FT-363545,Zacks,,,,,,
2019-03-22T08:00:00.000+08:00,Bull of the Day: DexCom (DXCM),LLY,http://www.zacks.com/commentary/362906/bull-of-the-day-dexcom-dxcm?cid=CS-BENZ-FT-362906,Zacks,,,,,,
2019-03-24T08:00:00.000+08:00,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018,LLY,https://www.benzinga.com/news/19/03/13413633/lilly-says-net-price-for-humalog-insulin-declines-8-1-from-2014-2018,Charles Gross,,,,,,
2019-03-25T08:00:00.000+08:00,"Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash ...",LLY,http://www.gurufocus.com/news/836961/recent-analysis-shows-mastercard-halliburton-keysight-technologies-eli-lilly-wabash-national-and-regeneron-pharmaceuticals-market-influences--renewed-outlook-key-drivers-of-growth,GuruFocus,,,,,,
2019-03-25T08:00:00.000+08:00,What Will Provide Gilead The Growth Needed For Multiple Expansion?,LLY,https://seekingalpha.com/article/4250764-will-provide-gilead-growth-needed-multiple-expansion?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-26T08:00:00.000+08:00,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment",LLY,https://www.benzinga.com/news/19/03/13427756/eli-lilly-announces-collaboration-with-immunext-to-develop-medicines-for-autoimm,Benzinga Newsdesk,,,,,,
2019-03-26T08:00:00.000+08:00,Lilly teams up with ImmuNext in autoimmune diseases,LLY,https://seekingalpha.com/news/3445892-lilly-teams-immunext-autoimmune-diseases?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-26T08:00:00.000+08:00,Trump reaches across the aisle on drug prices,LLY,https://seekingalpha.com/news/3445775-trump-reaches-across-aisle-drug-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",LLY,https://www.benzinga.com/general/biotech/19/03/13429944/the-daily-biotech-pulse-fda-nod-for-novartis-jazz-positive-late-stage,Shanthi Rexaline,,,,,,
2019-03-27T08:00:00.000+08:00,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27",LLY,https://www.benzinga.com/media/19/03/13429455/eli-lilly-eog-mcdonalds-gold-miners-etf-fast-money-picks-for-march-27,Craig Jones,,,,,,
2019-03-27T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Boost Portfolio Gains,LLY,http://www.zacks.com/stock/news/365746/5-cancer-fighting-stocks-to-boost-portfolio-gains?cid=CS-BENZ-FT-365746,Zacks,,,,,,
2019-03-27T08:00:00.000+08:00,Turning Point Therapeutics Files For U.S. IPO,LLY,https://seekingalpha.com/article/4251329-turning-point-therapeutics-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-27T08:00:00.000+08:00,Lilly (LLY) Signs New Immunology Deal With Private Biotech,LLY,http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-BENZ-FT-365638,Zacks,,,,,,
2019-03-29T08:00:00.000+08:00,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More",LLY,https://www.benzinga.com/media/19/03/13446672/jim-cramer-advised-his-viewers-on-canopy-growth-dowdupont-and-more,Craig Jones,,,,,,
2019-03-29T08:00:00.000+08:00,"Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals",LLY,http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-BENZ-FT-367176,Zacks,,,,,,
2019-03-29T08:00:00.000+08:00,Filgotinib worth as much as $6/share to Gilead - Leerink,LLY,https://seekingalpha.com/news/3446798-filgotinib-worth-much-6-share-gilead-leerink?source=partner_benzinga,Seeking Alpha,,,,,,
2019-03-30T08:00:00.000+08:00,How To Retire: Don't Go To College,LLY,https://seekingalpha.com/article/4251934-retire-go-college?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-01T08:00:00.000+08:00,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M,LLY,https://www.benzinga.com/news/19/04/13455989/arteaus-sold-its-royalty-interest-on-future-global-net-sales-of-eli-lillys-emgal,Charles Gross,,,,,,
2019-04-01T08:00:00.000+08:00,3 Big Pharma Stocks to Add to Your Portfolio This April,LLY,http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-BENZ-FT-368171,Zacks,,,,,,
2019-04-01T08:00:00.000+08:00,Arteaus Therapeutics sells Emgality royalty for $260M,LLY,https://seekingalpha.com/news/3447155-arteaus-therapeutics-sells-emgality-royalty-260m?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-02T08:00:00.000+08:00,Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe,LLY,http://www.zacks.com/stock/news/369262/tevas-anti-cgrp-injection-ajovy-gets-approval-in-europe?cid=CS-BENZ-FT-369262,Zacks,,,,,,
2019-04-03T08:00:00.000+08:00,"Cox Capital Co LLC Buys American Tower Corp, Crown Castle International Corp, Community ...",LLY,http://www.gurufocus.com/news/842155/cox-capital-co-llc-buys-american-tower-corp-crown-castle-international-corp-community-healthcare-trust-inc-sells-abbott-laboratories-amdocs,GuruFocus,,,,,,
2019-04-03T08:00:00.000+08:00,Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003,LLY,http://www.zacks.com/stock/news/370084/alector-alec-initiates-phase-i-alzheimers-study-on-al003?cid=CS-BENZ-FT-370084,Zacks,,,,,,
2019-04-04T08:00:00.000+08:00,"Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund - ...",LLY,http://www.gurufocus.com/news/842745/tibra-equities-europe-ltd-buys-union-pacific-corp-walmart-inc-spdr-select-sector-fund--consumer-staples-sells-spdr-sp-oil--gas-explor--product-oracle-corp-apple-inc,GuruFocus,,,,,,
2019-04-05T08:00:00.000+08:00,Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men,LLY,http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-BENZ-FT-371728,Zacks,,,,,,
2019-04-05T08:00:00.000+08:00,Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig,LLY,http://www.zacks.com/stock/news/371493/novartis-amgen-in-legal-dispute-over-migraine-drug-aimovig?cid=CS-BENZ-FT-371493,Zacks,,,,,,
2019-04-06T08:00:00.000+08:00,Stocks To Watch: Disney+ And Bank Majors Step Out,LLY,https://seekingalpha.com/article/4253106-stocks-watch-disney-bank-majors-step?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-07T08:00:00.000+08:00,Disney+ And Bank Majors Step Out (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4253136-disney-bank-majors-step-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-08T08:00:00.000+08:00,"Indiana Trust & Investment Management CO Buys Eli Lilly and Co, Amazon. ...",LLY,http://www.gurufocus.com/news/844171/indiana-trust--investment-management-co-buys-eli-lilly-and-co-amazoncom-inc-duke-energy-corp-sells-pnc-financial-services-group-inc-amgen-inc-bank-of-america-corporation,GuruFocus,,,,,,
2019-04-08T08:00:00.000+08:00,"XR Securities LLC Buys VanEck Vectors Gold Miners, SPDR S&P 5……, VanEck Vectors Junior ...",LLY,http://www.gurufocus.com/news/844173/xr-securities-llc-buys-vaneck-vectors-gold-miners-spdr-sp-500-vaneck-vectors-junior-gold-miners-sells-johnson--johnson-ishares-china-largecap-ishares-msci-emerging-index-fund,GuruFocus,,,,,,
2019-04-09T08:00:00.000+08:00,Enbridge: Halftime Report,LLY,https://seekingalpha.com/article/4253528-enbridge-halftime-report?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-10T08:00:00.000+08:00,"BKD Wealth Advisors, LLC Buys iShares S&P 5…… Growth, Eli Lilly and Co, Vanguard ...",LLY,http://www.gurufocus.com/news/845762/bkd-wealth-advisors-llc-buys-ishares-sp-500-growth-eli-lilly-and-co-vanguard-taxexempt-bond-sells-ishares-sp-500-value-ishares-national-muni-bond-ishares-core-us-aggregate-bond,GuruFocus,,,,,,
2019-04-10T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",LLY,http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-BENZ-FT-376965,Zacks,,,,,,
2019-04-10T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/376711/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-376711,Zacks,,,,,,
2019-04-10T08:00:00.000+08:00,Managing Biotech Investing Risk With Jonathan Faison (Podcast),LLY,https://seekingalpha.com/article/4253247-managing-biotech-investing-risk-jonathan-faison-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-11T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13522338/benzingas-top-upgrades-downgrades-for-april-11-2019,Lisa Levin,,,,,,
2019-04-11T08:00:00.000+08:00,Guggenheim Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/19/04/13520931/guggenheim-downgrades-eli-lilly-to-neutral,Vick Meyer,,,,,,
2019-04-11T08:00:00.000+08:00,"AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come",LLY,https://seekingalpha.com/article/4254083-abbvies-psoriasis-drug-approved-japan-main-event-yet-come?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-11T08:00:00.000+08:00,Biotechnology Market on a Tear: 5 ETFs in Spotlight,LLY,http://www.zacks.com/stock/news/379335/biotechnology-market-on-a-tear-5-etfs-in-spotlight?cid=CS-BENZ-FT-379335,Zacks,,,,,,
2019-04-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors",LLY,http://www.zacks.com/stock/news/379194/the-zacks-analyst-blog-highlights-eli-lilly-altria-becton-dickinson-t-mobile-and-general-motors?cid=CS-BENZ-FT-379194,Zacks,,,,,,
2019-04-11T08:00:00.000+08:00,This Is Why Stocks Are Poised To Surge Higher on April 11,LLY,https://www.benzinga.com/node/13522579,TalkMarkets,,,,,,
2019-04-11T08:00:00.000+08:00,Stifel neutral on Incyte in premarket analyst action,LLY,https://seekingalpha.com/news/3449953-stifel-neutral-incyte-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-12T08:00:00.000+08:00,"Jones Collombin Investment Counsel Inc Buys Eli Lilly and Co, Visa Inc, New Relic Inc, Sells ...",LLY,http://www.gurufocus.com/news/852818/jones-collombin-investment-counsel-inc-buys-eli-lilly-and-co-visa-inc-new-relic-inc-sells-pfizer-inc-brookfield-asset-management-inc-aon-plc,GuruFocus,,,,,,
2019-04-12T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 72,LLY,https://seekingalpha.com/article/4254153-bulletproof-investing-performance-update-week-72?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-15T08:00:00.000+08:00,J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer,LLY,http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-BENZ-FT-380671,Zacks,,,,,,
2019-04-16T08:00:00.000+08:00,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/04/13547205/shares-of-several-drug-companies-are-trading-lower-weakness-may-be-tied-to-uncertainty-over-healthca,Benzinga Newsdesk,,,,,,
2019-04-16T08:00:00.000+08:00,Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/382384/radius-health-rdus-rallies-334-ytd-on-robust-tymlos-sales?cid=CS-BENZ-FT-382384,Zacks,,,,,,
2019-04-16T08:00:00.000+08:00,Johnson & Johnson's Legal Troubles Eat Into Earnings,LLY,http://www.gurufocus.com/news/855111/johnson--johnsons-legal-troubles-eat-into-earnings,GuruFocus,,,,,,
2019-04-16T08:00:00.000+08:00,"Amgen prices Evenity at $1,825 per month",LLY,https://seekingalpha.com/news/3451100-amgen-prices-evenity-1825-per-month?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-17T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13552551/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,,,
2019-04-17T08:00:00.000+08:00,Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement,LLY,https://seekingalpha.com/article/4255101-johnson-and-johnson-looks-help-type-2-diabetes-patients-key-advancement?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-17T08:00:00.000+08:00,The Great Biotech Massacre As The Ghost Of Drug Pricing Past Return,LLY,https://www.benzinga.com/node/13556598,TalkMarkets,,,,,,
2019-04-17T08:00:00.000+08:00,"Chesapeake Wealth Management Buys The Communication Services Select Sector SPDR Fund, Comcast ...",LLY,http://www.gurufocus.com/news/856567/chesapeake-wealth-management-buys-the-communication-services-select-sector-spdr-fund-comcast-corp-cocacola-co-sells-eog-resources-inc-cintas-corp-integrated-device-technology-inc,GuruFocus,,,,,,
2019-04-17T08:00:00.000+08:00,Drugmaker selloff intensifies on D.C. pricing headwinds,LLY,https://seekingalpha.com/news/3451536-drugmaker-selloff-intensifies-d-c-pricing-headwinds?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-17T08:00:00.000+08:00,Cortexyme Files For U.S. IPO,LLY,https://seekingalpha.com/article/4254979-cortexyme-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-18T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13561029/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,,,
2019-04-18T08:00:00.000+08:00,Lilly and Pfizer's tanezumab shows mixed results in late-stage osteoarthritis study,LLY,https://seekingalpha.com/news/3452164-lilly-pfizers-tanezumab-shows-mixed-results-late-stage-osteoarthritis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-18T08:00:00.000+08:00,Pfizer-Lilly painkiller in lower dose misses main goals in Phase 3 study,LLY,https://seekingalpha.com/news/3452158-pfizer-lilly-painkiller-lower-dose-misses-main-goals-phase-3-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-18T08:00:00.000+08:00,Realty Income: Final Performance,LLY,https://seekingalpha.com/article/4255232-realty-income-final-performance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,,,
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,,,
2019-04-18T08:00:00.000+08:00,Is Healthcare Berning?,LLY,https://seekingalpha.com/article/4255169-healthcare-berning?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-19T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 73,LLY,https://seekingalpha.com/article/4255427-bulletproof-investing-performance-update-week-73?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-22T08:00:00.000+08:00,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",LLY,https://www.benzinga.com/general/biotech/19/04/13570340/eli-lilly-pfizers-non-opioid-painkiller-faces-safety-efficacy-concerns,Shanthi Rexaline,,,,,,
2019-04-22T08:00:00.000+08:00,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis",LLY,https://www.benzinga.com/news/19/04/13570231/pfizer-eli-lilly-late-thurs-announced-top-line-results-from-long-term-phase-3-study-of-tanezumab-in,Benzinga Newsdesk,,,,,,
2019-04-22T08:00:00.000+08:00,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints,LLY,https://www.benzinga.com/news/19/04/13569523/eli-lilly-says-its-coast-x-study-of-taltz-met-its-primary-and-key-secondary-endpoints,Benzinga Newsdesk,,,,,,
2019-04-22T08:00:00.000+08:00,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity",LLY,https://www.benzinga.com/news/19/04/13569477/eli-lilly-announces-research-and-licensing-collaboration-with-avidity-biosciences-to-pursue-therapeu,Benzinga Newsdesk,,,,,,
2019-04-22T08:00:00.000+08:00,"First National Bank Sioux Falls Buys Boeing Co, iShares MSCI EAFE, 'M Co, Sells Vectren Corp, ...",LLY,http://www.gurufocus.com/news/859663/first-national-bank-sioux-falls-buys-boeing-co-ishares-msci-eafe-3m-co-sells-vectren-corp-southern-co,GuruFocus,,,,,,
2019-04-22T08:00:00.000+08:00,Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death,LLY,https://seekingalpha.com/article/4255742-biotech-news-recap-pressure-shares-novartis-continues-following-zolgensma-patient-death?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-22T08:00:00.000+08:00,Lilly's Taltz successful in late-stage study in axial skeleton arthritis,LLY,https://seekingalpha.com/news/3452281-lillys-taltz-successful-late-stage-study-axial-skeleton-arthritis?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-22T08:00:00.000+08:00,Lilly teams up with Avidity Bio to develop new medicines,LLY,https://seekingalpha.com/news/3452269-lilly-teams-avidity-bio-develop-new-medicines?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-23T08:00:00.000+08:00,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",LLY,https://www.benzinga.com/markets/wiim/19/04/13579798/shares-of-several-healthcare-stocks-are-trading-higher-in-a-potential-rebound-from-last-weeks-sellof,Benzinga Newsdesk,,,,,,
2019-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",LLY,https://www.benzinga.com/general/biotech/19/04/13575392/the-daily-biotech-pulse-fda-accepts-alders-migraine-drug-application-gritstone-offering-lillys-ch,Shanthi Rexaline,,,,,,
2019-04-23T08:00:00.000+08:00,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M,LLY,https://www.benzinga.com/news/19/04/13575956/lilly-announces-sale-of-legacy-antibiotics-brands-and-manufacturing-facility-in-china-for-375m,Charles Gross,,,,,,
2019-04-23T08:00:00.000+08:00,Futures Tepid As Investors Await Earnings Jolt (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4255866-futures-tepid-investors-await-earnings-jolt-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-23T08:00:00.000+08:00,Wall Street Breakfast: Futures Tepid As Investors Await Earnings Jolt,LLY,https://seekingalpha.com/article/4255863-wall-street-breakfast-futures-tepid-investors-await-earnings-jolt?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-23T08:00:00.000+08:00,"Lilly to sell two antibiotics, plant in China for $375M",LLY,https://seekingalpha.com/news/3452661-lilly-sell-two-antibiotics-plant-china-375m?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 24, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13587104/benzingas-top-upgrades-downgrades-for-april-24-2019,Lisa Levin,,,,,,
2019-04-24T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy,LLY,https://www.benzinga.com/news/19/04/13584536/edward-jones-upgrades-eli-lilly-and-company-common-stock-to-buy,Vick Meyer,,,,,,
2019-04-24T08:00:00.000+08:00,Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity,LLY,https://seekingalpha.com/article/4256389-eli-lilly-looks-tap-potential-groundbreaking-technology-avidity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-24T08:00:00.000+08:00,Needham likes Zimmer Biomet in premarket analyst action,LLY,https://seekingalpha.com/news/3453345-needham-likes-zimmer-biomet-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-25T08:00:00.000+08:00,Lilly Prepares To Withdraw Lartruvo From Global Market,LLY,https://www.benzinga.com/general/biotech/19/04/13593927/lilly-prepares-to-withdraw-lartruvo-from-global-market,Benzinga Newsdesk,,,,,,
2019-04-25T08:00:00.000+08:00,MannKind up 2% on new Afrezza data,LLY,https://seekingalpha.com/news/3454280-mannkind-2-percent-new-afrezza-data?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-25T08:00:00.000+08:00,"Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-403595,Zacks,,,,,,
2019-04-25T08:00:00.000+08:00,Lilly pulling Lartruvo from market after failed late-stage study,LLY,https://seekingalpha.com/news/3454062-lilly-pulling-lartruvo-market-failed-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-25T08:00:00.000+08:00,Eli Lilly Receives Approval For Hard-To-Detect Inflammatory Arthritis,LLY,https://seekingalpha.com/article/4256557-eli-lilly-receives-approval-hard-detect-inflammatory-arthritis?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-26T08:00:00.000+08:00,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo,LLY,https://www.benzinga.com/general/biotech/19/04/13607710/recommends-withdrawal-of-marketing-authorisation-for-eli-lillys-cancer-medicine-lartruvo,Benzinga Newsdesk,,,,,,
2019-04-26T08:00:00.000+08:00,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/19/04/13607590/us-court-of-appeals-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,,,
2019-04-26T08:00:00.000+08:00,"Arrow Financial Corp Buys Occidental Petroleum Corp, iShares National Muni Bond, Air Products ...",LLY,http://www.gurufocus.com/news/864119/arrow-financial-corp-buys-occidental-petroleum-corp-ishares-national-muni-bond-air-products--chemicals-inc-sells-goldman-sachs-group-inc-nvidia-corp-caterpillar-inc,GuruFocus,,,,,,
2019-04-26T08:00:00.000+08:00,Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short,LLY,https://seekingalpha.com/article/4257146-biotech-news-recap-gilead-sciences-stellar-data-falls-short?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-26T08:00:00.000+08:00,Lilly prevails in Alimta patent appeal,LLY,https://seekingalpha.com/news/3455012-lilly-prevails-alimta-patent-appeal?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-26T08:00:00.000+08:00,European advisory group backs withdrawal of Lilly's Lartruvo,LLY,https://seekingalpha.com/news/3455006-european-advisory-group-backs-withdrawal-lillys-lartruvo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-26T08:00:00.000+08:00,"AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales",LLY,http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-BENZ-FT-404479,Zacks,,,,,,
2019-04-27T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://www.benzinga.com/node/13612300,TalkMarkets,,,,,,
2019-04-28T08:00:00.000+08:00,5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates,LLY,http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-BENZ-FT-405274,Zacks,,,,,,
2019-04-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 74,LLY,https://seekingalpha.com/article/4257568-bulletproof-investing-performance-update-week-74?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-28T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://seekingalpha.com/article/4257491-week-review-eddingpharm-pay-375-million-2-lilly-antibiotics-suzhou-manufacturing-facility?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-28T08:00:00.000+08:00,Summers Value Partners Q1 2019 Investor Letter,LLY,https://seekingalpha.com/article/4257456-summers-value-partners-q1-2019-investor-letter?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-29T08:00:00.000+08:00,"Market At New Highs, But Healthcare And Biotechs Feel The Heat",LLY,https://seekingalpha.com/article/4257727-market-new-highs-healthcare-biotechs-feel-heat?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-29T08:00:00.000+08:00,New migraine meds face tough price talks with PBMs,LLY,https://seekingalpha.com/news/3455418-new-migraine-meds-face-tough-price-talks-pbms?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-29T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/404799/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-404799,Zacks,,,,,,
2019-04-30T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.,LLY,https://www.benzinga.com/markets/wiim/19/04/13626512/eli-lilly-and-co-shares-are-trading-lower-after-the-the-company-reported-mixed-q1-results-and-fy19-g,Benzinga Newsdesk,,,,,,
2019-04-30T08:00:00.000+08:00,30 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/04/13625331/30-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,,,
2019-04-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/04/13623920/the-daily-biotech-pulse-earnings-deluge-g1-therapeutics-positive-fda-meeting-mustang-bio-offering,Shanthi Rexaline,,,,,,
2019-04-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting",LLY,https://www.benzinga.com/news/19/04/13624641/a-peek-into-the-markets-us-stock-futures-mixed-ahead-of-earnings-fed-meeting,Lisa Levin,,,,,,
2019-04-30T08:00:00.000+08:00,"15 Stocks To Watch For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623749/15-stocks-to-watch-for-april-30-2019,Lisa Levin,,,,,,
2019-04-30T08:00:00.000+08:00,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.,LLY,https://www.benzinga.com/news/19/04/13623520/eli-lilly-sees-fy19-eps-5-60-5-70-vs-5-64-est,Benzinga Newsdesk,,,,,,
2019-04-30T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate",LLY,https://www.benzinga.com/news/earnings/19/04/13623489/eli-lilly-q1-adj-eps-1-33-beats-1-26-estimate-sales-5-09b-miss-5-11b-estimate,Benzinga Newsdesk,,,,,,
2019-04-30T08:00:00.000+08:00,"Earnings Scheduled For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623421/earnings-scheduled-for-april-30-2019,Lisa Levin,,,,,,
2019-04-30T08:00:00.000+08:00,"Biotech News Recap: Merck Boasts Another Impressive Quarter, Keytruda Dominance Highlighted",LLY,https://seekingalpha.com/article/4258335-biotech-news-recap-merck-boasts-another-impressive-quarter-keytruda-dominance-highlighted?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4258185-eli-lilly-companys-lly-ceo-dave-ricks-q1-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-30T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-406067,Zacks,,,,,,
2019-04-30T08:00:00.000+08:00,Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut,LLY,http://www.zacks.com/stock/news/406076/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut?cid=CS-BENZ-FT-406076,Zacks,,,,,,
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q1 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4257970-eli-lilly-company-2019-q1-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-30T08:00:00.000+08:00,Eli Lilly down 2% on Q1 miss and lowered revenue guidance,LLY,https://seekingalpha.com/news/3455995-eli-lilly-2-percent-q1-miss-lowered-revenue-guidance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-04-30T08:00:00.000+08:00,"Eli Lilly EPS in-line, misses on revenue",LLY,https://seekingalpha.com/news/3455905-eli-lilly-eps-line-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-01T08:00:00.000+08:00,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133",LLY,https://www.benzinga.com/news/19/05/13639759/bmo-capital-maintains-outperform-on-eli-lilly-and-company-common-stock-raises-price-target-to-133,Vick Meyer,,,,,,
2019-05-01T08:00:00.000+08:00,"Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure",LLY,http://www.zacks.com/stock/news/406447/amgen-amgn-q1-earnings-top-sales-hurt-by-pricing-pressure?cid=CS-BENZ-FT-406447,Zacks,,,,,,
2019-05-02T08:00:00.000+08:00,Eli Lilly Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10,LLY,https://www.benzinga.com/news/19/05/13650889/eli-lilly-announces-it-will-present-19-scientific-abstracts-for-emgality-galcanezumab-gnlm-and-lasmi,Benzinga_Newsdesk,,,,,,
2019-05-02T08:00:00.000+08:00,"Newport Trust Co Buys Westinghouse Air Brake Technologies Corp, LiveRamp Holdings Inc, Eli ...",LLY,http://www.gurufocus.com/news/869682/newport-trust-co-buys-westinghouse-air-brake-technologies-corp-liveramp-holdings-inc-eli-lilly-and-co-sells-liveramp-holdings-inc-tcg-bdc-inc,GuruFocus,,,,,,
2019-05-02T08:00:00.000+08:00,"German American Bancorp, Inc. Buys Vanguard Real Estate, Morgan Stanley, General Electric Co, ...",LLY,http://www.gurufocus.com/news/869324/german-american-bancorp-inc-buys-vanguard-real-estate-morgan-stanley-general-electric-co-sells-spdr-select-sector-fund--financial-spdr-select-sector-fund--industrial-vectren-corp,GuruFocus,,,,,,
2019-05-02T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/407647/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-407647,Zacks,,,,,,
2019-05-03T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 75,LLY,https://seekingalpha.com/article/4259943-bulletproof-investing-performance-update-week-75?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-03T08:00:00.000+08:00,Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/408654/novo-nordisk-nvo-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-408654,Zacks,,,,,,
2019-05-03T08:00:00.000+08:00,FDA OKs AstraZeneca's combo pill for T2D,LLY,https://seekingalpha.com/news/3458570-fda-oks-astrazenecas-combo-pill-t2d?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-03T08:00:00.000+08:00,"Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down",LLY,http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-BENZ-FT-408333,Zacks,,,,,,
2019-05-03T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod",LLY,http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-BENZ-FT-408311,Zacks,,,,,,
2019-05-04T08:00:00.000+08:00,Stocks To Watch: Uber Time,LLY,https://seekingalpha.com/article/4260001-stocks-watch-uber-time?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-05T08:00:00.000+08:00,Dogs Of The Champions: An Improvement Over The Dogs Of The Dow,LLY,https://seekingalpha.com/article/4260285-dogs-champions-improvement-dogs-dow?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-05T08:00:00.000+08:00,Uber Time (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4260203-uber-time-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-06T08:00:00.000+08:00,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies",LLY,https://www.benzinga.com/news/19/05/13670541/eli-lilly-highlights-upcoming-presentation-of-results-from-pooled-subgroup-analyses-of-efficacy-data,Benzinga Newsdesk,,,,,,
2019-05-06T08:00:00.000+08:00,"Oral Ozempic: Finally, An Alpha Catalyst For Novo Nordisk?",LLY,https://seekingalpha.com/article/4260690-oral-ozempic-finally-alpha-catalyst-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-06T08:00:00.000+08:00,Cortexyme IPO Isn't Cheap,LLY,https://seekingalpha.com/article/4260662-cortexyme-ipo-cheap?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-06T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3459324-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-07T08:00:00.000+08:00,NextCure IPO: The Enterprise Value Could Increase In 2020,LLY,https://seekingalpha.com/article/4261011-nextcure-ipo-enterprise-value-increase-2020?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-07T08:00:00.000+08:00,"Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View",LLY,http://www.zacks.com/stock/news/410272/allergan-agn-beats-on-q1-earnings-sales-raises-19-view?cid=CS-BENZ-FT-410272,Zacks,,,,,,
2019-05-08T08:00:00.000+08:00,The Nextcure IPO: What You Need To Know,LLY,https://www.benzinga.com/general/biotech/19/05/13673725/the-nextcure-ipo-what-you-need-to-know,Elizabeth Balboa,,,,,,
2019-05-08T08:00:00.000+08:00,Drug makers to disclose prices in TV ads as early as this summer,LLY,https://seekingalpha.com/news/3460803-drug-makers-disclose-prices-tv-ads-early-summer?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-09T08:00:00.000+08:00,"Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues",LLY,http://www.zacks.com/stock/news/412113/radius-rdus-posts-narrower-q1-loss-misses-on-revenues?cid=CS-BENZ-FT-412113,Zacks,,,,,,
2019-05-09T08:00:00.000+08:00,TV ad disclosures to affect small group of drug makers,LLY,https://seekingalpha.com/news/3461894-tv-ad-disclosures-affect-small-group-drug-makers?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-09T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 76,LLY,https://seekingalpha.com/article/4261929-bulletproof-investing-performance-update-week-76?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-10T08:00:00.000+08:00,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019",LLY,https://www.benzinga.com/news/19/05/13716417/top-10-most-oversold-stocks-via-benzinga-pros-radar-tool-for-fri-may-10-2019,Benzinga Newsdesk,,,,,,
2019-05-10T08:00:00.000+08:00,"Bluestein R H & Co Buys Deere, Palo Alto Networks Inc, Delta Air Lines Inc, Sells ...",LLY,http://www.gurufocus.com/news/875529/bluestein-r-h--co-buys-deere-palo-alto-networks-inc-delta-air-lines-inc-sells-unitedhealth-group-inc-international-business-machines-corp-tesla-inc,GuruFocus,,,,,,
2019-05-10T08:00:00.000+08:00,Nektar: Undervalued And A Tremendous Prospect,LLY,https://seekingalpha.com/article/4262507-nektar-undervalued-tremendous-prospect?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-12T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - May 12, 2019",LLY,https://www.benzinga.com/node/13721692,TalkMarkets,,,,,,
2019-05-13T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points,LLY,https://www.benzinga.com/news/19/05/13723083/a-peek-into-the-markets-us-stock-futures-tumble-dow-futures-down-over-300-points,Lisa Levin,,,,,,
2019-05-13T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma,LLY,https://www.benzinga.com/news/19/05/13723042/eli-lilly-announces-fda-approval-for-its-cyramza-for-the-treatment-of-patients-with-hepatocellular-c,Benzinga Newsdesk,,,,,,
2019-05-13T08:00:00.000+08:00,"Hyman Charles D Buys International Business Machines Corp, Merck Inc, Cisco Systems Inc, Sells ...",LLY,http://www.gurufocus.com/news/876666/hyman-charles-d-buys-international-business-machines-corp-merck-inc-cisco-systems-inc-sells-blackrock-inc,GuruFocus,,,,,,
2019-05-13T08:00:00.000+08:00,FDA finalizes guidance on interchangeable biosimilars,LLY,https://seekingalpha.com/news/3462874-fda-finalizes-guidance-interchangeable-biosimilars?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-13T08:00:00.000+08:00,FDA OK's Lilly's CYRAMZA for liver cancer,LLY,https://seekingalpha.com/news/3462858-fda-oks-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",LLY,https://www.benzinga.com/markets/wiim/19/05/13736459/shares-of-several-healthcare-companies-are-trading-higher-as-the-us-market-rebounds-from-recent-weak,Benzinga Newsdesk,,,,,,
2019-05-14T08:00:00.000+08:00,"Top Research Reports for Alphabet, Eli Lilly & CVS Health",LLY,http://www.zacks.com/research-daily/413862/top-research-reports-for-alphabet-eli-lilly-cvs-health?cid=CS-BENZ-FT-413862,Zacks,,,,,,
2019-05-14T08:00:00.000+08:00,Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer,LLY,http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-BENZ-FT-413860,Zacks,,,,,,
2019-05-15T08:00:00.000+08:00,"Hunting Hill Global Capital, LLC Buys Red Hat Inc, Celgene Corp, iShares China Large-Cap, Sells ...",LLY,http://www.gurufocus.com/news/878607/hunting-hill-global-capital-llc-buys-red-hat-inc-celgene-corp-ishares-china-largecap-sells-shire-plc-spdr-bloomberg-barclays-high-yield-bond-dominion-energy-inc,GuruFocus,,,,,,
2019-05-15T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS",LLY,http://www.zacks.com/stock/news/414358/the-zacks-analyst-blog-highlights-alphabet-eli-lilly-cvs-marriott-and-telus?cid=CS-BENZ-FT-414358,Zacks,,,,,,
2019-05-15T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2019 Update,LLY,https://seekingalpha.com/article/4264177-tracking-ken-fishers-fisher-asset-management-portfolio-q1-2019-update?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-16T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 77,LLY,https://seekingalpha.com/article/4264627-bulletproof-investing-performance-update-week-77?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-16T08:00:00.000+08:00,"Citadel Advisors LLC Buys Eli Lilly and Co, McDonald's Corp, The Walt Disney Co, Sells Amazon. ...",LLY,http://www.gurufocus.com/news/879131/citadel-advisors-llc-buys-eli-lilly-and-co-mcdonalds-corp-the-walt-disney-co-sells-amazoncom-inc-spdr-sp-500-att-inc,GuruFocus,,,,,,
2019-05-17T08:00:00.000+08:00,ImmunoGen: Assessing The Possibility Of A Turnaround,LLY,https://seekingalpha.com/article/4265020-immunogen-assessing-possibility-turnaround?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-18T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",LLY,https://www.benzinga.com/general/biotech/19/05/13747491/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-readouts-and-ipos,Shanthi Rexaline,,,,,,
2019-05-19T08:00:00.000+08:00,6 Stock That May Drop During the Week of May 20,LLY,https://www.benzinga.com/node/13769693,TalkMarkets,,,,,,
2019-05-20T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/416747/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-416747,Zacks,,,,,,
2019-05-21T08:00:00.000+08:00,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/19/05/13782648/eli-lilly-reports-mirikizumab-met-primary-key-secondary-endpoints,Benzinga Newsdesk,,,,,,
2019-05-21T08:00:00.000+08:00,An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market,LLY,https://seekingalpha.com/article/4265645-fda-win-astrazeneca-shifts-expanded-label-type-2-diabetes-market?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-21T08:00:00.000+08:00,Lilly's mirikizumab shows positive effect in mid-stage Crohn's study,LLY,https://seekingalpha.com/news/3465778-lillys-mirikizumab-shows-positive-effect-mid-stage-crohns-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-21T08:00:00.000+08:00,Array Bio down 5% premarket on uneven results for Braftovi/Mektovi in CRC,LLY,https://seekingalpha.com/news/3465641-array-bio-5-percent-premarket-uneven-results-braftovi-mektovi-crc?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-22T08:00:00.000+08:00,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option",LLY,https://www.benzinga.com/news/19/05/13786675/eli-lilly-reports-insulin-lispro-injection-now-available-for-order-in-pharmacies-for-people-who-use,Benzinga Newsdesk,,,,,,
2019-05-22T08:00:00.000+08:00,Array BioPharma Gains on Colorectal Cancer Study Success,LLY,http://www.zacks.com/stock/news/418133/array-biopharma-gains-on-colorectal-cancer-study-success?cid=CS-BENZ-FT-418133,Zacks,,,,,,
2019-05-22T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-418127,Zacks,,,,,,
2019-05-22T08:00:00.000+08:00,Philip Morris International: Final Performance,LLY,https://seekingalpha.com/article/4265763-philip-morris-international-final-performance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-22T08:00:00.000+08:00,Lilly's Crohn's Disease Candidate Meets Phase II Study Goals,LLY,http://www.zacks.com/stock/news/417952/lillys-crohns-disease-candidate-meets-phase-ii-study-goals?cid=CS-BENZ-FT-417952,Zacks,,,,,,
2019-05-22T08:00:00.000+08:00,Merck to Buy Private Cancer Drugmaker Peloton Therapeutics,LLY,http://www.zacks.com/stock/news/417898/merck-to-buy-private-cancer-drugmaker-peloton-therapeutics?cid=CS-BENZ-FT-417898,Zacks,,,,,,
2019-05-23T08:00:00.000+08:00,FDA OKs Novocure's TTF for mesothelioma under HDE status; shares up 4% after hours,LLY,https://seekingalpha.com/news/3466629-fda-oks-novocures-ttf-mesothelioma-hde-status-shares-4-percent-hours?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-23T08:00:00.000+08:00,"Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)",LLY,http://www.zacks.com/stock/news/418682/earnings-preview-veeva-veev-palo-alto-networks-panw-workday-wday?cid=CS-BENZ-FT-418682,Zacks,,,,,,
2019-05-23T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 78,LLY,https://seekingalpha.com/article/4266153-bulletproof-investing-performance-update-week-78?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-23T08:00:00.000+08:00,Lilly (LLY) Launches Half-Priced Version of Humalog Insulin,LLY,http://www.zacks.com/stock/news/418337/lilly-lly-launches-half-priced-version-of-humalog-insulin?cid=CS-BENZ-FT-418337,Zacks,,,,,,
2019-05-24T08:00:00.000+08:00,"Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates",LLY,http://www.zacks.com/stock/news/419108/pharma-stock-roundup-mrks-cancer-biotech-buyout-abbv-llys-pipeline-updates?cid=CS-BENZ-FT-419108,Zacks,,,,,,
2019-05-27T08:00:00.000+08:00,Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi,LLY,http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-BENZ-FT-420060,Zacks,,,,,,
2019-05-28T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/05/13813592/benzingas-top-upgrades-downgrades-for-may-28-2019,Lisa Levin,,,,,,
2019-05-28T08:00:00.000+08:00,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones,LLY,https://www.benzinga.com/general/biotech/19/05/13812619/lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion-therapeutics-lilly-,Benzinga Newsdesk,,,,,,
2019-05-28T08:00:00.000+08:00,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target",LLY,https://www.benzinga.com/news/19/05/13812492/goldman-sachs-initiates-coverage-on-eli-lilly-with-buy-rating-announces-135-price-target,Benzinga_Newsdesk,,,,,,
2019-05-28T08:00:00.000+08:00,Lilly in-licenses non-opioid pain candidate from Centrexion for up ~$1B,LLY,https://seekingalpha.com/news/3467132-lilly-licenses-non-opioid-pain-candidate-centrexion-1b?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-29T08:00:00.000+08:00,Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate,LLY,http://www.zacks.com/stock/news/421715/lilly-in-licenses-private-biotechs-non-opoid-pain-candidate?cid=CS-BENZ-FT-421715,Zacks,,,,,,
2019-05-29T08:00:00.000+08:00,Here's Why Eli Lilly Is Cutting The Price Of Humalog,LLY,https://seekingalpha.com/article/4266973-eli-lilly-cutting-price-humalog?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-30T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 79,LLY,https://seekingalpha.com/article/4267280-bulletproof-investing-performance-update-week-79?source=partner_benzinga,Seeking Alpha,,,,,,
2019-05-30T08:00:00.000+08:00,Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/422212/lilly-lly-down-23-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-422212,Zacks,,,,,,
2019-05-30T08:00:00.000+08:00,Mereo Bio's setrusumab shows encouraging action in mid-stage bone disorder study,LLY,https://seekingalpha.com/news/3467821-mereo-bios-setrusumab-shows-encouraging-action-mid-stage-bone-disorder-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-02T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of June 2,LLY,https://seekingalpha.com/article/4267811-dividend-challenger-highlights-week-june-2?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-03T08:00:00.000+08:00,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program",LLY,https://www.benzinga.com/general/biotech/19/06/13849115/atomwise-announces-multi-year-multi-target-agreement-with-lilly-for-ai-driven-drug-discovery-prog,Benzinga Newsdesk,,,,,,
2019-06-03T08:00:00.000+08:00,Merck's Keytruda Improves 5-Year Survival in Lung Cancer,LLY,http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-BENZ-FT-423872,Zacks,,,,,,
2019-06-03T08:00:00.000+08:00,XBI: Biotech Performance And Valuation Update - June 2019,LLY,https://seekingalpha.com/article/4267925-xbi-biotech-performance-valuation-update-june-2019?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-04T08:00:00.000+08:00,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/06/13862233/fda-approves-eli-lillys-emgality-for-injection-for-treatment-of-episodic-cluster-headache-in-adults,Benzinga Newsdesk,,,,,,
2019-06-04T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13856380/eli-lilly-reports-fda-accepted-new-drug-application-for-triple-combo-tablet-for-adults-with-type-2-d,Benzinga Newsdesk,,,,,,
2019-06-04T08:00:00.000+08:00,FDA accepts Eli Lilly's NDA for triple combination tablet for adults with type 2 diabetes,LLY,https://seekingalpha.com/news/3468865-fda-accepts-eli-lillys-nda-triple-combination-tablet-adults-type-2-diabetes?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",LLY,https://www.benzinga.com/general/biotech/19/06/13864534/the-daily-biotech-pulse-curtains-down-on-asco-rewalk-flies-eli-lillys-migraine-drug-approved-for-,Shanthi Rexaline,,,,,,
2019-06-05T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More",LLY,https://www.benzinga.com/media/19/06/13864062/jim-cramer-shares-his-thoughts-on-amd-cme-group-microsoft-and-more,Craig Jones,,,,,,
2019-06-05T08:00:00.000+08:00,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology,LLY,https://www.benzinga.com/general/biotech/19/06/13864598/lilly-to-present-data-from-dermatology-portfolio-at-24th-world-congress-of-dermatology,Benzinga Newsdesk,,,,,,
2019-06-05T08:00:00.000+08:00,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks,LLY,https://www.benzinga.com/news/19/06/13864224/elililly-announces-fda-approval-of-emgality-as-the-first-and-only-medication-for-the-treatment-of-ep,Charles Gross,,,,,,
2019-06-05T08:00:00.000+08:00,FDA OKs expanded label for Lilly's migraine med Emgality,LLY,https://seekingalpha.com/news/3469110-fda-oks-expanded-label-lillys-migraine-med-emgality?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-05T08:00:00.000+08:00,"Credit Ratings And Quality Indicators For Dividend Champions, Contenders And Challengers",LLY,https://seekingalpha.com/article/4268351-credit-ratings-quality-indicators-dividend-champions-contenders-challengers?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-06T08:00:00.000+08:00,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019",LLY,https://www.benzinga.com/news/19/06/13872547/eli-lilly-highlights-will-present-data-for-taltz-olumiant-at-eular-2019-jun-12-15-2019,Benzinga Newsdesk,,,,,,
2019-06-06T08:00:00.000+08:00,Incyte Begins Phase III Study for Treatment of Duct Cancer,LLY,http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-BENZ-FT-425849,Zacks,,,,,,
2019-06-06T08:00:00.000+08:00,Lilly's Emgality Gets FDA Approval for Cluster Headache,LLY,http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-BENZ-FT-425463,Zacks,,,,,,
2019-06-07T08:00:00.000+08:00,Primecap Management Buys More Albemarle Corp,LLY,http://www.gurufocus.com/news/891292/primecap-management-buys-more-albemarle-corp,GuruFocus,,,,,,
2019-06-07T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 80,LLY,https://seekingalpha.com/article/4269191-bulletproof-investing-performance-update-week-80?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-07T08:00:00.000+08:00,Lilly petitions Supreme Court to protect Cialis BPH patent,LLY,https://seekingalpha.com/news/3469894-lilly-petitions-supreme-court-protect-cialis-bph-patent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-07T08:00:00.000+08:00,"Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache",LLY,http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-BENZ-FT-426292,Zacks,,,,,,
2019-06-07T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3468331-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-08T08:00:00.000+08:00,Novo's oral semaglutide successful in two late-stage T2D studies,LLY,https://seekingalpha.com/news/3469971-novos-oral-semaglutide-successful-two-late-stage-t2d-studies?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-09T08:00:00.000+08:00,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13892707/lilly-announces-trulicity-significantly-reduced-major-cardiovascular-events-for-broad-range-of-peopl,Charles Gross,,,,,,
2019-06-09T08:00:00.000+08:00,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions,LLY,https://www.benzinga.com/news/19/06/13892625/lilly-announces-tirzepatide-demonstrates-benefits-in-data-presented-at-american-diabetes-association,Charles Gross,,,,,,
2019-06-09T08:00:00.000+08:00,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions",LLY,https://www.benzinga.com/news/19/06/13892620/lilly-announces-ultra-rapid-lispro-provided-similar-a1c-reductions-vs-humalog-with-superior-post-mea,Charles Gross,,,,,,
2019-06-10T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.,LLY,https://www.benzinga.com/markets/wiim/19/06/13896019/eli-lilly-shares-are-trading-lower-after-the-company-announced-disappointing-data-for-the-treatment,Benzinga Newsdesk,,,,,,
2019-06-10T08:00:00.000+08:00,Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity,LLY,https://seekingalpha.com/article/4269514-xeris-gvoke-pdufa-gets-delayed-creates-buying-opportunity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-10T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript),LLY,https://seekingalpha.com/article/4269487-eli-lilly-company-lly-presents-webcast-discuss-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-10T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca",LLY,http://www.zacks.com/stock/news/427178/the-zacks-analyst-blog-highlights-bristol-myers-merck-roche-lilly-and-astrazeneca?cid=CS-BENZ-FT-427178,Zacks,,,,,,
2019-06-10T08:00:00.000+08:00,ADA Presentations and Diabetes Portfolio,LLY,https://seekingalpha.com/article/4269399-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-10T08:00:00.000+08:00,Lilly's Trulicity reduced CV risk in large-scale T2D study,LLY,https://seekingalpha.com/news/3470092-lillys-trulicity-reduced-cv-risk-large-scale-t2d-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-10T08:00:00.000+08:00,Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet,LLY,http://www.zacks.com/stock/news/427034/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet?cid=CS-BENZ-FT-427034,Zacks,,,,,,
2019-06-10T08:00:00.000+08:00,"Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO",LLY,https://seekingalpha.com/article/4269341-week-review-frontage-u-s-china-cro-stages-205-million-hong-kong-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/06/13900223/the-daily-biotech-pulse-lilly-reports-positive-long-term-efficacy-data-for-psoriasis-drug-provent,Shanthi Rexaline,,,,,,
2019-06-11T08:00:00.000+08:00,These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors,LLY,https://seekingalpha.com/article/4269682-27-fortune-500-dividend-stocks-made-best-total-returns-investors?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-11T08:00:00.000+08:00,Lilly's Taltz shows long-term benefit in psoriasis study,LLY,https://seekingalpha.com/news/3470448-lillys-taltz-shows-long-term-benefit-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-11T08:00:00.000+08:00,Lilly Announces Tradjenta Cardiovascular Outcome Study Data,LLY,http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-BENZ-FT-427738,Zacks,,,,,,
2019-06-11T08:00:00.000+08:00,Zymeworks: Leader In Bispecifics Space Makes Substantial Headway,LLY,https://seekingalpha.com/article/4269567-zymeworks-leader-bispecifics-space-makes-substantial-headway?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-11T08:00:00.000+08:00,Antares Pharma: What The Market Is Missing,LLY,https://seekingalpha.com/article/4269562-antares-pharma-market-missing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-12T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript),LLY,https://seekingalpha.com/article/4269972-eli-lilly-companys-lly-management-presents-goldman-sachs-40th-annual-global-helathcare?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-12T08:00:00.000+08:00,Boost Your Portfolio's Health With These 3 Big Drug Stocks,LLY,http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-BENZ-FT-428332,Zacks,,,,,,
2019-06-13T08:00:00.000+08:00,Akero Therapeutics Readies $75 Million IPO,LLY,https://seekingalpha.com/article/4270108-akero-therapeutics-readies-75-million-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-13T08:00:00.000+08:00,NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag,LLY,http://www.zacks.com/stock/news/429173/nucanas-biliary-tract-cancer-candidate-gets-orphan-drug-tag?cid=CS-BENZ-FT-429173,Zacks,,,,,,
2019-06-14T08:00:00.000+08:00,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'",LLY,https://www.benzinga.com/news/19/06/13924153/from-earlier-drug-makers-amgen-merck-lilly-and-the-association-of-national-advertisers-file-suit-to,Benzinga Newsdesk,,,,,,
2019-06-14T08:00:00.000+08:00,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology,LLY,https://www.benzinga.com/news/19/06/13921087/eli-lilly-presents-data-on-its-taltz-versus-abbvies-humira-in-patients-with-active-psoriatic-arthiri,Benzinga Newsdesk,,,,,,
2019-06-14T08:00:00.000+08:00,Drug companies file suit to block disclosure of drug prices in TV ads,LLY,https://seekingalpha.com/news/3471595-drug-companies-file-suit-block-disclosure-drug-prices-tv-ads?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-14T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 81,LLY,https://seekingalpha.com/article/4270327-bulletproof-investing-performance-update-week-81?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-14T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod",LLY,http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-BENZ-FT-429560,Zacks,,,,,,
2019-06-17T08:00:00.000+08:00,How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers,LLY,http://www.investors.com/research/the-income-investor/biotech-company-array-acquired-pfizer-deal-cancer-treatments/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-06-18T08:00:00.000+08:00,Stock Spotlight: A New Lifesaving Drug Is Reviving This Drugmaker's Stock,LLY,http://www.investors.com/stock-lists/stock-spotlight/incyte-stock-gets-boost-lifesaving-drug/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-06-18T08:00:00.000+08:00,The Best Places To Work: Delivering Strong Results Compared To The S&P 500 Over 10 Years,LLY,https://seekingalpha.com/article/4270853-best-places-work-delivering-strong-results-compared-s-and-p-500-10-years?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-18T08:00:00.000+08:00,Stock Upgrades: Eli Lilly Shows Rising Relative Strength,LLY,http://www.investors.com/ibd-data-stories/stock-upgrades-eli-lilly-shows-rising-relative-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-06-18T08:00:00.000+08:00,"Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio",LLY,http://www.zacks.com/stock/news/431106/pfizer-to-buy-array-biopharma-broaden-cancer-portfolio?cid=CS-BENZ-FT-431106,Zacks,,,,,,
2019-06-18T08:00:00.000+08:00,Microsoft: Final Performance,LLY,https://seekingalpha.com/article/4270801-microsoft-final-performance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-18T08:00:00.000+08:00,Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients,LLY,http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-BENZ-FT-431041,Zacks,,,,,,
2019-06-19T08:00:00.000+08:00,NASH And Diabetes Markets Could Soon Be Disrupted,LLY,https://seekingalpha.com/article/4271140-nash-diabetes-markets-soon-disrupted?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-19T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3472440-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-19T08:00:00.000+08:00,Eli Lilly Looks Into The Foray Of Developing Its Own NASH Drug,LLY,https://seekingalpha.com/article/4270974-eli-lilly-looks-foray-developing-nash-drug?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-19T08:00:00.000+08:00,Zai Lab: A Pearl In The Healthcare Market,LLY,https://seekingalpha.com/article/4270950-zai-lab-pearl-healthcare-market?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-21T08:00:00.000+08:00,Karuna Therapeutics Readies Plan For $70 Million IPO,LLY,https://seekingalpha.com/article/4271532-karuna-therapeutics-readies-plan-70-million-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-22T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 82,LLY,https://seekingalpha.com/article/4271593-bulletproof-investing-performance-update-week-82?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-25T08:00:00.000+08:00,Axsome Initiates Phase III Study on Depression Candidate,LLY,http://www.zacks.com/stock/news/434234/axsome-initiates-phase-iii-study-on-depression-candidate?cid=CS-BENZ-FT-434234,Zacks,,,,,,
2019-06-25T08:00:00.000+08:00,Key Factors Aligning To Short Pharmaceuticals,LLY,https://seekingalpha.com/article/4272056-key-factors-aligning-short-pharmaceuticals?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-25T08:00:00.000+08:00,Pharma players in green on AbbVie/Allergan deal,LLY,https://seekingalpha.com/news/3473634-pharma-players-green-abbvie-allergan-deal?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-26T08:00:00.000+08:00,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.,LLY,https://www.benzinga.com/markets/wiim/19/06/13987215/eli-lilly-shares-trading-lower-with-the-other-major-drugmakers-the-downside-comes-despite-news-empag,Benzinga Newsdesk,,,,,,
2019-06-26T08:00:00.000+08:00,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses,LLY,https://www.benzinga.com/general/biotech/19/06/13984718/lillys-heart-drug-snags-fast-track-designation-type-2-diabetes-drug-found-effective-at-higher-dos,Shanthi Rexaline,,,,,,
2019-06-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",LLY,https://www.benzinga.com/general/biotech/19/06/13983221/the-daily-biotech-pulse-decision-day-for-regeneron-sanofi-vermillion-offering-pdl-biopharma-cfo-t,Shanthi Rexaline,,,,,,
2019-06-26T08:00:00.000+08:00,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/06/13983619/lilly-announces-award-11-trial-studying-higher-investigational-doses-of-trulicity-demonstrated-su,Benzinga Newsdesk,,,,,,
2019-06-26T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/06/13983427/eli-lilly-announce-and-boehringer-ingelheim-announce-the-fda-grants-fast-track-designation-to-empagl,Benzinga_Newsdesk,,,,,,
2019-06-26T08:00:00.000+08:00,Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate,LLY,http://www.investors.com/research/ibd-industry-themes/health-care-stocks-dive-before-presidential-debate-democrats-drug-prices/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-06-26T08:00:00.000+08:00,Healthcare stocks under pressure ahead of Dem debate,LLY,https://seekingalpha.com/news/3473947-healthcare-stocks-pressure-ahead-dem-debate?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-26T08:00:00.000+08:00,Higher doses of Lilly's Trulicity successful in late-stage T2D study,LLY,https://seekingalpha.com/news/3473804-higher-doses-lillys-trulicity-successful-late-stage-t2d-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-26T08:00:00.000+08:00,Lilly's empagliflozin Fast Track'd for CV benefit claim in heart failure patients,LLY,https://seekingalpha.com/news/3473799-lillys-empagliflozin-fast-trackd-cv-benefit-claim-heart-failure-patients?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 83,LLY,https://seekingalpha.com/article/4272709-bulletproof-investing-performance-update-week-83?source=partner_benzinga,Seeking Alpha,,,,,,
2019-06-28T08:00:00.000+08:00,5 Stocks With Low Price-Sales Ratios,LLY,http://www.gurufocus.com/news/901562/5-stocks-with-low-pricesales-ratios,GuruFocus,,,,,,
2019-06-28T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger",LLY,http://www.zacks.com/stock/news/435476/pharma-stock-roundup-abbv-to-buy-agn-bmy-to-sell-celgs-otezla-to-close-merger?cid=CS-BENZ-FT-435476,Zacks,,,,,,
2019-06-28T08:00:00.000+08:00,European advisory group backs Lilly's Cyramza for liver cancer,LLY,https://seekingalpha.com/news/3474546-european-advisory-group-backs-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-01T08:00:00.000+08:00,"Cox Capital Co LLC Buys Digital Realty Trust Inc, AbbVie Inc, CVS Health Corp, Sells SPDR ...",LLY,http://www.gurufocus.com/news/902416/cox-capital-co-llc-buys-digital-realty-trust-inc-abbvie-inc-cvs-health-corp-sells-spdr-sp-500-royal-bank-of-canada-stock-yards-bancorp-inc,GuruFocus,,,,,,
2019-07-02T08:00:00.000+08:00,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH,LLY,https://www.benzinga.com/general/biotech/19/07/14016302/entera-announces-initiation-of-phase-2-dose-ranging-study-for-oral-pth,Benzinga Newsdesk,,,,,,
2019-07-02T08:00:00.000+08:00,Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity,LLY,https://seekingalpha.com/article/4273141-bristol-myers-otezla-divestiture-highlights-compelling-opportunity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-02T08:00:00.000+08:00,U.S. drugmakers institute new round of increases,LLY,https://seekingalpha.com/news/3475290-u-s-drugmakers-institute-new-round-increases?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-02T08:00:00.000+08:00,Gilead to Submit NDA for Inflammation Drug Filgotinib in '19,LLY,http://www.zacks.com/stock/news/437135/gilead-to-submit-nda-for-inflammation-drug-filgotinib-in-19?cid=CS-BENZ-FT-437135,Zacks,,,,,,
2019-07-02T08:00:00.000+08:00,M&A Activity A Favored Prescription For Biopharmaceutical Companies,LLY,https://seekingalpha.com/article/4273095-m-activity-favored-prescription-biopharmaceutical-companies?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-03T08:00:00.000+08:00,Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab,LLY,http://www.zacks.com/stock/news/437675/incyte-out-licenses-incmga0012-rights-in-china-to-zai-lab?cid=CS-BENZ-FT-437675,Zacks,,,,,,
2019-07-03T08:00:00.000+08:00,Will the Pharma Space Witness More Mega-Merger Deals in 2H?,LLY,http://www.zacks.com/stock/news/437588/will-the-pharma-space-witness-more-mega-merger-deals-in-2h?cid=CS-BENZ-FT-437588,Zacks,,,,,,
2019-07-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/437556/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-437556,Zacks,,,,,,
2019-07-04T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 84,LLY,https://seekingalpha.com/article/4273467-bulletproof-investing-performance-update-week-84?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-05T08:00:00.000+08:00,"Verde Servicos Internacionais S.A. Buys iShares Inc MSCI Brazil, NXP Semiconductors NV, ...",LLY,http://www.gurufocus.com/news/904387/verde-servicos-internacionais-sa-buys-ishares-inc-msci-brazil-nxp-semiconductors-nv-dominos-pizza-inc-sells-pagseguro-digital-visa-inc-microsoft-corp,GuruFocus,,,,,,
2019-07-05T08:00:00.000+08:00,Drug stocks slip after Trump talks up 'favored nations' plan,LLY,https://seekingalpha.com/news/3475917-drug-stocks-slip-trump-talks-favored-nations-plan?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-05T08:00:00.000+08:00,A First-Half Review Of The Markets,LLY,https://seekingalpha.com/article/4273561-first-half-review-markets?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-06T08:00:00.000+08:00,Most Favored Nation Protection For Abbott Laboratories,LLY,https://seekingalpha.com/article/4273686-favored-nation-protection-abbott-laboratories?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-08T08:00:00.000+08:00,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads,LLY,https://www.benzinga.com/news/19/07/14043197/u-s-judge-halts-trump-administration-rule-requiring-drug-prices-in-tv-ads,Charles Gross,,,,,,
2019-07-08T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",LLY,https://www.benzinga.com/markets/wiim/19/07/14041064/shares-of-several-healthcare-companies-are-trading-lower-after-trump-on-friday-said-he-was-preparing,Benzinga Newsdesk,,,,,,
2019-07-08T08:00:00.000+08:00,Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS,LLY,https://seekingalpha.com/news/3476366-biophytis-files-8_75m-share-u-s-ipo-7-9-ads?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-08T08:00:00.000+08:00,Biotechs and biopharmas under pressure ahead of Trump order on drug prices,LLY,https://seekingalpha.com/news/3476265-biotechs-biopharmas-pressure-ahead-trump-order-drug-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-09T08:00:00.000+08:00,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials,LLY,https://www.benzinga.com/government/19/07/14045927/judge-rules-against-trump-proposal-forcing-pharma-companies-to-disclose-drug-prices-in-commercials,Jayson Derrick,,,,,,
2019-07-09T08:00:00.000+08:00,"Ready, Set, Fedspeak (Wall Street Breakfast Podcast)",LLY,https://seekingalpha.com/article/4274018-ready-set-fedspeak-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-09T08:00:00.000+08:00,"Wall Street Breakfast: Ready, Set, Fedspeak",LLY,https://seekingalpha.com/article/4274002-wall-street-breakfast-ready-set-fedspeak?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-09T08:00:00.000+08:00,Rule requiring drug prices in TV ads blocked,LLY,https://seekingalpha.com/news/3476378-rule-requiring-drug-prices-tv-ads-blocked?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-10T08:00:00.000+08:00,Enbridge Portfolio: Final Performance,LLY,https://seekingalpha.com/article/4274346-enbridge-portfolio-final-performance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-10T08:00:00.000+08:00,Eli Lilly And Baricitinib In PBC: What's The Story?,LLY,https://seekingalpha.com/article/4274342-eli-lilly-baricitinib-pbc-story?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-10T08:00:00.000+08:00,"Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific",LLY,http://www.zacks.com/research-daily/440507/top-stock-reports-for-bank-of-america-eli-lilly-boston-scientific?cid=CS-BENZ-FT-440507,Zacks,,,,,,
2019-07-10T08:00:00.000+08:00,"Court Ruling Topples Trump Order, No Price Display in TV Ads",LLY,http://www.zacks.com/stock/news/440524/court-ruling-topples-trump-order-no-price-display-in-tv-ads?cid=CS-BENZ-FT-440524,Zacks,,,,,,
2019-07-11T08:00:00.000+08:00,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/07/14061352/shares-of-several-drug-manufacturing-companies-are-trading-lower-the-trump-administration-earlier-ro,Hal Lindon,,,,,,
2019-07-11T08:00:00.000+08:00,Eli Lilly Names Mike Harrington New General Counsel,LLY,https://www.benzinga.com/news/19/07/14059758/eli-lilly-names-mike-harrington-new-general-counsel,Benzinga Newsdesk,,,,,,
2019-07-11T08:00:00.000+08:00,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine',LLY,https://www.benzinga.com/news/19/07/14058909/eli-lilly-highlights-phase-3-study-results-of-emgality-for-treatment-of-episodic-cluster-headache-pu,Benzinga Newsdesk,,,,,,
2019-07-11T08:00:00.000+08:00,Here's Why The Stock Market May Make Its Next Move Higher On July 12,LLY,https://www.benzinga.com/node/14064708,TalkMarkets,,,,,,
2019-07-11T08:00:00.000+08:00,Big Biopharma in the red as investors wait for Trump's drug price plan,LLY,https://seekingalpha.com/news/3477237-big-biopharma-red-investors-wait-trumps-drug-price-plan?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-11T08:00:00.000+08:00,4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal,LLY,http://www.zacks.com/stock/news/441257/4-medical-stocks-to-consider-after-federal-judge-blocks-trump-proposal?cid=CS-BENZ-FT-441257,Zacks,,,,,,
2019-07-11T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 85,LLY,https://seekingalpha.com/article/4274520-bulletproof-investing-performance-update-week-85?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices",LLY,http://www.zacks.com/stock/news/441141/the-zacks-analyst-blog-highlights-bank-of-america-eli-lilly-boston-scientific-schwab-and-advanced-micro-devices?cid=CS-BENZ-FT-441141,Zacks,,,,,,
2019-07-11T08:00:00.000+08:00,Lilly Bio-Medicines chief to depart next month; shares down 3%,LLY,https://seekingalpha.com/news/3477097-lilly-bio-medicines-chief-depart-next-month-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-12T08:00:00.000+08:00,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14067050/novartis-amgen-scrap-pivotal-study-of-alzheimers-prevention-drug,Shanthi Rexaline,,,,,,
2019-07-12T08:00:00.000+08:00,Stock Market Eyes Records On Dovish Commentary From Federal Reserve,LLY,https://www.benzinga.com/news/19/07/14067261/stock-market-eyes-records-on-dovish-commentary-from-federal-reserve,JJ Kinahan,,,,,,
2019-07-12T08:00:00.000+08:00,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",LLY,https://www.benzinga.com/markets/wiim/19/07/14067031/shares-of-several-drug-manufacturing-companies-are-trading-lower-potentially-on-continued-weakness-a,Benzinga Newsdesk,,,,,,
2019-07-12T08:00:00.000+08:00,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study,LLY,https://www.benzinga.com/news/19/07/14066258/eli-lilly-highlights-upcoming-presentation-of-data-from-overcome-study,Benzinga Newsdesk,,,,,,
2019-07-12T08:00:00.000+08:00,"Univest Corp Of Pennsylvania Buys Monster Beverage Corp, Vanguard Total Bond Market ETF, ...",LLY,http://www.gurufocus.com/news/908234/univest-corp-of-pennsylvania-buys-monster-beverage-corp-vanguard-total-bond-market-etf-fastenal-co-sells-ugi-corp-spdr-select-sector-fund--consumer-staples-eli-lilly-and-co,GuruFocus,,,,,,
2019-07-12T08:00:00.000+08:00,Drug Pricing Woes Linger on Repealing Drug Rebate Proposal,LLY,http://www.zacks.com/stock/news/441711/drug-pricing-woes-linger-on-repealing-drug-rebate-proposal?cid=CS-BENZ-FT-441711,Zacks,,,,,,
2019-07-12T08:00:00.000+08:00,"Handelsbanken Fonder AB Buys AbbVie Inc, Columbia Sportswear Co, Boingo Wireless Inc, Sells ...",LLY,http://www.gurufocus.com/news/907957/handelsbanken-fonder-ab-buys-abbvie-inc-columbia-sportswear-co-boingo-wireless-inc-sells-johnson--johnson-apple-inc-mellanox-technologies,GuruFocus,,,,,,
2019-07-12T08:00:00.000+08:00,Pooled post-hoc data support efficacy of Lilly's migraine med Emaglity,LLY,https://seekingalpha.com/news/3477375-pooled-post-hoc-data-support-efficacy-lillys-migraine-med-emaglity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-13T08:00:00.000+08:00,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More",LLY,https://www.benzinga.com/media/19/07/14070792/barrons-picks-and-pans-dollar-tree-expedia-nvidia-prudential-and-more,Nelson Hem,,,,,,
2019-07-13T08:00:00.000+08:00,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study,LLY,https://www.benzinga.com/news/19/07/14070774/lilly-presents-new-findings-on-stigma-faced-by-people-with-migraine-based-on-interim-results-from-th,Charles Gross,,,,,,
2019-07-14T08:00:00.000+08:00,45 Fortune 500 Stocks Projected Top Total Returns To Investors To July 2020,LLY,https://seekingalpha.com/article/4274872-45-fortune-500-stocks-projected-top-total-returns-investors-july-2020?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-14T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 14, 2019",LLY,https://www.benzinga.com/node/14071181,TalkMarkets,,,,,,
2019-07-15T08:00:00.000+08:00,"Legacy Advisors, LLC Buys DuPont de Nemours Inc, PNC Financial Services Group Inc, Wells Fargo, ...",LLY,http://www.gurufocus.com/news/908995/legacy-advisors-llc-buys-dupont-de-nemours-inc-pnc-financial-services-group-inc-wells-fargo-sells-spdr-midcap-trust-series-i-spdr-sp-500-ishares-core-sp-500,GuruFocus,,,,,,
2019-07-15T08:00:00.000+08:00,AbbVie enters STING field with Mavupharma buy,LLY,https://seekingalpha.com/news/3477651-abbvie-enters-sting-field-mavupharma-buy?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-16T08:00:00.000+08:00,"Jim Cramer Weighs In On Marvell, General Motors And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/07/14078178/jim-cramer-weighs-in-on-marvell-general-motors-and-more,Brett Hershman,,,,,,
2019-07-16T08:00:00.000+08:00,Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path,LLY,https://seekingalpha.com/article/4275289-recent-progress-filgotinib-plus-latest-partnership-expansion-points-gileads-new-solid-path?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-16T08:00:00.000+08:00,"Gradient Investments LLC Buys SPDR Portfolio Short Term Corporate Bond, iShares MBS ETF, ...",LLY,http://www.gurufocus.com/news/909658/gradient-investments-llc-buys-spdr-portfolio-short-term-corporate-bond-ishares-mbs-etf-ishares-sp-500-value-sells-vanguard-intermediateterm-corporate-bond-etf-spdr-wells-fargo-preferred-stock-paychex-inc,GuruFocus,,,,,,
2019-07-16T08:00:00.000+08:00,"Whitnell & Co. Buys iShares Russell –……… Value, DuPont de Nemours Inc, Fastenal Co, ...",LLY,http://www.gurufocus.com/news/909659/whitnell--co-buys-ishares-russell-1000-value-dupont-de-nemours-inc-fastenal-co-sells-invesco-db-commodity-index-tracking-fund-ishares-russell-1000-growth-bank-of-america-corporation,GuruFocus,,,,,,
2019-07-16T08:00:00.000+08:00,ImmunoGen: Bold Move To Position A Comeback,LLY,https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease",LLY,https://www.benzinga.com/general/biotech/19/07/14086535/ac-immune-initiates-phase-1-study-of-aci-3024-small-molecule-tau-morphomer-an-investigational-tre,Benzinga Newsdesk,,,,,,
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase – Study of ACI-'…—4 Small Molecule Tau Morphomer™, an ...",LLY,http://www.gurufocus.com/news/910181/ac-immune-initiates-phase-1-study-of-aci3024-small-molecule-tau-morphomer-an-investigational-treatment-for-alzheimers-disease,GuruFocus,,,,,,
2019-07-18T08:00:00.000+08:00,"The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase",LLY,https://seekingalpha.com/article/4275850-pharma-scoop-vanda-meets-endpoints-aratana-acquired-einhorn-invests-neubase?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-18T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 86,LLY,https://seekingalpha.com/article/4275730-bulletproof-investing-performance-update-week-86?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-18T08:00:00.000+08:00,NuCana Initiates Dosing in Phase I Study for Solid Tumors,LLY,http://www.zacks.com/stock/news/444911/nucana-initiates-dosing-in-phase-i-study-for-solid-tumors?cid=CS-BENZ-FT-444911,Zacks,,,,,,
2019-07-18T08:00:00.000+08:00,AC Immune Initiates Phase I Study for Alzheimer's Disease,LLY,http://www.zacks.com/stock/news/444451/ac-immune-initiates-phase-i-study-for-alzheimers-disease?cid=CS-BENZ-FT-444451,Zacks,,,,,,
2019-07-18T08:00:00.000+08:00,Healthcare Sector Innovation: How Biopharma Scientists Save Lives Globally,LLY,https://seekingalpha.com/article/4275627-healthcare-sector-innovation-biopharma-scientists-save-lives-globally?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-19T08:00:00.000+08:00,"Bessemer Securities Llc Buys Kirkland Lake Gold, Eli Lilly and Co, Capri Holdings, Sells ...",LLY,http://www.gurufocus.com/news/912068/bessemer-securities-llc-buys-kirkland-lake-gold-eli-lilly-and-co-capri-holdings-sells-ishares-msci-pacific-exjapan-index-fund-green-plains-inc-unitedhealth-group-inc,GuruFocus,,,,,,
2019-07-19T08:00:00.000+08:00,Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?,LLY,http://www.zacks.com/stock/news/445359/eli-lilly-lly-is-a-top-dividend-stock-right-now-should-you-buy?cid=CS-BENZ-FT-445359,Zacks,,,,,,
2019-07-21T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 21, 2019",LLY,https://www.benzinga.com/node/14106904,TalkMarkets,,,,,,
2019-07-22T08:00:00.000+08:00,U.S. Senator introduces bill to cut insulin prices,LLY,https://seekingalpha.com/news/3479829-u-s-senator-introduces-bill-cut-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-22T08:00:00.000+08:00,Annovis Bio Begins U.S. IPO Effort,LLY,https://seekingalpha.com/article/4276487-annovis-bio-begins-u-s-ipo-effort?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-23T08:00:00.000+08:00,Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline,LLY,http://www.zacks.com/stock/news/447593/earnings-preview-eli-lilly-lly-q2-earnings-expected-to-decline?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-447593,Zacks,,,,,,
2019-07-24T08:00:00.000+08:00,Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World,LLY,https://seekingalpha.com/article/4277125-johnson-and-johnsons-stock-may-cheap-low-interest-rate-world?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-24T08:00:00.000+08:00,Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/448183/eli-lilly-lly-to-report-q2-earnings-whats-in-store?cid=CS-BENZ-FT-analyst_blog|earnings_preview-448183,Zacks,,,,,,
2019-07-25T08:00:00.000+08:00,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14130982/the-daily-biotech-pulse-setback-for-bristol-myers-squibb-gemphire-explodes-lillys-nasal-low-blood,Shanthi Rexaline,,,,,,
2019-07-25T08:00:00.000+08:00,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older,LLY,https://www.benzinga.com/news/19/07/14130965/lilly-announces-fda-approval-of-baqsimi-to-treat-severe-hypoglycemia-in-adults-and-children-with-dia,Charles Gross,,,,,,
2019-07-25T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 87,LLY,https://seekingalpha.com/article/4277815-bulletproof-investing-performance-update-week-87?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-25T08:00:00.000+08:00,FDA OKs Lilly's glucagon nasal powder for severe low blood sugar,LLY,https://seekingalpha.com/news/3481457-fda-oks-lillys-glucagon-nasal-powder-severe-low-blood-sugar?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-26T08:00:00.000+08:00,Drug pricing bill passes Senate committee,LLY,https://seekingalpha.com/news/3482384-drug-pricing-bill-passes-senate-committee?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-26T08:00:00.000+08:00,"Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment",LLY,http://www.zacks.com/stock/news/450794/pharma-stock-roundup-gsk-bmy-q2-earnings-fda-nod-to-llys-hypoglycemia-treatment?cid=CS-BENZ-FT-analyst_blog|stock_roundup-450794,Zacks,,,,,,
2019-07-27T08:00:00.000+08:00,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",LLY,https://www.benzinga.com/general/biotech/19/07/14136579/the-week-ahead-in-biotech-pending-clinical-readouts-earnings-dominate,Shanthi Rexaline,,,,,,
2019-07-28T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 28th, 2019",LLY,https://www.benzinga.com/node/14147979,TalkMarkets,,,,,,
2019-07-29T08:00:00.000+08:00,Q2 Earnings Preview For Eli Lilly,LLY,https://www.benzinga.com/news/earnings-previews/19/07/14153044/earnings-preview-eli-lilly,Benzinga Newsdesk,,,,,,
2019-07-29T08:00:00.000+08:00,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",LLY,http://www.zacks.com/stock/news/452891/sanofi-sny-q2-earnings-top-dupixent-shines-eps-view-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-452891,Zacks,,,,,,
2019-07-29T08:00:00.000+08:00,What's in Store for Array BioPharma (ARRY) in Q4 Earnings?,LLY,http://www.zacks.com/stock/news/452742/whats-in-store-for-array-biopharma-arry-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-452742,Zacks,,,,,,
2019-07-29T08:00:00.000+08:00,DivGro Stocks Ranked By Quality Score,LLY,https://seekingalpha.com/article/4278548-divgro-stocks-ranked-quality-score?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting",LLY,https://www.benzinga.com/news/earnings/19/07/14160136/apple-on-todays-menu-with-starring-roles-from-china-talks-fed-meeting,JJ Kinahan,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly Reports Q2 Earnings Beat,LLY,https://www.benzinga.com/news/earnings/19/07/14158268/eli-lilly-reports-q2-earnings-beat,Tanzeel Akhtar,,,,,,
2019-07-30T08:00:00.000+08:00,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",LLY,https://www.benzinga.com/general/biotech/19/07/14156757/the-daily-biotech-pulse-european-cheer-for-merck-legal-victory-for-coherus-medpace-picks-up-on-ea,Shanthi Rexaline,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.,LLY,https://www.benzinga.com/news/19/07/14157310/eli-lilly-sees-fy19-adj-eps-5-67-5-77-vs-5-66-est,Benzinga Newsdesk,,,,,,
2019-07-30T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate",LLY,https://www.benzinga.com/news/earnings/19/07/14157307/eli-lilly-q2-adj-eps-1-5-beats-1-45-estimate-sales-5-637b-beat-5-59b-estimate,Benzinga Newsdesk,,,,,,
2019-07-30T08:00:00.000+08:00,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The Clinical Trial,LLY,https://www.benzinga.com/general/biotech/19/07/14157155/lilly-announces-verzenio-demonstrated-significant-improvement-in-overall-survival-in-phase-3-mona,Benzinga Newsdesk,,,,,,
2019-07-30T08:00:00.000+08:00,"15 Stocks To Watch For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156849/15-stocks-to-watch-for-july-30-2019,Lisa Levin,,,,,,
2019-07-30T08:00:00.000+08:00,"Earnings Scheduled For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156797/earnings-scheduled-for-july-30-2019,Lisa Levin,,,,,,
2019-07-30T08:00:00.000+08:00,Flexion: The Time To Buy Is Now,LLY,https://seekingalpha.com/article/4279278-flexion-time-buy-now?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q2 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4279204-eli-lilly-companys-lly-ceo-dave-ricks-q2-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,"Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/453958/incyte-incy-q2-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-453958,Zacks,,,,,,
2019-07-30T08:00:00.000+08:00,"Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up",LLY,http://www.zacks.com/stock/news/453957/lilly-lly-q2-earnings-beat-new-drugs-drive-sales-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-453957,Zacks,,,,,,
2019-07-30T08:00:00.000+08:00,"Svenska Handelsbanken AB (publ) Buys Welbilt Inc, Eli Lilly and Co, Service Corp International, ...",LLY,http://www.gurufocus.com/news/918292/svenska-handelsbanken-ab-publ-buys-welbilt-inc-eli-lilly-and-co-service-corp-international-sells-worldpay-inc-svb-financial-group-facebook-inc,GuruFocus,,,,,,
2019-07-30T08:00:00.000+08:00,Economic and Earnings Date Deluge,LLY,http://www.zacks.com/stock/news/453798/economic-and-earnings-date-deluge?cid=CS-BENZ-FT-economic_highlights-453798,Zacks,,,,,,
2019-07-30T08:00:00.000+08:00,"Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More",LLY,http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-BENZ-FT-ahead_of_wall_street-453588,Zacks,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q2 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4278944-eli-lilly-company-2019-q2-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,5 Monster Stocks To Watch For the July 30 Trading Session,LLY,https://www.benzinga.com/node/14159964,TalkMarkets,,,,,,
2019-07-30T08:00:00.000+08:00,Trump readies plan allow drug imports from Canada,LLY,https://seekingalpha.com/news/3483442-trump-readies-plan-allow-drug-imports-canada?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly (LLY) Tops Q2 Earnings Estimates,LLY,http://www.zacks.com/stock/news/453335/eli-lilly-lly-tops-q2-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-453335,Zacks,,,,,,
2019-07-30T08:00:00.000+08:00,Eli Lilly up 1% premarket on Q2 beat,LLY,https://seekingalpha.com/news/3483330-eli-lilly-1-percent-premarket-q2-beat?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,Lilly's abemaciclib extends survival in late-stage breast cancer study,LLY,https://seekingalpha.com/news/3483290-lillys-abemaciclib-extends-survival-late-stage-breast-cancer-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-30T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.05, beats on revenue",LLY,https://seekingalpha.com/news/3483225-eli-lilly-eps-beats-0_05-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,,,
2019-07-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/07/14151998/attention-biotech-investors-mark-your-calendar-for-these-august-pdufa-dates,Shanthi Rexaline,,,,,,
2019-07-31T08:00:00.000+08:00,"Stevens Capital Management Lp Buys Merck Inc, Eli Lilly and Co, Morgan Stanley, Sells Duke ...",LLY,http://www.gurufocus.com/news/919699/stevens-capital-management-lp-buys-merck-inc-eli-lilly-and-co-morgan-stanley-sells-duke-energy-corp-cme-group-inc-cognizant-technology-solutions-corp,GuruFocus,,,,,,
2019-07-31T08:00:00.000+08:00,Wall Street Breakfast: First Rate Cut Since The Financial Crisis,LLY,https://seekingalpha.com/article/4279398-wall-street-breakfast-first-rate-cut-since-financial-crisis?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-02T08:00:00.000+08:00,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products",LLY,https://www.benzinga.com/news/19/08/14193688/eli-lilly-10-q-shows-co-received-subpoena-from-new-york-attorney-generals-office-civil-investigative,Benzinga Newsdesk,,,,,,
2019-08-02T08:00:00.000+08:00,Lilly subpoenaed over insulin pricing,LLY,https://seekingalpha.com/news/3486445-lilly-subpoenaed-insulin-pricing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-02T08:00:00.000+08:00,"Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger",LLY,http://www.zacks.com/stock/news/457515/pharma-stock-roundup-pfe-mrk-lly-q2-earnings-upjohn-myl-merger?cid=CS-BENZ-FT-analyst_blog|stock_roundup-457515,Zacks,,,,,,
2019-08-05T08:00:00.000+08:00,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.,LLY,https://www.benzinga.com/markets/wiim/19/08/14202009/shares-of-several-drugpharma-companies-trading-lower-given-weakness-in-broader-stock-market-followin,Benzinga Newsdesk,,,,,,
2019-08-05T08:00:00.000+08:00,Eli Lilly Announces Positive Results For Emgality,LLY,https://www.benzinga.com/news/19/08/14198981/eli-lilly-announces-positive-results-for-emgality,Tanzeel Akhtar,,,,,,
2019-08-05T08:00:00.000+08:00,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments,LLY,https://www.benzinga.com/news/19/08/14198592/lilly-announces-positive-results-for-emgality-from-the-conquer-study-in-patients-who-failed-previous,Benzinga Newsdesk,,,,,,
2019-08-05T08:00:00.000+08:00,Lexicon Pharmaceuticals Now Walking A Fine Line,LLY,https://seekingalpha.com/article/4281646-lexicon-pharmaceuticals-now-walking-fine-line?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2019 Update,LLY,https://seekingalpha.com/article/4281629-tracking-ken-fishers-fisher-asset-management-portfolio-q2-2019-update?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-05T08:00:00.000+08:00,Lilly's Emgality successful in late-stage study in treatment-resistant migraine,LLY,https://seekingalpha.com/news/3486658-lillys-emgality-successful-late-stage-study-treatment-resistant-migraine?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-06T08:00:00.000+08:00,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today.",LLY,https://www.benzinga.com/markets/wiim/19/08/14211788/eli-lilly-shares-trading-higher-rebounding-following-a-more-than-3-decline-on-monday-not-seeing-comp,Benzinga Newsdesk,,,,,,
2019-08-07T08:00:00.000+08:00,"Trellis Advisors, LLC Buys Amgen Inc, Eli Lilly and Co, Laboratory Corp of America Holdings",LLY,http://www.gurufocus.com/news/923921/trellis-advisors-llc-buys-amgen-inc-eli-lilly-and-co-laboratory-corp-of-america-holdings,GuruFocus,,,,,,
2019-08-07T08:00:00.000+08:00,Companies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity,LLY,https://seekingalpha.com/article/4282760-companies-healthcare-sector-consider-avoid-taking-account-patent-activity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-07T08:00:00.000+08:00,Execs on the move at Eli Lilly,LLY,https://seekingalpha.com/news/3488482-execs-move-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-08T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.,LLY,https://www.benzinga.com/markets/wiim/19/08/14232030/eli-lilly-shares-are-trading-higher-after-the-company-announced-positive-results-for-emgality-from-t,Benzinga Newsdesk,,,,,,
2019-08-08T08:00:00.000+08:00,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",LLY,https://www.benzinga.com/news/19/08/14228163/lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-identification,Charles Gross,,,,,,
2019-08-08T08:00:00.000+08:00,"Top Stock Reports: Disney, Eli Lilly, ADP & More",LLY,http://www.zacks.com/research-daily/461336/top-stock-reports-disney-eli-lilly-adp-more?cid=CS-BENZ-FT-research_daily-461336,Zacks,,,,,,
2019-08-08T08:00:00.000+08:00,"Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid",LLY,http://www.zacks.com/stock/news/461339/radius-rdus-q2-earnings-beat-estimates-tymlos-sales-solid?cid=CS-BENZ-FT-analyst_blog|earnings_article-461339,Zacks,,,,,,
2019-08-08T08:00:00.000+08:00,"Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down",LLY,http://www.zacks.com/stock/news/461108/teva-teva-q2-earnings-sales-top-estimates-cfo-steps-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-461108,Zacks,,,,,,
2019-08-08T08:00:00.000+08:00,Apple devices + mobile apps show potential to screen for Alzheimer's,LLY,https://seekingalpha.com/news/3489350-apple-devices-mobile-apps-show-potential-screen-alzheimers?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-09T08:00:00.000+08:00,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit,LLY,https://www.benzinga.com/news/19/08/14241295/eli-lilly-shares-unaffected-as-hearing-us-appeals-court-ruled-in-favor-of-co-in-alimta-alternate-sal,Benzinga Newsdesk,,,,,,
2019-08-09T08:00:00.000+08:00,"Intersect Capital LLC Buys Lockheed Martin Corp, Vornado Realty Trust, Berkshire Hathaway Inc, ...",LLY,http://www.gurufocus.com/news/925859/intersect-capital-llc-buys-lockheed-martin-corp-vornado-realty-trust-berkshire-hathaway-inc-sells-source-capital-inc-dupont-de-nemours-inc-amerigas-partners-lp,GuruFocus,,,,,,
2019-08-09T08:00:00.000+08:00,Lilly prevails in Alimta patent challenge,LLY,https://seekingalpha.com/news/3490347-lilly-prevails-alimta-patent-challenge?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-09T08:00:00.000+08:00,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2,LLY,http://www.zacks.com/stock/news/462902/intrexon-xon-reports-narrower-than-expected-loss-in-q2?cid=CS-BENZ-FT-analyst_blog|earnings_article-462902,Zacks,,,,,,
2019-08-09T08:00:00.000+08:00,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients",LLY,http://www.zacks.com/stock/news/462666/pharma-stock-roundup-agn-nvo-earnings-eu-nod-to-sny-abbv-drugs-for-new-patients?cid=CS-BENZ-FT-analyst_blog|stock_roundup-462666,Zacks,,,,,,
2019-08-10T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of August 11,LLY,https://seekingalpha.com/article/4284406-dividend-challenger-highlights-week-august-11?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-12T08:00:00.000+08:00,Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality,LLY,https://seekingalpha.com/article/4285002-eli-lilly-looks-positive-data-expand-market-opportunity-emgality?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-12T08:00:00.000+08:00,Q2 Biotech Updates,LLY,https://seekingalpha.com/article/4284783-q2-biotech-updates?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-13T08:00:00.000+08:00,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study,LLY,https://www.benzinga.com/general/biotech/19/08/14256933/lillys-psoriasis-drug-found-superior-to-j-js-tremfya-in-phase-4-study,Shanthi Rexaline,,,,,,
2019-08-13T08:00:00.000+08:00,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study,LLY,https://www.benzinga.com/general/biotech/19/08/14254207/lilly-announces-taltz-met-primary-and-all-major-secondary-endpoints-in-phase-4-ixora-r-study,Benzinga Newsdesk,,,,,,
2019-08-13T08:00:00.000+08:00,Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study,LLY,https://seekingalpha.com/news/3490959-lillys-taltz-beats-j-and-js-tremfya-post-market-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",LLY,https://www.benzinga.com/markets/wiim/19/08/14267484/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-after-t,Benzinga Newsdesk,,,,,,
2019-08-14T08:00:00.000+08:00,Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study,LLY,http://www.zacks.com/stock/news/470170/lillys-taltz-outshines-jjs-tremfya-in-psoriasis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-470170,Zacks,,,,,,
2019-08-15T08:00:00.000+08:00,"Gotham Asset Management, LLC Buys Intuit Inc, Oracle Corp, Cisco Systems Inc, Sells PayPal ...",LLY,http://www.gurufocus.com/news/929108/gotham-asset-management-llc-buys-intuit-inc-oracle-corp-cisco-systems-inc-sells-paypal-holdings-inc-wells-fargo-the-chemours-co,GuruFocus,,,,,,
2019-08-15T08:00:00.000+08:00,Agios Rides High on Tibsovo Sales Amid Acute Competition,LLY,http://www.zacks.com/stock/news/471900/agios-rides-high-on-tibsovo-sales-amid-acute-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-471900,Zacks,,,,,,
2019-08-16T08:00:00.000+08:00,FDA OKs AbbVie's Rinvoq rheumatoid arthritis; shares up 2%,LLY,https://seekingalpha.com/news/3492652-fda-oks-abbvies-rinvoq-rheumatoid-arthritis-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-16T08:00:00.000+08:00,Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe,LLY,http://www.zacks.com/stock/news/473330/gileads-gild-filgotinib-maa-for-ra-accepted-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-473330,Zacks,,,,,,
2019-08-18T08:00:00.000+08:00,AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue,LLY,https://seekingalpha.com/article/4286448-abbvies-fda-approval-rinvoq-sets-first-phase-deployment-plan-counter-humira-issue?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-19T08:00:00.000+08:00,Eli Lilly Taltz Data Points To A Solid Push Into The Psoriasis Space,LLY,https://seekingalpha.com/article/4286654-eli-lilly-taltz-data-points-solid-push-psoriasis-space?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-19T08:00:00.000+08:00,Roche prices Rozlytrek below Bayer & Lilly's Vitrakvi,LLY,https://seekingalpha.com/news/3492803-roche-prices-rozlytrek-bayer-and-lillys-vitrakvi?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-19T08:00:00.000+08:00,High-Quality Dividend Stocks,LLY,https://seekingalpha.com/article/4286474-high-quality-dividend-stocks?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-21T08:00:00.000+08:00,NuCana Stops Patient Enrollment in Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/481254/nucana-stops-patient-enrollment-in-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-481254,Zacks,,,,,,
2019-08-21T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/480986/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-480986,Zacks,,,,,,
2019-08-22T08:00:00.000+08:00,AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China,LLY,http://www.zacks.com/stock/news/483440/astrazenecas-kidney-drug-roxadustat-gets-second-nod-in-china?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-483440,Zacks,,,,,,
2019-08-22T08:00:00.000+08:00,Novo Nordisk: A Secular Growth Engine,LLY,https://seekingalpha.com/article/4287453-novo-nordisk-secular-growth-engine?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-22T08:00:00.000+08:00,Satsuma Pharmaceuticals Files For U.S. IPO,LLY,https://seekingalpha.com/article/4287341-satsuma-pharmaceuticals-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-22T08:00:00.000+08:00,MannKind - 'Fireside' Chat With CEO Mike Castagna,LLY,https://seekingalpha.com/article/4287312-mannkind-fireside-chat-ceo-mike-castagna?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-23T08:00:00.000+08:00,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019",LLY,https://www.benzinga.com/general/biotech/19/08/14321502/eli-lilly-reports-baricitinib-met-primary-endpoint-in-breeze-ad7-third-pivotal-phase-3-trial-in-b,Benzinga Newsdesk,,,,,,
2019-08-23T08:00:00.000+08:00,Lilly's baricitinib successful in third late-stage dermatitis study,LLY,https://seekingalpha.com/news/3494415-lillys-baricitinib-successful-third-late-stage-dermatitis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-23T08:00:00.000+08:00,Arbitration panel backs Lilly in dispute with former collaboration partner Adocia,LLY,https://seekingalpha.com/news/3494272-arbitration-panel-backs-lilly-dispute-former-collaboration-partner-adocia?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-24T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal,LLY,https://www.benzinga.com/node/14323616,TalkMarkets,,,,,,
2019-08-24T08:00:00.000+08:00,Elanco: Greater Risks And Rewards Following The Bayer Deal,LLY,https://seekingalpha.com/article/4287727-elanco-greater-risks-rewards-following-bayer-deal?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-25T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal,LLY,https://seekingalpha.com/article/4287759-week-review-biotheus-acquires-china-rights-3-bi-specifics-142-million-deal?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-26T08:00:00.000+08:00,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis,LLY,https://www.benzinga.com/news/19/08/14324889/lilly-receives-fda-approval-for-taltz-for-the-treatment-of-active-ankylosing-spondylitis,Charles Gross,,,,,,
2019-08-26T08:00:00.000+08:00,TFF Pharmaceuticals Readies $22 Million IPO,LLY,https://seekingalpha.com/article/4287981-tff-pharmaceuticals-readies-22-million-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-26T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study,LLY,http://www.zacks.com/stock/news/489424/lillys-olumiant-meets-primary-endpoint-in-3rd-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-489424,Zacks,,,,,,
2019-08-26T08:00:00.000+08:00,FDA OKs expanded use of Lilly's Taltz,LLY,https://seekingalpha.com/news/3494506-fda-oks-expanded-use-lillys-taltz?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-28T08:00:00.000+08:00,Eli Lilly's Latest Approval Adds To An Ever-Growing Market For Taltz,LLY,https://seekingalpha.com/article/4288535-eli-lillys-latest-approval-adds-ever-growing-market-taltz?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-28T08:00:00.000+08:00,J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?,LLY,http://www.zacks.com/stock/news/493075/jj-jnj-loses-landmark-opioid-case-whats-next-for-pharmaceuticals?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-493075,Zacks,,,,,,
2019-08-29T08:00:00.000+08:00,FDA tentatively OK's Mylan's pemetrexed; shares up 4%,LLY,https://seekingalpha.com/news/3495779-fda-tentatively-oks-mylans-pemetrexed-shares-4-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-29T08:00:00.000+08:00,Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/494219/lilly-lly-up-19-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-realtime_blog-494219,Zacks,,,,,,
2019-08-30T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3492969-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,,,
2019-08-31T08:00:00.000+08:00,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More",LLY,https://www.benzinga.com/media/19/08/14361134/barrons-picks-and-pans-activision-blizzard-best-buy-coca-cola-microsoft-and-more,Nelson Hem,,,,,,
2019-08-31T08:00:00.000+08:00,Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio,LLY,https://www.benzinga.com/node/14361212,TalkMarkets,,,,,,
2019-09-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie",LLY,http://www.zacks.com/stock/news/499580/the-zacks-analyst-blog-highlights-jj-eli-lilly-bristol-myers-roche-and-abbvie?cid=CS-BENZ-FT-press_releases-499580,Zacks,,,,,,
2019-09-03T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Add to Your Portfolio,LLY,http://www.zacks.com/stock/news/499386/5-cancer-fighting-stocks-to-add-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|investment_ideas-499386,Zacks,,,,,,
2019-09-04T08:00:00.000+08:00,Satsuma IPO: At Phase 3 Of Development,LLY,https://seekingalpha.com/article/4289688-satsuma-ipo-phase-3-development?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-04T08:00:00.000+08:00,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M,LLY,http://www.zacks.com/stock/news/501399/vertex-vrtx-inks-all-cash-deal-to-acquire-semma-for-%24950m?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-501399,Zacks,,,,,,
2019-09-05T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program,LLY,https://www.benzinga.com/news/19/09/14385756/eli-lilly-reports-fda-accepted-application-to-enter-complex-innovative-trial-designs-pilot-meeting-p,Benzinga Newsdesk,,,,,,
2019-09-05T08:00:00.000+08:00,Xeris: Preparing For The Gvoke PDUFA,LLY,https://seekingalpha.com/article/4290076-xeris-preparing-gvoke-pdufa?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-05T08:00:00.000+08:00,Lilly into FDA pilot program to modernize drug development,LLY,https://seekingalpha.com/news/3497458-lilly-fda-pilot-program-modernize-drug-development?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-05T08:00:00.000+08:00,AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC,LLY,http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503575,Zacks,,,,,,
2019-09-05T08:00:00.000+08:00,J&J's Stelara Gets Approval in EU for Ulcerative Colitis,LLY,http://www.zacks.com/stock/news/503348/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503348,Zacks,,,,,,
2019-09-06T08:00:00.000+08:00,"Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space",LLY,https://seekingalpha.com/article/4289833-xeris-pharmas-gvoke-strong-approval-chances-highly-competitive-space?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of September 8,LLY,https://seekingalpha.com/article/4290338-dividend-challenger-highlights-week-september-8?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-07T08:00:00.000+08:00,Vanguard Health Care ETF: A Good Fund To Benefit From An Ageing Demographic Trend,LLY,https://seekingalpha.com/article/4290324-vanguard-health-care-etf-good-fund-benefit-ageing-demographic-trend?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-07T08:00:00.000+08:00,"Stocks To Watch: Apple, IPOs And German Auto",LLY,https://seekingalpha.com/article/4290308-stocks-watch-apple-ipos-german-auto?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-08T08:00:00.000+08:00,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",LLY,https://www.benzinga.com/general/biotech/19/09/14385354/the-week-ahead-in-biotech-conference-presentations-ipo-news-flow-take-the-spotlight,Shanthi Rexaline,,,,,,
2019-09-08T08:00:00.000+08:00,"Apple, IPOs And German Auto (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4290354-apple-ipos-german-auto-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-09T08:00:00.000+08:00,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.,LLY,https://www.benzinga.com/markets/wiim/19/09/14398697/eli-lilly-shares-are-trading-lower-shares-traded-higher-in-mondays-pre-market-session-after-the-comp,Benzinga Newsdesk,,,,,,
2019-09-09T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/09/14396544/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,,,
2019-09-09T08:00:00.000+08:00,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/19/09/14395555/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a-68-percent-objective-res,Charles Gross,,,,,,
2019-09-09T08:00:00.000+08:00,"Wall Street's Top Stories For Monday, September 9, 2019",LLY,https://www.benzinga.com/node/14401753,TalkMarkets,,,,,,
2019-09-09T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow,LLY,https://seekingalpha.com/article/4290610-eli-lilly-company-lly-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-09T08:00:00.000+08:00,Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study,LLY,http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-509890,Zacks,,,,,,
2019-09-09T08:00:00.000+08:00,Thermo Fisher to develop companion diagnostic for Lilly's selpercatinib,LLY,https://seekingalpha.com/news/3497898-thermo-fisher-develop-companion-diagnostic-lillys-selpercatinib?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-09T08:00:00.000+08:00,Eli Lilly up 3% premarket on positive selpercatinib data,LLY,https://seekingalpha.com/news/3497844-eli-lilly-3-percent-premarket-positive-selpercatinib-data?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-10T08:00:00.000+08:00,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,LLY,https://www.benzinga.com/markets/wiim/19/09/14407152/shares-of-several-drugmakers-are-trading-lower-on-news-of-a-drug-pricing-bill-being-developed-by-hou,Benzinga Newsdesk,,,,,,
2019-09-10T08:00:00.000+08:00,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/19/09/14406163/bank-of-america-reiterates-neutral-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,,,
2019-09-10T08:00:00.000+08:00,Pfizer's Pneumococcal Vaccine Shows Potential in Infants,LLY,http://www.zacks.com/stock/news/511848/pfizers-pneumococcal-vaccine-shows-potential-in-infants?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-511848,Zacks,,,,,,
2019-09-10T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/510993/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-510993,Zacks,,,,,,
2019-09-10T08:00:00.000+08:00,"Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall",LLY,https://seekingalpha.com/article/4290590-novo-nordisk-joins-insulin-discount-party-prices-still-unlikely-fall?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-12T08:00:00.000+08:00,Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks,LLY,http://www.zacks.com/stock/news/514650/rising-p-e-an-often-ignored-trick-to-pick-5-winning-stocks?cid=CS-BENZ-FT-analyst_blog|rw-514650,Zacks,,,,,,
2019-09-13T08:00:00.000+08:00,FDA warns on rare side effect of breast cancer meds,LLY,https://seekingalpha.com/news/3499244-fda-warns-rare-side-effect-breast-cancer-meds?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival",LLY,http://www.zacks.com/stock/news/516999/zackscom-featured-highlights-include-columbia-sportswear-fossil-group-alexion-and-shoe-carnival?cid=CS-BENZ-FT-press_releases-516999,Zacks,,,,,,
2019-09-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others",LLY,http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-BENZ-FT-analyst_blog|stock_roundup-516828,Zacks,,,,,,
2019-09-16T08:00:00.000+08:00,Fitch Planning To Withdraw Ratings For Eli Lilly,LLY,https://www.benzinga.com/news/19/09/14436109/fitch-planning-to-withdraw-ratings-for-eli-lilly,Benzinga Newsdesk,,,,,,
2019-09-16T08:00:00.000+08:00,ADC Therapeutics Begins U.S. IPO Process,LLY,https://seekingalpha.com/article/4291811-adc-therapeutics-begins-u-s-ipo-process?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-16T08:00:00.000+08:00,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert,LLY,http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-BENZ-FT-analyst_blog|industry_focus-520833,Zacks,,,,,,
2019-09-17T08:00:00.000+08:00,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,LLY,https://www.benzinga.com/general/biotech/19/09/14433747/biotech-stock-on-the-radar-vtv-therapeutics-diabetes-pipeline,Shanthi Rexaline,,,,,,
2019-09-17T08:00:00.000+08:00,Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care,LLY,https://seekingalpha.com/article/4292021-kitov-pharma-ntminus-219-data-reveals-ability-reverse-pancreatic-cancer-drugs-resistance?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-17T08:00:00.000+08:00,Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck,LLY,http://www.zacks.com/stock/news/522796/alder-aldr-stock-up-on-acquisition-agreement-with-lundbeck?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-522796,Zacks,,,,,,
2019-09-17T08:00:00.000+08:00,"Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial",LLY,https://seekingalpha.com/article/4292001-lundbeck-makes-large-m-move-target-will-somewhat-controversial?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-20T08:00:00.000+08:00,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,LLY,https://www.benzinga.com/markets/wiim/19/09/14466308/shares-of-several-drug-companies-are-trading-higher-after-senate-majority-leader-mcconnell-suggested,Benzinga Newsdesk,,,,,,
2019-09-20T08:00:00.000+08:00,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program,LLY,https://www.benzinga.com/general/biotech/19/09/14463538/ac-immune-receives-first-milestone-payment-from-lilly-in-small-molecule-tau-morphomer-program,Benzinga Newsdesk,,,,,,
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/19/09/14463459/chmp-issues-positive-opinion-to-expand-lillys-trulicity-label-to-include-results-from-rewind-card,Benzinga Newsdesk,,,,,,
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,http://www.gurufocus.com/news/950178/3-pharmaceutical-companies-to-consider-as-lawmakers-continue-to-fight-for-lower-drug-prices,GuruFocus,,,,,,
2019-09-20T08:00:00.000+08:00,Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open,LLY,https://seekingalpha.com/article/4292757-nektar-hammered-multiple-setbacks-core-efficacy-questions-remain-open?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,https://www.benzinga.com/node/14468003,GuruFocus,,,,,,
2019-09-20T08:00:00.000+08:00,Drug makers up after McConnell thumbs down on Pelosi price pricing plan,LLY,https://seekingalpha.com/news/3500811-drug-makers-mcconnell-thumbs-pelosi-price-pricing-plan?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14464594,GuruFocus,,,,,,
2019-09-20T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3498627-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-20T08:00:00.000+08:00,European advisory group backs label update to Lilly's Trulicity,LLY,https://seekingalpha.com/news/3500736-european-advisory-group-backs-label-update-lillys-trulicity?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-20T08:00:00.000+08:00,AC Immune earns CHF30M milestone from Eli Lilly,LLY,https://seekingalpha.com/news/3500733-ac-immune-earns-chf30m-milestone-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-23T08:00:00.000+08:00,Eli Lilly to Present Data at the European Society for Medical Oncology,LLY,https://www.benzinga.com/news/19/09/14470457/eli-lilly-to-present-data-at-the-european-society-for-medical-oncology,Benzinga Newsdesk,,,,,,
2019-09-23T08:00:00.000+08:00,Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids,LLY,http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-532006,Zacks,,,,,,
2019-09-23T08:00:00.000+08:00,Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label,LLY,http://www.zacks.com/stock/news/531931/lilly-gets-chmp-nod-to-add-heart-indication-to-trulicity-label?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-531931,Zacks,,,,,,
2019-09-25T08:00:00.000+08:00,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company,Shanthi Rexaline,,,,,,
2019-09-25T08:00:00.000+08:00,"Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach",LLY,https://seekingalpha.com/article/4293545-eli-lilly-throws-hat-ring-lung-cancer-space-takes-targeted-treatment-approach?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-26T08:00:00.000+08:00,Immuno-Oncology Firm Innate Pharma Files For U.S. IPO,LLY,https://seekingalpha.com/article/4293772-immuno-oncology-firm-innate-pharma-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-26T08:00:00.000+08:00,6 Declining Stocks in Gurus' Portfolios,LLY,https://www.benzinga.com/node/14499201,GuruFocus,,,,,,
2019-09-26T08:00:00.000+08:00,IPO Update: ADC Therapeutics Readies $200 Million IPO,LLY,https://seekingalpha.com/article/4293669-ipo-update-adc-therapeutics-readies-200-million-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-26T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/536794/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-536794,Zacks,,,,,,
2019-09-27T08:00:00.000+08:00,IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA,LLY,http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-539102,Zacks,,,,,,
2019-09-27T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3500469-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-28T08:00:00.000+08:00,"Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx",LLY,https://seekingalpha.com/article/4293999-stocks-watch-spotlight-microsoft-tesla-xilinx?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 9/23/19,LLY,https://seekingalpha.com/article/4293985-daily-insider-ratings-round-9-23-19?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-29T08:00:00.000+08:00,"Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4294031-spotlight-microsoft-tesla-xilinx-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-30T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/09/14491876/attention-biotech-investors-mark-your-calendar-for-these-october-pdufa-dates,Shanthi Rexaline,,,,,,
2019-09-30T08:00:00.000+08:00,IPO Update: Annovis Bio Readies $10 Million IPO,LLY,https://seekingalpha.com/article/4294246-ipo-update-annovis-bio-readies-10-million-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-09-30T08:00:00.000+08:00,Earnings Estimates/Revisions - Healthcare,LLY,https://www.benzinga.com/node/14513590,TalkMarkets,,,,,,
2019-10-02T08:00:00.000+08:00,Eli Lilly Highlights Availability Of Emgality In Canada,LLY,https://www.benzinga.com/news/19/10/14531514/eli-lilly-highlights-availability-of-emgality-in-canada,Benzinga Newsdesk,,,,,,
2019-10-02T08:00:00.000+08:00,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,LLY,https://www.benzinga.com/markets/wiim/19/10/14530664/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont,Benzinga Newsdesk,,,,,,
2019-10-02T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript),LLY,https://seekingalpha.com/article/4294651-eli-lilly-companys-lly-management-presents-lilly-oncology-update-esmo-2019-conference?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-02T08:00:00.000+08:00,Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study,LLY,http://www.zacks.com/stock/news/546049/agios-tibsovo-improves-survival-in-cholangiocarcinoma-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-546049,Zacks,,,,,,
2019-10-02T08:00:00.000+08:00,Novartis (NVS) Announces Data on Asthma Drugs & Kisqali,LLY,http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-545899,Zacks,,,,,,
2019-10-02T08:00:00.000+08:00,Lilly Oncology Update at ESMO,LLY,https://seekingalpha.com/article/4294544-lilly-oncology-update-esmo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-03T08:00:00.000+08:00,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,LLY,https://www.benzinga.com/general/biotech/19/10/14527152/biotech-stock-on-the-radar-fda-comes-calling-for-pfenex-osteoporosis-biosimilar,Shanthi Rexaline,,,,,,
2019-10-03T08:00:00.000+08:00,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/19/10/14536755/eli-lilly-highlights-head-to-head-data-showed-taltz-superiority-vs-tremfya-in-people-with-moderate-t,Benzinga Newsdesk,,,,,,
2019-10-03T08:00:00.000+08:00,"Top Research Reports for Bank of America, Home Depot & Philip Morris",LLY,http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-BENZ-FT-research_daily-547512,Zacks,,,,,,
2019-10-03T08:00:00.000+08:00,Why Lilly (LLY) Could Beat Earnings Estimates Again,LLY,http://www.zacks.com/stock/news/547471/why-lilly-lly-could-beat-earnings-estimates-again?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-547471,Zacks,,,,,,
2019-10-03T08:00:00.000+08:00,Novartis Reports Additional Data on Spondylitis Drug Cosentyx,LLY,http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-547460,Zacks,,,,,,
2019-10-03T08:00:00.000+08:00,Here's Why You Should Add Thermo Fisher to Your Portfolio,LLY,http://www.zacks.com/stock/news/547523/heres-why-you-should-add-thermo-fisher-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-547523,Zacks,,,,,,
2019-10-03T08:00:00.000+08:00,Eli Lilly issues positive update on Taltz,LLY,https://seekingalpha.com/news/3503655-eli-lilly-issues-positive-update-taltz?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-04T08:00:00.000+08:00,"Keytruda on path to become world's no. 1 selling drug, research firm says",LLY,https://seekingalpha.com/news/3504108-keytruda-path-become-worlds-1-selling-drug-research-firm-says?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-04T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly",LLY,http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-BENZ-FT-press_releases-548879,Zacks,,,,,,
2019-10-06T08:00:00.000+08:00,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",LLY,https://www.benzinga.com/general/biotech/19/10/14541123/the-week-ahead-in-biotech-pfenex-and-clinuvel-on-the-radar-ahead-of-fda-decisions-2-ipos-on-deck,Shanthi Rexaline,,,,,,
2019-10-07T08:00:00.000+08:00,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology,LLY,https://www.benzinga.com/news/19/10/14551487/eli-lilly-announces-that-phase-3-cyramza-results-were-published-in-the-journal-lancet-oncology,Benzinga Newsdesk,,,,,,
2019-10-07T08:00:00.000+08:00,IPO Update: Innate Pharma Readies Plan For U.S. IPO,LLY,https://seekingalpha.com/article/4295471-ipo-update-innate-pharma-readies-plan-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-07T08:00:00.000+08:00,"Enterprise Bank & Trust Co Buys Intercontinental Exchange Inc, Eli Lilly and Co, JPMorgan ...",LLY,https://www.benzinga.com/node/14555422,GuruFocus,,,,,,
2019-10-07T08:00:00.000+08:00,UCB challenges Roche patent covering IL-17-targeting antibodies,LLY,https://seekingalpha.com/news/3504267-ucb-challenges-roche-patent-covering-ilminus-17-targeting-antibodies?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-07T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14554389,GuruFocus,,,,,,
2019-10-07T08:00:00.000+08:00,Novo Nordisk Focuses on Pipeline Development Amid Competition,LLY,http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-552953,Zacks,,,,,,
2019-10-07T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Phase ' Data in First-Line EGFR-Mutated Non-Small Cell Lung ...,LLY,https://www.benzinga.com/node/14552200,GuruFocus,,,,,,
2019-10-07T08:00:00.000+08:00,FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket,LLY,https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-9-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-08T08:00:00.000+08:00,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,LLY,https://www.benzinga.com/markets/wiim/19/10/14561148/shares-of-several-healthcare-companies-are-trading-lower-with-the-broader-market-after-the-us-expand,Benzinga Newsdesk,,,,,,
2019-10-08T08:00:00.000+08:00,BioNTech IPO: What You Need To Know,LLY,https://www.benzinga.com/news/19/10/14555357/biontech-ipo-what-you-need-to-know,Shanthi Rexaline,,,,,,
2019-10-08T08:00:00.000+08:00,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13,LLY,https://www.benzinga.com/general/biotech/19/10/14558613/lilly-to-present-new-data-for-treatments-of-complex-dermatological-conditions-at-the-28th-annual-,Benzinga Newsdesk,,,,,,
2019-10-08T08:00:00.000+08:00,AbbVie and Roche price hike leaders past two years,LLY,https://seekingalpha.com/news/3504522-abbvie-roche-price-hike-leaders-past-two-years?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-08T08:00:00.000+08:00,"A Look At Merck's Keytruda And Other Headlines: The Good, Bad, And Ugly Of Biopharma",LLY,https://seekingalpha.com/article/4295583-look-mercks-keytruda-headlines-good-bad-ugly-biopharma?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-08T08:00:00.000+08:00,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the —8th ...,LLY,https://www.benzinga.com/node/14559287,GuruFocus,,,,,,
2019-10-08T08:00:00.000+08:00,MannKind: Q3 Afrezza Sales In The Books - Brazil Launch Pending,LLY,https://seekingalpha.com/article/4295537-mannkind-q3-afrezza-sales-books-brazil-launch-pending?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-09T08:00:00.000+08:00,"Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors",LLY,https://seekingalpha.com/article/4295800-novartis-delivers-breast-cancer-study-lead-major-battle-competitors?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-09T08:00:00.000+08:00,Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan,LLY,http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-556224,Zacks,,,,,,
2019-10-09T08:00:00.000+08:00,"First National Bank of Mount Dora, Trust Investmen Buys Eli Lilly and Co, TJX Inc, The Hartford ...",LLY,https://www.benzinga.com/node/14567666,GuruFocus,,,,,,
2019-10-10T08:00:00.000+08:00,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis",LLY,https://www.benzinga.com/news/19/10/14578853/lilly-says-taltz-met-primary-secondary-endpoints-of-ixora-r-study-in-people-with-moderate-to-severe,Charles Gross,,,,,,
2019-10-10T08:00:00.000+08:00,"Country Trust Bank Buys Ingersoll-Rand PLC, PepsiCo Inc, NVIDIA Corp, Sells The Walt Disney Co, ...",LLY,https://www.benzinga.com/node/14577820,GuruFocus,,,,,,
2019-10-10T08:00:00.000+08:00,Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study,LLY,http://www.zacks.com/stock/news/557899/dermira-starts-lebrikizumab-dosing-in-late-stage-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-557899,Zacks,,,,,,
2019-10-11T08:00:00.000+08:00,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,LLY,https://www.benzinga.com/markets/wiim/19/10/14582266/shares-of-several-healthcare-companies-are-trading-higher-after-president-trump-made-positive-remark,Benzinga Newsdesk,,,,,,
2019-10-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",LLY,https://www.benzinga.com/general/biotech/19/10/14579916/the-daily-biotech-pulse-therapix-extends-merger-deadline-five-prime-restructures-gilead-galapagos,Shanthi Rexaline,,,,,,
2019-10-11T08:00:00.000+08:00,FDA OKs Lilly's lasmiditan for migraine,LLY,https://seekingalpha.com/news/3505358-fda-oks-lillys-lasmiditan-migraine?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-11T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment ...",LLY,https://www.benzinga.com/node/14584173,GuruFocus,,,,,,
2019-10-11T08:00:00.000+08:00,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study,LLY,https://seekingalpha.com/article/4296113-eli-lilly-shows-strength-taltz-positive-head-head-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-11T08:00:00.000+08:00,"Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals",LLY,http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-BENZ-FT-analyst_blog|stock_roundup-559573,Zacks,,,,,,
2019-10-11T08:00:00.000+08:00,Gilead-Galapagos Report Efficacy & Safety Results on RA Drug,LLY,http://www.zacks.com/stock/news/559457/gilead-galapagos-report-efficacy-safety-results-on-ra-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-559457,Zacks,,,,,,
2019-10-11T08:00:00.000+08:00,"Affiance Financial, LLC Buys Eli Lilly and Co, Mondelez International Inc, U.S. ...",LLY,https://www.benzinga.com/node/14580643,GuruFocus,,,,,,
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019,LLY,https://www.benzinga.com/news/19/10/14585556/lilly-presents-positive-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psori,Charles Gross,,,,,,
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to ...,LLY,https://www.benzinga.com/node/14585425,GuruFocus,,,,,,
2019-10-13T08:00:00.000+08:00,New Sanofi CEO Looks to Shake Things Up,LLY,https://www.benzinga.com/node/14585932,GuruFocus,,,,,,
2019-10-14T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14588565,GuruFocus,,,,,,
2019-10-14T08:00:00.000+08:00,Pfenex up 2% premarket on positive human factor data on PF708,LLY,https://seekingalpha.com/news/3505486-pfenex-2-percent-premarket-positive-human-factor-data-pf708?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-14T08:00:00.000+08:00,Lilly's Taltz successful in late-stage pediatric psoriasis study,LLY,https://seekingalpha.com/news/3505416-lillys-taltz-successful-late-stage-pediatric-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-15T08:00:00.000+08:00,Pelosi drug bill would save $345B - CBO,LLY,https://seekingalpha.com/news/3505888-pelosi-drug-bill-save-345b-cbo?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-15T08:00:00.000+08:00,Lilly to close UK research facility,LLY,https://seekingalpha.com/news/3505700-lilly-close-uk-research-facility?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-16T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/10/14602350/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-that-its-phase-3-study-in-patie,Benzinga Newsdesk,,,,,,
2019-10-16T08:00:00.000+08:00,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14601880/17-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,,,
2019-10-16T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/19/10/14601445/eli-lilly-reports-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-e,Benzinga Newsdesk,,,,,,
2019-10-16T08:00:00.000+08:00,BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action,LLY,https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-percent-upside-vertex-hours-analyst-action?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-16T08:00:00.000+08:00,Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth,LLY,http://www.zacks.com/stock/news/567502/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-567502,Zacks,,,,,,
2019-10-16T08:00:00.000+08:00,Lilly Announces Phase ' Study in Patients with Metastatic Pancreatic Cancer Did Not Meet ...,LLY,https://www.benzinga.com/node/14602124,GuruFocus,,,,,,
2019-10-16T08:00:00.000+08:00,Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket,LLY,https://seekingalpha.com/news/3506048-lillys-pegilodecakin-flunks-late-stage-study-shares-2-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-17T08:00:00.000+08:00,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133",LLY,https://www.benzinga.com/news/19/10/14611009/ubs-maintains-buy-on-eli-lilly-lowers-price-target-to-133,Vick Meyer,,,,,,
2019-10-17T08:00:00.000+08:00,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target",LLY,https://www.benzinga.com/news/19/10/14609995/bank-of-america-reinstates-buy-on-eli-lilly-announces-133-price-target,Benzinga_Newsdesk,,,,,,
2019-10-17T08:00:00.000+08:00,Pelosi drug bill passes first House committee,LLY,https://seekingalpha.com/news/3506633-pelosi-drug-bill-passes-first-house-committee?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-17T08:00:00.000+08:00,Lilly's Pancreatic Cancer Candidate Fails in Phase III Study,LLY,http://www.zacks.com/stock/news/569619/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-569619,Zacks,,,,,,
2019-10-17T08:00:00.000+08:00,Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?,LLY,http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-569574,Zacks,,,,,,
2019-10-18T08:00:00.000+08:00,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI,LLY,https://www.benzinga.com/news/19/10/14618168/european-medicines-agency-says-chmp-recommended-granting-a-marketing-authorization-for-eli-lillys-ba,Benzinga Newsdesk,,,,,,
2019-10-18T08:00:00.000+08:00,"Supplemental Annuity Collective Trust of NJ Buys Mastercard Inc, L'Harris Technologies Inc, ...",LLY,https://www.benzinga.com/node/14622509,GuruFocus,,,,,,
2019-10-18T08:00:00.000+08:00,"Hills Bank & Trust Co Buys Mastercard Inc, Alexion Pharmaceuticals Inc, NextEra Energy Inc, ...",LLY,https://www.benzinga.com/node/14621686,GuruFocus,,,,,,
2019-10-18T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow",LLY,http://www.zacks.com/stock/news/571300/pharma-stock-roundup-jnjs-q3-earnings-rhhbys-sales-fda-nod-to-lillys-reyvow?cid=CS-BENZ-FT-analyst_blog|stock_roundup-571300,Zacks,,,,,,
2019-10-18T08:00:00.000+08:00,New Gilead CFO: Let's Make A Deal,LLY,https://www.benzinga.com/node/14620155,GuruFocus,,,,,,
2019-10-18T08:00:00.000+08:00,European advisory group backs Lilly's nasally administered glucagon,LLY,https://seekingalpha.com/news/3506826-european-advisory-group-backs-lillys-nasally-administered-glucagon?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-20T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",LLY,https://www.benzinga.com/general/biotech/19/10/14614270/the-week-ahead-in-biotech-earnings-trickle-in-while-glaxo-melinta-foamix-and-eton-await-fda-verdi,Shanthi Rexaline,,,,,,
2019-10-21T08:00:00.000+08:00,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,LLY,https://www.benzinga.com/news/earnings/19/10/14628501/earnings-season-kicks-into-full-gear-in-round-3-of-the-wetrader-competition,Chris Dier-Scalise,,,,,,
2019-10-21T08:00:00.000+08:00,Lilly Declares Fourth-Quarter —…–9 Dividend,LLY,https://www.benzinga.com/node/14630613,GuruFocus,,,,,,
2019-10-21T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3507409-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-22T08:00:00.000+08:00,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses",LLY,https://www.benzinga.com/news/earnings/19/10/14636560/mixed-bag-better-outlooks-from-lockheed-united-technologies-but-mcdonalds-misses,JJ Kinahan,,,,,,
2019-10-22T08:00:00.000+08:00,Notable earnings before Wednesday's open,LLY,https://seekingalpha.com/news/3507808-notable-earnings-wednesday-s-open?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-22T08:00:00.000+08:00,— Large-Cap Stocks Announce Dividends,LLY,https://www.benzinga.com/node/14637510,GuruFocus,,,,,,
2019-10-23T08:00:00.000+08:00,Stocks That Hit 52-Week Lows On Wednesday,LLY,https://www.benzinga.com/news/19/10/14646280/stocks-that-hit-52-week-lows-on-wednesday,Lisa Levin,,,,,,
2019-10-23T08:00:00.000+08:00,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14644456/33-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,,,
2019-10-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",LLY,https://www.benzinga.com/general/biotech/19/10/14643503/the-daily-biotech-pulse-eli-lily-revenues-trail-estimates-moderna-gets-fast-track-designation-mac,Shanthi Rexaline,,,,,,
2019-10-23T08:00:00.000+08:00,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance",LLY,https://www.benzinga.com/news/earnings/19/10/14643457/eli-lilly-reports-mixed-q3-earnings-raises-guidance,Tanzeel Akhtar,,,,,,
2019-10-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.,LLY,https://www.benzinga.com/markets/wiim/19/10/14643410/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-worse-than-expected-q3-sales-re,Benzinga Newsdesk,,,,,,
2019-10-23T08:00:00.000+08:00,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est.",LLY,https://www.benzinga.com/news/19/10/14642841/lilly-raises-fy19-adj-eps-guidance-from-5-67-5-77-to-5-75-5-85-vs-5-72-est-sees-sales-22b-22-5b-vs-2,Benzinga Newsdesk,,,,,,
2019-10-23T08:00:00.000+08:00,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate",LLY,https://www.benzinga.com/news/earnings/19/10/14642837/eli-lilly-q3-adj-eps-1-48-beats-1-4-estimate-sales-5-48b-miss-5-5b-estimate,Benzinga Newsdesk,,,,,,
2019-10-23T08:00:00.000+08:00,"12 Stocks To Watch For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642240/12-stocks-to-watch-for-october-23-2019,Lisa Levin,,,,,,
2019-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642223/earnings-scheduled-for-october-23-2019,Lisa Levin,,,,,,
2019-10-23T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4298376-eli-lilly-company-lly-ceo-dave-ricks-q3-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-23T08:00:00.000+08:00,Biogen: A Trading Strategy,LLY,https://seekingalpha.com/article/4298175-biogen-trading-strategy?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-23T08:00:00.000+08:00,"Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down",LLY,http://www.zacks.com/stock/news/578857/lilly-lly-q3-earnings-top-estimates-sales-lag-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-578857,Zacks,,,,,,
2019-10-23T08:00:00.000+08:00,Lilly down 3% as sales lag expectations,LLY,https://seekingalpha.com/news/3508322-lilly-3-percent-sales-lag-expectations?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-23T08:00:00.000+08:00,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to ...",LLY,https://www.benzinga.com/node/14643872,GuruFocus,,,,,,
2019-10-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates,LLY,http://www.zacks.com/stock/news/578512/eli-lilly-lly-surpasses-q3-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-578512,Zacks,,,,,,
2019-10-23T08:00:00.000+08:00,Eli Lilly raises EPS guidance after Q3 earnings beat,LLY,https://seekingalpha.com/news/3508263-eli-lilly-raises-eps-guidance-q3-earnings-beat?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-23T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.07, misses on revenue",LLY,https://seekingalpha.com/news/3508202-eli-lilly-eps-beats-0_07-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-24T08:00:00.000+08:00,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",LLY,https://www.benzinga.com/general/biotech/19/10/14651754/the-daily-biotech-pulse-acorda-to-trim-jobs-glaxosmithkline-gets-fda-nod-edward-lifesciences-post,Shanthi Rexaline,,,,,,
2019-10-24T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $—. ...,LLY,https://www.benzinga.com/node/14656996,GuruFocus,,,,,,
2019-10-25T08:00:00.000+08:00,"Eli Lilly And Co (LLY) President & CEO David A Ricks Bought $5……,–74 of Shares",LLY,https://www.benzinga.com/node/14665857,GuruFocus,,,,,,
2019-10-25T08:00:00.000+08:00,"Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA",LLY,http://www.zacks.com/stock/news/584115/pharma-stock-roundup-lly-nvs-azns-q3-earnings-updates-from-fda?cid=CS-BENZ-FT-analyst_blog|stock_roundup-584115,Zacks,,,,,,
2019-10-26T08:00:00.000+08:00,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries",LLY,https://www.benzinga.com/news/19/10/14668908/notable-insider-buys-in-the-past-week-eli-lilly-jpmorgan-thor-industries,Nelson Hem,,,,,,
2019-10-26T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - October 26, 2019",LLY,https://www.benzinga.com/node/14669017,TalkMarkets,,,,,,
2019-10-26T08:00:00.000+08:00,"Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus",LLY,https://seekingalpha.com/article/4299364-stocks-watch-fomc-streaming-wars-jedi-focus?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-27T08:00:00.000+08:00,3 Stocks Seeing Notable Insider Buying,LLY,https://seekingalpha.com/article/4299479-3-stocks-seeing-notable-insider-buying?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-27T08:00:00.000+08:00,Top Insider Buys Highlight for the Week of Oct. —5,LLY,https://www.benzinga.com/node/14669347,GuruFocus,,,,,,
2019-10-27T08:00:00.000+08:00,"FOMC, Streaming Wars And JEDI In Focus (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4299416-fomc-streaming-wars-jedi-focus-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-28T08:00:00.000+08:00,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval",LLY,https://www.benzinga.com/news/19/10/14672812/eli-lilly-reports-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-m,Benzinga Newsdesk,,,,,,
2019-10-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/25/19,LLY,https://seekingalpha.com/article/4299646-daily-insider-ratings-round-10-25-19?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-28T08:00:00.000+08:00,Lilly's Taltz successful in pediatric psoriasis study; shares up 2%,LLY,https://seekingalpha.com/news/3510163-lillys-taltz-successful-pediatric-psoriasis-study-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-28T08:00:00.000+08:00,"Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More",LLY,http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895,Zacks,,,,,,
2019-10-29T08:00:00.000+08:00,"\"Drug shortages reflect \"\"broken market\"\" - FDA\"",LLY,https://seekingalpha.com/news/3510787-drug-shortages-reflect-broken-market-fda?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-29T08:00:00.000+08:00,"Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View",LLY,http://www.zacks.com/stock/news/590995/incyte-incy-beats-on-q3-earnings-sales-ups-jakafi-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-590995,Zacks,,,,,,
2019-10-29T08:00:00.000+08:00,S&P Goes Where It's Never Gone Before,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-23210,Zacks,,,,,,
2019-10-30T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/28/19,LLY,https://seekingalpha.com/article/4300437-daily-insider-ratings-round-10-28-19?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-30T08:00:00.000+08:00,Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option,LLY,https://seekingalpha.com/article/4300401-eli-lillys-approval-migraine-drug-provides-unique-treatment-option?source=partner_benzinga,Seeking Alpha,,,,,,
2019-10-31T08:00:00.000+08:00,"United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up",LLY,http://www.zacks.com/stock/news/596339/united-therapeutics-uthr-q3-earnings-sales-top-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-596339,Zacks,,,,,,
2019-10-31T08:00:00.000+08:00,"Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales",LLY,http://www.zacks.com/stock/news/596377/sanofi-sny-q3-earnings-beat-vaccines-chc-units-hurt-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-596377,Zacks,,,,,,
2019-11-01T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/11/14674520/attention-biotech-investors-mark-your-calendar-for-these-november-pdufa-dates,Shanthi Rexaline,,,,,,
2019-11-01T08:00:00.000+08:00,"Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/598502/agios-agio-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-598502,Zacks,,,,,,
2019-11-03T08:00:00.000+08:00,Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen,LLY,https://seekingalpha.com/article/4301966-week-review-beigene-forms-blockbuster-2_7-billion-collaboration-amgen?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance",LLY,https://www.benzinga.com/news/19/11/14720748/boehringer-ingelheim-eli-lilly-report-modernization-of-alliance-to-focus-full-expertise-on-jardiance,Benzinga Newsdesk,,,,,,
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513849-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513847-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513846-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513845-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,Value Biotech ETFs & Stocks to Buy Now,LLY,http://www.zacks.com/stock/news/602866/value-biotech-etfs-stocks-to-buy-now?cid=CS-BENZ-FT-etf_news_and_commentary-602866,Zacks,,,,,,
2019-11-04T08:00:00.000+08:00,What's in the Cards for Teva (TEVA) This Earnings Season?,LLY,http://www.zacks.com/stock/news/602734/whats-in-the-cards-for-teva-teva-this-earnings-season?cid=CS-BENZ-FT-analyst_blog|earnings_preview-602734,Zacks,,,,,,
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2019 Update,LLY,https://seekingalpha.com/article/4302912-tracking-ken-fishers-fisher-asset-management-portfolio-q3-2019-update?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-05T08:00:00.000+08:00,"Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View",LLY,http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-604652,Zacks,,,,,,
2019-11-06T08:00:00.000+08:00,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.,LLY,https://www.benzinga.com/markets/wiim/19/11/14747724/eli-lilly-shares-are-trading-higher-not-seeing-any-news-to-justify-the-price-action,Benzinga Newsdesk,,,,,,
2019-11-06T08:00:00.000+08:00,AstraZeneca Named The Most Innovative Global Pharma Company,LLY,https://www.benzinga.com/general/biotech/19/11/14734171/astrazeneca-named-the-most-innovative-global-pharma-company,Shanthi Rexaline,,,,,,
2019-11-06T08:00:00.000+08:00,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10,LLY,https://www.benzinga.com/general/biotech/19/11/14744185/eli-lilly-to-present-multiple-abstracts-for-loxo-305-at-ash-2019-dec-7-10,luke@benzinga.com,,,,,,
2019-11-06T08:00:00.000+08:00,US Indexes Close Mostly Flat Wednesday,LLY,https://www.benzinga.com/node/14750420,GuruFocus,,,,,,
2019-11-06T08:00:00.000+08:00,Eli Lilly and Company to Present Multiple Abstracts for LOXO-'…5 at ASH —…–9,LLY,https://www.benzinga.com/node/14746448,GuruFocus,,,,,,
2019-11-06T08:00:00.000+08:00,Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-606644,Zacks,,,,,,
2019-11-06T08:00:00.000+08:00,ArQule down 17% on early-stage data on ARQ 531,LLY,https://seekingalpha.com/news/3515381-arqule-17-percent-early-stage-data-arq-531?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-07T08:00:00.000+08:00,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities,LLY,https://www.benzinga.com/news/19/11/14759390/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2b-aggregate-principal-amount-o,Benzinga Newsdesk,,,,,,
2019-11-07T08:00:00.000+08:00,"Abbrea Capital, LLC Buys JPMorgan Ultra-Short Income ETF, Vanguard Short-Term ...",LLY,https://www.benzinga.com/node/14763934,GuruFocus,,,,,,
2019-11-07T08:00:00.000+08:00,Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to ...,LLY,https://www.benzinga.com/node/14761665,GuruFocus,,,,,,
2019-11-07T08:00:00.000+08:00,4 RNA Therapy Stocks For A Biotech Portfolio,LLY,https://seekingalpha.com/article/4303833-4-rna-therapy-stocks-biotech-portfolio?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-07T08:00:00.000+08:00,"Holistic Financial Partners Buys Eli Lilly and Co, Schwab Emerging Markets Equity ETF, Schwab ...",LLY,https://www.benzinga.com/node/14759889,GuruFocus,,,,,,
2019-11-07T08:00:00.000+08:00,Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to ...,LLY,https://www.benzinga.com/node/14758867,GuruFocus,,,,,,
2019-11-07T08:00:00.000+08:00,"Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/608635/nektar-nktr-q3-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-608635,Zacks,,,,,,
2019-11-07T08:00:00.000+08:00,Fidelity MSCI Health Care Index ETF Is Undervalued,LLY,https://seekingalpha.com/article/4303596-fidelity-msci-health-care-index-etf-undervalued?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-08T08:00:00.000+08:00,Ad Com on Lilly and BI's Jardiance for T1D,LLY,https://seekingalpha.com/news/3517323-ad-com-lilly-bis-jardiance-t1d?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-08T08:00:00.000+08:00,"Andesa Financial Management Inc. Buys Comcast Corp, Texas Instruments Inc, First Trust Value ...",LLY,https://www.benzinga.com/node/14769530,GuruFocus,,,,,,
2019-11-08T08:00:00.000+08:00,"Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales",LLY,http://www.zacks.com/stock/news/610314/corcept-cort-earnings-beat-in-q3-korlym-boosts-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-610314,Zacks,,,,,,
2019-11-08T08:00:00.000+08:00,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting,LLY,https://www.benzinga.com/node/14766998,GuruFocus,,,,,,
2019-11-09T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of November 10,LLY,https://seekingalpha.com/article/4304895-dividend-challenger-highlights-week-november-10?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-11T08:00:00.000+08:00,ImmunoGen: Profiting And Turning Around,LLY,https://seekingalpha.com/article/4305416-immunogen-profiting-turning-around?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-11T08:00:00.000+08:00,4 Biotech Stocks That Could Keep Beating Wall Street,LLY,http://www.zacks.com/stock/news/614227/4-biotech-stocks-that-could-keep-beating-wall-street?cid=CS-BENZ-FT-analyst_blog|investment_ideas-614227,Zacks,,,,,,
2019-11-11T08:00:00.000+08:00,Nektar up 5% premarket on encouraging NKTR-358 data,LLY,https://seekingalpha.com/news/3517501-nektar-5-percent-premarket-encouraging-nktrminus-358-data?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized,LLY,https://www.benzinga.com/general/biotech/19/11/14784437/boehringer-ingelheim-and-lilly-initiate-study-to-assess-jardiance-in-people-hospitalized-for-acut,Benzinga Newsdesk,,,,,,
2019-11-12T08:00:00.000+08:00,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study,LLY,https://www.benzinga.com/general/biotech/19/11/14783146/eli-lilly-and-co-announces-52-week-head-to-head-data-from-taltz-versus-humira-trial-in-psoriatic-,Benzinga Newsdesk,,,,,,
2019-11-12T08:00:00.000+08:00,"Diversified Portfolios, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14789886,GuruFocus,,,,,,
2019-11-12T08:00:00.000+08:00,"Palladium Partners Llc Buys iShares Edge MSCI USA Value Factor ETF, Facebook Inc, Eli Lilly and ...",LLY,https://www.benzinga.com/node/14789912,GuruFocus,,,,,,
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people ...,LLY,https://www.benzinga.com/node/14788008,GuruFocus,,,,,,
2019-11-12T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14785635,GuruFocus,,,,,,
2019-11-12T08:00:00.000+08:00,Lilly's Taltz tops Humira in psoriatic arthritis study,LLY,https://seekingalpha.com/news/3517948-lillys-taltz-tops-humira-psoriatic-arthritis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-12T08:00:00.000+08:00,ACR —…–9: Lilly Presents 5—-Week Head-to-Head (SPIRIT-H—H) Data from Taltz® ...,LLY,https://www.benzinga.com/node/14783804,GuruFocus,,,,,,
2019-11-12T08:00:00.000+08:00,"ACR —…–9: Lilly Presents Positive New Data from COAST-X, a Phase ' Study of Taltz® ...",LLY,https://www.benzinga.com/node/14783852,GuruFocus,,,,,,
2019-11-13T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks",LLY,https://www.benzinga.com/news/19/11/14803368/eli-lilly-boehringer-ingleheim-report-fda-endocrinologic-and-metabolic-drugs-advisory-committee-vote,Benzinga Newsdesk,,,,,,
2019-11-13T08:00:00.000+08:00,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/11/14801622/fda-panel-votes-14-2-against-approval-of-eli-lilly-and-boehringer-ingelheims-empagliflozin-as-an-,Benzinga Newsdesk,,,,,,
2019-11-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for ...,LLY,https://www.benzinga.com/node/14804357,GuruFocus,,,,,,
2019-11-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",LLY,https://www.benzinga.com/general/biotech/19/11/14805285/the-daily-biotech-pulse-amarin-braces-for-vascepa-adcom-verdict-biotechs-on-a-fundraising-spree-z,Shanthi Rexaline,,,,,,
2019-11-14T08:00:00.000+08:00,"HBK Sorce Advisory LLC Buys Global Payments Inc, SPDR Barclays Convertible Securities ETF, ...",LLY,https://www.benzinga.com/node/14817345,GuruFocus,,,,,,
2019-11-14T08:00:00.000+08:00,Livongo Bounces Back After Revenue Guidance Boost,LLY,https://www.benzinga.com/node/14816034,GuruFocus,,,,,,
2019-11-14T08:00:00.000+08:00,"Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/619674/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-619674,Zacks,,,,,,
2019-11-14T08:00:00.000+08:00,FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes,LLY,http://www.zacks.com/stock/news/619673/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-619673,Zacks,,,,,,
2019-11-14T08:00:00.000+08:00,FDA Ad Com thumbs down on BI and Lilly's empagliflozin for T1D,LLY,https://seekingalpha.com/news/3519118-fda-ad-com-thumbs-bi-lillys-empagliflozin-t1d?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-15T08:00:00.000+08:00,"Willis Investment Counsel Buys Paychex Inc, Eli Lilly and Co, Pfizer Inc, Sells United Parcel ...",LLY,https://www.benzinga.com/node/14823641,GuruFocus,,,,,,
2019-11-15T08:00:00.000+08:00,UCB's bimekizumab success in second late-stage psoriasis study,LLY,https://seekingalpha.com/news/3519817-ucbs-bimekizumab-success-second-late-stage-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-15T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates",LLY,http://www.zacks.com/stock/news/621121/pharma-stock-roundup-mrk-gsk-abbv-llys-pipeline-regulatory-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-621121,Zacks,,,,,,
2019-11-17T08:00:00.000+08:00,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists,LLY,https://www.benzinga.com/news/19/11/14826392/interim-analysis-from-emprise-real-world-study-shows-lillys-jardiance-decreased-risk-of-hospitalizat,Charles Gross,,,,,,
2019-11-17T08:00:00.000+08:00,Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of ...,LLY,https://www.benzinga.com/node/14826196,GuruFocus,,,,,,
2019-11-19T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for —…—… Financial Guidance Announcement,LLY,https://www.benzinga.com/node/14845243,GuruFocus,,,,,,
2019-11-19T08:00:00.000+08:00,"Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data ...",LLY,https://www.benzinga.com/node/14842904,GuruFocus,,,,,,
2019-11-19T08:00:00.000+08:00,Steven Cohen's Top 5 Buys in the 'rd Quarter,LLY,https://www.benzinga.com/node/14842459,GuruFocus,,,,,,
2019-11-19T08:00:00.000+08:00,Drug Legislation Likely to Dry Up Biotech Funding,LLY,https://www.benzinga.com/node/14839953,GuruFocus,,,,,,
2019-11-19T08:00:00.000+08:00,Nektar: Poised For A Rebound,LLY,https://seekingalpha.com/article/4307652-nektar-poised-rebound?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-20T08:00:00.000+08:00,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis,LLY,https://www.benzinga.com/news/19/11/14846669/lilly-announces-400m-capital-investment-in-manufacturing-facilities-in-indianapolis,Benzinga Newsdesk,,,,,,
2019-11-20T08:00:00.000+08:00,Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug,LLY,http://www.zacks.com/stock/news/629205/alkermes-submits-nda-to-fda-for-schizophrenia-bipolar-i-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-629205,Zacks,,,,,,
2019-11-20T08:00:00.000+08:00,Lilly announces $4…… million capital investment in manufacturing facilities in Indianapolis,LLY,https://www.benzinga.com/node/14847656,GuruFocus,,,,,,
2019-11-20T08:00:00.000+08:00,Launch of new generic drugs in U.S. still lags - WSJ,LLY,https://seekingalpha.com/news/3520772-launch-new-generic-drugs-u-s-still-lags-wsj?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-20T08:00:00.000+08:00,Lilly to invest $400M in Indianapolis manufacturing facilities,LLY,https://seekingalpha.com/news/3520758-lilly-invest-400m-indianapolis-manufacturing-facilities?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-21T08:00:00.000+08:00,Why Eli Lilly Can't Match Novo Nordisk,LLY,https://seekingalpha.com/article/4308457-eli-lilly-match-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-22T08:00:00.000+08:00,"\"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are \"\"MUCH CHEAPER\"\"\"",LLY,https://www.benzinga.com/general/politics/19/11/14868610/trump-says-he-will-release-a-plan-to-let-states-import-prescription-drugs-which-are-much-cheaper,Benzinga Newsdesk,,,,,,
2019-11-24T08:00:00.000+08:00,Acreage Holdings: The Best Investment In The Cannabis Space,LLY,https://seekingalpha.com/article/4308875-acreage-holdings-best-investment-cannabis-space?source=partner_benzinga,Seeking Alpha,,,,,,
2019-11-27T08:00:00.000+08:00,"Top Research Reports for Merck, Eli Lilly & Charter Communications",LLY,http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-BENZ-FT-research_daily-643445,Zacks,,,,,,
2019-12-02T08:00:00.000+08:00,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada,LLY,https://www.benzinga.com/general/biotech/19/12/14915526/u-s-considers-scaling-back-ip-protections-for-big-drugmakers-to-help-win-democratic-support-for-n,Benzinga Newsdesk,,,,,,
2019-12-02T08:00:00.000+08:00,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/14913226/biogens-alzheimers-drug-falls-far-short-of-compelling-argument-for-approval-baird-s,Shanthi Rexaline,,,,,,
2019-12-02T08:00:00.000+08:00,Lilly to Participate in Evercore ISI —nd Annual HealthCONx Conference,LLY,https://www.benzinga.com/node/14917145,GuruFocus,,,,,,
2019-12-02T08:00:00.000+08:00,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco,LLY,https://www.benzinga.com/node/14913666,GuruFocus,,,,,,
2019-12-02T08:00:00.000+08:00,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory ...,LLY,https://www.benzinga.com/node/14911109,GuruFocus,,,,,,
2019-12-02T08:00:00.000+08:00,Now Is A Good Time To Buy XLV,LLY,https://seekingalpha.com/article/4309959-now-good-time-buy-xlv?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-05T08:00:00.000+08:00,Health Care Select Sector SPDR Fund: Long-Term Growth Outlook Remains Intact,LLY,https://seekingalpha.com/article/4310774-health-care-select-sector-spdr-fund-long-term-growth-outlook-remains-intact?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-05T08:00:00.000+08:00,Lilly to combine Loxo with oncology research group,LLY,https://seekingalpha.com/news/3523979-lilly-to-combine-loxo-oncology-research-group?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-05T08:00:00.000+08:00,Lilly Announces New Leadership and Strategy in Oncology Research and Development,LLY,https://www.benzinga.com/node/14936990,GuruFocus,,,,,,
2019-12-06T08:00:00.000+08:00,Dicerna Pharmaceuticals: A Solid Pick For 2020,LLY,https://seekingalpha.com/article/4311121-dicerna-pharmaceuticals-solid-pick-for-2020?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-07T08:00:00.000+08:00,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",LLY,https://www.benzinga.com/general/biotech/19/12/14947992/the-week-ahead-in-biotech-ash-presentations-pick-up-steam-correvio-awaits-adcom-ruling,Shanthi Rexaline,,,,,,
2019-12-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of December 8,LLY,https://seekingalpha.com/article/4311216-dividend-challenger-highlights-week-of-december-8?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-07T08:00:00.000+08:00,"Stocks To Watch: Netflix, Cisco And Chewy On The Marquee",LLY,https://seekingalpha.com/article/4311202-stocks-to-watch-netflix-cisco-and-chewy-on-marquee?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019,LLY,https://www.benzinga.com/news/19/12/14951584/lilly-presents-interim-clinical-data-from-loxo-305-dose-escalation-trial-in-b-cell-leukemias-and-lym,Charles Gross,,,,,,
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-'…5 Dose Escalation Trial in B-Cell ...,LLY,https://www.benzinga.com/node/14951639,GuruFocus,,,,,,
2019-12-08T08:00:00.000+08:00,"Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4311222-netflix-cisco-and-chewy-on-marquee-stocks-to-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-09T08:00:00.000+08:00,Highlights From The Deutsche Bank ADR Virtual Investor Conference,LLY,https://www.benzinga.com/news/19/12/14923069/highlights-from-the-deutsche-bank-adr-virtual-investor-conference,Spencer Israel,,,,,,
2019-12-09T08:00:00.000+08:00,Kinase inhibitors in focus after Merck bid for ArQule,LLY,https://seekingalpha.com/news/3524810-kinase-inhibitors-in-focus-after-merck-bid-for-arqule?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-10T08:00:00.000+08:00,Aptose Shoots Up As Investors Focus On Reversible BTK Inhibitors,LLY,https://seekingalpha.com/article/4311702-aptose-shoots-up-investors-focus-on-reversible-btk-inhibitors?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-10T08:00:00.000+08:00,Sanofi to exit diabetes research; shares up 4% premarket,LLY,https://seekingalpha.com/news/3525050-sanofi-to-exit-diabetes-research-shares-up-4-premarket?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-11T08:00:00.000+08:00,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/14969892/lilly-opens-randomized-phase-3-clinical-trial-of-loxo-292-in-treatment-na-ve-ret-fusion-positive-,Benzinga Newsdesk,,,,,,
2019-12-11T08:00:00.000+08:00,Lilly Opens First Ever Randomized Phase ' Clinical Trial in Treatment-Naïve RET ...,LLY,https://www.benzinga.com/node/14970681,GuruFocus,,,,,,
2019-12-11T08:00:00.000+08:00,Lilly opens late-stage RET fusion-positive NSCLC study,LLY,https://seekingalpha.com/news/3525422-lilly-opens-late-stage-ret-fusion-positive-nsclc-study?source=partner_benzinga,Seeking Alpha,,,,,,
2019-12-12T08:00:00.000+08:00,Elanco Animal Health: Still Not Very Healthy,LLY,https://seekingalpha.com/article/4312269-elanco-animal-health-still-not-healthy?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-12T08:00:00.000+08:00,"House passes drug pricing bill, Senate unlikely to support",LLY,https://seekingalpha.com/news/3526005-house-passes-drug-pricing-bill-senate-unlikely-to-support?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-12T08:00:00.000+08:00,Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor,LLY,http://www.zacks.com/stock/news/667111/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-667111,Zacks,,,,,,
2019-12-13T08:00:00.000+08:00,'Fast Money' Picks For December 13,LLY,https://www.benzinga.com/media/19/12/14988782/fast-money-picks-for-december-13,Craig Jones,,,,,,
2019-12-13T08:00:00.000+08:00,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/12/14986985/boehringer-ingelheim-lilly-offer-update-on-jardiance-phase-3-exercise-ability-studies-in-chronic-hea,Benzinga Newsdesk,,,,,,
2019-12-13T08:00:00.000+08:00,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/19/12/14986467/lilly-reports-chmp-issues-positive-opinion-related-to-expanded-label-of-cyramza-to-include-results-f,Benzinga Newsdesk,,,,,,
2019-12-13T08:00:00.000+08:00,"Merger Mating Dance: We Explore Who Gets The Rose Next - Sectors And Targets, Part I",LLY,https://seekingalpha.com/article/4312437-merger-mating-dance-explore-who-gets-rose-next-sectors-and-targets-part-i?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-13T08:00:00.000+08:00,Eagle Pharma on go to launch Alimta alternative in early 2022,LLY,https://seekingalpha.com/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies ...,LLY,https://www.benzinga.com/node/14989381,GuruFocus,,,,,,
2019-12-13T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study",LLY,http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|stock_roundup-668756,Zacks,,,,,,
2019-12-13T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14987060,GuruFocus,,,,,,
2019-12-13T08:00:00.000+08:00,European advisory group backs expanded use of Lilly's Cyramza,LLY,https://seekingalpha.com/news/3526129-european-advisory-group-backs-expanded-use-of-lillys-cyramza?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-14T08:00:00.000+08:00,Stocks To Watch: Investors Dig Into Trade War Halt,LLY,https://seekingalpha.com/article/4312511-stocks-to-watch-investors-dig-trade-war-halt?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-15T08:00:00.000+08:00,Boris Bounce; Trump Tripwire,LLY,https://www.benzinga.com/node/14992968,TalkMarkets,,,,,,
2019-12-15T08:00:00.000+08:00,Investors Dig Into Trade War Halt (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4312534-investors-dig-trade-war-halt-stocks-to-watch-podcast?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,,,
2019-12-16T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share,LLY,https://www.benzinga.com/news/19/12/14998960/eli-lilly-raises-qtr-dividend-from-0-645-to-0-74share,Benzinga Newsdesk,,,,,,
2019-12-16T08:00:00.000+08:00,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System,LLY,https://www.benzinga.com/node/14993782,Benzinga Newsdesk,,,,,,
2019-12-17T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.,LLY,https://www.benzinga.com/wiim/19/12/15004129/eli-lilly-shares-are-trading-higher-after-the-company-issued-upbeat-fy20-guidance,Benzinga Newsdesk,,,,,,
2019-12-17T08:00:00.000+08:00,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward,LLY,https://www.benzinga.com/news/19/12/15003142/eli-lilly-executive-says-reasonable-to-expect-net-price-declines-in-the-low-single-digit-level-going,Benzinga Newsdesk,,,,,,
2019-12-17T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY",LLY,https://www.benzinga.com/pre-market-outlook/19/12/15002311/benzinga-pros-top-5-stocks-to-watch-for-tues-dec-17-2019-ba-aapl-blph-jnj-lly,Benzinga Newsdesk,,,,,,
2019-12-17T08:00:00.000+08:00,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est.",LLY,https://www.benzinga.com/news/19/12/15001141/lilly-reaffirms-prelim-fy19-adj-eps-guidance-5-75-5-85-vs-5-81-est-sales-guidance-22b-22-5b-vs-22-16,Benzinga Newsdesk,,,,,,
2019-12-17T08:00:00.000+08:00,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est.",LLY,https://www.benzinga.com/news/19/12/15001136/lilly-sees-fy20-adj-eps-6-70-6-80-vs-6-61-est-sales-23-6b-24-1b-vs-23-52b-est,Benzinga Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012286/update-morgan-stanley-on-eli-lilly-notes-while-novo-appears-set-to-win-market-share,Benzinga_Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012285/update-morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-150-notes-w,Benzinga_Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15010335/eli-lilly-ceo-hits-back-at-elizabeth-warren-blames-pbms-insurance-for-blocking-affo,Elizabeth Balboa,,,,,,
2019-12-18T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For December 18, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/12/15011287/benzingas-top-upgrades-downgrades-for-december-18-2019,Lisa Levin,,,,,,
2019-12-18T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.,LLY,https://www.benzinga.com/wiim/19/12/15010613/eli-lilly-and-co-shares-are-trading-higher-after-morgan-stanley-upgraded-the-stock-from-equal-weight,Benzinga Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15010028/jp-morgan-maintains-overweight-on-eli-lilly-raises-price-target-to-150,Vick Meyer,,,,,,
2019-12-18T08:00:00.000+08:00,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/12/15009648/30-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,,,
2019-12-18T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15009322/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-price-target-to-150,Benzinga_Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention,LLY,https://www.benzinga.com/general/biotech/19/12/15009001/lilly-announces-launch-of-triumph-real-world-evidence-study-of-emgality-for-migraine-prevention,Benzinga Newsdesk,,,,,,
2019-12-18T08:00:00.000+08:00,"Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial",LLY,http://www.zacks.com/research-daily/676738/top-stock-reports-for-johnson-johnson-eli-lilly-pnc-financial?cid=CS-BENZ-FT-research_daily-676738,Zacks,,,,,,
2019-12-18T08:00:00.000+08:00,Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU,LLY,http://www.zacks.com/stock/news/676816/dicernas-drna-a1at-candidate-gets-orphan-drug-tag-in-eu?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676816,Zacks,,,,,,
2019-12-18T08:00:00.000+08:00,Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020,LLY,http://www.zacks.com/stock/news/676513/lillys-stock-up-on-upbeat-sales-profit-outlook-for-2020?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676513,Zacks,,,,,,
2019-12-19T08:00:00.000+08:00,Eli Lilly Sees IBD RS Rating Climb To 72,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-sees-ibd-rs-rating-climb-to-72/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-12-19T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland",LLY,http://www.zacks.com/stock/news/678361/the-zacks-analyst-blog-highlights-johnson-johnson-eli-lilly-pnc-financial-eog-resources-and-archer-daniels-midland?cid=CS-BENZ-FT-press_releases-678361,Zacks,,,,,,
2019-12-20T08:00:00.000+08:00,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration,LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15027267/premarket-prep-recap-buyers-and-more-buyers-on-quadruple-witch-expiration,Joel Elconin,,,,,,
2019-12-20T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/19/12/15026655/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,,,
2019-12-20T08:00:00.000+08:00,"S&P 500, Transports Lead Market; These 2 Stocks Drag The IBD 50",LLY,http://www.investors.com/market-trend/stock-market-today/sp-500-today-leads-stock-market-ibd-50/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2019-12-20T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs",LLY,http://www.zacks.com/stock/news/679924/pharma-stock-roundup-lillys-upbeat-2020-outlook-fda-nod-for-pfe-mrks-drugs?cid=CS-BENZ-FT-analyst_blog|stock_roundup-679924,Zacks,,,,,,
2019-12-20T08:00:00.000+08:00,Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib,LLY,http://www.zacks.com/stock/news/679808/gilead-gild-files-nda-with-fda-for-ra-candidate-filgotinib?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-679808,Zacks,,,,,,
2019-12-23T08:00:00.000+08:00,A Perspective On Biopharma's Record M&A Run In 2019,LLY,https://www.benzinga.com/general/biotech/19/12/14981726/a-perspective-on-biopharmas-record-m-a-run-in-2019,Shanthi Rexaline,,,,,,
2019-12-23T08:00:00.000+08:00,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15034287/premarket-prep-recap-tslaq-crowd-continues-to-be-punished-eli-lillys-incredible-friday-o,Joel Elconin,,,,,,
2019-12-23T08:00:00.000+08:00,"Top Stock Reports for SAP, AbbVie & Sinopec",LLY,http://www.zacks.com/research-daily/684233/top-stock-reports-for-sap-abbvie-sinopec?cid=CS-BENZ-FT-research_daily-684233,Zacks,,,,,,
2019-12-24T08:00:00.000+08:00,Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy,LLY,http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-685884,Zacks,,,,,,
2019-12-24T08:00:00.000+08:00,Buy These 5 Low-Beta Stocks to Counter Market Volatility,LLY,http://www.zacks.com/stock/news/685699/buy-these-5-low-beta-stocks-to-counter-market-volatility?cid=CS-BENZ-FT-analyst_blog|rw-685699,Zacks,,,,,,
2019-12-26T08:00:00.000+08:00,Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance,LLY,http://www.zacks.com/stock/news/688652/incyte-incy-surges-44-ytd-on-jakafis-strong-performance?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-688652,Zacks,,,,,,
2019-12-29T08:00:00.000+08:00,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",LLY,https://www.benzinga.com/general/biotech/19/12/15047719/week-ahead-in-biotech-pdufa-date-ahead-for-astra-zeneca-mercks-lynparza-pending-clinical-readouts,Shanthi Rexaline,,,,,,
2019-12-30T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/19/12/15052912/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,,,
2019-12-30T08:00:00.000+08:00,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15051790/update-argus-maintains-buy-on-eli-lilly-raises-target-to-165-notes-we-see-increased,Benzinga_Newsdesk,,,,,,
2019-12-30T08:00:00.000+08:00,10 Biggest Price Target Changes For Monday,LLY,https://www.benzinga.com/analyst-ratings/price-target/19/12/15051040/10-biggest-price-target-changes-for-monday,Lisa Levin,,,,,,
2019-12-30T08:00:00.000+08:00,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165",LLY,https://www.benzinga.com/news/19/12/15050619/argus-research-maintains-buy-on-eli-lilly-raises-price-target-to-165,Vick Meyer,,,,,,
2019-12-30T08:00:00.000+08:00,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/15050433/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer,Benzinga Newsdesk,,,,,,
2019-12-31T08:00:00.000+08:00,Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study,LLY,http://www.zacks.com/stock/news/696056/axsomes-axsm-migraine-drug-meets-goals-in-late-stage-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-696056,Zacks,,,,,,
2020-01-02T08:00:00.000+08:00,3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020,LLY,http://www.zacks.com/stock/news/698989/3-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2020?cid=CS-BENZ-FT-analyst_blog|rank_focused-698989,Zacks,,,,,,
2020-01-06T08:00:00.000+08:00,AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA,LLY,http://www.zacks.com/stock/news/704636/astrazenecas-farxiga-snda-gets-priority-review-status-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-704636,Zacks,,,,,,
2020-01-08T08:00:00.000+08:00,"Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company",LLY,http://www.zacks.com/stock/news/708231/zackscom-featured-highlights-include-ruths-hospitality-cadence-design-system-toro-company-and-eli-lilly-and-company?cid=CS-BENZ-FT-press_releases-708231,Zacks,,,,,,
2020-01-09T08:00:00.000+08:00,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab",LLY,https://www.benzinga.com/general/biotech/20/01/15097676/eli-lilly-in-collaboration-with-strateos-inc-launches-remote-controlled-robotic-cloud-lab,Benzinga Newsdesk,,,,,,
2020-01-09T08:00:00.000+08:00,Stocks With Rising Composite Ratings: Eli Lilly,LLY,http://www.investors.com/ibd-data-stories/stocks-with-rising-composite-ratings-eli-lilly/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-01-09T08:00:00.000+08:00,"Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up",LLY,http://www.zacks.com/stock/news/709682/verastem-in-licenses-kras-focused-drug-from-chugai-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-709682,Zacks,,,,,,
2020-01-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,LLY,https://www.benzinga.com/news/20/01/15107226/mid-afternoon-market-update-dow-falls-90-points-rumbleon-shares-plummet,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",LLY,https://www.benzinga.com/general/biotech/20/01/15106641/california-gov-gavin-newsom-wants-the-state-to-become-the-first-to-create-its-own-generic-drug-la,Benzinga Newsdesk,,,,,,
2020-01-10T08:00:00.000+08:00,40 Stocks Moving In Friday's Mid-Day Session,LLY,https://www.benzinga.com/news/20/01/15106445/40-stocks-moving-in-fridays-mid-day-session,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/01/15106362/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,LLY,https://www.benzinga.com/news/20/01/15106324/mid-day-market-update-crude-oil-down-over-1-ultragenyx-pharmaceutical-shares-jump,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share,LLY,https://www.benzinga.com/news/earnings/20/01/15105179/mid-morning-market-update-markets-open-higher-eli-lilly-to-buy-dermira-for-18-75share,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR",LLY,https://www.benzinga.com/pre-market-outlook/20/01/15104511/benzinga-pros-top-5-stocks-to-watch-for-fri-jan-10-2020-lly-jpm-srne-elan-twtr,Benzinga Newsdesk,,,,,,
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $1.1B,LLY,https://www.benzinga.com/general/biotech/20/01/15103879/eli-lilly-reports-deal-to-buy-dermira-for-1-1b,Tanzeel Akhtar,,,,,,
2020-01-10T08:00:00.000+08:00,33 Stocks Moving in Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/01/15103893/33-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,,,
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash,LLY,https://www.benzinga.com/m-a/20/01/15103620/eli-lilly-reports-deal-to-buy-dermira-for-18-75share-in-cash,Benzinga Newsdesk,,,,,,
2020-01-10T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/711690/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-711690,Zacks,,,,,,
2020-01-11T08:00:00.000+08:00,Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020,LLY,https://talkmarkets.com/content/week-in-review-four-china-biopharmas-announce-100-million-deals-in-first-week-of-2020?post=246706,TalkMarkets,,,,,,
2020-01-13T08:00:00.000+08:00,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15110468/eli-lillys-phase-3-orient-11-study-of-tyvyt-combined-with-alimta-met-its-primary-endpoint,Benzinga Newsdesk,,,,,,
2020-01-13T08:00:00.000+08:00,Glaxo Files Marketing Application for Fostemsavir in Europe,LLY,http://www.zacks.com/stock/news/715692/glaxo-files-marketing-application-for-fostemsavir-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-715692,Zacks,,,,,,
2020-01-13T08:00:00.000+08:00,"Company News for Jan 13, 2020",LLY,http://www.zacks.com/stock/news/715585/company-news-for-jan-13-2020?cid=CS-BENZ-FT-corporate_summary-715585,Zacks,,,,,,
2020-01-14T08:00:00.000+08:00,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",LLY,https://www.benzinga.com/general/biotech/20/01/15117688/the-daily-biotech-pulse-phasebio-to-buy-hypertension-asset-stemline-falls-on-q4-pre-announcement-,Shanthi Rexaline,,,,,,
2020-01-14T08:00:00.000+08:00,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April",LLY,https://www.benzinga.com/general/health-care/20/01/15117761/lilly-announces-insulin-cost-saving-options-lower-priced-versions-of-humalog-junior-kwikpen-a,Benzinga Newsdesk,,,,,,
2020-01-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15125323/the-daily-biotech-pulse-nektar-withdraws-opioid-pain-drug-nda-galapagos-takes-stake-in-fibrocor-i,Shanthi Rexaline,,,,,,
2020-01-15T08:00:00.000+08:00,Which Stocks Join Market For Another New High?,LLY,https://talkmarkets.com/content/which-stocks-join-market-for-another-new-high?post=247244,TalkMarkets,,,,,,
2020-01-15T08:00:00.000+08:00,Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins,LLY,http://www.zacks.com/stock/news/719140/lilly-to-launch-cheaper-versions-of-humalog-kwikpen-insulins?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-719140,Zacks,,,,,,
2020-01-15T08:00:00.000+08:00,"Lilly, Anna Kaiser Launch ''…-Day Thriver Challenge' to Increase Awareness of Daily Stress ...",LLY,http://www.gurufocus.com/news/1015662/lilly-anna-kaiser-launch-30day-thriver-challenge-to-increase-awareness-of-daily-stress-of-living-with-metastatic-breast-cancer-elevate-support-for-women-and-men-living-with-the-disease,GuruFocus,,,,,,
2020-01-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/01/15135505/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,,,
2020-01-16T08:00:00.000+08:00,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15133299/the-daily-biotech-pulse-osmotica-soars-on-insider-buys-ultragenyxs-partnered-rare-disease-drug-mo,Shanthi Rexaline,,,,,,
2020-01-16T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/721414/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-721414,Zacks,,,,,,
2020-01-16T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for Fourth-Quarter —…–9 Financial Results Announcement,LLY,http://www.gurufocus.com/news/1016786/lilly-confirms-date-and-conference-call-for-fourthquarter-2019-financial-results-announcement,GuruFocus,,,,,,
2020-01-16T08:00:00.000+08:00,Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA,LLY,http://www.zacks.com/stock/news/720624/bristol-myers-opdivo-yervoy-sbla-for-nsclc-accepted-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-720624,Zacks,,,,,,
2020-01-17T08:00:00.000+08:00,9 Takeaways From The JPMorgan Healthcare Conference,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/01/15144617/9-takeaways-from-the-jpmorgan-healthcare-conference,Shanthi Rexaline,,,,,,
2020-01-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",LLY,https://www.benzinga.com/general/biotech/20/01/15141617/the-daily-biotech-pulse-novo-nordisks-ozempic-receives-label-expansion-for-cardiovascular-events-,Shanthi Rexaline,,,,,,
2020-01-17T08:00:00.000+08:00,Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction,LLY,http://www.zacks.com/stock/news/722212/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-722212,Zacks,,,,,,
2020-01-17T08:00:00.000+08:00,Castle Could Crumble When IPO Lockup Expires,LLY,https://talkmarkets.com/content/castle-could-crumble-when-ipo-lockup-expires?post=247483,TalkMarkets,,,,,,
2020-01-21T08:00:00.000+08:00,Pharma Company Buybacks: Do They Really Benefit Shareholders?,LLY,http://www.gurufocus.com/news/1019458/pharma-company-buybacks-do-they-really-benefit-shareholders,GuruFocus,,,,,,
2020-01-21T08:00:00.000+08:00,Governor Cooper Announces over 46… Jobs in Durham as Eli Lilly and Company Selects North ...,LLY,http://www.gurufocus.com/news/1019448/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-carolina-for-major-pharmaceutical-plant,GuruFocus,,,,,,
2020-01-22T08:00:00.000+08:00,Steven Cohen's Point7— Piles Into Menlo Therapeutics,LLY,http://www.gurufocus.com/news/1020274/steven-cohens-point72-piles-into-menlo-therapeutics,GuruFocus,,,,,,
2020-01-22T08:00:00.000+08:00,"Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",LLY,http://www.zacks.com/research-daily/729250/top-stock-analyst-reports-for-pfizer-wells-fargo-sap?cid=CS-BENZ-FT-research_daily-729250,Zacks,,,,,,
2020-01-22T08:00:00.000+08:00,Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/729106/glaxos-multiple-myeloma-candidate-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-729106,Zacks,,,,,,
2020-01-22T08:00:00.000+08:00,Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?,LLY,http://www.zacks.com/stock/news/729079/should-first-trust-capital-strength-etf-ftcs-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-729079,Zacks,,,,,,
2020-01-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",LLY,https://www.benzinga.com/general/biotech/20/01/15169823/the-daily-biotech-pulse-roche-reports-positive-sma-data-readout-vir-biotech-to-work-on-virus-trea,Shanthi Rexaline,,,,,,
2020-01-24T08:00:00.000+08:00,J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/731608/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-731608,Zacks,,,,,,
2020-01-24T08:00:00.000+08:00,Anat Hakim to join Lilly as General Counsel,LLY,http://www.gurufocus.com/news/1021273/anat-hakim-to-join-lilly-as-general-counsel,GuruFocus,,,,,,
2020-01-24T08:00:00.000+08:00,"Acima Private Wealth, Llc Buys SPDR Barclays Short Term Corporate Bond ETF, iShares MSCI ...",LLY,http://www.gurufocus.com/news/1021233/acima-private-wealth-llc-buys-spdr-barclays-short-term-corporate-bond-etf-ishares-msci-frontier-100-etf-ishares-msci-china-etf-sells-celgene-corp-vaneck-vectors-etf-trust--vaneck-vectors-vietnam--jpmorgan-ultrashort-i,GuruFocus,,,,,,
2020-01-26T08:00:00.000+08:00,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",LLY,https://www.benzinga.com/general/biotech/20/01/15181472/the-week-ahead-in-biotech-amgen-eli-lilly-pfizer-in-earnings-mix-ipo-flow-resumes,Shanthi Rexaline,,,,,,
2020-01-27T08:00:00.000+08:00,FDA Approves Lilly's Trijardy,LLY,https://www.benzinga.com/general/biotech/20/01/15194253/fda-approves-lillys-trijardy,Benzinga Newsdesk,,,,,,
2020-01-27T08:00:00.000+08:00,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15187132/eli-lilly-and-incytes-phase-3-breeze-ad4-study-met-its-primary-endpoint,Benzinga Newsdesk,,,,,,
2020-01-27T08:00:00.000+08:00,US FDA approves only triple-combination tablet with Jardiance® for adults with type — diabetes,LLY,http://www.gurufocus.com/news/1022645/us-fda-approves-only-triplecombination-tablet-with-jardiance-for-adults-with-type-2-diabetes,GuruFocus,,,,,,
2020-01-27T08:00:00.000+08:00,"Bremer Bank National Association Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Marsh ...",LLY,http://www.gurufocus.com/news/1022412/bremer-bank-national-association-buys-bristolmyers-squibb-company-eli-lilly-and-co-marsh--mclennan-inc-sells-powershares-qqq-trust-ser-1-celgene-corp-ishares-russell-1000-growth-etf,GuruFocus,,,,,,
2020-01-27T08:00:00.000+08:00,"British Airways Pensions Investment Management Ltd Buys Bristol-Myers Squibb Company, Zimmer ...",LLY,http://www.gurufocus.com/news/1022404/british-airways-pensions-investment-management-ltd-buys-bristolmyers-squibb-company-zimmer-biomet-holdings-inc-sysco-corp-sells-spdr-sp-500-etf-trust-stryker-corp-dr-horton-inc,GuruFocus,,,,,,
2020-01-27T08:00:00.000+08:00,Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-trading-near-top-of-buy-zone-with-earnings-on-tap/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-01-27T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/734952/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-734952,Zacks,,,,,,
2020-01-27T08:00:00.000+08:00,Lilly (LLY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/734541/lilly-lly-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-734541,Zacks,,,,,,
2020-01-27T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,,,
2020-01-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15195781/the-daily-biotech-pulse-accelerons-positive-data-readout-surface-oncology-gets-nod-for-pushing-2-,Shanthi Rexaline,,,,,,
2020-01-28T08:00:00.000+08:00,AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/736760/aveo-posts-data-on-ficlatuzumab-from-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736760,Zacks,,,,,,
2020-01-28T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Goal in Dermatitis Study,LLY,http://www.zacks.com/stock/news/736741/lillys-olumiant-meets-primary-goal-in-dermatitis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736741,Zacks,,,,,,
2020-01-28T08:00:00.000+08:00,"Lilly plans donation of —……,……… insulin KwikPens over next three years to support ...",LLY,http://www.gurufocus.com/news/1022897/lilly-plans-donation-of-200000-insulin-kwikpens-over-next-three-years-to-support-lowerincome-communities,GuruFocus,,,,,,
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application,LLY,https://www.benzinga.com/news/20/01/15206768/lilly-receives-fda-priority-review-for-selpercatinib-new-drug-application,Benzinga Newsdesk,,,,,,
2020-01-29T08:00:00.000+08:00,5 Top Non-Tech Earnings Charts,LLY,http://www.zacks.com/stock/news/739543/5-top-non-tech-earnings-charts?cid=CS-BENZ-FT-video_blog-739543,Zacks,,,,,,
2020-01-29T08:00:00.000+08:00,"Amazon Earnings, Q4 GDP Report Lead Investing Action Plan",LLY,http://www.investors.com/research/investing-action-plan/amazon-earnings-stock-eyes-buy-point-q4-2019-gdp-growth-estimate-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-01-29T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,,,
2020-01-29T08:00:00.000+08:00,Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review,LLY,http://www.zacks.com/stock/news/738792/alkermes-alks-nda-for-alks-3831-accepted-by-fda-for-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-738792,Zacks,,,,,,
2020-01-29T08:00:00.000+08:00,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",LLY,http://www.zacks.com/stock/news/738675/big-drug-biotech-stock-earnings-on-jan-30-biib-alxn-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-738675,Zacks,,,,,,
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application,LLY,http://www.gurufocus.com/news/1023784/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application,GuruFocus,,,,,,
2020-01-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,LLY,https://www.benzinga.com/wiim/20/01/15220945/eli-lilly-shares-are-trading-higher-after-the-company-reported-better-than-expected-q4-eps-and-sales,Benzinga Newsdesk,,,,,,
2020-01-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15215233/the-daily-biotech-pulse-sanofi-reports-positive-readout-tonix-vaccine-candidate-aces-animal-study,Shanthi Rexaline,,,,,,
2020-01-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data",LLY,https://www.benzinga.com/news/earnings/20/01/15215756/a-peek-into-the-markets-us-stock-futures-tumble-ahead-of-earnings-gdp-data,Lisa Levin,,,,,,
2020-01-30T08:00:00.000+08:00,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80,LLY,https://www.benzinga.com/news/20/01/15215575/eli-lilly-reaffirms-fy20-adj-eps-guidance-6-70-6-80,Benzinga Newsdesk,,,,,,
2020-01-30T08:00:00.000+08:00,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate",LLY,https://www.benzinga.com/news/earnings/20/01/15215574/eli-lilly-q4-adj-eps-1-73-beats-1-51-estimate-sales-6-114b-beat-5-9b-estimate,Benzinga Newsdesk,,,,,,
2020-01-30T08:00:00.000+08:00,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/01/15215540/eli-lilly-reports-top-line-results-from-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-in,Benzinga Newsdesk,,,,,,
2020-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215156/earnings-scheduled-for-january-30-2020,Lisa Levin,,,,,,
2020-01-30T08:00:00.000+08:00,"14 Stocks To Watch For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215081/14-stocks-to-watch-for-january-30-2020,Lisa Levin,,,,,,
2020-01-30T08:00:00.000+08:00,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?",LLY,http://www.gurufocus.com/news/1024833/thinking-about-buying-stock-in-applied-materials-general-electric-eli-lilly-qorvo-or-tesla,GuruFocus,,,,,,
2020-01-30T08:00:00.000+08:00,Lilly's NDA for Selpercatinib Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/740824/lillys-nda-for-selpercatinib-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-740824,Zacks,,,,,,
2020-01-30T08:00:00.000+08:00,"Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/740768/lilly-lly-q4-earnings-and-sales-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-740768,Zacks,,,,,,
2020-01-30T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase ...,LLY,http://www.gurufocus.com/news/1024618/lilly-and-incyte-announce-positive-topline-results-from-the-north-american-breezead5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,GuruFocus,,,,,,
2020-01-30T08:00:00.000+08:00,"Tesla soars on upbeat earnings, Facebook struggles with expenses",LLY,https://talkmarkets.com/content/tesla-soars-on-upbeat-earnings-facebook-struggles-with-expenses?post=249049,TalkMarkets,,,,,,
2020-01-31T08:00:00.000+08:00,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine,LLY,https://www.benzinga.com/news/20/01/15227875/lillys-announces-that-its-reyvow-c-v-is-the-first-and-only-medicine-in-a-new-class-of-acute-treatmen,Benzinga Newsdesk,,,,,,
2020-01-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",LLY,https://www.benzinga.com/general/biotech/20/01/15224639/the-daily-biotech-pulse-amgen-hurt-by-generic-competition-nanoviricides-confirms-working-on-wuhan,Shanthi Rexaline,,,,,,
2020-01-31T08:00:00.000+08:00,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion,LLY,https://www.benzinga.com/news/20/01/15225310/eli-lillys-liumjev-receives-positive-chmp-opinion,Benzinga Newsdesk,,,,,,
2020-01-31T08:00:00.000+08:00,"Opus Capital Group, LLC Buys iShares Short Treasury Bond ETF, Truist Financial Corp, SPDR ...",LLY,http://www.gurufocus.com/news/1026062/opus-capital-group-llc-buys-ishares-short-treasury-bond-etf-truist-financial-corp-spdr-portfolio-world-ex-us-etf-sells-vanguard-shortterm-corporate-bond-etf-schwab-intermediateterm-us-treasury-etf-hp-inc,GuruFocus,,,,,,
2020-01-31T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute ...",LLY,http://www.gurufocus.com/news/1025829/lillys-reyvow-lasmiditan-cv-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription,GuruFocus,,,,,,
2020-01-31T08:00:00.000+08:00,Bayer Seeks FDA Approval for New Formulation of Nifurtimox,LLY,http://www.zacks.com/stock/news/742609/bayer-seeks-fda-approval-for-new-formulation-of-nifurtimox?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-742609,Zacks,,,,,,
2020-02-02T08:00:00.000+08:00,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",LLY,https://www.benzinga.com/general/biotech/20/02/15229115/the-week-ahead-in-biotech-merck-bristol-myers-earnings-conference-presentations-in-focus,Shanthi Rexaline,,,,,,
2020-02-03T08:00:00.000+08:00,3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty,LLY,http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-BENZ-FT-stocks_in_the_news|major_headlines-747608,Zacks,,,,,,
2020-02-03T08:00:00.000+08:00,"Miller Investment Management, LP Buys Comcast Corp, Tortoise Pipeline & Energy Fund Inc, ...",LLY,http://www.gurufocus.com/news/1027358/miller-investment-management-lp-buys-comcast-corp-tortoise-pipeline--energy-fund-inc-eli-lilly-and-co-sells-jpmorgan-ultrashort-income-etf-centene-corp-lowes-inc,GuruFocus,,,,,,
2020-02-03T08:00:00.000+08:00,"United Bank Buys iShares Global Infrastructure ETF, Southern Co, Truist Financial Corp, Sells ...",LLY,http://www.gurufocus.com/news/1026995/united-bank-buys-ishares-global-infrastructure-etf-southern-co-truist-financial-corp-sells-celgene-corp-etrade-financial-corp-alexion-pharmaceuticals-inc,GuruFocus,,,,,,
2020-02-03T08:00:00.000+08:00,Amarillo National Bank Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1026853/amarillo-national-bank-buys-ishares-core-us-aggregate-bond-etf-eli-lilly-and-co-conocophillips-sells-berkshire-hathaway-inc,GuruFocus,,,,,,
2020-02-04T08:00:00.000+08:00,A Pick and Shovel Strategy to Avoid Competition and Speculation,LLY,http://www.gurufocus.com/news/1027985/a-pick-and-shovel-strategy-to-avoid-competition-and-speculation,GuruFocus,,,,,,
2020-02-04T08:00:00.000+08:00,Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal,LLY,http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-748888,Zacks,,,,,,
2020-02-04T08:00:00.000+08:00,Foster Dykema Cabot & Co Inc Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1027979/foster-dykema-cabot--co-inc-buys-ishares-core-us-value-etf-amphenol-corp-jpmorgan-chase-sells-ishares-sp-500-growth-etf-verisk-analytics-inc-msci-inc,GuruFocus,,,,,,
2020-02-04T08:00:00.000+08:00,"Analysts Forecast Huge Upsides for Aimmune, Biohaven",LLY,http://www.gurufocus.com/news/1027390/analysts-forecast-huge-upsides-for-aimmune-biohaven,GuruFocus,,,,,,
2020-02-05T08:00:00.000+08:00,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",LLY,https://www.benzinga.com/news/20/02/15264057/mizuho-initiates-abbvie-biohaven-with-buy-ratings-eli-lilly-alkermes-with-neutral-ratings,Benzinga Newsdesk,,,,,,
2020-02-05T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Wednesday,LLY,https://www.benzinga.com/news/20/02/15259090/stocks-that-hit-52-week-highs-on-wednesday,Lisa Levin,,,,,,
2020-02-05T08:00:00.000+08:00,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,LLY,https://www.benzinga.com/wiim/20/02/15258715/shares-of-several-healthcare-and-biotech-companies-are-trading-higher-as-unconfirmed-reports-of-prog,Benzinga Newsdesk,,,,,,
2020-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",LLY,https://www.benzinga.com/general/biotech/20/02/15256778/the-daily-biotech-pulse-merck-spins-off-slow-growth-businesses-ziopharm-announces-offering-phaseb,Shanthi Rexaline,,,,,,
2020-02-05T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/750129/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-750129,Zacks,,,,,,
2020-02-06T08:00:00.000+08:00,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15270875/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-targ,Benzinga Newsdesk,,,,,,
2020-02-06T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/02/15270346/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,,,
2020-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",LLY,https://www.benzinga.com/general/biotech/20/02/15266453/the-daily-biotech-pulse-tonix-slumps-on-failed-study-applied-genetic-announces-offering-beam-ther,Shanthi Rexaline,,,,,,
2020-02-06T08:00:00.000+08:00,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target",LLY,https://www.benzinga.com/news/20/02/15266407/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-target,Vick Meyer,,,,,,
2020-02-06T08:00:00.000+08:00,Paragon Capital Management Ltd Buys Vanguard Global ex-U.S. ...,LLY,http://www.gurufocus.com/news/1030331/paragon-capital-management-ltd-buys-vanguard-global-exus-real-estate-etf-vanguard-taxexempt-bond-etf-spdr-gold-trust-sells-suntrust-banks-inc-united-technologies-corp,GuruFocus,,,,,,
2020-02-06T08:00:00.000+08:00,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or ...",LLY,http://www.gurufocus.com/news/1029944/thinking-about-trading-options-or-stock-in-apple-eli-lilly-microchip-technology-tesla-or-unitedhealth-group,GuruFocus,,,,,,
2020-02-07T08:00:00.000+08:00,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",LLY,https://www.benzinga.com/general/biotech/20/02/15277159/the-daily-biotech-pulse-assertio-to-sell-opioid-pain-drug-milestone-payment-for-aduro-myriad-gene,Shanthi Rexaline,,,,,,
2020-02-07T08:00:00.000+08:00,"Smith, Moore & Co. Buys Vanguard Dividend Appreciation ETF, MPLX LP, Becton, Dickinson and ...",LLY,http://www.gurufocus.com/news/1032407/smith-moore--co-buys-vanguard-dividend-appreciation-etf-mplx-lp-becton-dickinson-and-co-sells-ishares-core-high-dividend-etf-blackrock-science-and-technology-trust-canadian-national-railway-co,GuruFocus,,,,,,
2020-02-07T08:00:00.000+08:00,Med Stock Dexcom In Buy Range Ahead Of Earnings,LLY,http://www.investors.com/stock-lists/stock-spotlight/med-stock-dexcom-in-buy-range-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-02-07T08:00:00.000+08:00,Lilly to Participate in Guggenheim Healthcare Talks Idea Forum,LLY,http://www.gurufocus.com/news/1032277/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum,GuruFocus,,,,,,
2020-02-07T08:00:00.000+08:00,"Jennison Associates Llc Buys Coupa Software Inc, Boston Scientific Corp, Eli Lilly and Co, ...",LLY,http://www.gurufocus.com/news/1032228/jennison-associates-llc-buys-coupa-software-inc-boston-scientific-corp-eli-lilly-and-co-sells-boeing-co-american-tower-corp-vertex-pharmaceuticals-inc,GuruFocus,,,,,,
2020-02-07T08:00:00.000+08:00,Teva (TEVA) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754447,Zacks,,,,,,
2020-02-07T08:00:00.000+08:00,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754325/incyte-incy-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754325,Zacks,,,,,,
2020-02-10T08:00:00.000+08:00,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/20/02/15290344/eli-lilly-suffers-setback-as-alzheimers-study-fails-to-meet-primary-endpoint,Shanthi Rexaline,,,,,,
2020-02-10T08:00:00.000+08:00,12 Healthcare Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/pre-market-outlook/20/02/15287557/12-healthcare-stocks-moving-in-mondays-pre-market-session,Benzinga Newsdesk,,,,,,
2020-02-10T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/02/15287528/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,,,
2020-02-10T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.,LLY,https://www.benzinga.com/wiim/20/02/15287485/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-the-results-for-solanezumba-fro,Benzinga Newsdesk,,,,,,
2020-02-10T08:00:00.000+08:00,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/20/02/15286645/lilly-announces-alzheimers-study-did-not-meet-primary-endpoint,Charles Gross,,,,,,
2020-02-10T08:00:00.000+08:00,"Lcnb Corp Buys Eli Lilly and Co, Bank of America Corp, Carnival Corp, Sells iShares Core MSCI ...",LLY,http://www.gurufocus.com/news/1034543/lcnb-corp-buys-eli-lilly-and-co-bank-of-america-corp-carnival-corp-sells-ishares-core-msci-emerging-markets-etf-ishares-13-year-credit-bond-etf-wisdomtree-total-dividend-fund,GuruFocus,,,,,,
2020-02-10T08:00:00.000+08:00,"Compton Capital Management Inc Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Truist ...",LLY,http://www.gurufocus.com/news/1034459/compton-capital-management-inc-buys-bristolmyers-squibb-company-eli-lilly-and-co-truist-financial-corp-sells-celgene-corp-cognizant-technology-solutions-corp-suntrust-banks-inc,GuruFocus,,,,,,
2020-02-10T08:00:00.000+08:00,Spiros Segalas Comments on Eli Lilly,LLY,http://www.gurufocus.com/news/1034323/spiros-segalas-comments-on-eli-lilly,GuruFocus,,,,,,
2020-02-10T08:00:00.000+08:00,Spiros Segalas' Harbor Capital Appreciation Fund 4th-Quarter Commentary,LLY,http://www.gurufocus.com/news/1034315/spiros-segalas-harbor-capital-appreciation-fund-4thquarter-commentary,GuruFocus,,,,,,
2020-02-10T08:00:00.000+08:00,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?",LLY,http://www.gurufocus.com/news/1034234/thinking-about-buying-stock-in-l-brands-eli-lilly-netflix-tesla-or-xylem,GuruFocus,,,,,,
2020-02-10T08:00:00.000+08:00,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network ...,LLY,http://www.gurufocus.com/news/1033506/lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-diantu-study,GuruFocus,,,,,,
2020-02-11T08:00:00.000+08:00,Citizens & Northern Corp Buys iShares J.P. ...,LLY,http://www.gurufocus.com/news/1036136/citizens--northern-corp-buys-ishares-jp-morgan-usd-emerging-markets-bond-etf-energy-select-sector-spdr-fund-ishares-nasdaq-biotechnology-index-fund-sells-celgene-corp-alexion-pharmaceuticals-inc-exxon-mobil-corp,GuruFocus,,,,,,
2020-02-11T08:00:00.000+08:00,"Ci Investments Inc. Buys Berry Global Group Inc, DuPont de Nemours Inc, iShares Core MSCI EAFE ...",LLY,http://www.gurufocus.com/news/1035896/ci-investments-inc-buys-berry-global-group-inc-dupont-de-nemours-inc-ishares-core-msci-eafe-etf-sells-spdr-gold-trust-verizon-communications-inc-pattern-energy-group-inc,GuruFocus,,,,,,
2020-02-11T08:00:00.000+08:00,Lilly Reports Disappointing Data on Alzheimer's Candidate,LLY,http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-760082,Zacks,,,,,,
2020-02-12T08:00:00.000+08:00,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",LLY,https://www.benzinga.com/general/biotech/20/02/15308201/the-daily-biotech-pulse-j-j-intensifies-efforts-on-covid-19-cure-adamas-reports-positive-long-ter,Shanthi Rexaline,,,,,,
2020-02-12T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/02/15307648/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-phase-3-study-breeze-ad5,Charles Gross,,,,,,
2020-02-12T08:00:00.000+08:00,"Halbert, Hargrove Buys iShares ESG USD Corporate Bond ETF, Bristol-Myers Squibb Company, ...",LLY,http://www.gurufocus.com/news/1036711/halbert-hargrove-buys-ishares-esg-usd-corporate-bond-etf-bristolmyers-squibb-company-ishares-core-us-reit-etf-sells-ishares-msci-emerging-markets-etf-ishares-core-msci-eafe-etf-procter--gamble-co,GuruFocus,,,,,,
2020-02-13T08:00:00.000+08:00,"Greenwood Capital Associates Llc Buys iShares Core MSCI Emerging Markets, Vanguard ...",LLY,http://www.gurufocus.com/news/1038613/greenwood-capital-associates-llc-buys-ishares-core-msci-emerging-markets-vanguard-ftseeuropean-spdr-select-sector-fund--health-care-sells-ishares-core-msci-total-international-stock-etf-walmart-inc-ishares-us-aerospac,GuruFocus,,,,,,
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Has Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-has-brighter-days-ahead,GuruFocus,,,,,,
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Sees Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-sees-brighter-days-ahead,GuruFocus,,,,,,
2020-02-13T08:00:00.000+08:00,Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales,LLY,http://www.zacks.com/stock/news/763949/incyte-incy-q4-earnings-top-estimates-on-solid-jakafi-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-763949,Zacks,,,,,,
2020-02-13T08:00:00.000+08:00,"Hudson Canyon Investment Counselors Llc Buys The Walt Disney Co, Zscaler Inc, Incyte Corp, ...",LLY,http://www.gurufocus.com/news/1037879/hudson-canyon-investment-counselors-llc-buys-the-walt-disney-co-zscaler-inc-incyte-corp-sells-acacia-communications-inc-summit-materials-inc-dycom-industries-inc,GuruFocus,,,,,,
2020-02-14T08:00:00.000+08:00,"Fayez Sarofim & Co Buys Progressive Corp, Booking Holdings Inc, Blackstone Group Inc, Sells ...",LLY,http://www.gurufocus.com/news/1039999/fayez-sarofim--co-buys-progressive-corp-booking-holdings-inc-blackstone-group-inc-sells-anheuserbusch-inbev-sanv-total-sa-constellation-brands-inc,GuruFocus,,,,,,
2020-02-14T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys iShares Short Maturity Bond, TJX Inc, Bristol-Myers ...",LLY,http://www.gurufocus.com/news/1039548/buckingham-capital-management-inc-buys-ishares-short-maturity-bond-tjx-inc-bristolmyers-squibb-company-sells-total-sa-celgene-corp-the-travelers-inc,GuruFocus,,,,,,
2020-02-14T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails",LLY,http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-BENZ-FT-analyst_blog|stock_roundup-765605,Zacks,,,,,,
2020-02-14T08:00:00.000+08:00,Stocks Stay Resilient Amid New Coronavirus Cases,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24304,Zacks,,,,,,
2020-02-16T08:00:00.000+08:00,Healthcare (Top 30 Weights) Earnings Estimates And Revisions,LLY,https://talkmarkets.com/content/healthcare-top-30-weights-earnings-estimates-and-revisions?post=251191,TalkMarkets,,,,,,
2020-02-17T08:00:00.000+08:00,"Mirova Buys First Solar Inc, Air Products & Chemicals Inc, Waste Management Inc, Sells ...",LLY,http://www.gurufocus.com/news/1041503/mirova-buys-first-solar-inc-air-products--chemicals-inc-waste-management-inc-sells-microsoft-corp-mastercard-inc-thermo-fisher-scientific-inc,GuruFocus,,,,,,
2020-02-17T08:00:00.000+08:00,"Woodley Farra Manion Portfolio Management Inc Buys Comcast Corp, JPMorgan Chase, iShares Core ...",LLY,http://www.gurufocus.com/news/1041489/woodley-farra-manion-portfolio-management-inc-buys-comcast-corp-jpmorgan-chase-ishares-core-sp-500-sells-fortive-corp-alcon-inc-nestle-sa,GuruFocus,,,,,,
2020-02-17T08:00:00.000+08:00,"Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, Envista Holdings Corp, ...",LLY,http://www.gurufocus.com/news/1041416/reynders-mcveigh-capital-management-llc-buys-becton-dickinson-and-co-envista-holdings-corp-tjx-inc-sells-american-eagle-outfitters-inc-alcon-inc-zuora-inc,GuruFocus,,,,,,
2020-02-20T08:00:00.000+08:00,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin",LLY,https://www.benzinga.com/news/20/02/15376985/watching-sanofi-shares-as-hearing-co-eli-lilly-will-face-claims-of-violation-of-rico-act-related-to,Benzinga Newsdesk,,,,,,
2020-02-20T08:00:00.000+08:00,"North Point Portfolio Managers Corp Buys Church & Dwight Co Inc, Gildan Activewear Inc, Eli ...",LLY,http://www.gurufocus.com/news/1045945/north-point-portfolio-managers-corp-buys-church--dwight-co-inc-gildan-activewear-inc-eli-lilly-and-co-sells-signature-bank-matson-inc-boeing-co,GuruFocus,,,,,,
2020-02-21T08:00:00.000+08:00,Trulicity® (dulaglutide) is the first and only type — diabetes medicine approved to reduce ...,LLY,http://www.gurufocus.com/news/1047429/trulicity-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,GuruFocus,,,,,,
2020-02-21T08:00:00.000+08:00,Mairs and Power: Top 4th-Quarter Trades,LLY,http://www.gurufocus.com/news/1047325/mairs-and-power-top-4thquarter-trades,GuruFocus,,,,,,
2020-02-21T08:00:00.000+08:00,Lilly To Participate in SVB Leerink Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1047212/lilly-to-participate-in-svb-leerink-global-healthcare-conference,GuruFocus,,,,,,
2020-02-21T08:00:00.000+08:00,Lilly to Participate in Cowen Health Care Conference,LLY,http://www.gurufocus.com/news/1047207/lilly-to-participate-in-cowen-health-care-conference,GuruFocus,,,,,,
2020-02-23T08:00:00.000+08:00,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,LLY,https://www.benzinga.com/general/biotech/20/02/15384645/the-week-ahead-in-biotech-biopharma-earnings-pick-up-pace,Shanthi Rexaline,,,,,,
2020-02-24T08:00:00.000+08:00,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/20/02/15393466/eli-lilly-yesterday-announced-it-has-received-fda-approval-for-trulicity-the-first-and-only-type-2-d,Benzinga Newsdesk,,,,,,
2020-02-24T08:00:00.000+08:00,Weekly Trades With Yields Up To 165%,LLY,https://talkmarkets.com/content/weekly-trades-with-yields-up-to-165?post=252194,TalkMarkets,,,,,,
2020-02-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",LLY,https://www.benzinga.com/general/biotech/20/02/15415577/the-daily-biotech-pulse-menlo-flunks-midstage-trial-gw-pharmas-earnings-covid-19-updates,Shanthi Rexaline,,,,,,
2020-02-26T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line ...,LLY,http://www.gurufocus.com/news/1054936/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-ramucirumab-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,,,
2020-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",LLY,https://www.benzinga.com/general/biotech/20/02/15425291/the-daily-biotech-pulse-gilead-kicks-off-coronavirus-drug-trials-adcom-nod-for-lily-fda-approves-,Shanthi Rexaline,,,,,,
2020-02-27T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/20/02/15425380/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-as-first-line-treatment-for-metastatic-egfr,Charles Gross,,,,,,
2020-02-27T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/786342/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-786342,Zacks,,,,,,
2020-02-28T08:00:00.000+08:00,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,LLY,https://www.benzinga.com/wiim/20/02/15440922/shares-of-several-healthcare-companies-are-trading-lower-as-the-global-coronavirus-spread-continues,Benzinga Newsdesk,,,,,,
2020-02-28T08:00:00.000+08:00,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache,LLY,https://www.benzinga.com/news/20/02/15439219/ema-says-adopted-negative-opinion-for-eli-lillys-indication-extension-for-emgality-to-add-prevention,Benzinga Newsdesk,,,,,,
2020-02-28T08:00:00.000+08:00,"Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit",LLY,http://www.zacks.com/stock/news/788467/pharma-stock-roundup-fda-updates-from-lly-gsk-nvs-sny-to-spin-off-api-unit?cid=CS-BENZ-FT-analyst_blog|stock_roundup-788467,Zacks,,,,,,
2020-02-28T08:00:00.000+08:00,"Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/788298/nektar-nktr-q4-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-788298,Zacks,,,,,,
2020-02-29T08:00:00.000+08:00,Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/790111/lilly-lly-down-116-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-790111,Zacks,,,,,,
2020-03-02T08:00:00.000+08:00,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA,LLY,https://www.benzinga.com/news/20/03/15452717/pfizers-biologics-license-application-for-tanezumab-accepted-for-review-by-the-fda,Benzinga Newsdesk,,,,,,
2020-03-02T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Union Pacific & Lockheed",LLY,http://www.zacks.com/research-daily/792580/top-stock-reports-for-eli-lilly-union-pacific-lockheed?cid=CS-BENZ-FT-research_daily-792580,Zacks,,,,,,
2020-03-02T08:00:00.000+08:00,This is Why Eli Lilly (LLY) is a Great Dividend Stock,LLY,http://www.zacks.com/stock/news/792843/this-is-why-eli-lilly-lly-is-a-great-dividend-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-792843,Zacks,,,,,,
2020-03-02T08:00:00.000+08:00,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for ...",LLY,http://www.gurufocus.com/news/1061635/us-fda-accepts-regulatory-submission-for-tanezumab-a-potential-firstinclass-treatment-for-patients-with-chronic-pain-due-to-moderatetosevere-osteoarthritis,GuruFocus,,,,,,
2020-03-02T08:00:00.000+08:00,Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/792360/radius-rdus-q4-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-792360,Zacks,,,,,,
2020-03-03T08:00:00.000+08:00,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",LLY,https://www.benzinga.com/general/biotech/20/03/15463518/the-daily-biotech-pulse-genmark-diagnostics-ships-covid-19-test-kits-karyopharm-to-offer-shares-a,Shanthi Rexaline,,,,,,
2020-03-03T08:00:00.000+08:00,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin",LLY,https://www.benzinga.com/news/20/03/15464651/lilly-issued-a-statement-on-coronavirus-and-the-reliable-syooly-of-the-companys-medicines-the-compan,Benzinga Newsdesk,,,,,,
2020-03-03T08:00:00.000+08:00,Sometimes The Best Trade Is No Trade,LLY,https://talkmarkets.com/content/sometimes-the-best-trade-is-no-trade?post=253102,TalkMarkets,,,,,,
2020-03-03T08:00:00.000+08:00,"Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA",LLY,http://www.zacks.com/stock/news/794372/pfizer-plans-coronavirus-therapy-progresses-with-tanezumab-bla?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-794372,Zacks,,,,,,
2020-03-03T08:00:00.000+08:00,Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines,LLY,http://www.gurufocus.com/news/1063461/lilly-statement-on-novel-coronavirus-and-the-reliable-supply-of-the-companys-medicines,GuruFocus,,,,,,
2020-03-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis",LLY,http://www.zacks.com/stock/news/794092/the-zacks-analyst-blog-highlights-eli-lilly-union-pacific-lockheed-martin-bayer-and-prologis?cid=CS-BENZ-FT-press_releases-794092,Zacks,,,,,,
2020-03-04T08:00:00.000+08:00,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,LLY,https://www.benzinga.com/wiim/20/03/15477290/shares-of-several-drugmakers-and-healthcare-companies-are-trading-higher-following-us-super-tuesday,luke@benzinga.com,,,,,,
2020-03-04T08:00:00.000+08:00,Lilly Expects No Drug Supply Shortages Due to Coronavirus,LLY,http://www.zacks.com/stock/news/796161/lilly-expects-no-drug-supply-shortages-due-to-coronavirus?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-796161,Zacks,,,,,,
2020-03-06T08:00:00.000+08:00,"Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates",LLY,http://www.zacks.com/stock/news/799956/pharma-stock-roundup-trump-pharma-executives-meeting-on-coronavirus-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-799956,Zacks,,,,,,
2020-03-07T08:00:00.000+08:00,Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics,LLY,https://talkmarkets.com/content/week-in-review-abpro-bio-signs-11-billion-deal-for-china-asian-rights-to-two-bi-specifics?post=253730,TalkMarkets,,,,,,
2020-03-09T08:00:00.000+08:00,Lilly to Participate in Barclays Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1068579/lilly-to-participate-in-barclays-global-healthcare-conference,GuruFocus,,,,,,
2020-03-09T08:00:00.000+08:00,"Thinking about trading options or stock in Dollar General, Eli Lilly, 'M, Regeneron ...",LLY,http://www.gurufocus.com/news/1068401/thinking-about-trading-options-or-stock-in-dollar-general-eli-lilly-3m-regeneron-pharmaceuticals-or-slack-technologies,GuruFocus,,,,,,
2020-03-11T08:00:00.000+08:00,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D,LLY,https://www.benzinga.com/general/health-care/20/03/15528798/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-me,luke@benzinga.com,,,,,,
2020-03-11T08:00:00.000+08:00,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List",LLY,https://www.benzinga.com/news/20/03/15525286/goldman-sachs-maintains-buy-on-eli-lilly-announces-168-price-target-adds-to-conviction-buy-list,Benzinga_Newsdesk,,,,,,
2020-03-11T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Correction Is A Bear; Apple, Tesla, AMD Show Strength",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-correction-is-bear-market-apple-tesla-show-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-03-11T08:00:00.000+08:00,Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in ...,LLY,http://www.gurufocus.com/news/1070532/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-medicare-part-d,GuruFocus,,,,,,
2020-03-11T08:00:00.000+08:00,Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4,LLY,http://www.zacks.com/stock/news/808270/aduros-adro-earnings-revenues-miss-estimates-in-q4?cid=CS-BENZ-FT-analyst_blog|earnings_article-808270,Zacks,,,,,,
2020-03-11T08:00:00.000+08:00,"\"Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will \"\"Stay At Home\"\" Stocks Win Big In 2020?\"",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-slammed-1151-points-on-coronavirus-fears-will-stay-at-home-stocks-win-big-in-2020/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-03-11T08:00:00.000+08:00,Pharma M&A Has Slowed to a Crawl,LLY,http://www.gurufocus.com/news/1069653/pharma-ma-has-slowed-to-a-crawl,GuruFocus,,,,,,
2020-03-12T08:00:00.000+08:00,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment",LLY,https://www.benzinga.com/news/20/03/15539101/eli-lilly-shares-make-parabolic-move-spike-higher-then-sell-off-hearing-co-said-to-join-race-to-deve,Benzinga Newsdesk,,,,,,
2020-03-12T08:00:00.000+08:00,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.,LLY,https://www.benzinga.com/wiim/20/03/15536434/eli-lilly-co-shares-are-trading-lower-despite-receiving-fast-track-designation-to-jardiance-by-the-f,Benzinga Newsdesk,,,,,,
2020-03-12T08:00:00.000+08:00,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease,LLY,https://www.benzinga.com/news/20/03/15534998/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,Benzinga Newsdesk,,,,,,
2020-03-12T08:00:00.000+08:00,AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-–9,LLY,http://www.gurufocus.com/news/1072123/abcellera-and-lilly-to-codevelop-antibody-therapies-for-the-treatment-of-covid19,GuruFocus,,,,,,
2020-03-12T08:00:00.000+08:00,US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease,LLY,http://www.gurufocus.com/news/1071067/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,GuruFocus,,,,,,
2020-03-13T08:00:00.000+08:00,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",LLY,https://www.benzinga.com/general/biotech/20/03/15546603/the-latest-coronavirus-developments-from-biotechs-la-jolla-provides-giapreza-in-italy-enanta-rese,Shanthi Rexaline,,,,,,
2020-03-13T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,LLY,https://www.benzinga.com/wiim/20/03/15546640/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-following-thursdays,Benzinga Newsdesk,,,,,,
2020-03-13T08:00:00.000+08:00,"Thinking about trading options or stock in Alphabet, Eli Lilly, Microsoft, Procter & ...",LLY,http://www.gurufocus.com/news/1072825/thinking-about-trading-options-or-stock-in-alphabet-eli-lilly-microsoft-procter--gamble-or-roku,GuruFocus,,,,,,
2020-03-13T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates",LLY,http://www.zacks.com/stock/news/811614/pharma-stock-roundup-abbv-lly-coronavirus-product-development-efforts-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-811614,Zacks,,,,,,
2020-03-13T08:00:00.000+08:00,Weekly Biotech Update After WHO Declares Coronavirus a Pandemic,LLY,http://www.zacks.com/stock/news/811616/weekly-biotech-update-after-who-declares-coronavirus-a-pandemic?cid=CS-BENZ-FT-analyst_blog|industry_focus-811616,Zacks,,,,,,
2020-03-13T08:00:00.000+08:00,Coronavirus Drug Development Efforts Pick Up Amid Sell-Off,LLY,http://www.zacks.com/stock/news/811498/coronavirus-drug-development-efforts-pick-up-amid-sell-off?cid=CS-BENZ-FT-analyst_blog|industry_focus-811498,Zacks,,,,,,
2020-03-13T08:00:00.000+08:00,When To Buy Large Cap Stocks During A Stock Market Crash: These 2 Sectors Offer Clues,LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/when-to-buy-large-cap-stocks-during-a-stock-market-crash-these-2-sectors-offer-clues/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-03-16T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15559452/shares-of-several-healthcare-companies-are-trading-lower-as-the-coronavirus-outbreak-continues-to-ca,Benzinga Newsdesk,,,,,,
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,LLY,https://www.benzinga.com/news/20/03/15556180/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-ar,luke@benzinga.com,,,,,,
2020-03-16T08:00:00.000+08:00,"Coronavirus Correction: Eli Lilly Stock Shows Strength Amid Accelerating Earnings, Sales",LLY,http://www.investors.com/stock-lists/stock-spotlight/eli-lilly-stock-shows-strength-during-coronavirus-stock-market-correction/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-03-16T08:00:00.000+08:00,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy,LLY,http://www.zacks.com/stock/news/816672/4-big-drug-biotech-stocks-up-in-coronavirus-hit-economy?cid=CS-BENZ-FT-analyst_blog|investment_ideas-816672,Zacks,,,,,,
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of ...,LLY,http://www.gurufocus.com/news/1074543/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata,GuruFocus,,,,,,
2020-03-17T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",LLY,https://www.benzinga.com/wiim/20/03/15568177/shares-of-several-healthcare-companies-are-trading-higher-rebounding-from-mondays-crash-stocks-may-a,Benzinga Newsdesk,,,,,,
2020-03-17T08:00:00.000+08:00,Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss,LLY,http://www.zacks.com/stock/news/818757/lillys-olumiant-gets-breakthrough-therapy-tag-for-hair-loss?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-818757,Zacks,,,,,,
2020-03-18T08:00:00.000+08:00,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana,LLY,https://www.benzinga.com/news/20/03/15583777/eli-lilly-reports-partnership-with-indiana-state-dept-of-health-with-support-from-fda-to-accelerate,Benzinga Newsdesk,,,,,,
2020-03-18T08:00:00.000+08:00,"Lilly, Indiana State Department of Health Partner to Accelerate COVID-–9 Testing Using Lilly ...",LLY,http://www.gurufocus.com/news/1078652/lilly-indiana-state-department-of-health-partner-to-accelerate-covid19-testing-using-lilly-research-laboratories,GuruFocus,,,,,,
2020-03-19T08:00:00.000+08:00,"Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, ...",LLY,http://www.gurufocus.com/news/1079527/thinking-about-trading-options-or-stock-in-akamai-technologies-citrix-systems-eli-lilly-veeva-systems-or-walmart,GuruFocus,,,,,,
2020-03-20T08:00:00.000+08:00,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly",LLY,https://www.benzinga.com/news/20/03/15621263/fda-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-t,Benzinga Newsdesk,,,,,,
2020-03-20T08:00:00.000+08:00,US FDA issues complete response letter for empagliflozin —. ...,LLY,http://www.gurufocus.com/news/1081165/us-fda-issues-complete-response-letter-for-empagliflozin-25-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,GuruFocus,,,,,,
2020-03-20T08:00:00.000+08:00,"Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates",LLY,http://www.zacks.com/stock/news/825091/pharma-stock-roundup-sny-rhhby-pfes-coronavirus-product-development-other-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-825091,Zacks,,,,,,
2020-03-22T08:00:00.000+08:00,Lilly to Provide Drive-Through COVID-–9 Testing for Indianapolis Health Care Workers,LLY,http://www.gurufocus.com/news/1082072/lilly-to-provide-drivethrough-covid19-testing-for-indianapolis-health-care-workers,GuruFocus,,,,,,
2020-03-23T08:00:00.000+08:00,Eli Lilly Delays New Study Starts,LLY,https://www.benzinga.com/news/20/03/15635955/eli-lilly-delays-new-study-starts,Tanzeel Akhtar,,,,,,
2020-03-23T08:00:00.000+08:00,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.,LLY,https://www.benzinga.com/wiim/20/03/15632908/eli-lilly-and-co-shares-are-trading-lower-after-the-company-announced-it-will-delay-most-of-the-new,Benzinga Newsdesk,,,,,,
2020-03-23T08:00:00.000+08:00,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly,LLY,https://www.benzinga.com/news/20/03/15632092/ac-immune-receives-a-second-milestone-payment-of-chf-10m-from-eli-lilly,luke@benzinga.com,,,,,,
2020-03-23T08:00:00.000+08:00,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus,LLY,https://www.benzinga.com/news/20/03/15631606/eli-lilly-says-it-will-delay-most-new-trial-starts-and-pause-enrollment-in-ongoing-studies-amid-coro,luke@benzinga.com,,,,,,
2020-03-23T08:00:00.000+08:00,Lilly Gets CRL for Jardiance in Type I Diabetes Indication,LLY,http://www.zacks.com/stock/news/829757/lilly-gets-crl-for-jardiance-in-type-i-diabetes-indication?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-829757,Zacks,,,,,,
2020-03-23T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck",LLY,http://www.zacks.com/stock/news/829731/the-zacks-analyst-blog-highlights-pfizer-roche-sanofi-lilly-and-merck?cid=CS-BENZ-FT-press_releases-829731,Zacks,,,,,,
2020-03-23T08:00:00.000+08:00,Lilly Provides Update on Clinical Trial Activities During COVID-–9 Pandemic,LLY,http://www.gurufocus.com/news/1082320/lilly-provides-update-on-clinical-trial-activities-during-covid19-pandemic,GuruFocus,,,,,,
2020-03-24T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",LLY,https://www.benzinga.com/wiim/20/03/15653267/shares-of-several-healthcare-companies-are-trading-higher-as-equities-gain-amid-hopes-of-a-us-stimul,Benzinga Newsdesk,,,,,,
2020-03-24T08:00:00.000+08:00,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers",LLY,https://www.benzinga.com/news/20/03/15649668/eli-lilly-offers-update-on-insulin-supply-affordability-says-does-not-source-active-pharma-ingredien,Benzinga Newsdesk,,,,,,
2020-03-24T08:00:00.000+08:00,Agios' IND for PKR Activator AG-946 Gets FDA Clearance,LLY,http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-832392,Zacks,,,,,,
2020-03-24T08:00:00.000+08:00,"Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure",LLY,http://www.zacks.com/stock/news/831913/lilly-halts-enrollment-biotechs-focus-to-find-coronavirus-cure?cid=CS-BENZ-FT-analyst_blog|industry_focus-831913,Zacks,,,,,,
2020-03-24T08:00:00.000+08:00,Updates from Lilly about insulin supply and affordability,LLY,http://www.gurufocus.com/news/1083554/updates-from-lilly-about-insulin-supply-and-affordability,GuruFocus,,,,,,
2020-03-26T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15674560/shares-of-several-healthcare-companies-are-trading-higher-following-senate-passage-of-a-2-trillion-e,Benzinga Newsdesk,,,,,,
2020-03-27T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",LLY,https://www.benzinga.com/wiim/20/03/15682782/shares-of-several-healthcare-companies-are-trading-lower-selling-off-from-this-weeks-strength-while,Benzinga Newsdesk,,,,,,
2020-03-27T08:00:00.000+08:00,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,LLY,https://www.benzinga.com/news/20/03/15679170/veeva-systems-crm-product-is-seeing-ten-times-more-usage-during-coronavirus-pandemic,Neer Varshney,,,,,,
2020-03-27T08:00:00.000+08:00,Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio,LLY,http://www.gurufocus.com/news/1087247/spiros-segalas-starts-the-new-year-adding-5-stocks-to-portfolio-,GuruFocus,,,,,,
2020-03-27T08:00:00.000+08:00,Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia,LLY,http://www.zacks.com/stock/news/838749/bristol-myers-bmy-clinches-fda-nod-for-ms-drug-zeposia?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-838749,Zacks,,,,,,
2020-03-27T08:00:00.000+08:00,"Eli Lilly Clears Key Benchmark, Hitting 90-Plus RS Rating",LLY,http://www.investors.com/ibd-data-stories/eli-lilly-clears-key-benchmark-hitting-90-plus-rs-rating/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-03-30T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/03/15695621/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,,,
2020-03-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.,LLY,https://www.benzinga.com/wiim/20/03/15694884/eli-lilly-shares-are-trading-higher-after-the-company-received-fda-approval-for-taltz-for-treatment,Benzinga Newsdesk,,,,,,
2020-03-30T08:00:00.000+08:00,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/20/03/15692388/eli-lillys-taltz-receives-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-seve,luke@benzinga.com,,,,,,
2020-03-30T08:00:00.000+08:00,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View",LLY,http://www.zacks.com/stock/news/845617/vertex-to-halt-enrollment-due-to-coronavirus-keeps-sales-view?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-845617,Zacks,,,,,,
2020-03-30T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives U.S. ...,LLY,http://www.gurufocus.com/news/1089445/lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis,GuruFocus,,,,,,
2020-03-31T08:00:00.000+08:00,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy,LLY,https://www.benzinga.com/news/20/03/15708775/patent-court-rejects-eli-lilly-challenge-to-teva-patents-on-migraine-drug-ajovy,Benzinga Newsdesk,,,,,,
2020-03-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",LLY,https://www.benzinga.com/general/biotech/20/03/15704595/the-daily-biotech-pulse-amarin-faces-legal-setback-milestone-payment-kicks-in-for-cytomx-savara-r,Shanthi Rexaline,,,,,,
2020-03-31T08:00:00.000+08:00,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines,LLY,https://www.benzinga.com/general/biotech/20/03/15703815/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immuno,Benzinga Newsdesk,,,,,,
2020-03-31T08:00:00.000+08:00,Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus,LLY,http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-BENZ-FT-video_blog-847731,Zacks,,,,,,
2020-03-31T08:00:00.000+08:00,Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-847430,Zacks,,,,,,
2020-04-01T08:00:00.000+08:00,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,LLY,https://www.benzinga.com/wiim/20/04/15717065/shares-of-several-healthcare-companies-are-trading-lower-amid-market-weakness-as-growing-coronavirus,Benzinga Newsdesk,,,,,,
2020-04-01T08:00:00.000+08:00,Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy,LLY,http://www.zacks.com/stock/news/849899/pharma-giant-eli-lilly-lly-stock-is-a-buy-during-the-coronavirus-economy?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-849899,Zacks,,,,,,
2020-04-01T08:00:00.000+08:00,"Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA",LLY,http://www.zacks.com/stock/news/849395/bristol-myers-bluebird-submit-bla-for-myeloma-drug-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-849395,Zacks,,,,,,
2020-04-01T08:00:00.000+08:00,Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/849155/is-eli-lilly-and-lly-outperforming-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-849155,Zacks,,,,,,
2020-04-01T08:00:00.000+08:00,3 Drugmakers Still Worth Betting on Amid Coronavirus Woes,LLY,http://www.zacks.com/stock/news/849056/3-drugmakers-still-worth-betting-on-amid-coronavirus-woes?cid=CS-BENZ-FT-analyst_blog|investment_ideas-849056,Zacks,,,,,,
2020-04-02T08:00:00.000+08:00,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148",LLY,https://www.benzinga.com/news/20/04/15727486/morgan-stanley-maintains-overweight-on-eli-lilly-lowers-price-target-to-148,Vick Meyer,,,,,,
2020-04-02T08:00:00.000+08:00,Stock Indexes Jump As Jobless Claims Soar Again,LLY,http://www.investors.com/videos/stock-indexes-jump-as-jobless-claims-soar-again/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-02T08:00:00.000+08:00,"Top Analyst Reports for Eli Lilly, Charter Communications & Eaton",LLY,http://www.zacks.com/research-daily/851105/top-analyst-reports-for-eli-lilly-charter-communications-eaton?cid=CS-BENZ-FT-research_daily-851105,Zacks,,,,,,
2020-04-02T08:00:00.000+08:00,Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis,LLY,http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-BENZ-FT-analyst_blog|rank_focused-851267,Zacks,,,,,,
2020-04-02T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/849904/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-849904,Zacks,,,,,,
2020-04-03T08:00:00.000+08:00,IBD Stock Of The Day: Why Eli Lilly Is Outplaying Its Pharma Giant Peers,LLY,http://www.investors.com/research/ibd-stock-of-the-day/lly-stock-pharma-giant-winning-despite-coronavirus-pandemic/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor",LLY,http://www.zacks.com/stock/news/853139/the-zacks-analyst-blog-highlights-eli-lilly-charter-eaton-autodesk-and-cypress-semiconductor?cid=CS-BENZ-FT-press_releases-853139,Zacks,,,,,,
2020-04-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/852982/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-852982,Zacks,,,,,,
2020-04-04T08:00:00.000+08:00,Stocks Move Lower but Stay Calm After Dreary Jobs Report,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24917,Zacks,,,,,,
2020-04-06T08:00:00.000+08:00,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb",LLY,https://www.benzinga.com/news/20/04/15749782/there-are-four-main-antibody-programs-underway-in-u-s-by-lilly-regeneron-vir-and-amgen-regeneron-may,Benzinga Newsdesk,,,,,,
2020-04-06T08:00:00.000+08:00,Another Drug to Fight Coronavirus & 3 Picks,LLY,http://www.zacks.com/stock/news/857483/another-drug-to-fight-coronavirus-3-picks?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-857483,Zacks,,,,,,
2020-04-06T08:00:00.000+08:00,Why the Earnings Surprise Streak Could Continue for Lilly (LLY),LLY,http://www.zacks.com/stock/news/857355/why-the-earnings-surprise-streak-could-continue-for-lilly-lly?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-857355,Zacks,,,,,,
2020-04-06T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",LLY,http://www.zacks.com/stock/news/857136/the-zacks-analyst-blog-highlights-jj-sanofi-astrazeneca-lilly-and-merck?cid=CS-BENZ-FT-press_releases-857136,Zacks,,,,,,
2020-04-07T08:00:00.000+08:00,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus,LLY,https://www.benzinga.com/general/health-care/20/04/15755030/eli-lilly-and-co-says-new-35-co-pay-now-available-through-lilly-insulin-value-program-in-resp,Benzinga Newsdesk,,,,,,
2020-04-07T08:00:00.000+08:00,Eli Lilly and Company to Hold —…—… Annual Meeting of Shareholders Virtually,LLY,http://www.gurufocus.com/news/1098422/eli-lilly-and-company-to-hold-2020-annual-meeting-of-shareholders-virtually,GuruFocus,,,,,,
2020-04-07T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts",LLY,http://www.zacks.com/stock/news/858933/the-zacks-analyst-blog-highlights-eli-lilly-qualcomm-and-electronic-arts?cid=CS-BENZ-FT-press_releases-858933,Zacks,,,,,,
2020-04-07T08:00:00.000+08:00,"Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day",LLY,http://www.zacks.com/stock/news/858915/agilysys-manpower-eli-lilly-and-company-innoviva-and-abbvie-highlighted-as-zacks-bull-and-bear-of-the-day?cid=CS-BENZ-FT-press_releases-858915,Zacks,,,,,,
2020-04-07T08:00:00.000+08:00,New $'5 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-–9 ...,LLY,http://www.gurufocus.com/news/1098140/new-35-copay-now-available-through-lilly-insulin-value-program-in-response-to-covid19-crisis-in-us,GuruFocus,,,,,,
2020-04-08T08:00:00.000+08:00,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus.",LLY,https://www.benzinga.com/wiim/20/04/15766253/eli-lilly-shares-are-trading-higher-not-seeing-company-specific-news-from-the-session-note-the-healt,Benzinga Newsdesk,,,,,,
2020-04-08T08:00:00.000+08:00,Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market,LLY,http://www.zacks.com/commentary/860406/large-cap-pharma-stocks-to-benefit-in-post-pandemic-market?cid=CS-BENZ-FT-industry_outlook-860406,Zacks,,,,,,
2020-04-08T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for First-Quarter —…—… Financial Results ...,LLY,http://www.gurufocus.com/news/1099259/lilly-confirms-date-and-conference-call-for-firstquarter-2020-financial-results-announcement,GuruFocus,,,,,,
2020-04-09T08:00:00.000+08:00,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15775641/bofa-downgrades-lilly-on-valuation-says-growth-pipeline-potential-balanced-by-stock,Shanthi Rexaline,,,,,,
2020-04-09T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",LLY,https://www.benzinga.com/analyst-ratings/upgrades/20/04/15775842/benzingas-top-upgrades-downgrades-for-april-9-2020,Lisa Levin,,,,,,
2020-04-09T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.,LLY,https://www.benzinga.com/wiim/20/04/15774537/eli-lilly-and-co-shares-are-trading-lower-after-morgan-stanley-downgraded-the-stock-from-overweight,Benzinga Newsdesk,,,,,,
2020-04-09T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/20/04/15773342/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Vick Meyer,,,,,,
2020-04-09T08:00:00.000+08:00,"Nadler Financial Group, Inc. Buys PIMCO Corporate & Income Opportunity Fds, Eli Lilly and ...",LLY,http://www.gurufocus.com/news/1100943/nadler-financial-group-inc-buys-pimco-corporate--income-opportunity-fds-eli-lilly-and-co-netflix-inc-sells-copart-inc-philip-morris-international-inc-ishares-msci-india,GuruFocus,,,,,,
2020-04-09T08:00:00.000+08:00,Highly Rated Eli Lilly Near Buy Zone Ahead Of Earnings,LLY,http://www.investors.com/ibd-data-stories/highly-rated-eli-lilly-near-buy-zone-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-09T08:00:00.000+08:00,Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer,LLY,http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-863161,Zacks,,,,,,
2020-04-09T08:00:00.000+08:00,J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma,LLY,http://www.zacks.com/stock/news/862892/jj-jnj-q1-earnings-may-indicate-coronavirus-impact-on-pharma?cid=CS-BENZ-FT-analyst_blog|earnings_preview-862892,Zacks,,,,,,
2020-04-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/862816/the-zacks-analyst-blog-highlights-a10-networks-chemed-core-mark-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-862816,Zacks,,,,,,
2020-04-10T08:00:00.000+08:00,Lilly Begins Clinical Testing of Therapies for COVID-–9,LLY,http://www.gurufocus.com/news/1102076/lilly-begins-clinical-testing-of-therapies-for-covid19,GuruFocus,,,,,,
2020-04-10T08:00:00.000+08:00,"Perkins Coie Trust Co Buys First Financial Corp, Truist Financial Corp, Vanguard Mid-Cap, Sells ...",LLY,http://www.gurufocus.com/news/1101996/perkins-coie-trust-co-buys-first-financial-corp-truist-financial-corp-vanguard-midcap-sells-truist-financial-corp-ishares-gold-trust-spdr-midcap-trust-series-i,GuruFocus,,,,,,
2020-04-11T08:00:00.000+08:00,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/20/04/15784941/benzingas-bulls-and-bears-of-the-week-apple-disney-intel-and-more,Nelson Hem,,,,,,
2020-04-12T08:00:00.000+08:00,This Trio of Strong Performers Is Predicted to Outperform,LLY,http://www.gurufocus.com/news/1102568/this-trio-of-strong-performers-is-predicted-to-outperform-,GuruFocus,,,,,,
2020-04-13T08:00:00.000+08:00,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus,LLY,https://www.benzinga.com/news/20/04/15789003/lilly-on-friday-anounced-it-has-begun-clinical-testing-of-therapies-for-coronavirus,Benzinga Newsdesk,,,,,,
2020-04-13T08:00:00.000+08:00,"Norman Fields, Gottscho Capital Management, LLC Buys Amazon.com Inc, Liberty Global PLC, D.R. ...",LLY,http://www.gurufocus.com/news/1103317/norman-fields-gottscho-capital-management-llc-buys-amazoncom-inc-liberty-global-plc-dr-horton-inc-sells-delta-air-lines-inc-southwest-airlines-co-carmax-inc,GuruFocus,,,,,,
2020-04-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/868599/zackscom-featured-highlights-include-electromed-novagold-resources-fti-consulting-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-868599,Zacks,,,,,,
2020-04-13T08:00:00.000+08:00,Lilly Announces Clinical Study Plans for Coronavirus Disease,LLY,http://www.zacks.com/stock/news/868591/lilly-announces-clinical-study-plans-for-coronavirus-disease?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-868591,Zacks,,,,,,
2020-04-14T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,LLY,https://www.benzinga.com/wiim/20/04/15798567/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-on-positive-coronavirus-ou,Benzinga Newsdesk,,,,,,
2020-04-14T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Tuesday,LLY,https://www.benzinga.com/news/20/04/15798317/stocks-that-hit-52-week-highs-on-tuesday,Benzinga Insights,,,,,,
2020-04-14T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Soars As Two Wrongs Go Right; Amazon, Nvidia Lead New Breakouts",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-soars-amazon-microsoft-nvidia-apple-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-14T08:00:00.000+08:00,Indexes Near Session Highs As These Top Stocks Finally Clear Buy Points,LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-near-session-highs-techs-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-14T08:00:00.000+08:00,"Six Surprising Stocks Making New Highs Today, One Especially",LLY,https://talkmarkets.com/content/six-surprising-stocks-making-new-highs-today-one-especially?post=258512,TalkMarkets,,,,,,
2020-04-14T08:00:00.000+08:00,SNY vs. LLY: Which Stock Is the Better Value Option?,LLY,http://www.zacks.com/stock/news/870517/sny-vs-lly-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-870517,Zacks,,,,,,
2020-04-14T08:00:00.000+08:00,"OneAscent Financial Services LLC Buys S&P Global Inc, Eli Lilly and Co, Brookfield ...",LLY,http://www.gurufocus.com/news/1104035/oneascent-financial-services-llc-buys-sp-global-inc-eli-lilly-and-co-brookfield-renewable-partners-lp-sells-vanguard-intermediateterm-government-bond-etf-vanguard-mortgagebacked-securities-etf-phillips-66,GuruFocus,,,,,,
2020-04-14T08:00:00.000+08:00,"J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact",LLY,http://www.zacks.com/stock/news/870325/jj-jnj-beats-on-q1-earnings-cuts-view-on-coronavirus-impact?cid=CS-BENZ-FT-analyst_blog|earnings_article-870325,Zacks,,,,,,
2020-04-15T08:00:00.000+08:00,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,LLY,https://www.benzinga.com/news/20/04/15808727/every-member-of-trumps-great-american-economic-revival-industry-groups,Tanzeel Akhtar,,,,,,
2020-04-15T08:00:00.000+08:00,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160",LLY,https://www.benzinga.com/news/20/04/15807720/cowen-co-maintains-outperform-on-eli-lilly-raises-price-target-to-160,Benzinga_Newsdesk,,,,,,
2020-04-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",LLY,https://www.benzinga.com/general/biotech/20/04/15806223/the-daily-biotech-pulse-applied-dna-ships-vaccine-constructs-for-animal-testing-herceptin-biosimi,Shanthi Rexaline,,,,,,
2020-04-15T08:00:00.000+08:00,AstraZeneca to Begin Calquence Study for Coronavirus Treatment,LLY,http://www.zacks.com/stock/news/872061/astrazeneca-to-begin-calquence-study-for-coronavirus-treatment?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-872061,Zacks,,,,,,
2020-04-15T08:00:00.000+08:00,Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month,LLY,http://www.zacks.com/stock/news/871880/buy-5-top-stocks-set-to-beat-on-q1-earnings-this-month?cid=CS-BENZ-FT-analyst_blog|investment_ideas-871880,Zacks,,,,,,
2020-04-16T08:00:00.000+08:00,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic,LLY,https://www.benzinga.com/general/education/20/04/15822818/10-stocks-hitting-all-time-highs-amid-the-covid-19-pandemic,Tyree Gorges,,,,,,
2020-04-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15820155/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,,,
2020-04-16T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",LLY,https://www.benzinga.com/general/biotech/20/04/15817454/the-daily-biotech-pulse-fda-nod-for-urogen-novavax-coronavirus-vaccine-to-enter-clinics-soligenix,Shanthi Rexaline,,,,,,
2020-04-16T08:00:00.000+08:00,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies",LLY,https://www.benzinga.com/news/20/04/15816917/eli-lilly-reports-non-branded-versions-of-humalog-kwikpen-humalog-junior-kwikpen-now-available-for-o,Benzinga Newsdesk,,,,,,
2020-04-16T08:00:00.000+08:00,"Are These 5 Stocks Coronavirus-Proof? What Fortinet, Veeva, Eli Lilly Charts Say Now",LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/top-stocks-to-watch-are-these-5-growth-stocks-coronavirus-proof-what-fortinet-veeva-eli-lilly-charts/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-16T08:00:00.000+08:00,Eli Lilly Just Within Buy Range As Quarterly Report Nears,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-just-within-buy-range-as-quarterly-report-nears/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-16T08:00:00.000+08:00,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?,LLY,http://www.zacks.com/stock/news/874609/eli-lilly-lly-earnings-expected-to-grow-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-874609,Zacks,,,,,,
2020-04-16T08:00:00.000+08:00,"Roche Most Innovative, Astra Zeneca Most Inventive",LLY,http://www.gurufocus.com/news/1106135/roche-most-innovative-astra-zeneca-most-inventive,GuruFocus,,,,,,
2020-04-16T08:00:00.000+08:00,Lower-priced versions of Humalog® Mix75/—5™ KwikPen® and Humalog® Junior KwikPen® now ...,LLY,http://www.gurufocus.com/news/1106532/lowerpriced-versions-of-humalog-mix7525-kwikpen-and-humalog-junior-kwikpen-now-available,GuruFocus,,,,,,
2020-04-17T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15830602/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,,,
2020-04-17T08:00:00.000+08:00,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting",LLY,https://www.benzinga.com/news/earnings/20/04/15830154/big-earnings-day-as-honeywell-procter-gamble-schlumberger-among-those-reporting,JJ Kinahan,,,,,,
2020-04-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",LLY,https://www.benzinga.com/general/biotech/20/04/15828432/the-daily-biotech-pulse-moderna-secures-483m-in-barda-funding-gilead-remdesivir-data-veracytes-po,Shanthi Rexaline,,,,,,
2020-04-17T08:00:00.000+08:00,Coronavirus Stocks Hitting New Highs This Week In Current Stock Market Rally Include Eli Lilly,LLY,http://www.investors.com/stock-lists/new-highs/coronavirus-stocks-new-highs-bio-rad-eli-lilly-breakouts-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-17T08:00:00.000+08:00,"Netflix Stock Rallies Bullishly Ahead Of Earnings, But Is All The Good News Priced In?",LLY,http://www.investors.com/research/earnings-preview/netflix-stock-rallies-bullishly-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-17T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts",LLY,http://www.zacks.com/stock/news/876163/pharma-stock-roundup-jnjs-q1-earnings-coronavirus-product-development-efforts?cid=CS-BENZ-FT-analyst_blog|stock_roundup-876163,Zacks,,,,,,
2020-04-17T08:00:00.000+08:00,"Bremer Bank National Association Buys Xilinx Inc, iShares Cohen & Steers REIT, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1107689/bremer-bank-national-association-buys-xilinx-inc-ishares-cohen--steers-reit-eli-lilly-and-co-sells-ishares-core-msci-eafe-microchip-technology-inc-phillips-66,GuruFocus,,,,,,
2020-04-17T08:00:00.000+08:00,Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results,LLY,http://www.zacks.com/stock/news/875830/buy-5-top-medical-stocks-on-coronavirus-drug-trial-results?cid=CS-BENZ-FT-analyst_blog|investment_ideas-875830,Zacks,,,,,,
2020-04-19T08:00:00.000+08:00,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",LLY,https://www.benzinga.com/general/biotech/20/04/15833296/the-week-ahead-in-biotech-april-19-25-eli-lilly-biogen-earnings-on-tap-sanofi-awaits-fda-decision,Shanthi Rexaline,,,,,,
2020-04-20T08:00:00.000+08:00,Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880332/will-lower-warnermedia-margins-hurt-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880332,Zacks,,,,,,
2020-04-20T08:00:00.000+08:00,Will Communications Segment Buoy AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880327/will-communications-segment-buoy-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880327,Zacks,,,,,,
2020-04-20T08:00:00.000+08:00,Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?,LLY,http://www.zacks.com/stock/news/880321/ericsson-eric-to-report-q1-earnings-whats-in-the-offing?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880321,Zacks,,,,,,
2020-04-20T08:00:00.000+08:00,"Steigerwald, Gordon & Koch Inc. Buys Adobe Inc, The Walt Disney Co, ViacomCBS Inc, Sells T. ...",LLY,http://www.gurufocus.com/news/1109977/steigerwald-gordon--koch-inc-buys-adobe-inc-the-walt-disney-co-viacomcbs-inc-sells-t-rowe-price-group-inc-viacomcbs-inc-exxon-mobil-corp,GuruFocus,,,,,,
2020-04-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly",LLY,http://www.zacks.com/stock/news/880271/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-moderna-sanofi-vaxart-and-eli-lilly?cid=CS-BENZ-FT-press_releases-880271,Zacks,,,,,,
2020-04-21T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",LLY,https://www.benzinga.com/wiim/20/04/15849176/shares-of-several-healthcare-companies-are-trading-lower-with-the-overall-market-on-continued-downwa,Benzinga Newsdesk,,,,,,
2020-04-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",LLY,https://www.benzinga.com/general/biotech/20/04/15846249/the-daily-biotech-pulse-applied-dna-begins-validating-covid-19-test-caras-positive-readout-novan-,Shanthi Rexaline,,,,,,
2020-04-21T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings",LLY,https://www.benzinga.com/news/earnings/20/04/15845466/a-peek-into-the-markets-us-stock-futures-fall-ahead-of-coca-cola-lockheed-martin-earnings,Lisa Levin,,,,,,
2020-04-21T08:00:00.000+08:00,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158",LLY,https://www.benzinga.com/news/20/04/15845335/ubs-downgrades-eli-lilly-to-neutral-raises-price-target-to-158,Vick Meyer,,,,,,
2020-04-21T08:00:00.000+08:00,"Cordatus Wealth Management LLC Buys Apple Inc, Eli Lilly and Co, Netflix Inc, Sells Danaher ...",LLY,http://www.gurufocus.com/news/1111561/cordatus-wealth-management-llc-buys-apple-inc-eli-lilly-and-co-netflix-inc-sells-danaher-corp-moodys-corporation-zoetis-inc,GuruFocus,,,,,,
2020-04-21T08:00:00.000+08:00,"VeraBank, N.A. Buys Vanguard High Dividend Yield, Exxon Mobil Corp, Chevron Corp, Sells Wells ...",LLY,http://www.gurufocus.com/news/1111569/verabank-na-buys-vanguard-high-dividend-yield-exxon-mobil-corp-chevron-corp-sells-wells-fargo-metlife-inc-valero-energy-corp,GuruFocus,,,,,,
2020-04-21T08:00:00.000+08:00,Health Care Leading In New Highs,LLY,https://talkmarkets.com/content/health-care-leading-in-new-highs?post=259318,TalkMarkets,,,,,,
2020-04-21T08:00:00.000+08:00,Stocks Drop as May Oil Contract Goes Negative,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25078,Zacks,,,,,,
2020-04-22T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Powers Back; Apple, AMD, Tesla, Intel, Microsoft Near Buy Points, But Watch Out For This",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-apple-tesla-intel-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-22T08:00:00.000+08:00,"Anderson Fisher Llc Buys Kulicke & Soffa Industries Inc, Bloomin Brands Inc, ...",LLY,http://www.gurufocus.com/news/1113183/anderson-fisher-llc-buys-kulicke--soffa-industries-inc-bloomin-brands-inc-louisianapacific-corp-sells-cms-energy-corp-allegiant-travel-co-lyondellbasell-industries-nv,GuruFocus,,,,,,
2020-04-22T08:00:00.000+08:00,Chip Earnings To Continue With Intel Stock Near Buy Point; Domino's Due: Investing Action Plan,LLY,http://www.investors.com/research/investing-action-plan/chip-earnings-continue-intel-stock-near-buy-point-dominos-pizza-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-22T08:00:00.000+08:00,"Railway Pension Investments Ltd Buys AbbVie Inc, Intel Corp, Eli Lilly and Co, Sells iShares ...",LLY,http://www.gurufocus.com/news/1112498/railway-pension-investments-ltd-buys-abbvie-inc-intel-corp-eli-lilly-and-co-sells-ishares-iboxx--high-yield-corporate-bond-walmart-inc-comcast-corp,GuruFocus,,,,,,
2020-04-22T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke",LLY,http://www.zacks.com/stock/news/883863/the-zacks-analyst-blog-highlights-exxon-mobil-oracle-eli-lilly-and-coke?cid=CS-BENZ-FT-press_releases-883863,Zacks,,,,,,
2020-04-22T08:00:00.000+08:00,Is a Surprise Coming for Lilly (LLY) This Earnings Season?,LLY,http://www.zacks.com/stock/news/883574/is-a-surprise-coming-for-lilly-lly-this-earnings-season?cid=CS-BENZ-FT-tale_of_the_tape|earnings_surprise-883574,Zacks,,,,,,
2020-04-23T08:00:00.000+08:00,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop,LLY,https://www.benzinga.com/news/earnings/20/04/15868998/mid-afternoon-market-update-sleep-number-surges-on-strong-q1-results-netgear-shares-drop,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,Afternoon Market Stats in 5 Minutes,LLY,https://www.benzinga.com/intraday-update/20/04/15867187/afternoon-market-stats-in-5-minutes,Benzinga Insights,,,,,,
2020-04-23T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings,LLY,https://www.benzinga.com/news/earnings/20/04/15867563/mid-day-market-update-crude-oil-jumps-31-invesco-shares-slide-on-downbeat-earnings,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15866414/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,,,
2020-04-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views,LLY,https://www.benzinga.com/news/earnings/20/04/15866179/mid-morning-market-update-markets-open-higher-eli-lilly-beats-q1-views,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close,LLY,https://www.benzinga.com/news/earnings/20/04/15865752/eli-lilly-kicks-off-earnings-day-with-a-beat-and-investors-prepare-for-intel-after-close,JJ Kinahan,,,,,,
2020-04-23T08:00:00.000+08:00,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021",LLY,https://www.benzinga.com/news/20/04/15865645/from-eli-lilly-earnings-conference-call-cfo-says-expecting-muted-impact-from-unemployment-in-2020-se,Benzinga Newsdesk,,,,,,
2020-04-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.,LLY,https://www.benzinga.com/wiim/20/04/15864917/eli-lilly-and-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-eps-an,Benzinga Newsdesk,,,,,,
2020-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",LLY,https://www.benzinga.com/general/biotech/20/04/15863794/the-daily-biotech-pulse-fda-nod-for-immunomedics-lillys-solid-q1-beat-predictive-oncology-restruc,Shanthi Rexaline,,,,,,
2020-04-23T08:00:00.000+08:00,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90",LLY,https://www.benzinga.com/news/20/04/15863392/update-eli-lilly-fy20-adj-eps-guidance-raised-widened-from-6-70-6-80-to-6-70-6-90,Benzinga Newsdesk,,,,,,
2020-04-23T08:00:00.000+08:00,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est.",LLY,https://www.benzinga.com/news/20/04/15863388/eli-lilly-sees-fy20-adj-eps-6-70-6-90-vs-6-73-estimate-sales-23-7b-24-2b-vs-23-84b-est,Benzinga Newsdesk,,,,,,
2020-04-23T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate",LLY,https://www.benzinga.com/news/earnings/20/04/15863376/eli-lilly-q1-adj-eps-1-750-beats-1-480-estimate-sales-5-860b-beat-5-510b-estimate,Benzinga Newsdesk,,,,,,
2020-04-23T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",LLY,https://www.benzinga.com/news/earnings/20/04/15863165/a-peek-into-the-markets-us-stock-futures-flat-ahead-of-earnings-economic-reports,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,"8 Stocks To Watch For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862800/8-stocks-to-watch-for-april-23-2020,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862746/earnings-scheduled-for-april-23-2020,Lisa Levin,,,,,,
2020-04-23T08:00:00.000+08:00,Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for ...,LLY,http://www.gurufocus.com/news/1114896/innovent-and-eli-lilly-announce-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-alimta-pemetrexed-and-platinum-as-firstline-therapy-in-nonsquamous-nsclc,GuruFocus,,,,,,
2020-04-23T08:00:00.000+08:00,"Van Leeuwen & Company, LLC Buys UnitedHealth Group Inc, Microsoft Corp, SPDR S&P ...",LLY,http://www.gurufocus.com/news/1114596/van-leeuwen--company-llc-buys-unitedhealth-group-inc-microsoft-corp-spdr-sp-500-sells-allstate-corp-boeing-co-first-trust-vl-dividend,GuruFocus,,,,,,
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know,LLY,http://www.zacks.com/stock/news/885692/eli-lilly-lly-is-up-793-in-one-week-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-885692,Zacks,,,,,,
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/885139/eli-lilly-lly-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-885139,Zacks,,,,,,
2020-04-24T08:00:00.000+08:00,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167",LLY,https://www.benzinga.com/news/20/04/15875697/cfra-maintains-hold-on-eli-lilly-raises-price-target-to-167,Vick Meyer,,,,,,
2020-04-24T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.,LLY,https://www.benzinga.com/wiim/20/04/15874985/eli-lilly-shares-are-trading-higher-after-the-company-announced-the-nmpa-has-of-china-has-accepted-t,Benzinga Newsdesk,,,,,,
2020-04-24T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15874963/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,,,
2020-04-24T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",LLY,https://www.benzinga.com/general/biotech/20/04/15873096/the-daily-biotech-pulse-fda-approves-sanofis-meningococcal-vaccine-pluristem-secures-54m-in-fundi,Shanthi Rexaline,,,,,,
2020-04-24T08:00:00.000+08:00,Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio,LLY,http://www.investors.com/research/eli-lilly-stock-joins-ibds-long-term-leaders-portfolio/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-04-24T08:00:00.000+08:00,"Thinking about trading options or stock in Eli Lilly, Square, Tesla, UnitedHealth Group, or ...",LLY,http://www.gurufocus.com/news/1115456/thinking-about-trading-options-or-stock-in-eli-lilly-square-tesla-unitedhealth-group-or-zoom-video-communications,GuruFocus,,,,,,
2020-04-24T08:00:00.000+08:00,Will Eli Lilly and Company Continue to Surge Higher?,LLY,http://www.zacks.com/stock/news/887487/will-eli-lilly-and-company-continue-to-surge-higher?cid=CS-BENZ-FT-tale_of_the_tape|20_day_moving_average-887487,Zacks,,,,,,
2020-04-24T08:00:00.000+08:00,"Company News for Apr 24, 2020",LLY,http://www.zacks.com/stock/news/887485/company-news-for-apr-24-2020?cid=CS-BENZ-FT-corporate_summary-887485,Zacks,,,,,,
2020-04-24T08:00:00.000+08:00,S&P 500 Stocks That Rose In The Crisis: It's A Market Of Stocks - Part 2,LLY,https://talkmarkets.com/content/sp-500-stocks-that-rose-in-the-crisis-its-a-market-of-stocks-part-2?post=259792,TalkMarkets,,,,,,
2020-04-24T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN",LLY,http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-887364,Zacks,,,,,,
2020-04-27T08:00:00.000+08:00,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead",LLY,https://www.benzinga.com/news/earnings/20/04/15884587/apple-and-amazon-earnings-fed-meeting-among-highlights-in-busy-week-ahead,JJ Kinahan,,,,,,
2020-04-27T08:00:00.000+08:00,"Geneva Partners, LLC Buys Eli Lilly and Co, Netflix Inc, Veeva Systems Inc, Sells Vanguard High ...",LLY,http://www.gurufocus.com/news/1118071/geneva-partners-llc-buys-eli-lilly-and-co-netflix-inc-veeva-systems-inc-sells-vanguard-high-dividend-yield-the-walt-disney-co-jpmorgan-chase,GuruFocus,,,,,,
2020-04-27T08:00:00.000+08:00,"Huntington National Bank Buys Apple Inc, NVIDIA Corp, Fidelity Total Bond, Sells iShares Core ...",LLY,http://www.gurufocus.com/news/1118091/huntington-national-bank-buys-apple-inc-nvidia-corp-fidelity-total-bond-sells-ishares-core-sp-midcap-dollar-tree-inc-constellation-brands-inc,GuruFocus,,,,,,
2020-04-28T08:00:00.000+08:00,"Sym Financial Corporation Buys Vanguard Total World Stock Index, Schwab Short-Term U.S. ...",LLY,http://www.gurufocus.com/news/1118941/sym-financial-corporation-buys-vanguard-total-world-stock-index-schwab-shortterm-us-treasury-lincoln-national-corp-sells-vanguard-total-stock-market-corteva-inc-ishares-edge-msci-min-vol-usa,GuruFocus,,,,,,
2020-04-28T08:00:00.000+08:00,Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/894178/merck-mrk-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-894178,Zacks,,,,,,
2020-04-28T08:00:00.000+08:00,Axsome Shares Jump —5% on Alzheimer's Study Results,LLY,http://www.gurufocus.com/news/1118254/axsome-shares-jump-25-on-alzheimers-study-results,GuruFocus,,,,,,
2020-04-28T08:00:00.000+08:00,Solid Rally Kicks Off Tech Week,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25159,Zacks,,,,,,
2020-04-29T08:00:00.000+08:00,"Chronos Wealth Management, LLC Buys Illinois Tool Works Inc, Facebook Inc, iShares U.S. ...",LLY,http://www.gurufocus.com/news/1120767/chronos-wealth-management-llc-buys-illinois-tool-works-inc-facebook-inc-ishares-us-preferred-stock-sells-constellation-brands-inc-alibaba-group-holding-3m-co,GuruFocus,,,,,,
2020-04-29T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/897187/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-897187,Zacks,,,,,,
2020-04-30T08:00:00.000+08:00,Lilly to Participate in Bank of America Securities Health Care Conference,LLY,http://www.gurufocus.com/news/1122780/lilly-to-participate-in-bank-of-america-securities-health-care-conference,GuruFocus,,,,,,
2020-04-30T08:00:00.000+08:00,"Chartwell Investment Partners, Inc. Buys Allison Transmission Holdings Inc, Truist Financial ...",LLY,http://www.gurufocus.com/news/1121910/chartwell-investment-partners-inc-buys-allison-transmission-holdings-inc-truist-financial-corp-amdocs-sells-duke-realty-corp-mantech-international-corp-truist-financial-corp,GuruFocus,,,,,,
2020-04-30T08:00:00.000+08:00,"Moody Lynn & Lieberson, Inc. Buys ishares Gold Trust, Eli Lilly and Co, ServiceNow Inc, ...",LLY,http://www.gurufocus.com/news/1121851/moody-lynn--lieberson-inc-buys-ishares-gold-trust-eli-lilly-and-co-servicenow-inc-sells-sysco-corp-chevron-corp-trane-technologies-plc,GuruFocus,,,,,,
2020-04-30T08:00:00.000+08:00,"Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/901586/hologic-holx-beats-q2-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-901586,Zacks,,,,,,
2020-04-30T08:00:00.000+08:00,Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat,LLY,http://www.zacks.com/stock/news/900034/remdesivir-progresses-on-coronavirus-trial-pharma-upbeat?cid=CS-BENZ-FT-analyst_blog|industry_focus-900034,Zacks,,,,,,
2020-04-30T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/899914/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-analyst_blog|earnings_article-899914,Zacks,,,,,,
2020-05-01T08:00:00.000+08:00,"Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/910477/illumina-ilmn-beats-q1-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-910477,Zacks,,,,,,
2020-05-03T08:00:00.000+08:00,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies,LLY,https://www.benzinga.com/news/20/05/15941096/shanghai-junshi-biosciences-says-entered-research-collaboration-and-license-agreement-with-eli-lilly,Charles Gross,,,,,,
2020-05-04T08:00:00.000+08:00,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19,LLY,https://www.benzinga.com/general/biotech/20/05/15943172/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of,Benzinga Newsdesk,,,,,,
2020-05-04T08:00:00.000+08:00,Lilly Declares Second-Quarter —…—… Dividend,LLY,http://www.gurufocus.com/news/1125493/lilly-declares-secondquarter-2020-dividend,GuruFocus,,,,,,
2020-05-04T08:00:00.000+08:00,"Cookson Peirce & Co Inc Buys Eli Lilly and Co, Vertex Pharmaceuticals Inc, Netflix Inc, ...",LLY,http://www.gurufocus.com/news/1125063/cookson-peirce--co-inc-buys-eli-lilly-and-co-vertex-pharmaceuticals-inc-netflix-inc-sells-hilton-worldwide-holdings-inc-transdigm-group-inc-abbott-laboratories,GuruFocus,,,,,,
2020-05-04T08:00:00.000+08:00,"Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand",LLY,http://www.zacks.com/stock/news/913172/hill-roms-hrc-q2-earnings-top-estimates-margins-expand?cid=CS-BENZ-FT-analyst_blog|earnings_article-913172,Zacks,,,,,,
2020-05-04T08:00:00.000+08:00,Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/913170/teleflex-tfx-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-913170,Zacks,,,,,,
2020-05-04T08:00:00.000+08:00,"Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down",LLY,http://www.zacks.com/stock/news/913095/syneos-health-synh-tops-q1-earnings-estimates-margins-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-913095,Zacks,,,,,,
2020-05-04T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/912721/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-sector_etf-912721,Zacks,,,,,,
2020-05-04T08:00:00.000+08:00,Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment ...,LLY,http://www.gurufocus.com/news/1124937/lilly-and-junshi-biosciences-to-codevelop-antibody-therapies-for-the-prevention-and-treatment-of-covid19,GuruFocus,,,,,,
2020-05-05T08:00:00.000+08:00,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,LLY,https://www.benzinga.com/wiim/20/05/15957697/shares-of-several-healthcare-companies-are-trading-higher-amid-positive-investor-sentiment-as-some-u,Benzinga Newsdesk,,,,,,
2020-05-05T08:00:00.000+08:00,Lilly to Participate in UBS Virtual Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1127200/lilly-to-participate-in-ubs-virtual-global-healthcare-conference,GuruFocus,,,,,,
2020-05-05T08:00:00.000+08:00,"The Vanguard Health Care Fund Exits CVS Health, Teva Pharmaceutical",LLY,http://www.gurufocus.com/news/1126786/the-vanguard-health-care-fund-exits-cvs-health-teva-pharmaceutical,GuruFocus,,,,,,
2020-05-05T08:00:00.000+08:00,"Highland Capital Management, Llc Buys Johnson & Johnson, Truist Financial Corp, Honeywell ...",LLY,http://www.gurufocus.com/news/1126269/highland-capital-management-llc-buys-johnson--johnson-truist-financial-corp-honeywell-international-inc-sells-boeing-co-ishares-core-msci-eafe-delta-air-lines-inc,GuruFocus,,,,,,
2020-05-05T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/914066/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-914066,Zacks,,,,,,
2020-05-05T08:00:00.000+08:00,"Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues",LLY,http://www.zacks.com/stock/news/914228/incyte-incy-misses-q1-earnings-estimates-beats-on-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-914228,Zacks,,,,,,
2020-05-05T08:00:00.000+08:00,Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates,LLY,http://www.zacks.com/stock/news/914225/henry-schein-hsic-q1-earnings-and-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914225,Zacks,,,,,,
2020-05-05T08:00:00.000+08:00,"Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates",LLY,http://www.zacks.com/stock/news/914196/tandem-diabetes-tndm-q1-loss-widens-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914196,Zacks,,,,,,
2020-05-05T08:00:00.000+08:00,"First Quadrant L P Buys UnitedHealth Group Inc, Eli Lilly and Co, Sanmina Corp, Sells Vanguard ...",LLY,http://www.gurufocus.com/news/1126066/first-quadrant-l-p-buys-unitedhealth-group-inc-eli-lilly-and-co-sanmina-corp-sells-vanguard-real-estate-vanguard-global-exus-real-estate-etf-ishares-iboxx--high-yield-corporate-bond,GuruFocus,,,,,,
2020-05-06T08:00:00.000+08:00,Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum ...,LLY,http://www.gurufocus.com/news/1128601/tyvyt-sintilimab-injection-combined-with-gemzar-gemcitabine-for-injection-and-platinum-chemotherapy-met-the-predefined-primary-endpoint-in-the-phase-3-orient12-study-as-firstline-therapy-in-patients-with-locally-advan,GuruFocus,,,,,,
2020-05-06T08:00:00.000+08:00,"Mengis Capital Management, Inc. Buys 'M Co, SPDR S&P 5……, Eli Lilly and Co, Sells ...",LLY,http://www.gurufocus.com/news/1128307/mengis-capital-management-inc-buys-3m-co-spdr-sp-500-eli-lilly-and-co-sells-williams-inc-nuveen-energy-mlp-total-return-fund-allegheny-technologies-inc,GuruFocus,,,,,,
2020-05-06T08:00:00.000+08:00,"Jennison Associates Llc Buys Eli Lilly and Co, Uber Technologies Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127973/jennison-associates-llc-buys-eli-lilly-and-co-uber-technologies-inc-goldman-sachs-group-inc-sells-the-walt-disney-co-intuitive-surgical-inc-nike-inc,GuruFocus,,,,,,
2020-05-06T08:00:00.000+08:00,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",LLY,http://www.zacks.com/stock/news/915656/myriad-genetics-mygn-lags-q3-earnings-estimates-cancels-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-915656,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,"Pearl River Capital, LLC Buys American Electric Power Co Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127563/pearl-river-capital-llc-buys-american-electric-power-co-inc-goldman-sachs-group-inc-electronic-arts-inc-sells-honeywell-international-inc-sp-global-inc-northern-trust-corp,GuruFocus,,,,,,
2020-05-06T08:00:00.000+08:00,"CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate",LLY,http://www.zacks.com/stock/news/915641/cvs-health-cvs-q1-earnings-top-estimates-costs-escalate?cid=CS-BENZ-FT-analyst_blog|earnings_article-915641,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates,LLY,http://www.zacks.com/stock/news/915493/inogens-ingn-q1-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915493,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,DaVita (DVA) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/915484/davita-dva-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-915484,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,"Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin",LLY,http://www.zacks.com/stock/news/915230/cardiovascular-systems-csii-reports-q3-loss-lower-margin?cid=CS-BENZ-FT-analyst_blog|earnings_article-915230,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/915190/perkinelmer-pki-q1-earnings-and-revenues-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915190,Zacks,,,,,,
2020-05-06T08:00:00.000+08:00,"NN Investment Partners Holdings N.V. Buys Mastercard Inc, Apple Inc, The Estee Lauder Inc, ...",LLY,http://www.gurufocus.com/news/1127520/nn-investment-partners-holdings-nv-buys-mastercard-inc-apple-inc-the-estee-lauder-inc-sells-cigna-corp-simon-property-group-inc-merck-inc,GuruFocus,,,,,,
2020-05-08T08:00:00.000+08:00,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes',LLY,https://www.benzinga.com/news/20/05/15992034/eli-lilly-press-release-highlights-higher-investigational-doses-of-trulicity-dulaglutide-meaningfull,Benzinga Newsdesk,,,,,,
2020-05-08T08:00:00.000+08:00,5 Biopharmas Where BofA Would Put Its Money To Work,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15989612/5-biopharmas-where-bofa-would-put-its-money-to-work,Shanthi Rexaline,,,,,,
2020-05-08T08:00:00.000+08:00,"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically ...",LLY,http://www.gurufocus.com/news/1131696/lilly-receives-us-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-for-patients-with-advanced-retdriven-lung-and-thyroid-cancers,GuruFocus,,,,,,
2020-05-08T08:00:00.000+08:00,"Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass",LLY,http://www.zacks.com/stock/news/918318/radius-rdus-q1-earnings-miss-estimates-sales-surpass?cid=CS-BENZ-FT-analyst_blog|earnings_article-918318,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A–C and body ...,LLY,http://www.gurufocus.com/news/1131363/higher-investigational-doses-of-trulicity-dulaglutide-meaningfully-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes,GuruFocus,,,,,,
2020-05-08T08:00:00.000+08:00,"Sustainable Insight Capital Management, LLC Buys Apple Inc, Eli Lilly and Co, Truist Financial ...",LLY,http://www.gurufocus.com/news/1131193/sustainable-insight-capital-management-llc-buys-apple-inc-eli-lilly-and-co-truist-financial-corp-sells-citigroup-inc-simon-property-group-inc-becton-dickinson-and-co,GuruFocus,,,,,,
2020-05-08T08:00:00.000+08:00,"Mastrapasqua Asset Management Inc Buys II-VI Inc, Ciena Corp, Skyworks Solutions Inc, Sells ...",LLY,http://www.gurufocus.com/news/1131220/mastrapasqua-asset-management-inc-buys-iivi-inc-ciena-corp-skyworks-solutions-inc-sells-aramark-air-lease-corp-sealed-air-corp,GuruFocus,,,,,,
2020-05-08T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY",LLY,http://www.zacks.com/stock/news/918157/pharma-stock-roundup-q1-earnings-of-bmy-nvo-coronavirus-update-from-pfe-rhhby?cid=CS-BENZ-FT-analyst_blog|stock_roundup-918157,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,"OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates",LLY,http://www.zacks.com/stock/news/918074/opko-health-opk-reports-q1-loss-lags-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-918074,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,Globus Medical (GMED) Misses on Q1 Earnings and Revenues,LLY,http://www.zacks.com/stock/news/918003/globus-medical-gmed-misses-on-q1-earnings-and-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-918003,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,"Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises",LLY,http://www.zacks.com/stock/news/917984/omnicell-omcl-q1-earnings-top-operating-margin-rises?cid=CS-BENZ-FT-analyst_blog|earnings_article-917984,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,"Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top",LLY,http://www.zacks.com/stock/news/917867/avanos-medical-avns-q1-earnings-lag-estimates-revenues-top?cid=CS-BENZ-FT-analyst_blog|earnings_article-917867,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results,LLY,http://www.zacks.com/stock/news/917851/dentsply-sirona-xray-posts-weak-q1-preliminary-results?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-917851,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/917857/glaukos-gkos-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917857,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,"Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook",LLY,http://www.zacks.com/stock/news/917856/integra-iart-lags-q1-earnings-estimates-withdraws-outlook?cid=CS-BENZ-FT-analyst_blog|earnings_article-917856,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,"Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended",LLY,http://www.zacks.com/stock/news/917849/bruker-brkr-q1-earnings-miss-estimates-guidance-suspended?cid=CS-BENZ-FT-analyst_blog|earnings_article-917849,Zacks,,,,,,
2020-05-08T08:00:00.000+08:00,Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates,LLY,http://www.zacks.com/stock/news/917790/pacific-biosciences-pacb-q1-earnings-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917790,Zacks,,,,,,
2020-05-09T08:00:00.000+08:00,Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly,LLY,https://talkmarkets.com/content/week-in-review-junshi-out-licenses-ex-china-rights-for-covid-19-therapeutic-to-lilly?post=261491,TalkMarkets,,,,,,
2020-05-10T08:00:00.000+08:00,8 Monster Stock Market Predictions For The Week Of May 11,LLY,https://talkmarkets.com/content/8-monster-stock-market-predictions-for-the-week-of-may-11?post=261550,TalkMarkets,,,,,,
2020-05-11T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/05/16003134/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,,,
2020-05-11T08:00:00.000+08:00,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.,LLY,https://www.benzinga.com/wiim/20/05/16002972/eli-lilly-shares-are-trading-higher-amid-strength-in-the-healthcare-sector-the-company-late-friday-a,Benzinga Newsdesk,,,,,,
2020-05-11T08:00:00.000+08:00,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",LLY,https://www.benzinga.com/news/20/05/16001162/lilly-late-friday-announced-co-received-u-s-fda-approval-for-retevmo-selpercatinib-the-first-therapy,Benzinga Newsdesk,,,,,,
2020-05-11T08:00:00.000+08:00,LLY Stock Approaching Support: Here Are Two Option Trade Ideas,LLY,http://www.investors.com/research/options/lly-stock-approaching-support-here-are-two-option-trade-ideas/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,,,
2020-05-11T08:00:00.000+08:00,"Varma Mutual Pension Insurance Co Buys PowerShares QQQ Trust Ser –, iShares MSCI China ETF, ...",LLY,http://www.gurufocus.com/news/1133017/varma-mutual-pension-insurance-co-buys-powershares-qqq-trust-ser-1-ishares-msci-china-etf-kraneshares-trust-csi-china-internet-sells-ishares-core-sp-500-ishares-core-msci-emerging-markets-vanguard-sp-500,GuruFocus,,,,,,
2020-05-11T08:00:00.000+08:00,Health Care's Market-Beating Performance,LLY,https://talkmarkets.com/content/health-cares-market-beating-performance?post=261681,TalkMarkets,,,,,,
2020-05-12T08:00:00.000+08:00,"Oxford Financial Group Ltd Buys Intuitive Surgical Inc, Eli Lilly and Co, Vanguard Value, Sells ...",LLY,http://www.gurufocus.com/news/1134552/oxford-financial-group-ltd-buys-intuitive-surgical-inc-eli-lilly-and-co-vanguard-value-sells-ishares-core-msci-emerging-markets-vanguard-real-estate-ishares-north-american-natural-resources,GuruFocus,,,,,,
2020-05-12T08:00:00.000+08:00,Smith Asset Management Group LP Buys Amazon. ...,LLY,http://www.gurufocus.com/news/1134321/smith-asset-management-group-lp-buys-amazoncom-inc-nvidia-corp-jpmorgan-chase-sells-facebook-inc-vf-corp-varian-medical-systems-inc,GuruFocus,,,,,,
2020-05-13T08:00:00.000+08:00,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16022153/abbvies-potential-is-underappreciated-says-morgan-stanley-analyst,Shanthi Rexaline,,,,,,
2020-05-13T08:00:00.000+08:00,"'6– Capital Llc Buys Spire Inc, McKesson Corp, Berry Global Group Inc, Sells Jazz ...",LLY,http://www.gurufocus.com/news/1135880/361-capital-llc-buys-spire-inc-mckesson-corp-berry-global-group-inc-sells-jazz-pharmaceuticals-plc-paccar-inc-spotify-technology-sa,GuruFocus,,,,,,
2020-05-13T08:00:00.000+08:00,"AlphaCrest Capital Management LLC Buys AT&T Inc, Eli Lilly and Co, Apple Inc, Sells The ...",LLY,http://www.gurufocus.com/news/1135824/alphacrest-capital-management-llc-buys-att-inc-eli-lilly-and-co-apple-inc-sells-the-torontodominion-bank-oracle-corp-charles-schwab-corp,GuruFocus,,,,,,
2020-05-13T08:00:00.000+08:00,"Pitcairn Co Buys Mastercard Inc, Eli Lilly and Co, Seagate Technology PLC, Sells IQ Hedge ...",LLY,http://www.gurufocus.com/news/1135209/pitcairn-co-buys-mastercard-inc-eli-lilly-and-co-seagate-technology-plc-sells-iq-hedge-multiiq-hedge-multistrategy-tracker-visa-inc-bwx-technologies-inc,GuruFocus,,,,,,
2020-05-13T08:00:00.000+08:00,"Skandinaviska Enskilda Banken AB (publ) Buys Align Technology Inc, Eli Lilly and Co, Alibaba ...",LLY,http://www.gurufocus.com/news/1135118/skandinaviska-enskilda-banken-ab-publ-buys-align-technology-inc-eli-lilly-and-co-alibaba-group-holding-sells-hewlett-packard-enterprise-co-gilead-sciences-inc-target-corp,GuruFocus,,,,,,
2020-05-14T08:00:00.000+08:00,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",LLY,https://www.benzinga.com/general/biotech/20/05/16029961/the-daily-biotech-pulse-asco-abstracts-create-stock-ripples-applied-dnas-coronavirus-test-receive,Shanthi Rexaline,,,,,,
2020-05-14T08:00:00.000+08:00,"Summit Global Investments Buys Amazon.com Inc, Clorox Co, Adobe Inc, Sells NVR Inc, TJX Inc, ...",LLY,http://www.gurufocus.com/news/1137307/summit-global-investments-buys-amazoncom-inc-clorox-co-adobe-inc-sells-nvr-inc-tjx-inc-sysco-corp,GuruFocus,,,,,,
2020-05-14T08:00:00.000+08:00,"GCIC Ltd. Buys Brookfield Asset Management Inc, Eli Lilly and Co, Stryker Corp, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1136972/gcic-ltd-buys-brookfield-asset-management-inc-eli-lilly-and-co-stryker-corp-sells-bank-of-nova-scotia-visa-inc-enbridge-inc,GuruFocus,,,,,,
2020-05-14T08:00:00.000+08:00,"Tekla Capital Management LLC Buys Centene Corp, Moderna Inc, Eli Lilly and Co, Sells Anthem ...",LLY,http://www.gurufocus.com/news/1136990/tekla-capital-management-llc-buys-centene-corp-moderna-inc-eli-lilly-and-co-sells-anthem-inc-the-medicines-co-esperion-therapeutics-inc,GuruFocus,,,,,,
2020-05-15T08:00:00.000+08:00,"Asahi Life Asset Management Co., Ltd. Buys Facebook Inc, Alibaba Group Holding, Amazon. ...",LLY,http://www.gurufocus.com/news/1138088/asahi-life-asset-management-co-ltd-buys-facebook-inc-alibaba-group-holding-amazoncom-inc-sells-gilead-sciences-inc-texas-instruments-inc-qualcomm-inc,GuruFocus,,,,,,
2020-05-15T08:00:00.000+08:00,"UBP Investment Advisors SA Buys iShares Short Maturity Bond, iShares MSCI China ETF, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1137997/ubp-investment-advisors-sa-buys-ishares-short-maturity-bond-ishares-msci-china-etf-eli-lilly-and-co-sells-vanguard-shortterm-government-bond-etf-exact-sciences-corp-the-walt-disney-co,GuruFocus,,,,,,
2020-05-19T08:00:00.000+08:00,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease",LLY,https://www.benzinga.com/news/20/05/16064469/eli-lilly-reports-results-of-geras-us-study-showed-societal-cost-burden-for-patients-caregivers-duri,Benzinga Newsdesk,,,,,,
2020-05-19T08:00:00.000+08:00,Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During ...,LLY,http://www.gurufocus.com/news/1141850/results-of-gerasus-study-demonstrate-societal-cost-burden-for-patients-and-caregivers-during-early-stages-of-alzheimers-disease,GuruFocus,,,,,,
2020-05-20T08:00:00.000+08:00,J&J to Stop Sale of Talc-Based Baby Powder in North America,LLY,http://www.zacks.com/stock/news/934832/jj-to-stop-sale-of-talc-based-baby-powder-in-north-america?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-934832,Zacks,,,,,,
2020-05-21T08:00:00.000+08:00,Clovis Oncology Needs a Savior,LLY,http://www.gurufocus.com/news/1144188/clovis-oncology-needs-a-savior,GuruFocus,,,,,,
2020-05-23T08:00:00.000+08:00,Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?,LLY,http://www.zacks.com/stock/news/940216/why-is-lilly-lly-down-55-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-940216,Zacks,,,,,,
2020-05-26T08:00:00.000+08:00,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet,LLY,https://www.benzinga.com/news/20/05/16110564/list-of-external-participants-expected-at-rose-garden-event-starting-momentarily-where-potus-will-an,Benzinga Newsdesk,,,,,,
2020-05-26T08:00:00.000+08:00,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies",LLY,https://www.benzinga.com/news/20/05/16105875/eli-lilly-intend-to-file-an-ind-initiate-clinical-trials-in-u-s-china-in-q2-2020-for-companys-covid,Benzinga Newsdesk,,,,,,
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction,LLY,https://www.benzinga.com/general/biotech/20/05/16104895/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmati,Benzinga Newsdesk,,,,,,
2020-05-26T08:00:00.000+08:00,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients,LLY,https://www.benzinga.com/general/biotech/20/05/16104029/eli-lilly-announces-emgality-significantly-improved-work-productivity-and-reduced-interictal-burd,Benzinga Newsdesk,,,,,,
2020-05-26T08:00:00.000+08:00,Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model,LLY,http://www.gurufocus.com/news/1147739/statement-from-lilly-chairman-and-ceo-dave-ricks-on-new-part-d-senior-savings-model,GuruFocus,,,,,,
2020-05-26T08:00:00.000+08:00,"GCIC Ltd. Buys Amazon.com Inc, Brookfield Asset Management Inc, Eli Lilly and Co, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1147522/gcic-ltd-buys-amazoncom-inc-brookfield-asset-management-inc-eli-lilly-and-co-sells-bank-of-america-corp-jpmorgan-chase-nike-inc,GuruFocus,,,,,,
2020-05-26T08:00:00.000+08:00,CanSino Biologics' Covid-–9 Vaccine Shows Early Promise,LLY,http://www.gurufocus.com/news/1147372/cansino-biologics-covid19-vaccine-shows-early-promise-,GuruFocus,,,,,,
2020-05-26T08:00:00.000+08:00,Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi ...,LLY,http://www.gurufocus.com/news/1147266/nature-publishes-preclinical-characterization-and-primate-efficacy-data-on-junshi-biosciences-covid19-neutralizing-antibodies,GuruFocus,,,,,,
2020-05-26T08:00:00.000+08:00,Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in ...,LLY,http://www.gurufocus.com/news/1147282/emgality-shows-improvement-in-work-productivity-and-health-and-wellbeing-between-attacks-in-patients-with-migraine-and-a-history-of-preventive-treatment-failure,GuruFocus,,,,,,
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a ...,LLY,http://www.gurufocus.com/news/1146886/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmatic-trial-examining-jardiances-effects-following-an-acute-myocardial-infarction,GuruFocus,,,,,,
2020-05-27T08:00:00.000+08:00,"\"Trumpdesivir: Operation Warp Speed, \"\"Engage.\"\"\"",LLY,https://talkmarkets.com/content/trumpdesivir-operation-warp-speed-engage?post=263499,TalkMarkets,,,,,,
2020-05-28T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",LLY,https://www.benzinga.com/wiim/20/05/16129874/shares-of-several-healthcare-companies-are-trading-higher-amid-market-strength-strength-potentially,Benzinga Newsdesk,,,,,,
2020-05-28T08:00:00.000+08:00,Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F –8 injection) for Use in ...,LLY,http://www.gurufocus.com/news/1150170/lilly-receives-us-fda-approval-of-tauvid-flortaucipir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-disease,GuruFocus,,,,,,
2020-05-28T08:00:00.000+08:00,Thursday Morning Market Highlights,LLY,http://www.gurufocus.com/news/1149518/thursday-morning-market-highlights,GuruFocus,,,,,,
2020-05-28T08:00:00.000+08:00,"3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020",LLY,http://www.zacks.com/stock/news/949284/3-investing-facts-about-required-minimum-distributions-you-need-to-know-may-28-2020?cid=CS-BENZ-FT-retirement_ideas|required_minimum_distribution-949284,Zacks,,,,,,
2020-05-29T08:00:00.000+08:00,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease,LLY,https://www.benzinga.com/general/biotech/20/05/16138311/lilly-yesterday-received-u-s-fda-approval-of-tauvid-for-use-in-patients-being-evaluated-for-alzhe,Benzinga Newsdesk,,,,,,
2020-05-29T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic ...,LLY,http://www.gurufocus.com/news/1151826/lillys-cyramza-ramucirumab-receives-fda-approval-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,,,
2020-05-29T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN",LLY,http://www.zacks.com/stock/news/951712/pharma-stock-roundup-mrk-rhhby-give-coronavirus-updatessny-to-sell-stake-in-regn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-951712,Zacks,,,,,,
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO,LLY,https://www.benzinga.com/news/20/05/16146249/innovent-biologics-and-lilly-jointly-announced-the-long-term-follow-up-results-of-tyvyt-sintilimab-i,Charles Gross,,,,,,
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152283/innovent-biologics-and-lilly-jointly-announced-the-longterm-followup-results-of-tyvyt-sintilimab-injection-in-the-treatment-of-patients-with-relapsedrefractory-classic-hodgkins-lymphoma,GuruFocus,,,,,,
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152284/innovent-biologics-and-lilly-jointly-announced-the-pivotal-clinical-study-results-of-tyvyt-sintilimab-injection-in-the-secondline-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carc,GuruFocus,,,,,,
2020-05-31T08:00:00.000+08:00,Bristol-Myers Deserves Better Than a Single-Digit Multiple,LLY,http://www.gurufocus.com/news/1151961/bristolmyers-deserves-better-than-a-singledigit-multiple,GuruFocus,,,,,,
2020-06-01T08:00:00.000+08:00,Lilly Begins World's First Study of a Potential COVID-–9 Antibody Treatment in Humans,LLY,http://www.gurufocus.com/news/1152544/lilly-begins-worlds-first-study-of-a-potential-covid19-antibody-treatment-in-humans,GuruFocus,,,,,,
2020-06-01T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) is the First IL-–7A Antagonist to Receive U.S. ...,LLY,http://www.gurufocus.com/news/1152576/lillys-taltz-ixekizumab-is-the-first-il17a-antagonist-to-receive-us-fda-approval-for-the-treatment-of-nonradiographic-axial-spondyloarthritis-nraxspa,GuruFocus,,,,,,
2020-06-01T10:31:40.000+08:00,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment,LLY,https://www.benzinga.com/news/20/06/16147397/eli-lilly-doses-patients-in-its-phase-1-coronavirus-antibody-treatment,Luke J Jacobi,,,,,,
2020-06-01T10:49:07.000+08:00,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA,LLY,https://www.benzinga.com/news/20/06/16147522/eli-lillys-supplemental-biologics-license-application-for-taltz-for-the-treatment-of-active-non-radi,Luke J Jacobi,,,,,,
2020-06-01T19:40:17.000+08:00,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy',LLY,https://www.benzinga.com/general/biotech/20/06/16151876/eli-lilly-ceo-talks-coronavirus-treatment-progress-this-is-an-important-bridge-therapy,Jayson Derrick,,,,,,
2020-06-02T08:00:00.000+08:00,"AstraZeneca Ranked Most Inventive, Roche Most Innovative",LLY,http://www.gurufocus.com/news/1153150/astrazeneca-ranked-most-inventive-roche-most-innovative,GuruFocus,,,,,,
2020-06-03T08:00:00.000+08:00,EULAR —…—…: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent ...,LLY,http://www.gurufocus.com/news/1154415/eular-2020-lillys-taltz-ixekizumab-continues-to-show-robust-and-consistent-efficacy-in-psoriatic-arthritis,GuruFocus,,,,,,
2020-06-03T11:39:19.000+08:00,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",LLY,https://www.benzinga.com/general/biotech/20/06/16167710/the-daily-biotech-pulse-regulatory-delay-for-novartis-multiple-sclerosis-drug-fsd-gets-nod-for-co,Shanthi Rexaline,,,,,,
2020-06-05T16:36:32.000+08:00,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials",LLY,https://www.benzinga.com/news/20/06/16191947/fauci-need-to-definitively-show-treatments-are-effective-on-eli-lillys-recent-human-trials,Benzinga Newsdesk,,,,,,
2020-06-08T11:18:03.000+08:00,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient",LLY,https://www.benzinga.com/news/20/06/16199696/lilly-announces-start-of-a-phase-1-study-for-its-second-potential-covid-19-antibody-treatment-doses,Luke J Jacobi,,,,,,
2020-06-09T10:47:38.000+08:00,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/20/06/16209618/first-patient-dose-delivered-for-lillys-tirzepatide-cardiovascular-outcomes-trial,Benzinga Newsdesk,,,,,,
2020-06-09T13:49:09.000+08:00,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally,LLY,https://www.benzinga.com/news/20/06/16212137/travel-stocks-lose-momentum-in-pre-market-after-leading-yesterdays-sharp-rally,JJ Kinahan,,,,,,
2020-06-10T19:40:33.000+08:00,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept.",LLY,https://www.benzinga.com/news/20/06/16225883/eli-lilly-shares-spike-to-session-high-up-1-7-following-report-co-chief-scientist-has-said-one-of-co,Benzinga Newsdesk,,,,,,
2020-06-11T09:40:14.000+08:00,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September,LLY,https://www.benzinga.com/news/20/06/16229931/lillys-chief-scientist-says-cos-covid-19-treatment-could-be-authorized-for-use-by-september,Charles Gross,,,,,,
